<!DOCTYPE html><html lang="en-us" >

<head>

  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="generator" content="Source Themes Academic 4.8.0">

  

  
  
  
  
  
  

  

  
  
  
    
  
  <meta name="description" content="Table 1. List of all 3787 articles with abstract clustered as Clinical, signs &amp; Symptoms in PlatOMICs for mesothelioma. *Curation represents the number of person that analyzed the information   Title  Journal      P53-immunoreactive cells in benign and malignant effusions: diagnostic value using a panel of monoclonal antibodies and comparison with CEA-staining.">

  
  <link rel="alternate" hreflang="en-us" href="/mesothelioma/tables/abstract/signs/">

  


  
  
  
  <meta name="theme-color" content="#2962ff">
  

  
  

  
  
  
  
    
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/academicons/1.8.6/css/academicons.min.css" integrity="sha256-uFVgMKfistnJAfoCUQigIl+JfUaP47GrRKjf6CTPVmw=" crossorigin="anonymous">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.12.0-1/css/all.min.css" integrity="sha256-4w9DunooKSr3MFXHXWyFER38WmPdm361bQS/2KUWZbU=" crossorigin="anonymous">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.5.7/jquery.fancybox.min.css" integrity="sha256-Vzbj7sDDS/woiFS3uNKo8eIuni59rjyNGtXfstRzStA=" crossorigin="anonymous">

    
    
    
      
    
    
      
      
        
          <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.18.1/styles/github.min.css" crossorigin="anonymous" title="hl-light">
          <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.18.1/styles/dracula.min.css" crossorigin="anonymous" title="hl-dark" disabled>
        
      
    

    

    

    
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
        <script src="https://cdnjs.cloudflare.com/ajax/libs/lazysizes/5.1.2/lazysizes.min.js" integrity="sha256-Md1qLToewPeKjfAHU1zyPwOutccPAm5tahnaw7Osw0A=" crossorigin="anonymous" async></script>
      
    
      

      
      

      
    
      

      
      

      
    
      

      
      
        
      

      
    
      

      
      

      
    

  

  
  
  
  <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Montserrat:400,700%7CRoboto:400,400italic,700%7CRoboto+Mono&display=swap">
  

  
  
  
  
  <link rel="stylesheet" href="/mesothelioma/css/academic.css">

  





<script async src="https://www.googletagmanager.com/gtag/js?id=google_analytics_ID"></script>
<script>
  window.dataLayer = window.dataLayer || [];

  function gtag() {
      dataLayer.push(arguments);
  }

  function trackOutboundLink(url, target) {
    gtag('event', 'click', {
         'event_category': 'outbound',
         'event_label': url,
         'transport_type': 'beacon',
         'event_callback': function () {
           if (target !== '_blank') {
             document.location = url;
           }
         }
    });
    console.debug("Outbound link clicked: " + url);
  }

  function onClickCallback(event) {
    if ((event.target.tagName !== 'A') || (event.target.host === window.location.host)) {
      return;
    }
    trackOutboundLink(event.target, event.target.getAttribute('target'));  
  }

  gtag('js', new Date());
  gtag('config', 'google_analytics_ID', {});

  
  document.addEventListener('click', onClickCallback, false);
</script>


  


  
  

  

  <link rel="manifest" href="/mesothelioma/index.webmanifest">
  <link rel="icon" type="image/png" href="/mesothelioma/images/icon_hu7e12209333f22d741aca7d462871821f_9877_32x32_fill_lanczos_center_2.png">
  <link rel="apple-touch-icon" type="image/png" href="/mesothelioma/images/icon_hu7e12209333f22d741aca7d462871821f_9877_192x192_fill_lanczos_center_2.png">

  <link rel="canonical" href="/mesothelioma/tables/abstract/signs/">

  
  
  
  
  
  
  
    
    
  
  
  <meta property="twitter:card" content="summary">
  
  <meta property="og:site_name" content="mesothelioma">
  <meta property="og:url" content="/mesothelioma/tables/abstract/signs/">
  <meta property="og:title" content="Clinical, signs &amp; Symptoms Articles | mesothelioma">
  <meta property="og:description" content="Table 1. List of all 3787 articles with abstract clustered as Clinical, signs &amp; Symptoms in PlatOMICs for mesothelioma. *Curation represents the number of person that analyzed the information   Title  Journal      P53-immunoreactive cells in benign and malignant effusions: diagnostic value using a panel of monoclonal antibodies and comparison with CEA-staining."><meta property="og:image" content="/mesothelioma/images/icon_hu7e12209333f22d741aca7d462871821f_9877_512x512_fill_lanczos_center_2.png">
  <meta property="twitter:image" content="/mesothelioma/images/icon_hu7e12209333f22d741aca7d462871821f_9877_512x512_fill_lanczos_center_2.png"><meta property="og:locale" content="en-us">
  
    
      <meta property="article:published_time" content="2018-09-09T00:00:00&#43;00:00">
    
    <meta property="article:modified_time" content="2018-09-09T00:00:00&#43;00:00">
  

  



  


  


  





  <title>Clinical, signs &amp; Symptoms Articles | mesothelioma</title>

</head>

<body id="top" data-spy="scroll" data-offset="70" data-target="#TableOfContents" >

  <aside class="search-results" id="search">
  <div class="container">
    <section class="search-header">

      <div class="row no-gutters justify-content-between mb-3">
        <div class="col-6">
          <h1>Search</h1>
        </div>
        <div class="col-6 col-search-close">
          <a class="js-search" href="#"><i class="fas fa-times-circle text-muted" aria-hidden="true"></i></a>
        </div>
      </div>

      <div id="search-box">
        
        <input name="q" id="search-query" placeholder="Search..." autocapitalize="off"
        autocomplete="off" autocorrect="off" spellcheck="false" type="search">
        
      </div>

    </section>
    <section class="section-search-results">

      <div id="search-hits">
        
      </div>

    </section>
  </div>
</aside>


  







<nav class="navbar navbar-expand-lg navbar-light compensate-for-scrollbar" id="navbar-main">
  <div class="container">

    
    <div class="d-none d-lg-inline-flex">
      <a class="navbar-brand" href="/mesothelioma/">mesothelioma</a>
    </div>
    

    
    <button type="button" class="navbar-toggler" data-toggle="collapse"
            data-target="#navbar-content" aria-controls="navbar" aria-expanded="false" aria-label="Toggle navigation">
    <span><i class="fas fa-bars"></i></span>
    </button>
    

    
    <div class="navbar-brand-mobile-wrapper d-inline-flex d-lg-none">
      <a class="navbar-brand" href="/mesothelioma/">mesothelioma</a>
    </div>
    

    
    
    <div class="navbar-collapse main-menu-item collapse justify-content-start" id="navbar-content">

      
      <ul class="navbar-nav d-md-inline-flex">
        

        

        
        
        
          
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link " href="/mesothelioma/syntax/"><span>Syntax</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link " href="/mesothelioma/genepanel/"><span>Gene Panel</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link " href="/mesothelioma/drugpanel/"><span>Drug Panel</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link " href="/mesothelioma/tissuepanel/"><span>Tissue Panel</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link " href="/mesothelioma/syntax_summary/"><span>Literature Consensus</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        
          
          
          
            
          
          
        

        <li class="nav-item">
          <a class="nav-link " href="/mesothelioma/#about"><span>Contact</span></a>
        </li>

        
        

      

        
      </ul>
    </div>

    <ul class="nav-icons navbar-nav flex-row ml-auto d-flex pl-md-2">
      
      <li class="nav-item">
        <a class="nav-link js-search" href="#"><i class="fas fa-search" aria-hidden="true"></i></a>
      </li>
      

      

      

    </ul>

  </div>
</nav>


  

<div class="container-fluid docs">
  <div class="row flex-xl-nowrap">
    <div class="col-12 col-md-3 col-xl-2 docs-sidebar">
      





  
    
  




<form class="docs-search d-flex align-items-center">
  <button class="btn docs-toggle d-md-none p-0 mr-3" type="button" data-toggle="collapse" data-target="#docs-nav" aria-controls="docs-nav" aria-expanded="false" aria-label="Toggle section navigation">
    <span><i class="fas fa-bars"></i></span>
  </button>

  
  <input name="q" type="search" class="form-control" placeholder="Search..." autocomplete="off">
  
</form>

<nav class="collapse docs-links" id="docs-nav">
  

  
  
  
  
  <div class="docs-toc-item">
    <a class="docs-toc-link" href="/mesothelioma/tables/abstract/">Table List</a>
    <ul class="nav docs-sidenav">
      
      <li >
        <a href="/mesothelioma/tables/abstract/diagnose/">Diagnosis</a>
      </li>
      
      <li >
        <a href="/mesothelioma/tables/abstract/treatment/">Treatment</a>
      </li>
      
      <li >
        <a href="/mesothelioma/tables/abstract/epidemiology/">Epidemiology</a>
      </li>
      
      <li >
        <a href="/mesothelioma/tables/abstract/transmission/">Transmission</a>
      </li>
      
      <li class="active">
        <a href="/mesothelioma/tables/abstract/signs/">Clinical, signs &amp; Symptoms</a>
      </li>
      
      <li >
        <a href="/mesothelioma/tables/abstract/no_category/">No Category</a>
      </li>
      
      <li >
        <a href="/mesothelioma/tables/abstract/no_abstract/">No Abstract</a>
      </li>
      
    </ul>
    

  </div>
  
  
</nav>

    </div>

    

    <main class="col-12 col-md-9 col-xl-8 py-md-3 pl-md-5 docs-content" role="main">

      <article class="article">

        <div class="docs-article-container">
          <h1>Clinical, signs &amp; Symptoms Articles</h1>

          <div class="article-style">
            
<script src="/mesotheliomarmarkdown-libs/kePrint/kePrint.js"></script>


<br>
<p style="font-size:12px" align="center">
<strong>Table 1.</strong> List of all 3787 articles with abstract clustered as Clinical, signs &amp; Symptoms in PlatOMICs for mesothelioma. <br>*Curation represents the number of person that analyzed the information
</p>
<hr />
<table class="table table-striped" style="width: auto !important; margin-left: auto; margin-right: auto;">
<thead>
<tr>
<th style="text-align:left;position: sticky; top:0; background-color: #FFFFFF;">
Title
</th>
<th style="text-align:left;position: sticky; top:0; background-color: #FFFFFF;">
Journal
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
P53-immunoreactive cells in benign and malignant effusions: diagnostic value using a panel of monoclonal antibodies and comparison with CEA-staining.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
</tr>
<tr>
<td style="text-align:left;">
SWORD ’97: surveillance of work-related and occupational respiratory disease in the UK.
</td>
<td style="text-align:left;">
Occup Med (Lond)
</td>
</tr>
<tr>
<td style="text-align:left;">
[Primary malignant tumors of the pleura. Pleural Mesothelioma (P.M.)].
</td>
<td style="text-align:left;">
Minerva Chir
</td>
</tr>
<tr>
<td style="text-align:left;">
The clinical importance of magnetic resonance imaging versus computed tomography in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Factors influencing the outcome of radiotherapy in malignant mesothelioma of the pleura–a single-institution experience with 189 patients.
</td>
<td style="text-align:left;">
Int. J. Radiat. Oncol. Biol. Phys.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural space perfusion with cisplatin in the multimodality treatment of malignant mesothelioma: a feasibility and pharmacokinetic study.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Thoracic solitary fibrous tumor: clinical and pathological diversity.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
[Primary pericardial mesothelioma: report of a case (author’s transl)].
</td>
<td style="text-align:left;">
G Ital Cardiol
</td>
</tr>
<tr>
<td style="text-align:left;">
Telomerase activity in human pleural mesothelioma.
</td>
<td style="text-align:left;">
Thorax
</td>
</tr>
<tr>
<td style="text-align:left;">
Magnetic resonance appearance of asbestos-related benign and malignant pleural diseases.
</td>
<td style="text-align:left;">
Scand J Work Environ Health
</td>
</tr>
<tr>
<td style="text-align:left;">
Syndecan-1 expression in malignant mesothelioma: correlation with cell differentiation, WT1 expression, and clinical outcome.
</td>
<td style="text-align:left;">
J. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Case series of mesotheliomas from hospital archives as contribution to preventive intervention].
</td>
<td style="text-align:left;">
Ann. Ist. Super. Sanita
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pleural mesotheliomas. Current knowledge].
</td>
<td style="text-align:left;">
Ann Chir
</td>
</tr>
<tr>
<td style="text-align:left;">
Simian virus 40 and human pleural mesothelioma.
</td>
<td style="text-align:left;">
Thorax
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesotheliomas].
</td>
<td style="text-align:left;">
Medicina (B Aires)
</td>
</tr>
<tr>
<td style="text-align:left;">
Occupational cancer in Germany.
</td>
<td style="text-align:left;">
Environ. Health Perspect.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: US-guided histologic core-needle biopsy.
</td>
<td style="text-align:left;">
Radiology
</td>
</tr>
<tr>
<td style="text-align:left;">
Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma: a pilot phase II clinical trial and pharmacokinetic profile.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Pseudomesotheliomatous carcinoma involving pleura and peritoneum: A clinicopathologic and immunohistochemical study of three cases.
</td>
<td style="text-align:left;">
Ann Diagn Pathol
</td>
</tr>
<tr>
<td style="text-align:left;">
Thrombospondin-1 expression and clinical implications in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
A Phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
[Horner’s syndrome in a patient with diffuse malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Nihon Kokyuki Gakkai Zasshi
</td>
</tr>
<tr>
<td style="text-align:left;">
Thallium-201 scintigraphy in malignant mesothelioma.
</td>
<td style="text-align:left;">
Br J Radiol
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesothelioma.
</td>
<td style="text-align:left;">
Curr Opin Pulm Med
</td>
</tr>
<tr>
<td style="text-align:left;">
[Therapy of malignant pleural mesothelioma–a permanent dilemma].
</td>
<td style="text-align:left;">
Pneumologie
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: a problematic review.
</td>
<td style="text-align:left;">
Surg Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
SV40 large T-antigen and human pleural mesothelioma. Screening by polymerase chain reaction and tyramine-amplified immunohistochemistry.
</td>
<td style="text-align:left;">
Virchows Arch.
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of vascular endothelial growth factor in diffuse malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Virchows Arch.
</td>
</tr>
<tr>
<td style="text-align:left;">
How should we treat malignant pleural mesothelioma (MPM)?
</td>
<td style="text-align:left;">
Acta Chir Hung
</td>
</tr>
<tr>
<td style="text-align:left;">
The hazards of chrysotile asbestos: a critical review.
</td>
<td style="text-align:left;">
Ind Health
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma of the pleural space.
</td>
<td style="text-align:left;">
Oncology (Williston Park, N.Y.)
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic value of FDG PET imaging in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Nucl. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Cisplatin, mitomycin, and interferon-alpha2a combination chemoimmunotherapy in the treatment of diffuse malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Advances in the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
[Solitary fibrous tumors of the pleura].
</td>
<td style="text-align:left;">
Chirurg
</td>
</tr>
<tr>
<td style="text-align:left;">
Environmental asbestos exposure and malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Respir Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic value of the serum tumour markers Cyfra 21-1 and tissue polypeptide antigen in malignant mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
[Clinical comparison of diffuse malignant mesothelioma of the pleura and pseudomesotheliomatous carcinoma of the lung for each case].
</td>
<td style="text-align:left;">
Kyobu Geka
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma with an unusual radiologic manifestation].
</td>
<td style="text-align:left;">
An Med Interna
</td>
</tr>
<tr>
<td style="text-align:left;">
Increased but low incidence and poor survival of malignant mesothelioma in the southeastern part of The Netherlands since 1970: a population-based study.
</td>
<td style="text-align:left;">
Eur. J. Cancer Prev.
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytopathology of malignant mesothelioma of the pleura in fine-needle aspiration biopsy.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Posttranscriptional regulation of urokinase receptor gene expression in human lung carcinoma and mesothelioma cells in vitro.
</td>
<td style="text-align:left;">
Mol. Cell. Biochem.
</td>
</tr>
<tr>
<td style="text-align:left;">
Localized benign fibrous mesothelioma mimicking a malignant tumor of the pleura.
</td>
<td style="text-align:left;">
JBR-BTR
</td>
</tr>
<tr>
<td style="text-align:left;">
Hyaluronan in serum as an indicator of progressive disease in hyaluronan-producing malignant mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Bull Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Diagnosis of malignant pleural mesothelioma and asbestosis].
</td>
<td style="text-align:left;">
Ned Tijdschr Geneeskd
</td>
</tr>
<tr>
<td style="text-align:left;">
Palliative treatment of malignant pleural effusions by video-assisted thoracoscopic surgery.
</td>
<td style="text-align:left;">
Acta Chir Hung
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleuro-pulmonary tumours detected by clinical and chest X-ray analyses in rats transplanted with mesothelioma cells.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma eight years after a diagnosis of atypical mesothelial hyperplasia.
</td>
<td style="text-align:left;">
J. Clin. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Simian virus 40 and human tumors: It is time to study mechanisms.
</td>
<td style="text-align:left;">
J. Cell. Biochem.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleuropneumonectomy in the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Emerging translational therapies for mesothelioma.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Antisense to SV40 early gene region induces growth arrest and apoptosis in T-antigen-positive human pleural mesothelioma cells.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Value of morphometry, texture analysis, densitometry, and histometry in the differential diagnosis and prognosis of malignant mesothelioma.
</td>
<td style="text-align:left;">
J. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Contemporary management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncologist
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression profile of telomerase subunits in human pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Application of the cell block method, utilizing mount quick mounting medium.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant epithelioid vascular tumors of the pleura: report of a series and literature review.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnosis of malignant mesothelioma by fine needle aspiration of a cervical lymph node. A case report.
</td>
<td style="text-align:left;">
Acta Cytol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[VATS in malignant pleural effusions].
</td>
<td style="text-align:left;">
Zhonghua Wai Ke Za Zhi
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytologic differential diagnosis among reactive mesothelial cells, malignant mesothelioma, and adenocarcinoma: utility of combined E-cadherin and calretinin immunostaining.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Long term survival of a patient with malignant pleural mesothelioma as a late complication of radiotherapy for Hodgkin’s disease treated with 90yttrium-silicate.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
[The incidence of malignant mesothelioma (1977-1996) and asbestos exposure in the population of an area neighboring Lake Iseo, northern Italy].
</td>
<td style="text-align:left;">
Med Lav
</td>
</tr>
<tr>
<td style="text-align:left;">
Monitoring of impending myocardial damage after pleuropneumonectomy and intraoperative photodynamic therapy for malignant pleural mesothelioma using biochemical markers.
</td>
<td style="text-align:left;">
Photochem. Photobiol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Manganese superoxide dismutase as a diagnostic marker for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Intrapleural administration of tumour necrosis factor-alpha (TNFalpha) in patients with mesothelioma: cytokine patterns and acute-phase protein response.
</td>
<td style="text-align:left;">
Eur. J. Clin. Invest.
</td>
</tr>
<tr>
<td style="text-align:left;">
18-FDG positron emission tomography in the evaluation of malignant pleural diseases - a pilot study.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma in subjects with Marfan’s syndrome and Ehlers-Danlos syndrome: only an apparent association?
</td>
<td style="text-align:left;">
Respiration
</td>
</tr>
<tr>
<td style="text-align:left;">
The diagnostic yield of pleural fluid cytology in malignant pleural effusions.
</td>
<td style="text-align:left;">
Singapore Med J
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural diseases.
</td>
<td style="text-align:left;">
Monaldi Arch Chest Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Adenovirus-mediated wild-type p53 overexpression reverts tumourigenicity of human mesothelioma cells.
</td>
<td style="text-align:left;">
Int. J. Mol. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant fibrous mesothelioma. Metastatic to brain and liver.
</td>
<td style="text-align:left;">
Acta Neuropathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Relation between natural killer cells and neoplastic cells in serous fluids.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant peritoneal mesothelioma presenting with respiratory symptoms.
</td>
<td style="text-align:left;">
Eur Radiol
</td>
</tr>
<tr>
<td style="text-align:left;">
Computed tomography-guided fine needle aspiration of peripheral lung opacities. An initial diagnostic procedure?
</td>
<td style="text-align:left;">
Acta Cytol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunoreactivity for cadherins, HGF/SF, met, and erbB-2 in pleural malignant mesotheliomas.
</td>
<td style="text-align:left;">
Histopathology
</td>
</tr>
<tr>
<td style="text-align:left;">
[Primary biphasic synovial sarcoma of the pleura].
</td>
<td style="text-align:left;">
Rev Mal Respir
</td>
</tr>
<tr>
<td style="text-align:left;">
Loss of heterozygosity analysis of 13q and 14q in human malignant mesothelioma.
</td>
<td style="text-align:left;">
Genes Chromosomes Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural disease.
</td>
<td style="text-align:left;">
Eur J Radiol
</td>
</tr>
<tr>
<td style="text-align:left;">
Multicentric study on malignant pleural mesothelioma and non-occupational exposure to asbestos.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Docetaxel and irinotecan (CPT-11) in the treatment of malignant pleural mesothelioma–a feasibility study.
</td>
<td style="text-align:left;">
Anticancer Drugs
</td>
</tr>
<tr>
<td style="text-align:left;">
Management of malignant pleural mesothelioma: a critical review.
</td>
<td style="text-align:left;">
Curr Opin Pulm Med
</td>
</tr>
<tr>
<td style="text-align:left;">
[Clinical analysis of 19 patients with pleural mesothelioma].
</td>
<td style="text-align:left;">
Zhonghua Zhong Liu Za Zhi
</td>
</tr>
<tr>
<td style="text-align:left;">
The long-term morbidity of pleuroperitoneal shunts in the management of recurrent malignant effusions.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Primary malignant gonadal mesotheliomas and asbestos.
</td>
<td style="text-align:left;">
Histopathology
</td>
</tr>
<tr>
<td style="text-align:left;">
An optimized battery of eight antibodies that can distinguish most cases of epithelial mesothelioma from adenocarcinoma.
</td>
<td style="text-align:left;">
Am. J. Clin. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Caelyx in malignant mesothelioma: a phase II EORTC study.
</td>
<td style="text-align:left;">
Ann. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
HHV-8 is not a cofactor in the pathogenesis of environmentally induced malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Monaldi Arch Chest Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic usefulness of tumour marker levels in pleural effusions of malignant and benign origin.
</td>
<td style="text-align:left;">
Clin. Chim. Acta
</td>
</tr>
<tr>
<td style="text-align:left;">
Simian virus-40 sequences are a negative prognostic cofactor in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Genes Chromosomes Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Proliferation, apoptosis, and manganese superoxide dismutase in malignant mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant solitary fibrous tumor of the pleura: two cases and review of the literature].
</td>
<td style="text-align:left;">
Nihon Igaku Hoshasen Gakkai Zasshi
</td>
</tr>
<tr>
<td style="text-align:left;">
Mortality of workers at two asbestos-cement plants in Poland.
</td>
<td style="text-align:left;">
Int J Occup Med Environ Health
</td>
</tr>
<tr>
<td style="text-align:left;">
Gene-modified PA1-STK cells home to tumor sites in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
The separation of benign and malignant mesothelial proliferations.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant vascular tumours of the pleura in “asbestos” workers and endothelial differentiation in malignant mesothelioma.
</td>
<td style="text-align:left;">
Thorax
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma of the pleura, pericardium and peritoneum. 1: Etiology, pathogenesis, pathology].
</td>
<td style="text-align:left;">
Chirurg
</td>
</tr>
<tr>
<td style="text-align:left;">
Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial ovarian carcinoma: evidence of up-regulated Tn and Sialyl Tn antigen expression in effusions.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Use of tumor markers for differential diagnosis of mesothelioma and secondary pleural malignancies.
</td>
<td style="text-align:left;">
Clin. Biochem.
</td>
</tr>
<tr>
<td style="text-align:left;">
Differential gene expression in mesothelioma.
</td>
<td style="text-align:left;">
FEBS Lett.
</td>
</tr>
<tr>
<td style="text-align:left;">
The difficult diagnostic approach of the intraperitoneal mesothelioma.
</td>
<td style="text-align:left;">
Neth J Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma in a 13-year-old girl.
</td>
<td style="text-align:left;">
Pediatr Radiol
</td>
</tr>
<tr>
<td style="text-align:left;">
Role of occupational asbestos exposure in Hungarian lung cancer patients.
</td>
<td style="text-align:left;">
Int Arch Occup Environ Health
</td>
</tr>
<tr>
<td style="text-align:left;">
Environmental malignant mesothelioma in southern Anatolia: a study of fifty cases.
</td>
<td style="text-align:left;">
Environ. Health Perspect.
</td>
</tr>
<tr>
<td style="text-align:left;">
Comparison of the effectiveness of some pleural sclerosing agents used for control of effusions in malignant pleural mesothelioma: a review of 117 cases.
</td>
<td style="text-align:left;">
Respiration
</td>
</tr>
<tr>
<td style="text-align:left;">
<ol start="11" style="list-style-type: decimal">
<li>Evaluation of Patients with Known Mesothelioma with 18F-Fluorodeoxyglucose and PET. Comparison with Computed Tomography.
</td>
<td style="text-align:left;">
Clin. Positron Imaging
</td>
</tr>
<tr>
<td style="text-align:left;">
Efficacy of repeated adenoviral suicide gene therapy in a localized murine tumor model.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic value of CEA, CA 15-3, CA 19-9, CYFRA 21-1, NSE and TSA assay in pleural effusions.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: Results of a phase II study on 31 consecutive patients.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Solitary fibrous tumour of the pleura: surgical treatment.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Increased mesothelioma incidence in New Zealand: the asbestos-cancer epidemic has started.
</td>
<td style="text-align:left;">
N. Z. Med. J.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma: clinical and radiological description of 45 cases with and without asbestos exposure].
</td>
<td style="text-align:left;">
Salud Publica Mex
</td>
</tr>
<tr>
<td style="text-align:left;">
Radicular involvement and medullary invasion from a malignant mesothelioma.
</td>
<td style="text-align:left;">
Respiration
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Treat. Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
A pilot study of systemic corticosteroid administration in conjunction with intrapleural adenoviral vector administration in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Gene Ther.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma in the industrial area of Colleferro].
</td>
<td style="text-align:left;">
Med Lav
</td>
</tr>
<tr>
<td style="text-align:left;">
SV40 and the pathogenesis of mesothelioma.
</td>
<td style="text-align:left;">
Semin. Cancer Biol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma produces functional granulocyte-colony stimulating factor.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
[Thoracoscopic pleural biopsy under local anesthesia using a 2 mm laparoscope].
</td>
<td style="text-align:left;">
Nihon Kokyuki Gakkai Zasshi
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunotherapy-based treatment strategies for malignant mesothelioma.
</td>
<td style="text-align:left;">
Curr. Opin. Mol. Ther.
</td>
</tr>
<tr>
<td style="text-align:left;">
Trimodality management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Gene expression profiling of malignant mesothelioma cell lines: cDNA array study.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Extrapleural pneumonectomy for diffuse malignant pleural mesothelioma. A treatment option in selected cases?
</td>
<td style="text-align:left;">
Jpn. J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Basic fibroblast growth factor in mesothelioma pleural effusions: correlation with patient survival and angiogenesis.
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic value of CYFRA 21-1 tumor marker and CEA in pleural effusion due to mesothelioma.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Nodular thickening of interlobar fissures: an early manifestation of malignant mesothelioma: a case report.
</td>
<td style="text-align:left;">
Jpn. J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Superior vena cava obstruction: is stenting necessary?
</td>
<td style="text-align:left;">
Support Care Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
[Gene expression profiling in human mesothelioma cells using DNA microarray and high-density filter array technologies].
</td>
<td style="text-align:left;">
Bull Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Combination chemotherapy with mitoxantrone, methotrexate, and mitomycin (MMM regimen) in malignant pleural mesothelioma: a phase II study.
</td>
<td style="text-align:left;">
Am. J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Percutaneous image-guided cutting-needle biopsy of the pleura in the presence of a suspected malignant effusion.
</td>
<td style="text-align:left;">
Radiology
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment of malignant mesothelioma.
</td>
<td style="text-align:left;">
World J Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos-related lung cancer and mesothelioma in Japan.
</td>
<td style="text-align:left;">
Ind Health
</td>
</tr>
<tr>
<td style="text-align:left;">
Epidemiology of occupational asbestos-related diseases in China.
</td>
<td style="text-align:left;">
Ind Health
</td>
</tr>
<tr>
<td style="text-align:left;">
Synovial sarcoma and malignant mesothelioma of the pleura: review, differential diagnosis and possible role of apoptosis.
</td>
<td style="text-align:left;">
Pathology
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant solitary fibrous tumor of pleura with focal expression of cytokeratin].
</td>
<td style="text-align:left;">
Ann Pathol
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II trial of liposomal daunorubicin in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Use of an implantable pleural catheter for trapped lung syndrome in patients with malignant pleural effusion.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
[Occupational exposure to asbestos and recognition of pleural mesothelioma as occupational disease in the province of Genoa].
</td>
<td style="text-align:left;">
Epidemiol Prev
</td>
</tr>
<tr>
<td style="text-align:left;">
[Treatment of malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Minerva Chir
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunohistochemical differential diagnosis of pleural effusions, with emphasis on malignant mesothelioma.
</td>
<td style="text-align:left;">
Curr Opin Pulm Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Wedge-shaped applicator for additional light delivery and dosimetry in the diaphragmal sinus during photodynamic therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Phys Med Biol
</td>
</tr>
<tr>
<td style="text-align:left;">
Glucose transporter Glut-1 is of limited value for detecting breast carcinoma in serous effusions.
</td>
<td style="text-align:left;">
Mod. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Combined regimen of cisplatin, doxorubicin, and alpha-2b interferon in the treatment of advanced malignant pleural mesothelioma: a Phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FONICAP).
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural amyloidosis mimicking mesothelioma: a clinicopathologic study of two cases.
</td>
<td style="text-align:left;">
Ann Diagn Pathol
</td>
</tr>
<tr>
<td style="text-align:left;">
[A case of desmoplastic malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Nihon Kokyuki Gakkai Zasshi
</td>
</tr>
<tr>
<td style="text-align:left;">
[Unusual case of mesothelioma of the tunica vaginalis associated with prostatic adenocarcinoma].
</td>
<td style="text-align:left;">
Minerva Urol Nefrol
</td>
</tr>
<tr>
<td style="text-align:left;">
Information about occupational exposure to asbestos given to cases in an etiological study: ethical aspects.
</td>
<td style="text-align:left;">
Eur. J. Epidemiol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Comparison of antibodies to HBME-1 and calretinin for the detection of mesothelial cells in effusion cytology.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Evaluation of pleural disease using MR and CT. With special reference to malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Acta Radiol
</td>
</tr>
<tr>
<td style="text-align:left;">
Historical cohort study of US man-made vitreous fiber production workers: II. Mortality from mesothelioma.
</td>
<td style="text-align:left;">
J. Occup. Environ. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma–German mesothelioma register 1987-1999.
</td>
<td style="text-align:left;">
Int Arch Occup Environ Health
</td>
</tr>
<tr>
<td style="text-align:left;">
Hyaluronan content in pleural fluid as a prognostic factor in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Intraoperative photodynamic therapy after pleuropneumonectomy in patients with malignant pleural mesothelioma: dose finding and toxicity results.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Absence of SV-40 large T antigen (Tag) in malignant mesothelioma effusions: an immunocytochemical study.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic factors in diffuse malignant pleural mesothelioma: effects of pretreatment clinical and laboratory characteristics.
</td>
<td style="text-align:left;">
Respir Med
</td>
</tr>
<tr>
<td style="text-align:left;">
K-ras and rho A mutations in malignant pleural effusion.
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Increased risk of malignant mesothelioma of the pleura after residential or domestic exposure to asbestos: a case-control study in Casale Monferrato, Italy.
</td>
<td style="text-align:left;">
Environ. Health Perspect.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Incidence of malignant mesothelioma (1980-1999) and asbestos exposure in 190 cases diagnosed among residents of the province of Brescia].
</td>
<td style="text-align:left;">
Med Lav
</td>
</tr>
<tr>
<td style="text-align:left;">
Well-differentiated papillary mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma following chemotherapy for breast cancer.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Technology evaluation: gene therapy (mesothelioma), NCI.
</td>
<td style="text-align:left;">
Curr. Opin. Mol. Ther.
</td>
</tr>
<tr>
<td style="text-align:left;">
Palliative surgical debulking in malignant mesothelioma. Predictors of survival and symptom control.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Minerva Chir
</td>
</tr>
<tr>
<td style="text-align:left;">
[Etiology of pleural effusion based on material from the Hospital of Lung Diseases and Tuberculosis].
</td>
<td style="text-align:left;">
Pneumonol Alergol Pol
</td>
</tr>
<tr>
<td style="text-align:left;">
Pulmonary adenocarcinoma simulating malignant mesothelioma.
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Percutaneous image-guided cutting needle biopsy of the pleura in the diagnosis of malignant mesothelioma.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Survival after conservative (palliative) management of pleural malignant mesothelioma.
</td>
<td style="text-align:left;">
J Surg Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
[Two cases of malignant mesothelioma of the pleura within one family].
</td>
<td style="text-align:left;">
Pol. Merkur. Lekarski
</td>
</tr>
<tr>
<td style="text-align:left;">
Pseudomesotheliomatous adenocarcinoma of the lung with rhabdoid features.
</td>
<td style="text-align:left;">
Pathol. Res. Pract.
</td>
</tr>
<tr>
<td style="text-align:left;">
Additional proteins in BAL fluid of Metsovites environmentally exposed to asbestos: more evidence of “protection” against neoplasia?
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
[Value of thoracoscopy in undiagnosed pleural effusion].
</td>
<td style="text-align:left;">
Zhonghua Jie He He Hu Xi Za Zhi
</td>
</tr>
<tr>
<td style="text-align:left;">
[Results of phase II clinical trial of cycloplatam in refractory solid tumors].
</td>
<td style="text-align:left;">
Vopr Onkol
</td>
</tr>
<tr>
<td style="text-align:left;">
Induction of apoptosis in malignant pleural mesothelioma cells by activation of the Fas (Apo-1/CD95) death-signal pathway.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
The epidemiology of mesothelioma.
</td>
<td style="text-align:left;">
Semin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of imaging in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Semin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic factors in mesothelioma.
</td>
<td style="text-align:left;">
Semin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Multimodality treatment of diffuse malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Semin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
The emerging role of antifolates in the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Semin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Multicenter randomized controlled trial of the management of unresectable malignant mesothelioma proposed by the British Thoracic Society and the British Medical Research Council.
</td>
<td style="text-align:left;">
Semin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Thyroid transcription factor-1 is highly sensitive and specific in differentiating metastatic pulmonary from extrapulmonary adenocarcinoma in effusion fluid cytology specimens.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
[Current insights in malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Bull Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Hyperthermia and mafosfamide in a human-derived malignant pleural mesothelioma cell line.
</td>
<td style="text-align:left;">
J. Cancer Res. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
[Clinical utility and safety of diagnostic thoracoscopy].
</td>
<td style="text-align:left;">
Nihon Kokyuki Gakkai Zasshi
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II study of repeated intrapleural chemotherapy using implantable access system for management of malignant pleural effusion.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse malignant epithelial mesotheliomas of the peritoneum in women: a clinicopathologic study of 25 patients.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma in Australia, 1945-2000.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Phosphatase and tensin analog gene overexpression engenders cellular death in human malignant mesothelioma cells via inhibition of AKT phosphorylation.
</td>
<td style="text-align:left;">
Ann. Surg. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of p21 in SV40 large T antigen positive human pleural mesothelioma: relationship with survival.
</td>
<td style="text-align:left;">
Thorax
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma. From diagnosis to prognosis].
</td>
<td style="text-align:left;">
Presse Med
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma. Present data and perspectives for treatment].
</td>
<td style="text-align:left;">
Presse Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant deciduoid mesothelioma of the pleura: report of two cases with long survival.
</td>
<td style="text-align:left;">
Histopathology
</td>
</tr>
<tr>
<td style="text-align:left;">
[Solitary fibrous thoracic tumor: a rare tumor with unpredictable course].
</td>
<td style="text-align:left;">
Rev Pneumol Clin
</td>
</tr>
<tr>
<td style="text-align:left;">
Oxaliplatin and raltitrexed in the treatment of inoperable malignant pleural mesothelioma: results of a pilot study.
</td>
<td style="text-align:left;">
Tumori
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytopathology of pleural mesotheliomas.
</td>
<td style="text-align:left;">
Am. J. Clin. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Flow cytometric analysis of a localized malignant mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: a phase II trial with docetaxel.
</td>
<td style="text-align:left;">
Ann. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Non-asbestos related diffuse malignant mesothelioma.
</td>
<td style="text-align:left;">
Tumori
</td>
</tr>
<tr>
<td style="text-align:left;">
Primary thoracic sarcomas.
</td>
<td style="text-align:left;">
Radiographics
</td>
</tr>
<tr>
<td style="text-align:left;">
[Surgery and hyperthermic pleural perfusion–a new approach for malignancies with pleural involvement].
</td>
<td style="text-align:left;">
Harefuah
</td>
</tr>
<tr>
<td style="text-align:left;">
The pathogenesis of pseudoachalasia: a clinicopathologic study of 13 cases of a rare entity.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed for diffuse malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Semin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Current therapy for malignant mesothelioma.
</td>
<td style="text-align:left;">
Curr Oncol Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
Current surgical management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Curr Oncol Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Photodynamic therapy for mesothelioma.
</td>
<td style="text-align:left;">
Curr Treat Options Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant peritoneal mesothelioma.
</td>
<td style="text-align:left;">
Curr Treat Options Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Pericardial mesothelioma.
</td>
<td style="text-align:left;">
Curr Treat Options Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Curr Treat Options Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Cyclooxygenase-2 expression is a novel prognostic factor in malignant mesothelioma.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Diagnosis and staging of malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Pneumologie
</td>
</tr>
<tr>
<td style="text-align:left;">
Intrapleural infusion of activated macrophages and gamma-interferon in malignant pleural mesothelioma: a phase II study.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Inhibitor of apoptosis protein-1 promotes tumor cell survival in mesothelioma.
</td>
<td style="text-align:left;">
Carcinogenesis
</td>
</tr>
<tr>
<td style="text-align:left;">
Black spots of the parietal pleura: morphology and formal pathogenesis.
</td>
<td style="text-align:left;">
Respiration
</td>
</tr>
<tr>
<td style="text-align:left;">
Molecular cytogenetic differences between histological subtypes of malignant mesotheliomas: DNA cytometry and comparative genomic hybridization of 90 cases.
</td>
<td style="text-align:left;">
J. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Primary thymic epithelial tumours of the pleura mimicking malignant mesothelioma.
</td>
<td style="text-align:left;">
Histopathology
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic DNA-flow- vs. -image-cytometry in effusion cytology.
</td>
<td style="text-align:left;">
Anal Cell Pathol
</td>
</tr>
<tr>
<td style="text-align:left;">
The management of malignant pleural mesothelioma; single centre experience in 10 years.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic utility of thyroid transcription factor-1 expression in adenocarcinomas presenting in serous fluids.
</td>
<td style="text-align:left;">
Acta Cytol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse malignant mesothelioma of the pleural space and its management.
</td>
<td style="text-align:left;">
Oncology (Williston Park, N.Y.)
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma in Emilia-Romagna: incidence and asbestos exposure].
</td>
<td style="text-align:left;">
Epidemiol Prev
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma: PAS-diastase positivity and inversion of polarity in intravascular tumour.
</td>
<td style="text-align:left;">
Histopathology
</td>
</tr>
<tr>
<td style="text-align:left;">
Translation of microarray data into clinically relevant cancer diagnostic tests using gene expression ratios in lung cancer and mesothelioma.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Synergistic effect of the anti-HER-2/neu antibody and cisplatin in immortalized and primary mesothelioma cell lines.
</td>
<td style="text-align:left;">
J. Cell. Physiol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Assessment of malignant pleural mesothelioma with (18)F-FDG dual-head gamma-camera coincidence imaging: comparison with histopathology.
</td>
<td style="text-align:left;">
J. Nucl. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Report on the study of hyaluronic acid in the diagnosis of pleural mesotheliomas: study of 100 hyaluronic acid rich effusions].
</td>
<td style="text-align:left;">
Biomedicine
</td>
</tr>
<tr>
<td style="text-align:left;">
[Prognosis, staging and therapy of malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Med. Klin. (Munich)
</td>
</tr>
<tr>
<td style="text-align:left;">
Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Etiology and clinical diagnosis of diffuse pleural mesothelioma (author’s transl)].
</td>
<td style="text-align:left;">
Z Erkr Atmungsorgane
</td>
</tr>
<tr>
<td style="text-align:left;">
[Asbestos as an envoronmental carcinogen (author’s transl)].
</td>
<td style="text-align:left;">
Z Erkr Atmungsorgane
</td>
</tr>
<tr>
<td style="text-align:left;">
Synovial sarcoma of the pleura: a clinical and pathologic study of three cases.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos: when the dust settles an imaging review of asbestos-related disease.
</td>
<td style="text-align:left;">
Radiographics
</td>
</tr>
<tr>
<td style="text-align:left;">
Low molecular weight hyaluronan induces malignant mesothelioma cell (MMC) proliferation and haptotaxis: role of CD44 receptor in MMC proliferation and haptotaxis.
</td>
<td style="text-align:left;">
Oncol. Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Intrapleural interleukin-2 induces nitric oxide production in pleural effusions from malignant mesothelioma: a possible mechanism of interleukin-2-mediated cytotoxicity?
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Survival after pleural malignant mesothelioma: a population-based study in Italy.
</td>
<td style="text-align:left;">
Tumori
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma in a child: long-term survival with ICE-WAC chemotherapy regimen.
</td>
<td style="text-align:left;">
Turk. J. Pediatr.
</td>
</tr>
<tr>
<td style="text-align:left;">
Potential of interferon-alpha in solid tumours: part 2.
</td>
<td style="text-align:left;">
BioDrugs
</td>
</tr>
<tr>
<td style="text-align:left;">
A cluster of familial malignant mesothelioma with del(9p) as the sole chromosomal anomaly.
</td>
<td style="text-align:left;">
Cancer Genet. Cytogenet.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma of the pericardium: case reports and immunohistochemical studies including Ki-67 expression.
</td>
<td style="text-align:left;">
Pathol. Int.
</td>
</tr>
<tr>
<td style="text-align:left;">
Simian virus 40 and malignant mesothelioma (Review).
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma: options for management.
</td>
<td style="text-align:left;">
Surg. Clin. North Am.
</td>
</tr>
<tr>
<td style="text-align:left;">
Induction of apoptosis in mesothelioma cells by antisurvivin oligonucleotides.
</td>
<td style="text-align:left;">
Mol. Cancer Ther.
</td>
</tr>
<tr>
<td style="text-align:left;">
Leptomeningeal infiltration of malignant mesothelioma.
</td>
<td style="text-align:left;">
Med. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Concurrent malignant mesothelioma of the pleura and hepatocellular carcinoma in the same patient: a report of five cases.
</td>
<td style="text-align:left;">
Ind Health
</td>
</tr>
<tr>
<td style="text-align:left;">
Experimental photodynamic therapy for malignant pleural mesothelioma with pegylated mTHPC.
</td>
<td style="text-align:left;">
Lasers Surg Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Interferons and their application in the diseases of the lung.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Ultrastructurally “invasive” microvilli in an aggressively metastasizing biphasic malignant mesothelioma.
</td>
<td style="text-align:left;">
Ultrastruct Pathol
</td>
</tr>
<tr>
<td style="text-align:left;">
Molecular analyses, morphology and immunohistochemistry together differentiate pleural synovial sarcomas from mesotheliomas: clinical implications.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Unusual intraparenchymal growth patterns of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Histopathology
</td>
</tr>
<tr>
<td style="text-align:left;">
[Diagnosis and treatment of pleural mesothelioma].
</td>
<td style="text-align:left;">
Medicina (Kaunas)
</td>
</tr>
<tr>
<td style="text-align:left;">
The activity of raltitrexed (Tomudex) in malignant pleural mesothelioma: an EORTC phase II study (08992).
</td>
<td style="text-align:left;">
Eur. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Emerging insights into the biology and therapy of malignant mesothelioma.
</td>
<td style="text-align:left;">
Semin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Intensity-modulated radiation therapy: a novel approach to the management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Radiat. Oncol. Biol. Phys.
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgical treatment of malignant pleural mesothelioma: a review.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Long microvilli of mesothelioma are conspicuous in pleural effusions processed by Ultrafast Papanicolaou stain.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
[SV40: a possible co-carcinogen of asbestos in the pathogenesis of mesothelioma?].
</td>
<td style="text-align:left;">
Med Lav
</td>
</tr>
<tr>
<td style="text-align:left;">
[Tuscany mesothelioma registry (1988-2000): evaluation of asbestos exposure].
</td>
<td style="text-align:left;">
Med Lav
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of new imaging techniques in diagnosis and staging of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Curr Opin Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of surgery in diagnosis and treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Curr Opin Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Indications and limitations of radiotherapy in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Curr Opin Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemotherapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Curr Opin Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Over-expression of tenascin-C in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Histopathology
</td>
</tr>
<tr>
<td style="text-align:left;">
Adenoviral transfer of mda-7 leads to BAX up-regulation and apoptosis in mesothelioma cells, and is abrogated by over-expression of BCL-XL.
</td>
<td style="text-align:left;">
Mol. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Ifosfamide, carboplatin and etoposide combined with 41.8 degrees C whole body hyperthermia for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemotherapy for malignant pleural mesothelioma: past results and recent developments.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pleuro-pneumonectomy, RT and CT for pleural mesothelioma. Prospective study].
</td>
<td style="text-align:left;">
Chir Ital
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma. Report of 19 cases.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
A phase I study of Foscan-mediated photodynamic therapy and surgery in patients with mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Cardiac tamponade due to pericardial mesothelioma in an 11-year-old dog: diagnosis, medical and interventional treatments].
</td>
<td style="text-align:left;">
Schweiz. Arch. Tierheilkd.
</td>
</tr>
<tr>
<td style="text-align:left;">
Transfer into a mesothelioma cell line of tumor suppressor gene p16 by cholesterol-based cationic lipids.
</td>
<td style="text-align:left;">
Biochim. Biophys. Acta
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Standard pleural biopsy versus CT-guided cutting-needle biopsy for diagnosis of malignant disease in pleural effusions: a randomised controlled trial.
</td>
<td style="text-align:left;">
Lancet
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed and its emerging role in the treatment of thoracic malignancies.
</td>
<td style="text-align:left;">
Expert Opin Investig Drugs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Gemcitabine improved QOL and survival in a case of diffuse malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Gan To Kagaku Ryoho
</td>
</tr>
<tr>
<td style="text-align:left;">
Exposure to brake dust and malignant mesothelioma: a study of 10 cases with mineral fiber analyses.
</td>
<td style="text-align:left;">
Ann Occup Hyg
</td>
</tr>
<tr>
<td style="text-align:left;">
Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II study.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Matrix metalloproteinases 2 and 9 (gelatinases A and B) expression in malignant mesothelioma and benign pleura.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Radiological manifestations of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Australas Radiol
</td>
</tr>
<tr>
<td style="text-align:left;">
Advances in the management of malignant mesothelioma.
</td>
<td style="text-align:left;">
Curr Oncol Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic value of CA 549 in pleural fluid. Comparison with CEA, CA 15.3 and CA 72.4.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Menstruation in an unusual place: a case of thoracic endometriosis in Kampala, Uganda.
</td>
<td style="text-align:left;">
Afr Health Sci
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Gan To Kagaku Ryoho
</td>
</tr>
<tr>
<td style="text-align:left;">
The value of chest computer tomography and cervical mediastinoscopy in the preoperative assessment of patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Microarray analysis and RNA silencing link fra-1 to cd44 and c-met expression in mesothelioma.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Cutaneous metastasis of pleural mesothelioma: two cases].
</td>
<td style="text-align:left;">
Ann Dermatol Venereol
</td>
</tr>
<tr>
<td style="text-align:left;">
Second-line treatment of advanced gastric cancer with oxaliplatin plus raltitrexed.
</td>
<td style="text-align:left;">
Onkologie
</td>
</tr>
<tr>
<td style="text-align:left;">
Non-melanoma and non-renal cell carcinoma malignancies treated with interleukin-2.
</td>
<td style="text-align:left;">
Hepatogastroenterology
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma: Drug treatment and other interventions.
</td>
<td style="text-align:left;">
Drugs Today
</td>
</tr>
<tr>
<td style="text-align:left;">
[The in vitro release of hydroxyl radicals from dust containing fluoro-edenite fibers identified in the volcanic rocks of Biancavilla (eastern Sicily)].
</td>
<td style="text-align:left;">
Med Lav
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma: experience at the Singapore General Hospital.
</td>
<td style="text-align:left;">
Ann. Acad. Med. Singap.
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Hemithoracic radiation after extrapleural pneumonectomy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Radiat. Oncol. Biol. Phys.
</td>
</tr>
<tr>
<td style="text-align:left;">
Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Interferon-alpha and -gamma in combination with chemotherapeutic drugs: in vitro sensitivity studies in four human mesothelioma cell lines.
</td>
<td style="text-align:left;">
Anticancer Drugs
</td>
</tr>
<tr>
<td style="text-align:left;">
Enhanced effectiveness of last generation antiblastic compounds vs. cisplatin on malignant pleural mesothelioma cell lines.
</td>
<td style="text-align:left;">
Eur. J. Pharmacol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Growth factors regulate the expression profile of their syndecan co-receptors and the differentiation of mesothelioma cells.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Gene expression profiling of malignant mesothelioma.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Miliary pulmonary metastases from a clinically occult pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann Diagn Pathol
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed (Alimta, MTA, multitargeted antifolate, LY231514) for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Semin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
c-Kit is not expressed in malignant mesothelioma.
</td>
<td style="text-align:left;">
Mod. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Detection of numerical aberrations of chromosomes 7 and 9 in cytologic specimens of pleural malignant mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse malignant pleural mesothelioma: Part I. An overview of diagnosis, staging, and treatment options.
</td>
<td style="text-align:left;">
Clin J Oncol Nurs
</td>
</tr>
<tr>
<td style="text-align:left;">
Elevated serum cytokine levels in mesothelioma patients who have undergone pleurectomy or extrapleural pneumonectomy and adjuvant intraoperative photodynamic therapy.
</td>
<td style="text-align:left;">
Photochem. Photobiol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment of mesothelioma in Bloemfontein, South Africa.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Issues in the management of chest malignancies.
</td>
<td style="text-align:left;">
Clin. Chest Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunoreactivity for the beta chain of the platelet-derived growth factor receptor in malignant mesothelioma and non-neoplastic mesothelium.
</td>
<td style="text-align:left;">
J. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Spontaneous pneumothorax. Graduated concept of surgical therapy].
</td>
<td style="text-align:left;">
Zentralbl Chir
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma: clinical characteristics, asbestos mineralogy and chromosomal abnormalities of 41 patients.
</td>
<td style="text-align:left;">
Eur. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma due to environmental mineral fiber exposure in Turkey. Analysis of 135 cases.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunoreactivity for P-170 glycoprotein in malignant mesothelioma and in non-neoplastic mesothelium of the pleura using the murine monoclonal antibody JSB-1.
</td>
<td style="text-align:left;">
J. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Thrombomodulin expression in malignant pleural mesothelioma and pulmonary adenocarcinoma.
</td>
<td style="text-align:left;">
Am. J. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
DNA ploidy analysis of pleural mesotheliomas: its usefulness for their distinction from lung adenocarcinomas.
</td>
<td style="text-align:left;">
Mod. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
CD7 expression in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Jpn. J. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma producing human chorionic gonadotropin. Report of two cases.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Photodynamic therapy for thoracic malignancies.
</td>
<td style="text-align:left;">
Semin Surg Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of closed pleural needle biopsy in the diagnosis of malignant mesothelioma of the pleura.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
p53 expression is common in malignant mesothelioma.
</td>
<td style="text-align:left;">
Histopathology
</td>
</tr>
<tr>
<td style="text-align:left;">
[An operated case of malignant localized mesothelioma of the pleura].
</td>
<td style="text-align:left;">
Nihon Kyobu Geka Gakkai Zasshi
</td>
</tr>
<tr>
<td style="text-align:left;">
A dual-isotope method for studying protein kinetics in pleural effusions in humans.
</td>
<td style="text-align:left;">
Nucl Med Commun
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: value of CT and MR imaging in predicting resectability.
</td>
<td style="text-align:left;">
AJR Am J Roentgenol
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic importance of the DNA ploidy pattern in malignant mesothelioma of the pleura.
</td>
<td style="text-align:left;">
Anal. Quant. Cytol. Histol.
</td>
</tr>
<tr>
<td style="text-align:left;">
DNA analysis of malignant effusions. Comparison with cytologic diagnosis and carcinoembryonic antigen content.
</td>
<td style="text-align:left;">
Anal. Quant. Cytol. Histol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Survival of asbestos insulation workers with mesothelioma.
</td>
<td style="text-align:left;">
Br J Ind Med
</td>
</tr>
<tr>
<td style="text-align:left;">
A phase II evaluation of ifosfamide and mesna in unresectable diffuse malignant mesothelioma. A Southwest Oncology Group study.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Multimodality treatment programs for malignant pleural mesothelioma using high-dose hemithorax irradiation.
</td>
<td style="text-align:left;">
Int. J. Radiat. Oncol. Biol. Phys.
</td>
</tr>
<tr>
<td style="text-align:left;">
Imaging manifestations of pleural tumors.
</td>
<td style="text-align:left;">
Radiographics
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnosis and prognostic factors in malignant pleural mesothelioma: a retrospective analysis of sixty-five patients.
</td>
<td style="text-align:left;">
Respiration
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma of the vulva. About one case].
</td>
<td style="text-align:left;">
Gynecol Obstet Fertil
</td>
</tr>
<tr>
<td style="text-align:left;">
Desmoplastic malignant mesothelioma: two cases and a literature review.
</td>
<td style="text-align:left;">
Med Electron Microsc
</td>
</tr>
<tr>
<td style="text-align:left;">
Localized pleural malignant mesothelioma.
</td>
<td style="text-align:left;">
Pathol. Int.
</td>
</tr>
<tr>
<td style="text-align:left;">
Widespread cutaneous and perioral metastases of mesothelioma.
</td>
<td style="text-align:left;">
J. Cutan. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Stereotactic intensity-modulated radiation therapy (IMRT) and inverse treatment planning for advanced pleural mesothelioma. Feasibility and initial results.
</td>
<td style="text-align:left;">
Strahlenther Onkol
</td>
</tr>
<tr>
<td style="text-align:left;">
New strategies are needed in diffuse malignant mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Synchronous diffuse malignant mesothelioma and carcinomas in asbestos-exposed individuals.
</td>
<td style="text-align:left;">
Histopathology
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant and non-malignant asbestos-related pleural and lung disease: 10-year follow-up study.
</td>
<td style="text-align:left;">
Croat. Med. J.
</td>
</tr>
<tr>
<td style="text-align:left;">
Evaluation of Rare Tumors with [F-18]Fluorodeoxyglucose Positron Emission Tomography.
</td>
<td style="text-align:left;">
Clin. Positron Imaging
</td>
</tr>
<tr>
<td style="text-align:left;">
Autocrine inhibitory influences of alpha-melanocyte-stimulating hormone in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Leukoc. Biol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Cold abscess due to malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Indian J Chest Dis Allied Sci
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemotherapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse malignant pleural mesothelioma: Part II. Symptom management.
</td>
<td style="text-align:left;">
Clin J Oncol Nurs
</td>
</tr>
<tr>
<td style="text-align:left;">
Tumor necrosis correlates with angiogenesis and is a predictor of poor prognosis in malignant mesothelioma.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural effusions: is thoracoscopy a reliable investigation? A retrospective review.
</td>
<td style="text-align:left;">
Respir Med
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of smoking and exposure to asbestos and man-made vitreous fibers in a questionable case of mesothelioma.
</td>
<td style="text-align:left;">
Ind Health
</td>
</tr>
<tr>
<td style="text-align:left;">
[Primary malignant pleural neoplasms. Diagnostic code 163.09].
</td>
<td style="text-align:left;">
Ugeskr. Laeg.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Diagnostic difficulties in pleural mesothelioma].
</td>
<td style="text-align:left;">
Wiad. Lek.
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelin-family proteins and diagnosis of mesothelioma.
</td>
<td style="text-align:left;">
Lancet
</td>
</tr>
<tr>
<td style="text-align:left;">
CT findings and serum ca 125 levels in malignant peritoneal mesothelioma: report of 11 new cases and review of the literature.
</td>
<td style="text-align:left;">
Eur Radiol
</td>
</tr>
<tr>
<td style="text-align:left;">
Localized benign pleural mesothelioma: a case report.
</td>
<td style="text-align:left;">
Monaldi Arch Chest Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
‘Pseudomesotheliomatous’ carcinomas of the pleura: a 10-year analysis of cases from the Environmental Lung Disease Research Group, Cardiff.
</td>
<td style="text-align:left;">
Histopathology
</td>
</tr>
<tr>
<td style="text-align:left;">
Is there a role for pre-operative contrast-enhanced magnetic resonance imaging for radical surgery in malignant pleural mesothelioma?
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: surgical roles and novel therapies.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Molecular pathogenesis of malignant mesothelioma and its relationship to simian virus 40.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Bronchial cytology in pleural mesothelioma. A report of 3 positive cases, including 1 diagnosed initially on bronchial brushings.
</td>
<td style="text-align:left;">
Acta Cytol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma in Italy, 1997.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Inadequacy of the new Response Evaluation Criteria in Solid Tumors (RECIST) in patients with malignant pleural mesothelioma: report of four cases.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Metsovo-tremolite asbestos fibres: in vitro effects on mutation, chromosome aberration, cell transformation and intercellular communication.
</td>
<td style="text-align:left;">
Mutagenesis
</td>
</tr>
<tr>
<td style="text-align:left;">
[[18F]-FDG imaging in apparently isolated pleural lesions].
</td>
<td style="text-align:left;">
Rev Pneumol Clin
</td>
</tr>
<tr>
<td style="text-align:left;">
Mutation analysis of the BRAF codon 599 in malignant pleural mesothelioma by enriched PCR-RFLP.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
</tr>
<tr>
<td style="text-align:left;">
Disseminated malignant solitary fibrous tumor of the pleura.
</td>
<td style="text-align:left;">
Pathol. Int.
</td>
</tr>
<tr>
<td style="text-align:left;">
Cell protection, resistance and invasiveness of two malignant mesotheliomas as assessed by 10K-microarray.
</td>
<td style="text-align:left;">
Biochim. Biophys. Acta
</td>
</tr>
<tr>
<td style="text-align:left;">
Promising early local control of malignant pleural mesothelioma following postoperative intensity modulated radiotherapy (IMRT) to the chest.
</td>
<td style="text-align:left;">
Cancer J
</td>
</tr>
<tr>
<td style="text-align:left;">
Pulmonary neoplasms in rats that inhaled cerium-144 dioxide.
</td>
<td style="text-align:left;">
Toxicol Pathol
</td>
</tr>
<tr>
<td style="text-align:left;">
Modified RECIST criteria for assessment of response in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
BTS randomised feasibility study of active symptom control with or without chemotherapy in malignant pleural mesothelioma: ISRCTN 54469112.
</td>
<td style="text-align:left;">
Thorax
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunoreactivity for p53 protein in malignant mesothelioma and non-neoplastic mesothelium.
</td>
<td style="text-align:left;">
J. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
p53 immunostaining in the distinction between benign and malignant mesothelial proliferations using formalin-fixed paraffin sections.
</td>
<td style="text-align:left;">
J. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Gene expression profiles predict survival and progression of pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Mesothelioma of the pleura–pathological anatomy].
</td>
<td style="text-align:left;">
Langenbecks Arch Chir Suppl Kongressbd
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse malignant mesothelioma of the peritoneum and pleura, analysis of markers.
</td>
<td style="text-align:left;">
Mod. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Localized fibrous mesothelioma with bloody pleural effusion; report of a case].
</td>
<td style="text-align:left;">
Kyobu Geka
</td>
</tr>
<tr>
<td style="text-align:left;">
Microdissection, mRNA amplification and microarray: a study of pleural mesothelial and malignant mesothelioma cells.
</td>
<td style="text-align:left;">
Biochimie
</td>
</tr>
<tr>
<td style="text-align:left;">
Factors influencing long-term survival in mesothelioma patients–results of the German mesothelioma register.
</td>
<td style="text-align:left;">
Int Arch Occup Environ Health
</td>
</tr>
<tr>
<td style="text-align:left;">
A vitamin E analogue suppresses malignant mesothelioma in a preclinical model: a future drug against a fatal neoplastic disease?
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Behaviour of the new asbestos amphibole fluor-edenite in different lung cell systems.
</td>
<td style="text-align:left;">
Int. J. Biochem. Cell Biol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Patterns of lymphadenopathy in thoracic malignancies.
</td>
<td style="text-align:left;">
Radiographics
</td>
</tr>
<tr>
<td style="text-align:left;">
Ultrastructural and chromosomal studies on manganese superoxide dismutase in malignant mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Respir. Cell Mol. Biol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Recurrent solitary fibrous tumor of the pleura with malignant transformation.
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma–an update.
</td>
<td style="text-align:left;">
Int J Occup Environ Health
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytotoxic T cell responses against mesothelioma by apoptotic cell-pulsed dendritic cells.
</td>
<td style="text-align:left;">
Am. J. Respir. Crit. Care Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of the nerve growth factor receptors TrkA and p75 in malignant mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (39807).
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Well-differentiated papillary mesothelioma of the pleura: a series of 24 cases.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma: diagnostic and management strategies for 1992.
</td>
<td style="text-align:left;">
Semin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Significance of psammoma bodies in serous cavity fluid: a cytopathologic analysis.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
[Estimates of pleural mesothelioma incidence in the Lazio region (Italy), 1997-2000].
</td>
<td style="text-align:left;">
Med Lav
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed alone and in combination with platinum compounds in the management of malignant mesothelioma.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Novel combinations using pemetrexed in malignant mesothelioma.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Metastatic mesothelioma presenting with proptosis.
</td>
<td style="text-align:left;">
Am. J. Ophthalmol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma: risk factors and current management.
</td>
<td style="text-align:left;">
Nurs Times
</td>
</tr>
<tr>
<td style="text-align:left;">
[Surgery for malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Rev Pneumol Clin
</td>
</tr>
<tr>
<td style="text-align:left;">
Gene expression profiling identifies matriptase overexpression in malignant mesothelioma.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Antisense oligonucleotides directed at the bcl-xl gene product augment chemotherapy response in mesothelioma.
</td>
<td style="text-align:left;">
Mol. Cancer Ther.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pulmonary fibre burden in sheep living in the Biancavilla area (Sicily): preliminary results.
</td>
<td style="text-align:left;">
Sci. Total Environ.
</td>
</tr>
<tr>
<td style="text-align:left;">
Use of immunohistochemical marker calretinin in the diagnosis of a diffuse malignant metastatic mesothelioma in an equine.
</td>
<td style="text-align:left;">
J. Vet. Diagn. Invest.
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of hyaluronan synthases and hyaluronan in malignant mesothelioma cells.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed (Alimta): improving outcomes in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Expert Rev Anticancer Ther
</td>
</tr>
<tr>
<td style="text-align:left;">
Defective core-apoptosis signalling in diffuse malignant pleural mesothelioma: opportunities for effective drug development.
</td>
<td style="text-align:left;">
Lancet Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Role of 18F-FDG PET for evaluating malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Biother. Radiopharm.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma–a diagnostic challenge].
</td>
<td style="text-align:left;">
Rev Port Pneumol
</td>
</tr>
<tr>
<td style="text-align:left;">
A randomised trial of single-dose radiotherapy to prevent procedure tract metastasis by malignant mesothelioma.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
The effect of extent of local resection on patterns of disease progression in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Evaluation of malignant mesothelioma in central Anatolia: a study of 67 cases.
</td>
<td style="text-align:left;">
Can. Respir. J.
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II study of OK-432 intrapleural administration followed by systemic cisplatin and gemcitabine for non-small cell lung cancer with pleuritis carcinomatosa.
</td>
<td style="text-align:left;">
J. Exp. Ther. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Epidemiology of malignant mesothelioma in Australia.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Epidemiology of pleural mesothelioma in Italy.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Pathology of malignant mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Staging and response to therapy of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
The use of magnetic resonance imaging in malignant mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Positron emission tomography in the diagnosis of mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Considerations for post-operative radiotherapy to the hemithorax following extrapleural pneumonectomy in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemotherapy for malignant pleural mesothelioma: past results and recent developments.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of Alimta in the treatment of malignant pleural mesothelioma: an overview of preclinical and clinical trials.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma. Medical oncology: standards, new trends, trials–the French experience.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed: a novel antifolate agent enters clinical practice.
</td>
<td style="text-align:left;">
Expert Rev Anticancer Ther
</td>
</tr>
<tr>
<td style="text-align:left;">
Adapting the Lung Cancer Symptom Scale (LCSS) to mesothelioma: using the LCSS-Meso conceptual model for validation.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Interleukin-4 receptor cytotoxin as therapy for human malignant pleural mesothelioma xenografts.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Respiratory tract cancers: lung and mesothelioma.
</td>
<td style="text-align:left;">
Epidemiol Prev
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural plaques in a rural population in central Macedonia, Greece.
</td>
<td style="text-align:left;">
Med Lav
</td>
</tr>
<tr>
<td style="text-align:left;">
Thoracic actinomycosis with mainly pleural involvement.
</td>
<td style="text-align:left;">
J. Infect. Chemother.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Survival analysis of malignant mesothelioma treated in Brescia, northern Italy, 1982-2000].
</td>
<td style="text-align:left;">
Epidemiol Prev
</td>
</tr>
<tr>
<td style="text-align:left;">
Decreasing prevalence of pleural calcifications among Metsovites with nonoccupational asbestos exposure.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
The palliative benefits of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma.
</td>
<td style="text-align:left;">
Ann. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Soluble type II transforming growth factor-beta receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunity.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic and prognostic value of Ki67 proliferation fraction in serous effusions.
</td>
<td style="text-align:left;">
Cell. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Establishment of permanent cell lines purified from human mesothelioma: morphological aspects, new marker expression and karyotypic analysis.
</td>
<td style="text-align:left;">
Histochem. Cell Biol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma.
</td>
<td style="text-align:left;">
Mod. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
L1CAM, INP10, P-cadherin, tPA and ITGB4 over-expression in malignant pleural mesotheliomas revealed by combined use of cDNA and tissue microarray.
</td>
<td style="text-align:left;">
Carcinogenesis
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesothelioma: little evidence, still time to do trials.
</td>
<td style="text-align:left;">
Lancet
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant effusions: from diagnosis to biology.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Safety and yield of ultrasound-assisted transthoracic biopsy performed by pulmonologists.
</td>
<td style="text-align:left;">
Respiration
</td>
</tr>
<tr>
<td style="text-align:left;">
Methodology for lognormal modelling of malignant pleural mesothelioma survival time distributions: a study of 5580 case histories from Europe and USA.
</td>
<td style="text-align:left;">
Phys Med Biol
</td>
</tr>
<tr>
<td style="text-align:left;">
[Significance of combining detection of E-cadherin, carcinoembryonic antigen, and calretinin in cytological differential diagnosis of serous effusion].
</td>
<td style="text-align:left;">
Ai Zheng
</td>
</tr>
<tr>
<td style="text-align:left;">
Susceptibility of mesothelioma cell lines to adeno-associated virus 2 vector-based suicide gene therapy.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
FDA drug approval summaries: pemetrexed (Alimta).
</td>
<td style="text-align:left;">
Oncologist
</td>
</tr>
<tr>
<td style="text-align:left;">
Investigation of simian virus 40 large T antigen in 18 autopsied malignant mesothelioma patients in Japan.
</td>
<td style="text-align:left;">
J. Med. Virol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: update, current management, and newer therapeutic strategies.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignancy in a massive localized fibrous tumour of pleura.
</td>
<td style="text-align:left;">
Aust N Z J Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
A cytokeratin- and calretinin-negative staining sarcomatoid malignant mesothelioma.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Multimodality therapy for diffuse malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Kyobu Geka
</td>
</tr>
<tr>
<td style="text-align:left;">
Presentation of malignant pleural mesothelioma with symptomatic brain metastasis: report of a case.
</td>
<td style="text-align:left;">
Tumori
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural biopsy: a reliable method for determining the diagnosis but not subtype in mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Cerebral metastases in malignant mesothelioma: case report and literature review.
</td>
<td style="text-align:left;">
J Clin Neurosci
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma of the pleura in a worker with brief atypical exposure to chrysotile asbestos].
</td>
<td style="text-align:left;">
Med Lav
</td>
</tr>
<tr>
<td style="text-align:left;">
Extraskeletal myxoid chondrosarcoma of the pleura. Report of a case clinically simulating mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Clin. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
HMBA induces cell death and potentiates doxorubicin toxicity in malignant mesothelioma cells.
</td>
<td style="text-align:left;">
Cancer Chemother. Pharmacol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Spontaneous pneumothorax revealing malignant pleural mesothelioma. Three case reports].
</td>
<td style="text-align:left;">
Rev Pneumol Clin
</td>
</tr>
<tr>
<td style="text-align:left;">
del(6q) as a possible primary change in malignant mesothelioma.
</td>
<td style="text-align:left;">
Cancer Genet. Cytogenet.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Small bowel metastases from lung cancer].
</td>
<td style="text-align:left;">
Chir Ital
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma metastasis to the mandible.
</td>
<td style="text-align:left;">
Int J Oral Maxillofac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Preoperative assessment and therapeutic options for patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Thorac Surg Clin
</td>
</tr>
<tr>
<td style="text-align:left;">
Extrapleural pneumonectomy for diffuse malignant pleural mesothelioma: techniques and complications.
</td>
<td style="text-align:left;">
Thorac Surg Clin
</td>
</tr>
<tr>
<td style="text-align:left;">
Patterns of failure following surgical resection for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Thorac Surg Clin
</td>
</tr>
<tr>
<td style="text-align:left;">
Fibrinolysis of loculated pleural effusion in malignant mesothelioma.
</td>
<td style="text-align:left;">
Singapore Med J
</td>
</tr>
<tr>
<td style="text-align:left;">
Current chemotherapeutic treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Expert Opin Pharmacother
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma of the pleura among women].
</td>
<td style="text-align:left;">
Med Lav
</td>
</tr>
<tr>
<td style="text-align:left;">
[Carcinoembryonic antigen in pleural effusion. Adenocarcinoma versus mesothelioma].
</td>
<td style="text-align:left;">
Rev Clin Esp
</td>
</tr>
<tr>
<td style="text-align:left;">
TTF-1 and surfactant-B as co-adjuvants in the diagnosis of lung adenocarcinoma and pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann Diagn Pathol
</td>
</tr>
<tr>
<td style="text-align:left;">
Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[A case report of disseminated malignant mesothelioma of peritoneum responding remarkably to thalidomide, celecoxib, vinorelbine and CDDP].
</td>
<td style="text-align:left;">
Gan To Kagaku Ryoho
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II trial of vinorelbine and oxaliplatin as first-line therapy in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
[Long-term prognostic analysis of patients with malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Ai Zheng
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncology (Williston Park, N.Y.)
</td>
</tr>
<tr>
<td style="text-align:left;">
Heparanase and basic fibroblast growth factor are co-expressed in malignant mesothelioma.
</td>
<td style="text-align:left;">
Clin. Exp. Metastasis
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemotherapy options and new advances in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
The combination of CEA, EMA, and BerEp4 and hyaluronan analysis specifically identifies 79% of all histologically verified mesotheliomas causing an effusion.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
The value of ThinPrep and cytospin preparation in pleural effusion cytological diagnosis of mesothelioma and adenocarcinoma.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
The value of epithelial membrane antigen expression in separating benign mesothelial proliferation from malignant mesothelioma: a comparative study.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Image cytometry: an aid for cytological diagnosis of pleural effusions.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Differentiation of mesothelioma from adenocarcinoma in serous effusions: the role of hyaluronic acid and CD44 localization.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma of the pleura–diagnostic difficulties].
</td>
<td style="text-align:left;">
Pol. Merkur. Lekarski
</td>
</tr>
<tr>
<td style="text-align:left;">
Pathogenesis of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Respirology
</td>
</tr>
<tr>
<td style="text-align:left;">
Iodized talc pleurodesis for the treatment of pleural effusions.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
The effects of intrapleural injections of alumina and aluminosilicate (ceramic) fibres.
</td>
<td style="text-align:left;">
Int J Exp Pathol
</td>
</tr>
<tr>
<td style="text-align:left;">
Comparison of monoclonal versus polyclonal calretinin antibodies for immunohistochemical diagnosis of malignant mesothelioma.
</td>
<td style="text-align:left;">
Appl. Immunohistochem. Mol. Morphol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Second-line treatment of malignant pleural mesothelioma with Pemetrexed (Alimta) – a case report].
</td>
<td style="text-align:left;">
Pneumologie
</td>
</tr>
<tr>
<td style="text-align:left;">
[Management of malignant pleural effusions].
</td>
<td style="text-align:left;">
Pneumologie
</td>
</tr>
<tr>
<td style="text-align:left;">
Hyaluronan synthase expression in pleural malignant mesotheliomas.
</td>
<td style="text-align:left;">
Virchows Arch.
</td>
</tr>
<tr>
<td style="text-align:left;">
A pilot trial of high-dose-rate intraoperative radiation therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Brachytherapy
</td>
</tr>
<tr>
<td style="text-align:left;">
Extra-pleural pneumonectomy for malignant pleural mesothelioma: the risks of induction chemotherapy, right-sided procedures and prolonged operations.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Analysis of chromosomes 9 and 11 aneuploidy frequency in pleural effusion of patients with and without malignancy: interphase FISH technique.
</td>
<td style="text-align:left;">
Cancer Biol. Ther.
</td>
</tr>
<tr>
<td style="text-align:left;">
Assessment of immunological competence and SV40 specific recall immunity in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Vaccine
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann Pharmacother
</td>
</tr>
<tr>
<td style="text-align:left;">
Farnesyltransferase inhibitors and human malignant pleural mesothelioma: a first-step comparative translational study.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Predictors of pleural malignancy in patients with pleural effusion undergoing thoracoscopy.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Desmoplastic malignant mesothelioma: a review of 17 cases.
</td>
<td style="text-align:left;">
J. Clin. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Improved survival with VATS pleurectomy-decortication in advanced malignant mesothelioma.
</td>
<td style="text-align:left;">
Eur J Surg Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
The positive pleural effusion. A retrospective study of cytopathologic diagnoses with autopsy confirmation.
</td>
<td style="text-align:left;">
Acta Cytol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural malignant mesothelioma in Tuscany, Italy (1970-1988): I. Anatomo-pathologic aspects.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Characterization of a tumor necrosis factor-alpha inhibitor activity in cancer patients.
</td>
<td style="text-align:left;">
Am. J. Respir. Cell Mol. Biol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Development of malignant mesothelioma during treatment for prolymphocytic leukemia: is asbestos or simian virus 40 a link?
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed (Alimta) in small cell lung cancer.
</td>
<td style="text-align:left;">
Semin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgical management of malignant pleural mesothelioma: a systematic review and evidence summary.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Quantitative evaluation of the apoptosis regulating genes Survivin, Bcl-2 and Bax in inflammatory and malignant pleural lesions.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Thalidomide in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma.
</td>
<td style="text-align:left;">
Cancer Biol. Ther.
</td>
</tr>
<tr>
<td style="text-align:left;">
Epirubicin and gemcitabine as first-line treatment in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Tumori
</td>
</tr>
<tr>
<td style="text-align:left;">
The selective epidermal growth factor receptor tyrosine kinase inhibitor PD153035 suppresses expression of prometastasis phenotypes in malignant pleural mesothelioma cells in vitro.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Intrapleural cisplatin and mitomycin for malignant mesothelioma following pleurectomy: pharmacokinetic studies.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Irinotecan for malignant mesothelioma A phase II trial by the Cancer and Leukemia Group B.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Raltitrexed-Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
[Therapeutic options in malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Pneumologie
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesothelioma.
</td>
<td style="text-align:left;">
Curr Opin Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Palliative intracavitary carboplatin therapy in a cat with suspected pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Feline Med. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Photodynamic therapy as an adjunct to surgery for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling.
</td>
<td style="text-align:left;">
Am. J. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Management of malignant pleural effusions.
</td>
<td style="text-align:left;">
Curr Opin Pulm Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma in Hong Kong.
</td>
<td style="text-align:left;">
Respir Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: Staging implications.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical trials in malignant pleural mesothelioma in Australasia.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Overview on ongoing or planned clinical trials in Europe.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Epidemic of mesothelioma in Egypt.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of PET in the surgical management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
CT, RECIST, and malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Induction chemotherapy, extrapleural pneumonectomy, and radiotherapy in the treatment of malignant pleural mesothelioma: the Memorial Sloan-Kettering experience.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment planning system evaluation for mesothelioma IMRT.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Inverse planned stereotactic intensity modulated radiotherapy (IMRT) in the palliative treatment of malignant mesothelioma of the pleura: the Heidelberg experience.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Implications of P16/CDKN2A deletion in pleural mesotheliomas.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Advances in the diagnosis, evaluation, and management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Respirology
</td>
</tr>
<tr>
<td style="text-align:left;">
Validation of genomics-based prognostic tests in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural malignant mesothelioma, genetic susceptibility and asbestos exposure.
</td>
<td style="text-align:left;">
Mutat. Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Measuring quality of life in patients with pleural mesothelioma using a modified version of the Lung Cancer Symptom Scale (LCSS): psychometric properties of the LCSS-Meso.
</td>
<td style="text-align:left;">
Support Care Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Primary diagnosis of malignant mesothelioma by fine-needle aspiration of a supraclavicular lymph node.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical significance of the expression of tumor-associated antigen, RCAS1, and its soluble protein in pleural fluid in malignant mesothelioma.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
</tr>
<tr>
<td style="text-align:left;">
Chromosomal alterations in early stages of malignant mesotheliomas.
</td>
<td style="text-align:left;">
Virchows Arch.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma with a pronounced myxoid stroma: a clinical and pathological evaluation of 19 cases.
</td>
<td style="text-align:left;">
Virchows Arch.
</td>
</tr>
<tr>
<td style="text-align:left;">
[A case of malignant pleural mesothelioma with osseous and cartilaginous formation].
</td>
<td style="text-align:left;">
Nihon Kyobu Shikkan Gakkai Zasshi
</td>
</tr>
<tr>
<td style="text-align:left;">
Intensity-modulated radiation therapy for mesothelioma: impact of multileaf collimator leaf width and pencil beam size on planning quality and delivery efficiency.
</td>
<td style="text-align:left;">
Int. J. Radiat. Oncol. Biol. Phys.
</td>
</tr>
<tr>
<td style="text-align:left;">
A molecular epidemiology case control study on pleural malignant mesothelioma.
</td>
<td style="text-align:left;">
Cancer Epidemiol. Biomarkers Prev.
</td>
</tr>
<tr>
<td style="text-align:left;">
Occupational asbestos exposure and predictable asbestos-related diseases in India.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma.
</td>
<td style="text-align:left;">
Lancet
</td>
</tr>
<tr>
<td style="text-align:left;">
PET in lung cancer.
</td>
<td style="text-align:left;">
Chang Gung Med J
</td>
</tr>
<tr>
<td style="text-align:left;">
Differential diagnosis between mesothelioma and adenocarcinoma: a multimodal approach based on ultrastructure and immunocytochemistry.
</td>
<td style="text-align:left;">
Semin Diagn Pathol
</td>
</tr>
<tr>
<td style="text-align:left;">
The concept of mesothelioma in situ: implications for diagnosis and histogenesis.
</td>
<td style="text-align:left;">
Semin Diagn Pathol
</td>
</tr>
<tr>
<td style="text-align:left;">
The spectrum of histologic growth patterns in benign and malignant fibrous tumors of the pleura.
</td>
<td style="text-align:left;">
Semin Diagn Pathol
</td>
</tr>
<tr>
<td style="text-align:left;">
Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Serum PDGF-AB in pleural mesothelioma.
</td>
<td style="text-align:left;">
Tumour Biol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunocytochemical detection of XIAP in body cavity effusions and washes.
</td>
<td style="text-align:left;">
Mod. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pseudomesothelioma resulting from metastatic malignant melanoma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
The effects of thermochemotherapy using cyclophosphamide plus hyperthermia on the malignant pleural mesothelioma in vivo.
</td>
<td style="text-align:left;">
Ann. Anat.
</td>
</tr>
<tr>
<td style="text-align:left;">
Cox and mesothelioma: an overview.
</td>
<td style="text-align:left;">
Histol. Histopathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
The evolution of cancer research and drug discovery at Lilly Research Laboratories.
</td>
<td style="text-align:left;">
Adv. Enzyme Regul.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma: current status of histopathologic diagnosis and molecular profile.
</td>
<td style="text-align:left;">
Expert Rev. Mol. Diagn.
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical efficacy and safety of thoracoscopic talc pleurodesis in malignant pleural effusions.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression and prognostic significance of hypoxia-inducible factor 1alpha (HIF-1alpha) in malignant pleural mesothelioma (MPM).
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
The additional risk of malignant mesothelioma in former workers and residents of Wittenoom with benign pleural disease or asbestosis.
</td>
<td style="text-align:left;">
Occup Environ Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Spindle cell tumours of the pleura: a clinical, histological and comparative genomic hybridization analysis of 14 cases.
</td>
<td style="text-align:left;">
Virchows Arch.
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunocytochemical staining of serous effusions with the monoclonal antibody Ber-EP4.
</td>
<td style="text-align:left;">
Cytopathology
</td>
</tr>
<tr>
<td style="text-align:left;">
Second cancers among 40,576 testicular cancer patients: focus on long-term survivors.
</td>
<td style="text-align:left;">
J. Natl. Cancer Inst.
</td>
</tr>
<tr>
<td style="text-align:left;">
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Recent progress in treatment of malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Cancer Radiother
</td>
</tr>
<tr>
<td style="text-align:left;">
Physical and chemical stability of pemetrexed solutions in plastic syringes.
</td>
<td style="text-align:left;">
Ann Pharmacother
</td>
</tr>
<tr>
<td style="text-align:left;">
Differential expression of the 67 kilodalton laminin receptor in epithelioid malignant mesothelioma and carcinomas that spread to serosal cavities.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Quantitative analysis of integrin expression in effusions using flow cytometric immunophenotyping.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Long-term follow-up of patients with malignant pleural mesothelioma receiving high-dose adenovirus herpes simplex thymidine kinase/ganciclovir suicide gene therapy.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Review and update of uncommon primary pleural tumors: a practical approach to diagnosis.
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinicopathological analysis of lung cancer resembling malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Respirology
</td>
</tr>
<tr>
<td style="text-align:left;">
[Assessment of asbestos exposure, mortality study, and health intervention in workers formerly exposed to asbestos in a small factory making drying machines for textile finishing and the paper mill industry in Pistoia, Italy].
</td>
<td style="text-align:left;">
Med Lav
</td>
</tr>
<tr>
<td style="text-align:left;">
Update on malignant mesothelioma.
</td>
<td style="text-align:left;">
Oncology (Williston Park, N.Y.)
</td>
</tr>
<tr>
<td style="text-align:left;">
Use of imaging in the management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin Radiol
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed: a multitargeted antifolate.
</td>
<td style="text-align:left;">
Clin Ther
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed: a new cytotoxic agent in the development for first-line non-small-cell lung cancer.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Standard therapy for the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Seeking new options for the treatment of small-cell lung cancer.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Perspective on the development of new agents in thoracic cancers.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Cisplatin-induced GADD34 upregulation potentiates oncolytic viral therapy in the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Biol. Ther.
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic significance of vascular endothelial growth factor, tumor necrosis, and mitotic activity index in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Extended surgical staging for potentially resectable malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Asbestos and malignant pleural mesothelioma: molecular, cellular and physiopathological aspects].
</td>
<td style="text-align:left;">
Bull Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial.
</td>
<td style="text-align:left;">
Ann. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Autofluorescence videothoracoscopy in exudative pleural effusions: preliminary results.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
</tr>
<tr>
<td style="text-align:left;">
Multimodality treatments in the management of malignant pleural mesothelioma: an update.
</td>
<td style="text-align:left;">
Hematol. Oncol. Clin. North Am.
</td>
</tr>
<tr>
<td style="text-align:left;">
Radiotherapy for mesothelioma.
</td>
<td style="text-align:left;">
Hematol. Oncol. Clin. North Am.
</td>
</tr>
<tr>
<td style="text-align:left;">
Gene therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Hematol. Oncol. Clin. North Am.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: a case report.
</td>
<td style="text-align:left;">
J Manipulative Physiol Ther
</td>
</tr>
<tr>
<td style="text-align:left;">
The immunohistochemical profile of malignant mesotheliomas of the tunica vaginalis: a study of 20 cases.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma: early diagnosis and multimodality management].
</td>
<td style="text-align:left;">
G Chir
</td>
</tr>
<tr>
<td style="text-align:left;">
Multimodality approach in management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Patterns of recurrence and long-term survival after curative resection of localized fibrous tumors of the pleura.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Estimation of future mortality from pleural malignant mesothelioma in Japan based on an age-cohort model.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Subcutaneous metastases of sarcomatoid mesothelioma with its differential diagnosis on fine needle aspiration–a case report.
</td>
<td style="text-align:left;">
Indian J Pathol Microbiol
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytopathology of malignant mesothelioma: a stepwise logistic regression analysis.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Magnetic resonance imaging in the evaluation of pneumonia].
</td>
<td style="text-align:left;">
Radiologe
</td>
</tr>
<tr>
<td style="text-align:left;">
Lung Cancer Highlights from ASCO 2005.
</td>
<td style="text-align:left;">
Oncologist
</td>
</tr>
<tr>
<td style="text-align:left;">
Paradoxic technetium-99 methylene diphosphonate localization in malignant mesothelioma.
</td>
<td style="text-align:left;">
Clin Nucl Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemotherapy for intrathoracic cancer in dogs and cats.
</td>
<td style="text-align:left;">
Probl Vet Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Depletion of DNA methyltransferase 1 and/or DNA methyltransferase 3b mediates growth arrest and apoptosis in lung and esophageal cancer and malignant pleural mesothelioma cells.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Differential diagnosis of preneoplastic lesions of the pleura and of early mesothelioma: immunohistochemical and morphological findings].
</td>
<td style="text-align:left;">
Pathologe
</td>
</tr>
<tr>
<td style="text-align:left;">
Additional value of hybrid PET/CT fusion imaging vs. conventional CT scan alone in the staging and management of patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Nucl Med Rev Cent East Eur
</td>
</tr>
<tr>
<td style="text-align:left;">
Intrapleural hypotonic cisplatin treatment for malignant pleural mesothelioma: in vitro experiments and clinical application.
</td>
<td style="text-align:left;">
Surg. Today
</td>
</tr>
<tr>
<td style="text-align:left;">
Short-term treatment-related symptoms and quality of life: results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Respir. Crit. Care Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Descriptive epidemiology of malignant mesothelioma.
</td>
<td style="text-align:left;">
Med Lav
</td>
</tr>
<tr>
<td style="text-align:left;">
Nordic experience: expected decline in the incidence of mesotheliomas resulting from ceased exposure?
</td>
<td style="text-align:left;">
Med Lav
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma and the working environment: the viewpoint of the occupational physician.
</td>
<td style="text-align:left;">
Med Lav
</td>
</tr>
<tr>
<td style="text-align:left;">
Epidemiologic surveillance for primary prevention of malignant mesothelioma: the Italian experience.
</td>
<td style="text-align:left;">
Med Lav
</td>
</tr>
<tr>
<td style="text-align:left;">
Peculiar features of mesothelioma occurrence as related to exposure patterns and circumstances in the Lombard Region, Italy.
</td>
<td style="text-align:left;">
Med Lav
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma in 2004: How advanced technology and new drugs are changing the perspectives of mesothelioma patients. Highlights from the VIIth Meeting of the International Mesothelioma Interest Group.
</td>
<td style="text-align:left;">
Med Lav
</td>
</tr>
<tr>
<td style="text-align:left;">
Computed tomographic characterization of malignant peritoneal mesothelioma.
</td>
<td style="text-align:left;">
Tumori
</td>
</tr>
<tr>
<td style="text-align:left;">
Lung asbestos fiber content and mesothelioma cell type, site, and survival.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
The French National Mesothelioma Surveillance Program.
</td>
<td style="text-align:left;">
Occup Environ Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Incidence and management of complications after neoadjuvant chemotherapy followed by extrapleural pneumonectomy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Occupational asbestos exposure: how to deal with suspected mesothelioma cases–the Dutch approach.
</td>
<td style="text-align:left;">
Ann. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Establishment and characterization of 20 human non-small cell lung cancer cell lines in a serum-free defined medium (ACL-4).
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
BCG therapy of pleural and peritoneal growth of transplanted rat tumours.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Wnt inhibitory factor-1, a Wnt antagonist, is silenced by promoter hypermethylation in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Biochem. Biophys. Res. Commun.
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse malignant mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Clin. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Fluorescence detection of pleural malignancies using 5-aminolaevulinic acid.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of HLA-G in malignant mesothelioma and clinically aggressive breast carcinoma.
</td>
<td style="text-align:left;">
Virchows Arch.
</td>
</tr>
<tr>
<td style="text-align:left;">
Novel orthotopic implantation model of human malignant pleural mesothelioma (EHMES-10 cells) highly expressing vascular endothelial growth factor and its receptor.
</td>
<td style="text-align:left;">
Cancer Sci.
</td>
</tr>
<tr>
<td style="text-align:left;">
Sequential chemotherapy with cisplatin/gemcitabine (CG) followed by mitoxantrone/methotrexate/mitomycin (MMM) in patients with malignant pleural mesothelioma. A multicenter Italian Phase II Study (SITMP1).
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical activity of pemetrexed: a multitargeted antifolate anticancer agent.
</td>
<td style="text-align:left;">
Future Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Recombinant GM-CSF plus autologous tumor cells as a vaccine for patients with mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Polymorphisms in DNA repair genes as risk factors for asbestos-related malignant mesothelioma in a general population study.
</td>
<td style="text-align:left;">
Mutat. Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Comparative genomic hybridisation in malignant deciduoid mesothelioma.
</td>
<td style="text-align:left;">
J. Clin. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Thoracoscopic pleurodesis in malignant pleural effusions].
</td>
<td style="text-align:left;">
Rev Med Chir Soc Med Nat Iasi
</td>
</tr>
<tr>
<td style="text-align:left;">
Systemic chemotherapy in the management of malignant peritoneal mesothelioma.
</td>
<td style="text-align:left;">
Eur J Surg Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Mortality from malignant neoplasms among workers of an asbestos processing plant in Poland: results of prolonged observation.
</td>
<td style="text-align:left;">
Int J Occup Med Environ Health
</td>
</tr>
<tr>
<td style="text-align:left;">
h-Caldesmon, a useful positive marker in the diagnosis of pleural malignant mesothelioma, epithelioid type.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Monitoring of lung motion in patients with malignant pleural mesothelioma using two-dimensional and three-dimensional dynamic magnetic resonance imaging: comparison with spirometry.
</td>
<td style="text-align:left;">
Invest Radiol
</td>
</tr>
<tr>
<td style="text-align:left;">
Infrequent existence of simian virus 40 large T antigen DNA in malignant mesothelioma in Japan.
</td>
<td style="text-align:left;">
Cancer Sci.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed, a novel antifolate therapeutic alternative for cancer chemotherapy.
</td>
<td style="text-align:left;">
Pharmacotherapy
</td>
</tr>
<tr>
<td style="text-align:left;">
The pattern of lymph node involvement influences outcome after extrapleural pneumonectomy for malignant mesothelioma.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic value of pleural fluid pH in malignant epithelial mesothelioma after talc poudrage.
</td>
<td style="text-align:left;">
Respiration
</td>
</tr>
<tr>
<td style="text-align:left;">
Imaging before and after multimodal treatment for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Radiol Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Synchronous pulmonary carcinoma and pleural diffuse malignant mesothelioma.
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
A novel radiation therapy technique for malignant pleural mesothelioma combining electrons with intensity-modulated photons.
</td>
<td style="text-align:left;">
Radiother Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Characterization of human malignant mesothelioma cell lines orthotopically implanted in the pleural cavity of immunodeficient mice for their ability to grow and form metastasis.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
[Two cases of pleural mesothelioma following unusual and unrecognized exposure to asbestos. The role of Occupational Health and Safety Service in identifying past occupational exposure].
</td>
<td style="text-align:left;">
Med Lav
</td>
</tr>
<tr>
<td style="text-align:left;">
Management of malignant mesothelioma by decortication and adjunct phototherapy.
</td>
<td style="text-align:left;">
Asian Cardiovasc Thorac Ann
</td>
</tr>
<tr>
<td style="text-align:left;">
Management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin. Chest Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Physical and chemical stability of pemetrexed in infusion solutions.
</td>
<td style="text-align:left;">
Ann Pharmacother
</td>
</tr>
<tr>
<td style="text-align:left;">
My approach to the diagnosis of mesothelial lesions.
</td>
<td style="text-align:left;">
J. Clin. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Diachronic study of pleural plaques in rural population with environmental exposure to asbestos.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Nodular glomeruloid pleuroblastoma: a biphasic pleural-based malignant tumor with immature elements.
</td>
<td style="text-align:left;">
Virchows Arch.
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of renal cell carcinoma-associated markers erythropoietin, CD10, and renal cell carcinoma marker in diffuse malignant mesothelioma and metastatic renal cell carcinoma.
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Preoperative evaluation of patients with malignant pleural mesothelioma: role of integrated CT-PET imaging.
</td>
<td style="text-align:left;">
J Thorac Imaging
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of Abrams percutaneous pleural biopsy in the investigation of exudative pleural effusions.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Dynamic contrast-enhanced MRI of malignant pleural mesothelioma: a feasibility study of noninvasive assessment, therapeutic follow-up, and possible predictor of improved outcome.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Fluoro-edenitic fibres in the sputum of subjects from Biancavilla (Sicily): a pilot study.
</td>
<td style="text-align:left;">
Environ Health
</td>
</tr>
<tr>
<td style="text-align:left;">
Preclinical comparison of mTHPC and verteporfin for intracavitary photodynamic therapy of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur Surg Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Cellular and molecular parameters of mesothelioma.
</td>
<td style="text-align:left;">
J. Cell. Biochem.
</td>
</tr>
<tr>
<td style="text-align:left;">
Nature and extent of the exposure to fibrous amphiboles in Biancavilla.
</td>
<td style="text-align:left;">
Sci. Total Environ.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed and malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Epithelioid and sarcomatoid malignant pleural mesothelioma in endoscopic gastric biopsies: a diagnostic pitfall.
</td>
<td style="text-align:left;">
Pathol. Res. Pract.
</td>
</tr>
<tr>
<td style="text-align:left;">
D2-40 is not a specific marker for cells of mesothelial origin in serous effusions.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Physical instability of frozen pemetrexed solutions in PVC bags.
</td>
<td style="text-align:left;">
Ann Pharmacother
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma in patients with nonoccupational asbestos exposure. An evidence-based approach to causation assessment.
</td>
<td style="text-align:left;">
Ann Diagn Pathol
</td>
</tr>
<tr>
<td style="text-align:left;">
Perineural spread of malignant mesothelioma resulting in an intradural spinal cord mass: case report.
</td>
<td style="text-align:left;">
J. Neurooncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Plasma and cerebrospinal fluid pharmacokinetics of pemetrexed after intravenous administration in non-human primates.
</td>
<td style="text-align:left;">
Cancer Chemother. Pharmacol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Radiotherapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cochrane Database Syst Rev
</td>
</tr>
<tr>
<td style="text-align:left;">
The diagnosis of malignancy in effusion cytology: a pattern recognition approach.
</td>
<td style="text-align:left;">
Adv Anat Pathol
</td>
</tr>
<tr>
<td style="text-align:left;">
p53-induced apoptosis occurs in the absence of p14(ARF) in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Neoplasia
</td>
</tr>
<tr>
<td style="text-align:left;">
Promoter methylation of RASSF1A, RARbeta and DAPK predict poor prognosis of patients with malignant mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
The treatment of malignant mesothelioma of the pleura: review of a 5-year experience, with special reference to radiotherapy.
</td>
<td style="text-align:left;">
Am. J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma: diagnosis, therapy and prognosis].
</td>
<td style="text-align:left;">
Schweiz. Rundsch. Med. Prax.
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic value of thoracoscopic pleural biopsy for pleurisy under local anaesthesia.
</td>
<td style="text-align:left;">
ANZ J Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Animal models of malignant mesothelioma.
</td>
<td style="text-align:left;">
Inhal Toxicol
</td>
</tr>
<tr>
<td style="text-align:left;">
Tumor suppressor gene alterations in patients with malignant mesothelioma due to environmental asbestos exposure in Turkey.
</td>
<td style="text-align:left;">
J Carcinog
</td>
</tr>
<tr>
<td style="text-align:left;">
A molecular diagnostic test for distinguishing lung adenocarcinoma from malignant mesothelioma using cells collected from pleural effusions.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Exclusive intrapulmonary lepidic growth of a malignant pleural mesothelioma presenting with pneumothorax and involving the peritoneum.
</td>
<td style="text-align:left;">
Int. J. Surg. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma–diagnosis and treatment strategies].
</td>
<td style="text-align:left;">
Gan To Kagaku Ryoho
</td>
</tr>
<tr>
<td style="text-align:left;">
[Recurrent pneumothorax as alone manifestation of mesothelioma pleurae].
</td>
<td style="text-align:left;">
Pneumonol Alergol Pol
</td>
</tr>
<tr>
<td style="text-align:left;">
Biology and management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed-induced edema of the eyelid.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of Snail, Slug and Sip1 in malignant mesothelioma effusions is associated with matrix metalloproteinase, but not with cadherin expression.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Positron emission tomography predicts survival in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
[New challenges in thoracic surgery as exemplified in asbestos exposure and mesothelioma treatment].
</td>
<td style="text-align:left;">
Offentl Gesundheitswes
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesothelioma: sensitivity and incidence of needle track seeding after image-guided biopsy versus surgical biopsy.
</td>
<td style="text-align:left;">
Radiology
</td>
</tr>
<tr>
<td style="text-align:left;">
Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]fluorodeoxyglucose.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnosis of asbestos-related pleuropolmonary diseases.
</td>
<td style="text-align:left;">
Med Lav
</td>
</tr>
<tr>
<td style="text-align:left;">
Extrapleural pneumonectomy in children.
</td>
<td style="text-align:left;">
J. Pediatr. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
5-year prospective results of trimodality treatment for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Cardiovasc Surg (Torino)
</td>
</tr>
<tr>
<td style="text-align:left;">
Silencing the receptor EphA2 suppresses the growth and haptotaxis of malignant mesothelioma cells.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of immunohistochemistry in distinguishing squamous cell carcinoma from mesothelioma and adenocarcinoma in pleural effusion.
</td>
<td style="text-align:left;">
Semin Diagn Pathol
</td>
</tr>
<tr>
<td style="text-align:left;">
Use of mesothelin as a marker for mesothelial cells in cytologic specimens.
</td>
<td style="text-align:left;">
Semin Diagn Pathol
</td>
</tr>
<tr>
<td style="text-align:left;">
Pathological recognition of diffuse malignant mesothelioma of the pleura: the significance of the historical perspective as regards this signal tumor.
</td>
<td style="text-align:left;">
Semin Diagn Pathol
</td>
</tr>
<tr>
<td style="text-align:left;">
Spindle cell tumors of the pleura: differential diagnosis.
</td>
<td style="text-align:left;">
Semin Diagn Pathol
</td>
</tr>
<tr>
<td style="text-align:left;">
EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
The use of monoclonal antibody 44-3A6 in cell blocks in the diagnosis of lung carcinoma, carcinomas metastatic to lung and pleura, and pleural malignant mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Clin. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Feasibility of boron neutron capture therapy (BNCT) for malignant pleural mesothelioma from a viewpoint of dose distribution analysis.
</td>
<td style="text-align:left;">
Int. J. Radiat. Oncol. Biol. Phys.
</td>
</tr>
<tr>
<td style="text-align:left;">
Autocrine growth by granulocyte colony-stimulating factor in malignant mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Can pemetrexed help in malignant mesothelioma?
</td>
<td style="text-align:left;">
Drug Ther Bull
</td>
</tr>
<tr>
<td style="text-align:left;">
Applications and limitations of immunohistochemistry in the diagnosis of malignant mesothelioma.
</td>
<td style="text-align:left;">
Adv Anat Pathol
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: a comprehensive review.
</td>
<td style="text-align:left;">
Cancer Control
</td>
</tr>
<tr>
<td style="text-align:left;">
Solitary fibrous tumor of the pleura.
</td>
<td style="text-align:left;">
Cancer Control
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma with non-pleural malignancy: a red herring or just an uncommon pairing?
</td>
<td style="text-align:left;">
J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Hyperthermia combined with intra-thoracic chemotherapy and radiotherapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int J Hyperthermia
</td>
</tr>
<tr>
<td style="text-align:left;">
Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: outcomes of an expanded access program.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Intracranial metastases from malignant pleural mesothelioma. Report of three autopsy cases and review of the literature.
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunocytochemical panel for the identification of malignant cells in serous effusions.
</td>
<td style="text-align:left;">
Am. J. Clin. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunocytochemical differential diagnosis of diffuse malignant pleural mesotheliomas–a clinicomorphological study of 158 cases.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Atypical mesothelial hyperplasia associated with bronchogenic carcinoma.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Guidelines of the French Speaking Society for Chest Medicine for management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Respir Med
</td>
</tr>
<tr>
<td style="text-align:left;">
In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Mortality and hospital discharges in the population of Biancavilla (Sicily) contaminated by natural fibres].
</td>
<td style="text-align:left;">
Epidemiol Prev
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed disodium for the treatment of malignant pleural mesothelioma: a systematic review and economic evaluation.
</td>
<td style="text-align:left;">
Health Technol Assess
</td>
</tr>
<tr>
<td style="text-align:left;">
Prolonged survival due to spontaneous regression and surgical excision of malignant mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Thoracic stop-flow perfusion in the treatment of refractory malignant pleural mesothelioma: a phase I-II evaluation/trial.
</td>
<td style="text-align:left;">
In Vivo
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of palliative radiotherapy in malignant mesothelioma.
</td>
<td style="text-align:left;">
Clin Oncol (R Coll Radiol)
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of vascular endothelial growth factor in malignant mesothelioma.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Kallikrein 4 is expressed in malignant mesothelioma–further evidence for the histogenetic link between mesothelial and epithelial cells.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Immunotherapy and malignant mesothelioma: clinical perspectives].
</td>
<td style="text-align:left;">
Bull Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma: a case presentation and review.
</td>
<td style="text-align:left;">
J Am Osteopath Assoc
</td>
</tr>
<tr>
<td style="text-align:left;">
[Histopathologic diagnosis of malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Kyobu Geka
</td>
</tr>
<tr>
<td style="text-align:left;">
[Current problems in the diagnosis of malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Kyobu Geka
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Kyobu Geka
</td>
</tr>
<tr>
<td style="text-align:left;">
[Diffuse malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Kyobu Geka
</td>
</tr>
<tr>
<td style="text-align:left;">
Talc mediates angiostasis in malignant pleural effusions via endostatin induction.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cochrane Database Syst Rev
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression patterns of inhibitor of apoptosis proteins in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Clinical types of thoracic cancer. Pleural mesothelioma].
</td>
<td style="text-align:left;">
Rev Mal Respir
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinico-pathological features and somatic gene alterations in refractory ceramic fibre-induced murine mesothelioma reveal mineral fibre-induced mesothelioma identities.
</td>
<td style="text-align:left;">
Carcinogenesis
</td>
</tr>
<tr>
<td style="text-align:left;">
Novel marker D2-40, combined with calretinin, CEA, and TTF-1: an optimal set of immunodiagnostic markers for pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
MESOMARK: a potential test for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin. Chem.
</td>
</tr>
<tr>
<td style="text-align:left;">
Polymorphisms of glutathione-S-transferase M1 and manganese superoxide dismutase are associated with the risk of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
[Expanded access program in the United States and Alimta program for malignant mesothelioma patients].
</td>
<td style="text-align:left;">
Gan To Kagaku Ryoho
</td>
</tr>
<tr>
<td style="text-align:left;">
A novel small-molecule inhibitor of transforming growth factor beta type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Molecular basis of antifolate resistance.
</td>
<td style="text-align:left;">
Cancer Metastasis Rev.
</td>
</tr>
<tr>
<td style="text-align:left;">
Detection of SS18-SSX fusion transcripts in formalin-fixed paraffin-embedded neoplasms: analysis of conventional RT-PCR, qRT-PCR and dual color FISH as diagnostic tools for synovial sarcoma.
</td>
<td style="text-align:left;">
Mod. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Palliative intravenous cisplatin treatment for concurrent peritoneal and pleural mesothelioma in a dog.
</td>
<td style="text-align:left;">
J. Vet. Med. Sci.
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of inhibitor-of-apoptosis protein family members in malignant mesothelioma.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Primary pleural epithelioid hemangioendothelioma with rhabdoid phenotype: report and review of the literature.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Stathmin is overexpressed in malignant mesothelioma.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Emerging drugs for mesothelioma.
</td>
<td style="text-align:left;">
Expert Opin Emerg Drugs
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of the proliferation-associated Ki-67 antigen of transferrin receptors and of DNA polymerase alpha in human tumour lines: implications for in vitro chemoresistance.
</td>
<td style="text-align:left;">
J. Cancer Res. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of radiotherapy in the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin Oncol (R Coll Radiol)
</td>
</tr>
<tr>
<td style="text-align:left;">
Myasthenia gravis in ectopic thymoma presenting as pleural masses.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos-related lung disease.
</td>
<td style="text-align:left;">
Am Fam Physician
</td>
</tr>
<tr>
<td style="text-align:left;">
Taurolidine and povidone-iodine induce different types of cell death in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Retroperitoneal malignant schwannoma and peritoneal malignant mesothelioma: a case report.
</td>
<td style="text-align:left;">
J BUON
</td>
</tr>
<tr>
<td style="text-align:left;">
A case of malignant mesothelioma in a rice-starch factory.
</td>
<td style="text-align:left;">
Int Arch Occup Environ Health
</td>
</tr>
<tr>
<td style="text-align:left;">
Medical thoracoscopy in an Australian regional hospital.
</td>
<td style="text-align:left;">
Intern Med J
</td>
</tr>
<tr>
<td style="text-align:left;">
Inhibition of survivin and aurora B kinase sensitizes mesothelioma cells by enhancing mitotic arrests.
</td>
<td style="text-align:left;">
Int. J. Radiat. Oncol. Biol. Phys.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: two cases in first degree relatives.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): Feasibility and results.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma in blood related subjects: report of 11 clusters among 1954 Italy cases and review of the literature.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II trial of pralatrexate (10-propargyl-10-deazaaminopterin, PDX) in patients with unresectable malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed maintenance therapy in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Targeting mesothelioma using an infectivity enhanced survivin-conditionally replicative adenoviruses.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed as second-line treatment in malignant pleural mesothelioma after platinum-based first-line treatment.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Catheter-tract metastases associated with chronic indwelling pleural catheters.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Treatment of malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Gan To Kagaku Ryoho
</td>
</tr>
<tr>
<td style="text-align:left;">
Potential role of ferritin heavy chain in oxidative stress and apoptosis in human mesothelial and mesothelioma cells: implications for asbestos-induced oncogenesis.
</td>
<td style="text-align:left;">
Carcinogenesis
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemokine receptors are infrequently expressed in malignant and benign mesothelial cells.
</td>
<td style="text-align:left;">
Am. J. Clin. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Late-onset chylothorax following extrapleural pneumonectomy for mesothelioma.
</td>
<td style="text-align:left;">
Gen Thorac Cardiovasc Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma with intracytoplasmic crystalline inclusions.
</td>
<td style="text-align:left;">
Ultrastruct Pathol
</td>
</tr>
<tr>
<td style="text-align:left;">
Sequence-dependent administration of raloxifene and 5-fluorouracil/pemetrexed protects against pemetrexed cytotoxicity in human bone marrow.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Radiat. Oncol. Biol. Phys.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma following thoracic radiotherapy for lung cancer.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelin family proteins and diagnosis of mesothelioma: analytical evaluation of an automated immunoassay and preliminary clinical results.
</td>
<td style="text-align:left;">
Clin. Chem. Lab. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Computer-assisted diagnosis for early stage pleural mesothelioma: towards automated detection and quantitative assessment of pleural thickening from thoracic CT images.
</td>
<td style="text-align:left;">
Methods Inf Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic utility of D2-40 and podoplanin in effusion cell blocks.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Sudden death of an elderly man with multiple malignant neoplasms.
</td>
<td style="text-align:left;">
Am J Forensic Med Pathol
</td>
</tr>
<tr>
<td style="text-align:left;">
Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
The diagnostic role of claudins in serous effusions.
</td>
<td style="text-align:left;">
Am. J. Clin. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Low prevalence of SV40 in Swiss mesothelioma patients after elimination of false-positive PCR results.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
A preliminary experimental study of boron neutron capture therapy for malignant tumors spreading in thoracic cavity.
</td>
<td style="text-align:left;">
Jpn. J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Severe cutaneous toxicity after Pemetrexed as second line treatment for a refractory non small cell lung cancer].
</td>
<td style="text-align:left;">
Rev Mal Respir
</td>
</tr>
<tr>
<td style="text-align:left;">
Management options for malignant pleural mesothelioma: clinical and cost considerations.
</td>
<td style="text-align:left;">
Drugs
</td>
</tr>
<tr>
<td style="text-align:left;">
Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Chemother. Pharmacol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Evidence-based guidelines for the utilization of immunostains in diagnostic pathology: pulmonary adenocarcinoma versus mesothelioma.
</td>
<td style="text-align:left;">
Appl. Immunohistochem. Mol. Morphol.
</td>
</tr>
<tr>
<td style="text-align:left;">
The risk of mesothelioma from exposure to chrysotile asbestos.
</td>
<td style="text-align:left;">
Curr Opin Pulm Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Local adoptive immunotherapy using lymphokine-activated killer cells and interleukin-2 against malignant pleural mesothelioma: report of two cases.
</td>
<td style="text-align:left;">
Jpn. J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: current concepts in treatment.
</td>
<td style="text-align:left;">
Nat Clin Pract Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
MN/CA9: a potential gene marker for detection of malignant cells in effusions.
</td>
<td style="text-align:left;">
Biomarkers
</td>
</tr>
<tr>
<td style="text-align:left;">
Recent discovery of an old disease: malignant pleural mesothelioma in a village in south-east Turkey.
</td>
<td style="text-align:left;">
Respirology
</td>
</tr>
<tr>
<td style="text-align:left;">
[A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
</td>
<td style="text-align:left;">
Pneumonol Alergol Pol
</td>
</tr>
<tr>
<td style="text-align:left;">
Solitary fibrous tumor of the mediastinum.
</td>
<td style="text-align:left;">
Ultrastruct Pathol
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Effect of the TAT-RasGAP(317-326) peptide on apoptosis of human malignant mesothelioma cells and fibroblasts exposed to meso-tetra-hydroxyphenyl-chlorin and light.
</td>
<td style="text-align:left;">
J. Photochem. Photobiol. B, Biol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pseudomesotheliomatous carcinoma of the lung. A variant of peripheral lung cancer.
</td>
<td style="text-align:left;">
Am. J. Clin. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
The essential role of the mitochondria and reactive oxygen species in Cisplatin-mediated enhancement of fas ligand-induced apoptosis in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Surg. Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Establishment and characterization of two distinct malignant mesothelioma cell lines with common clonal origin.
</td>
<td style="text-align:left;">
Cancer Genet. Cytogenet.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Management of malignant pleural effusion].
</td>
<td style="text-align:left;">
Rev Prat
</td>
</tr>
<tr>
<td style="text-align:left;">
A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Radiother Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
[Peritoneal mesothelioma: an inusual clinical presentation in a patient without exposure to asbestos].
</td>
<td style="text-align:left;">
An Med Interna
</td>
</tr>
<tr>
<td style="text-align:left;">
Constrictive pericarditis after left extrapleural pneumonectomy and radiotherapy for malignant mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Evaluation of simian virus-40 as a biological prognostic factor in Egyptian patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Pathol. Int.
</td>
</tr>
<tr>
<td style="text-align:left;">
Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
DNA methylation profile of 28 potential marker loci in malignant mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Polyhematoporphyrin-mediated photodynamic therapy and decortication in palliation of malignant pleural mesothelioma: a clinical pilot study.
</td>
<td style="text-align:left;">
Interact Cardiovasc Thorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
The MARS trial: mesothelioma and radical surgery.
</td>
<td style="text-align:left;">
Interact Cardiovasc Thorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Multidisciplinary treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncologist
</td>
</tr>
<tr>
<td style="text-align:left;">
D2-40-positive solitary fibrous tumors of the pleura: diagnostic pitfall of biopsy specimen.
</td>
<td style="text-align:left;">
Pathol. Int.
</td>
</tr>
<tr>
<td style="text-align:left;">
Optimising survival in malignant mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Accuracy and reproducibility of pleural effusion cytology.
</td>
<td style="text-align:left;">
Leg Med (Tokyo)
</td>
</tr>
<tr>
<td style="text-align:left;">
Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans.
</td>
<td style="text-align:left;">
J. Nucl. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II testing of sunitinib: the National Cancer Institute of Canada Clinical Trials Group IND Program Trials IND.182-185.
</td>
<td style="text-align:left;">
Curr Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Incidence trends and gender differences in malignant mesothelioma in New South Wales, Australia.
</td>
<td style="text-align:left;">
Scand J Work Environ Health
</td>
</tr>
<tr>
<td style="text-align:left;">
[Clinical utility of thoracoscopy under local anesthesia].
</td>
<td style="text-align:left;">
Kyobu Geka
</td>
</tr>
<tr>
<td style="text-align:left;">
Assessment of tumor response in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Treat. Rev.
</td>
</tr>
<tr>
<td style="text-align:left;">
Correlations between findings at computed tomography (CT) and at thoracoscopy/thoracotomy/autopsy in pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pemetrexed development in oncology].
</td>
<td style="text-align:left;">
Bull Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Accuracy of pleural biopsy using thoracoscopy for the diagnosis of histologic subtype in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
The therapeutic efficacy of anti vascular endothelial growth factor antibody, bevacizumab, and pemetrexed against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mediastinal tumor with bone formation–mesothelioma or sarcoma?
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Primary pleural thymoma with coexistent incidental small hepatocellular carcinoma - an autopsy case report with brief review of literature.
</td>
<td style="text-align:left;">
Pathol. Res. Pract.
</td>
</tr>
<tr>
<td style="text-align:left;">
The value of calretinin and cytokeratin 5/6 as markers for mesothelioma in cell block preparations of serous effusions.
</td>
<td style="text-align:left;">
Cytopathology
</td>
</tr>
<tr>
<td style="text-align:left;">
Gene methylation in pleural mesothelioma: correlations with clinico-pathological features and patient’s follow-up.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
[Role of DNA microarrays in the diagnosis of pleural exudates: a feasibility study].
</td>
<td style="text-align:left;">
Rev Mal Respir
</td>
</tr>
<tr>
<td style="text-align:left;">
The incidence of malignant mesothelioma in Australia 1982-1988.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Combined photon and electron three-dimensional conformal versus intensity-modulated radiotherapy with integrated boost for adjuvant treatment of malignant pleural mesothelioma after pleuropneumonectomy.
</td>
<td style="text-align:left;">
Int. J. Radiat. Oncol. Biol. Phys.
</td>
</tr>
<tr>
<td style="text-align:left;">
Non-invasive diagnosis of pleural malignancies: the role of tumour markers.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelin targeted cancer immunotherapy.
</td>
<td style="text-align:left;">
Eur. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II study of vinflunine in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunohistochemical detection of XIAP in mesothelium and mesothelial lesions.
</td>
<td style="text-align:left;">
Am. J. Clin. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Increased pleural fluid adenosine deaminase levels in patients with malignant pleural effusions: a potential predictor of talc pleurodesis outcome.
</td>
<td style="text-align:left;">
Lung
</td>
</tr>
<tr>
<td style="text-align:left;">
Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin.
</td>
<td style="text-align:left;">
Mol. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Morphologic and functional imaging of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Radiol
</td>
</tr>
<tr>
<td style="text-align:left;">
Low-dose computed tomography screening for lung cancer and pleural mesothelioma in an asbestos-exposed population: baseline results of a prospective, nonrandomized feasibility trial–an Alpe-adria Thoracic Oncology Multidisciplinary Group Study (ATOM 002).
</td>
<td style="text-align:left;">
Oncologist
</td>
</tr>
<tr>
<td style="text-align:left;">
Peritoneal mesothelioma presenting as an acute surgical abdomen due to jejunal perforation.
</td>
<td style="text-align:left;">
J Dig Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Flowcytometric immunophenotyping of peripheral-blood leukocytes in relation to immunopathology and cellular proliferation of pleural mesothelioma.
</td>
<td style="text-align:left;">
Egypt J Immunol
</td>
</tr>
<tr>
<td style="text-align:left;">
Analysis of latency time and its determinants in asbestos related malignant mesothelioma cases of the Italian register.
</td>
<td style="text-align:left;">
Eur. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Pseudomesotheliomatous adenocarcinoma of the lung with synchronous gastric and esophageal cancer.
</td>
<td style="text-align:left;">
Australas Radiol
</td>
</tr>
<tr>
<td style="text-align:left;">
Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810).
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
MUC4 is upregulated in ovarian carcinoma effusions and differentiates carcinoma cells from mesothelial cells.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunohistochemical expression and distribution of VEGFR-3 in malignant mesothelioma.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Role of fragile histidine triad protein expression in pathogenesis of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Pathology
</td>
</tr>
<tr>
<td style="text-align:left;">
Solitary fibrous tumor of the anterior mediastinum: a rare extrapleural neoplasm.
</td>
<td style="text-align:left;">
Tumori
</td>
</tr>
<tr>
<td style="text-align:left;">
Mortality of former crocidolite (blue asbestos) miners and millers at Wittenoom.
</td>
<td style="text-align:left;">
Occup Environ Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Reactivity of integrin-linked kinase in human mesothelial cell proliferation.
</td>
<td style="text-align:left;">
Interact Cardiovasc Thorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
[Epidemiological surveillance of malignant mesothelioma cases in Italy: incidence and asbestos exposure figures by the Italian mesothelioma registry (ReNaM)].
</td>
<td style="text-align:left;">
Epidemiol Prev
</td>
</tr>
<tr>
<td style="text-align:left;">
[Asbestos exposure in the non-asbestos textile industry: the experience of the Lombardy Mesothelioma Registry].
</td>
<td style="text-align:left;">
Epidemiol Prev
</td>
</tr>
<tr>
<td style="text-align:left;">
[Renal cell carcinoma with malignant pleural mesothelioma after asbestos exposure: a case report].
</td>
<td style="text-align:left;">
Hinyokika Kiyo
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of video assisted thoracoscopic pleurectomy/decortication in the therapeutic management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
The potential role of pemetrexed in gastrointestinal cancer.
</td>
<td style="text-align:left;">
Chemotherapy
</td>
</tr>
<tr>
<td style="text-align:left;">
Utility of WT-1, p63, MOC31, mesothelin, and cytokeratin (K903 and CK5/6) immunostains in differentiating adenocarcinoma, squamous cell carcinoma, and malignant mesothelioma in effusions.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Integrated FDG PET-CT imaging improves staging in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Nuklearmedizin
</td>
</tr>
<tr>
<td style="text-align:left;">
Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Absence of evidence for a significant background incidence of diffuse malignant mesothelioma apart from asbestos exposure.
</td>
<td style="text-align:left;">
Ann. N. Y. Acad. Sci.
</td>
</tr>
<tr>
<td style="text-align:left;">
Analysis of asbestos fibers in lung parenchyma, pleural plaques, and mesothelioma tissues of North American insulation workers.
</td>
<td style="text-align:left;">
Ann. N. Y. Acad. Sci.
</td>
</tr>
<tr>
<td style="text-align:left;">
Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: surgical management in 285 patients.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Localised malignant pleural mesothelioma: a separate clinical entity requiring aggressive local surgery.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Gene copy number analysis in malignant pleural mesothelioma using oligonucleotide array CGH.
</td>
<td style="text-align:left;">
Cytogenet. Genome Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: clinicopathologic and survival characteristics in a consecutive series of 394 patients.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma: interrogations and hopes concerning the expected epidemic].
</td>
<td style="text-align:left;">
Rev Pneumol Clin
</td>
</tr>
<tr>
<td style="text-align:left;">
Presence of malignant mesothelial cells in the sputum.
</td>
<td style="text-align:left;">
Intern. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytologic malignancy versus benignancy: how useful are the “newer” markers in body fluid cytology?
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Twenty-five years of fiber analysis: what have we learned?
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Helical tomotherapy. Experiences of the first 150 patients in Heidelberg.
</td>
<td style="text-align:left;">
Strahlenther Onkol
</td>
</tr>
<tr>
<td style="text-align:left;">
Population based epidemiology and prognosis of mesothelioma in Leeds, UK.
</td>
<td style="text-align:left;">
Thorax
</td>
</tr>
<tr>
<td style="text-align:left;">
Tissue inhibitor of metalloproteinase 2 (TIMP-2) expression in adenocarcinoma pleural effusions.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
</tr>
<tr>
<td style="text-align:left;">
Evaluating target coverage and normal tissue sparing in the adjuvant radiotherapy of malignant pleural mesothelioma: helical tomotherapy compared with step-and-shoot IMRT.
</td>
<td style="text-align:left;">
Radiother Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Advances in the systemic therapy of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Nat Clin Pract Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
[Epidemiology, molecular biology, diagnostic and therapeutic strategy of malignant pleural mesothelioma in 2007 - an update].
</td>
<td style="text-align:left;">
Rev Mal Respir
</td>
</tr>
<tr>
<td style="text-align:left;">
Cost-effectiveness of pemetrexed plus cisplatin: malignant pleural mesothelioma treatment in UK clinical practice.
</td>
<td style="text-align:left;">
Value Health
</td>
</tr>
<tr>
<td style="text-align:left;">
PTEN expression is a strong predictor of survival in mesothelioma patients.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Intensity-modulated radiotherapy for resected mesothelioma: the Duke experience.
</td>
<td style="text-align:left;">
Int. J. Radiat. Oncol. Biol. Phys.
</td>
</tr>
<tr>
<td style="text-align:left;">
Diploid predominance and prognostic significance of S-phase cells in malignant mesothelioma.
</td>
<td style="text-align:left;">
Eur. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
[The Lombardy Mesothelioma Register, Regional Operating Centre (ROC) of National Mesothelioma Register: organizational aspects].
</td>
<td style="text-align:left;">
Epidemiol Prev
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma: multidisciplinary experience in a public tertiary hospital].
</td>
<td style="text-align:left;">
J Bras Pneumol
</td>
</tr>
<tr>
<td style="text-align:left;">
Pericardial malignant mesothelioma: a latent complication of radiotherapy?
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Intracavitary radioimmunotherapy to treat solid tumors.
</td>
<td style="text-align:left;">
Cancer Biother. Radiopharm.
</td>
</tr>
<tr>
<td style="text-align:left;">
Biological characteristics of cancers involving the serosal cavities.
</td>
<td style="text-align:left;">
Crit Rev Oncog
</td>
</tr>
<tr>
<td style="text-align:left;">
Unusual features of malignant pleural mesothelioma metastatic to the mediastinal lymph nodes.
</td>
<td style="text-align:left;">
Appl. Immunohistochem. Mol. Morphol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesothelioma: diagnostic problems and evaluation of prognostic factors.
</td>
<td style="text-align:left;">
J Egypt Natl Canc Inst
</td>
</tr>
<tr>
<td style="text-align:left;">
Transcriptome sequencing of malignant pleural mesothelioma tumors.
</td>
<td style="text-align:left;">
Proc. Natl. Acad. Sci. U.S.A.
</td>
</tr>
<tr>
<td style="text-align:left;">
[New diagnostic markers for malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Bull Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
9p21 Deletion in the diagnosis of malignant mesothelioma in serous effusions additional to immunocytochemistry, DNA-ICM, and AgNOR analysis.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos exposure predicts cell cycle control gene promoter methylation in pleural mesothelioma.
</td>
<td style="text-align:left;">
Carcinogenesis
</td>
</tr>
<tr>
<td style="text-align:left;">
Characterization of human mesothelioma cell lines as tumor models for suicide gene therapy.
</td>
<td style="text-align:left;">
Onkologie
</td>
</tr>
<tr>
<td style="text-align:left;">
Improved identification of malignant cells in serous effusions using a small, robust panel of antibodies on paraffin-embedded cell suspensions.
</td>
<td style="text-align:left;">
Acta Cytol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Advances in the molecular biology of malignant mesothelioma.
</td>
<td style="text-align:left;">
Acta Med. Okayama
</td>
</tr>
<tr>
<td style="text-align:left;">
Localized malignant mesenteric mesothelioma causing small bowel obstruction.
</td>
<td style="text-align:left;">
Pathol. Int.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma in the Veneto Region (north-east of Italy), 1988-2002: incidence, geographical analysis, trends and comparison with mortality].
</td>
<td style="text-align:left;">
Epidemiol Prev
</td>
</tr>
<tr>
<td style="text-align:left;">
A conditional mouse model for malignant mesothelioma.
</td>
<td style="text-align:left;">
Cancer Cell
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural effusion].
</td>
<td style="text-align:left;">
Ann Ital Chir
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: utility of 18 F-FDG PET.
</td>
<td style="text-align:left;">
Ann Ital Chir
</td>
</tr>
<tr>
<td style="text-align:left;">
[Evaluation of the rehabilitation program in a patient submitted to pleuropneumonectomy for malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Ann Ital Chir
</td>
</tr>
<tr>
<td style="text-align:left;">
Regional pharmacokinetic selectivity of intrapleural cisplatin.
</td>
<td style="text-align:left;">
Eur. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Erionite series minerals: mineralogical and carcinogenic properties.
</td>
<td style="text-align:left;">
Environ Geochem Health
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: computed tomography and correlation with histology.
</td>
<td style="text-align:left;">
Eur J Radiol
</td>
</tr>
<tr>
<td style="text-align:left;">
Bcl-xL antisense oligonucleotide and cisplatin combination therapy extends survival in SCID mice with established mesothelioma xenografts.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Novel dual targeting strategy with vandetanib induces tumor cell apoptosis and inhibits angiogenesis in malignant pleural mesothelioma cells expressing RET oncogenic rearrangement.
</td>
<td style="text-align:left;">
Cancer Lett.
</td>
</tr>
<tr>
<td style="text-align:left;">
Therapy response in malignant pleural mesothelioma-role of MRI using RECIST, modified RECIST and volumetric approaches in comparison with CT.
</td>
<td style="text-align:left;">
Eur Radiol
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of muscle flap in preventing bronchus stump insufficiency after pneumonectomy for malignant pleural mesothelioma in high-risk patients.
</td>
<td style="text-align:left;">
Interact Cardiovasc Thorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Management of malignant pleural effusion associated with trapped lung syndrome.
</td>
<td style="text-align:left;">
Asian Cardiovasc Thorac Ann
</td>
</tr>
<tr>
<td style="text-align:left;">
Establishment of three novel human malignant pleural mesothelioma cell lines: morphological and cytogenetical studies and EGFR mutation status.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
The diagnostic value of Ki-67 and repp86 in distinguishing between benign and malignant mesothelial proliferations.
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Epidermal growth factor receptor gene mutation, amplification and protein expression in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Cancer Res. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Frequent p16 inactivation by homozygous deletion or methylation is associated with a poor prognosis in Japanese patients with pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Outcome after extrapleural pneumonectomy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
[Evaluation of a series of serum mesothelin in patients with pleural malignant mesothelioma].
</td>
<td style="text-align:left;">
G Ital Med Lav Ergon
</td>
</tr>
<tr>
<td style="text-align:left;">
[Serum mesothelin dosages in follow-up of previously exposed workers].
</td>
<td style="text-align:left;">
G Ital Med Lav Ergon
</td>
</tr>
<tr>
<td style="text-align:left;">
Measurement of trends in incidence of work-related skin and respiratory diseases, UK 1996-2005.
</td>
<td style="text-align:left;">
Occup Environ Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Genetic susceptibility to malignant pleural mesothelioma and other asbestos-associated diseases.
</td>
<td style="text-align:left;">
Mutat. Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic value of carcinoembryonic antigen in malignant pleural effusion: a meta-analysis.
</td>
<td style="text-align:left;">
Respirology
</td>
</tr>
<tr>
<td style="text-align:left;">
Pharmacokinetic analysis of malignant pleural mesothelioma-initial results of tumor microcirculation and its correlation to microvessel density (CD-34).
</td>
<td style="text-align:left;">
Acad Radiol
</td>
</tr>
<tr>
<td style="text-align:left;">
Individual versus standard quality of life assessment in a phase II clinical trial in mesothelioma patients: feasibility and responsiveness to clinical changes.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Efficacy and safety of pemetrexed in combination with cisplatin for malignant pleural mesothelioma: a phase I/II study in Japanese patients.
</td>
<td style="text-align:left;">
Jpn. J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Incidence of pleural mesotheliomas in Poland (preliminary report)].
</td>
<td style="text-align:left;">
Pneumonol Alergol Pol
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant peritoneal mesothelioma as a rare cause of ascites: a case report.
</td>
<td style="text-align:left;">
J Med Case Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma with unexpected contralateral mediastinal shift: a case report.
</td>
<td style="text-align:left;">
J Med Case Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
Trimodality treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
[The contribution of positron emission tomography in pleural disease].
</td>
<td style="text-align:left;">
Rev Mal Respir
</td>
</tr>
<tr>
<td style="text-align:left;">
Video-assisted cervical thoracoscopy: a novel approach for diagnosis, staging and pleurodesis of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
CT findings in malignant pleural mesothelioma related to nonoccupational exposure to asbestos and fibrous zeolite (erionite).
</td>
<td style="text-align:left;">
J Comput Assist Tomogr
</td>
</tr>
<tr>
<td style="text-align:left;">
Thoracoscopy in pleural malignant mesothelioma diagnosis.
</td>
<td style="text-align:left;">
Diagn Ther Endosc
</td>
</tr>
<tr>
<td style="text-align:left;">
[Erionite-induced pleural plaques. Exposition to urban pollution in a female Turkish migrant in Germany].
</td>
<td style="text-align:left;">
Chirurg
</td>
</tr>
<tr>
<td style="text-align:left;">
Pulmonary paragonimiasis with coincidental malignant mesothelioma.
</td>
<td style="text-align:left;">
Intern. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
The relationship between simian virus 40 and mesothelioma.
</td>
<td style="text-align:left;">
Curr Opin Pulm Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Prophylactic radiotherapy for pleural puncture sites in mesothelioma: the controversy continues.
</td>
<td style="text-align:left;">
Curr Opin Pulm Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Image-guided pleural biopsy.
</td>
<td style="text-align:left;">
Curr Opin Pulm Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Response of a patient with pleural and peritoneal mesothelioma after second-line chemotherapy with lipoplatin and gemcitabine.
</td>
<td style="text-align:left;">
Oncology
</td>
</tr>
<tr>
<td style="text-align:left;">
Excess of mesotheliomas after exposure to chrysotile in Balangero, Italy.
</td>
<td style="text-align:left;">
Occup Environ Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Uroplakin is not a reliable immunohistochemical marker for malignant mesothelioma of the pleura.
</td>
<td style="text-align:left;">
Appl. Immunohistochem. Mol. Morphol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical activity of vinflunine in transitional cell carcinoma of the urothelium and other solid tumors.
</td>
<td style="text-align:left;">
Semin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Schedule-dependent synergistic effect of pemetrexed combined with gemcitabine against malignant pleural mesothelioma and non-small cell lung cancer cell lines.
</td>
<td style="text-align:left;">
Chemotherapy
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos burden predicts survival in pleural mesothelioma.
</td>
<td style="text-align:left;">
Environ. Health Perspect.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pathology of primary tumours of the pleura].
</td>
<td style="text-align:left;">
Zentralbl Chir
</td>
</tr>
<tr>
<td style="text-align:left;">
[Chemotherapy of malignant pleural mesothelioma: have we made any progress?].
</td>
<td style="text-align:left;">
Zentralbl Chir
</td>
</tr>
<tr>
<td style="text-align:left;">
Piroxicam and intracavitary platinum-based chemotherapy for the treatment of advanced mesothelioma in pets: preliminary observations.
</td>
<td style="text-align:left;">
J. Exp. Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Induction of apoptosis by intrapleural perfusion hyperthermo-chemotherapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann Thorac Cardiovasc Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Solitary fibrous pleural tumor.
</td>
<td style="text-align:left;">
J Am Osteopath Assoc
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma with heterologous elements: clinicopathological correlation of 27 cases and literature review.
</td>
<td style="text-align:left;">
Mod. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Multiple mechanisms of telomere maintenance exist and differentially affect clinical outcome in diffuse malignant peritoneal mesothelioma.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Single-agent pemetrexed for chemonaïve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma: current status and perspective in Japan and the world.
</td>
<td style="text-align:left;">
Gen Thorac Cardiovasc Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pemetrexed].
</td>
<td style="text-align:left;">
Gan To Kagaku Ryoho
</td>
</tr>
<tr>
<td style="text-align:left;">
Assessment of biomarkers in asbestos-exposed workers as indicators of cancer risk.
</td>
<td style="text-align:left;">
Mutat. Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Long-term indwelling pleural catheter (PleurX) for malignant pleural effusion unsuitable for talc pleurodesis.
</td>
<td style="text-align:left;">
Eur J Surg Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
The comparative accuracy of different pleural biopsy techniques in the diagnosis of malignant mesothelioma.
</td>
<td style="text-align:left;">
Histopathology
</td>
</tr>
<tr>
<td style="text-align:left;">
[A case of malignant pleural mesothelioma presenting as pneumothorax].
</td>
<td style="text-align:left;">
Nihon Kyobu Shikkan Gakkai Zasshi
</td>
</tr>
<tr>
<td style="text-align:left;">
Use of monoclonal antibody B72.3 as a marker of metastatic carcinoma cells in neoplastic effusions.
</td>
<td style="text-align:left;">
Pathologica
</td>
</tr>
<tr>
<td style="text-align:left;">
Establishment of a human malignant fibrous mesothelioma cell line and the biological characteristics compared with malignant epithelial mesothelioma cell line.
</td>
<td style="text-align:left;">
Hum. Cell
</td>
</tr>
<tr>
<td style="text-align:left;">
Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
MET as a target for treatment of chest tumors.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
[Use of hospital discharge records to estimate the incidence of malignant mesotheliomas].
</td>
<td style="text-align:left;">
Epidemiol Prev
</td>
</tr>
<tr>
<td style="text-align:left;">
Sensitivity analysis of the relationship between disease occurrence and distance from a putative source of pollution.
</td>
<td style="text-align:left;">
Geospat Health
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma in garment sewing-machine workers].
</td>
<td style="text-align:left;">
Med Lav
</td>
</tr>
<tr>
<td style="text-align:left;">
[Full-thickness pleural biopsy using an Insulation-tipped Diathermic Knife in a patient with malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Kyobu Geka
</td>
</tr>
<tr>
<td style="text-align:left;">
Enhanced antitumor therapy by inhibition of p21waf1 in human malignant mesothelioma.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma epidemiology, carcinogenesis, and pathogenesis.
</td>
<td style="text-align:left;">
Curr Treat Options Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Review of pemetrexed in combination with cisplatin for the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ther Clin Risk Manag
</td>
</tr>
<tr>
<td style="text-align:left;">
Novel oncolytic agent GLV-1h68 is effective against malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Hum. Gene Ther.
</td>
</tr>
<tr>
<td style="text-align:left;">
Lysophosphatidic acid stimulates the proliferation and motility of malignant pleural mesothelioma cells through lysophosphatidic acid receptors, LPA1 and LPA2.
</td>
<td style="text-align:left;">
Cancer Sci.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma-targeted CREBBP/EP300 inhibitory protein 1 promoter system for gene therapy and virotherapy.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Recent advances in the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnosis, staging, and surgical treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Curr Treat Options Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
[Diagnosis of diffuse pleural mesotheliomas].
</td>
<td style="text-align:left;">
Pneumologie
</td>
</tr>
<tr>
<td style="text-align:left;">
Protein kinase C beta in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Anticancer Drugs
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical consequences of asbestos-related diffuse pleural thickening: A review.
</td>
<td style="text-align:left;">
J Occup Med Toxicol
</td>
</tr>
<tr>
<td style="text-align:left;">
Pathogenesis of malignant pleural mesothelioma and the role of environmental and genetic factors.
</td>
<td style="text-align:left;">
J. Cancer Res. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Survival of pleural malignant mesothelioma in Italy: a population-based study.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Proteasome Inhibitor MG132 Induces Apoptosis and Inhibits Invasion of Human Malignant Pleural Mesothelioma Cells.
</td>
<td style="text-align:left;">
Transl Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
The impact of lymph node station on survival in 348 patients with surgically resected malignant pleural mesothelioma: implications for revision of the American Joint Committee on Cancer staging system.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Predicted mortality from malignant mesothelioma among women exposed to blue asbestos at Wittenoom, Western Australia.
</td>
<td style="text-align:left;">
Occup Environ Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Inhibition of Hsp90 leads to cell cycle arrest and apoptosis in human malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Transesophageal endoscopic ultrasound with fine needle aspiration in the preoperative staging of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Assessment of Survival and Clinical Benefit in Malignant Pleural Mesothelioma (MPM) Patients Treated with Gemcitabine and Carboplatin.
</td>
<td style="text-align:left;">
J Egypt Natl Canc Inst
</td>
</tr>
<tr>
<td style="text-align:left;">
Pulmonary epithelioid hemangioendothelioma mimicking mesothelioma.
</td>
<td style="text-align:left;">
Pathol. Int.
</td>
</tr>
<tr>
<td style="text-align:left;">
Histologic assessment and prognostic factors of malignant pleural mesothelioma treated with extrapleural pneumonectomy.
</td>
<td style="text-align:left;">
Am. J. Clin. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
A useful antibody panel for differential diagnosis between peritoneal mesothelioma and ovarian serous carcinoma in Japanese cases.
</td>
<td style="text-align:left;">
Am. J. Clin. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Cardiac tamponade as primary manifestation of angioimmunoblastic T-cell lymphoma (AILT). Coexistence with malignant mesothelioma.
</td>
<td style="text-align:left;">
Onkologie
</td>
</tr>
<tr>
<td style="text-align:left;">
Down-regulation of inhibition of differentiation-1 via activation of activating transcription factor 3 and Smad regulates REIC/Dickkopf-3-induced apoptosis.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Carboplatin and pemetrexed in the management of malignant pleural mesothelioma: a realistic treatment option?
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
A case of solid pseudopapillary tumour of the pancreas and malignant mesothelioma.
</td>
<td style="text-align:left;">
J Gastrointest Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse malignant pleural mesothelioma: a multi-institutional clinicopathological study.
</td>
<td style="text-align:left;">
Surg. Today
</td>
</tr>
<tr>
<td style="text-align:left;">
[Other thoracic cancers. Malignant pleural mesothelioma: biology and diagnosis].
</td>
<td style="text-align:left;">
Rev Mal Respir
</td>
</tr>
<tr>
<td style="text-align:left;">
Genomic events associated with progression of pleural malignant mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Polyneuropathy in a patient with malignant pleural mesothelioma: a paraneoplastic syndrome.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Effective chemotherapy based on a chemosensitivity test for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann Thorac Cardiovasc Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
The CREST biorepository: a tool for molecular epidemiology and translational studies on malignant mesothelioma, lung cancer, and other respiratory tract diseases.
</td>
<td style="text-align:left;">
Cancer Epidemiol. Biomarkers Prev.
</td>
</tr>
<tr>
<td style="text-align:left;">
Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: a review of practice in British Columbia.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma of the tunica vaginalis of the testis without exposure to asbestos.
</td>
<td style="text-align:left;">
Cases J
</td>
</tr>
<tr>
<td style="text-align:left;">
Compensator-based intensity-modulated radiation therapy for malignant pleural mesothelioma post extrapleural pneumonectomy.
</td>
<td style="text-align:left;">
J Appl Clin Med Phys
</td>
</tr>
<tr>
<td style="text-align:left;">
Biomarkers for malignant pleural mesothelioma: current status.
</td>
<td style="text-align:left;">
Mol Diagn Ther
</td>
</tr>
<tr>
<td style="text-align:left;">
Problems in mesothelioma diagnosis.
</td>
<td style="text-align:left;">
Histopathology
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of GATA-6 transcription factor in pleural malignant mesothelioma and metastatic pulmonary adenocarcinoma.
</td>
<td style="text-align:left;">
J. Clin. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Telomerase activity in effusions: a comparison between telomere repeat amplification protocol in situ and conventional telomere repeat amplification protocol assay.
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
[An autopsy case of sarcomatoid malignant mesothelioma mimicking adenocarcinoma with sarcomatoid elements of lung].
</td>
<td style="text-align:left;">
Nihon Kokyuki Gakkai Zasshi
</td>
</tr>
<tr>
<td style="text-align:left;">
Simian virus 40 sequences in blood specimens from healthy individuals of Casale Monferrato, an industrial town with a history of asbestos pollution.
</td>
<td style="text-align:left;">
J. Infect.
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse malignant peritoneal mesothelioma: Failure analysis following cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).
</td>
<td style="text-align:left;">
Ann. Surg. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos-related occupational lung diseases in NSW, Australia and potential exposure of the general population.
</td>
<td style="text-align:left;">
Ind Health
</td>
</tr>
<tr>
<td style="text-align:left;">
Vitamin D-mediated hypercalcemia and Cushing syndrome as manifestations of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Endocr Pract
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma.
</td>
<td style="text-align:left;">
Orphanet J Rare Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural effusion as the presenting site of cancer: comparison with metastatic pleural effusions from known cancers].
</td>
<td style="text-align:left;">
Rev Mal Respir
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase I and pharmacokinetic study of pemetrexed plus cisplatin in chemonaive patients with locally advanced or metastatic malignant pleural mesothelioma or non-small cell lung cancer.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
A new electrocautery pleural biopsy technique using an insulated-tip diathermic knife during semirigid pleuroscopy.
</td>
<td style="text-align:left;">
Surg Endosc
</td>
</tr>
<tr>
<td style="text-align:left;">
A feasibility study of induction pemetrexed plus cisplatin followed by extrapleural pneumonectomy and postoperative hemithoracic radiation for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Jpn. J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
In vitro-chemosensitivity test using the collagen gel droplet embedded culture drug test (CD-DST) for malignant pleural mesothelioma: possibility of clinical application.
</td>
<td style="text-align:left;">
Ann Thorac Cardiovasc Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Does video-assisted thoracoscopic decortication in advanced malignant mesothelioma improve prognosis?
</td>
<td style="text-align:left;">
Interact Cardiovasc Thorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed disodium for the treatment of NSCLC: an update.
</td>
<td style="text-align:left;">
Drugs Today
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnosis of epithelial mesothelioma using tree-based regression analysis and a minimal panel of antibodies.
</td>
<td style="text-align:left;">
Pathology
</td>
</tr>
<tr>
<td style="text-align:left;">
Tryptase mast cells in malignant pleural mesothelioma as an independent favorable prognostic factor.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Texture- and object-related automated information analysis in histological still images of various organs.
</td>
<td style="text-align:left;">
Anal. Quant. Cytol. Histol.
</td>
</tr>
<tr>
<td style="text-align:left;">
A phase I study of extrapleural pneumonectomy and intracavitary intraoperative hyperthermic cisplatin with amifostine cytoprotection for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure.
</td>
<td style="text-align:left;">
Cancer Epidemiol. Biomarkers Prev.
</td>
</tr>
<tr>
<td style="text-align:left;">
Gene therapy for malignant pleural mesothelioma: present and future.
</td>
<td style="text-align:left;">
Oncol. Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment.
</td>
<td style="text-align:left;">
Am. J. Respir. Crit. Care Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Early detection of malignant pleural mesothelioma through measurement of soluble mesothelin-related protein and positron emission tomography.
</td>
<td style="text-align:left;">
Med. J. Aust.
</td>
</tr>
<tr>
<td style="text-align:left;">
Death certificate categorization of malignant pleural and peritoneal mesothelioma in a cohort of asbestos insulation workers.
</td>
<td style="text-align:left;">
J Soc Occup Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Identification of potential therapeutic targets in malignant mesothelioma using cell-cycle gene expression analysis.
</td>
<td style="text-align:left;">
Am. J. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemotherapy of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Expert Opin Pharmacother
</td>
</tr>
<tr>
<td style="text-align:left;">
[Remission of malignant pleural mesothelioma using high-dose cisplatin in monochemotherapy].
</td>
<td style="text-align:left;">
Rev Mal Respir
</td>
</tr>
<tr>
<td style="text-align:left;">
Hyperthermic chemoperfusion for the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Semin. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Establishment of novel mAb to human ERC/mesothelin useful for study and diagnosis of ERC/mesothelin-expressing cancers.
</td>
<td style="text-align:left;">
Pathol. Int.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Asbestos fibre lung burden and exposure indices in asbestos-cement workers].
</td>
<td style="text-align:left;">
Med Lav
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunohistochemical distribution patterns of epidermal growth factor receptor in malignant mesothelioma and non-neoplastic mesothelium.
</td>
<td style="text-align:left;">
Virchows Arch A Pathol Anat Histopathol
</td>
</tr>
<tr>
<td style="text-align:left;">
Three-dimensional evaluation of chemotherapy response in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Radiol
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed in first-line treatment of non-small cell lung cancer.
</td>
<td style="text-align:left;">
Cancer Treat. Rev.
</td>
</tr>
<tr>
<td style="text-align:left;">
Ultrastructural and immunohistochemical analysis of fibrous long-spacing collagen fibrils in malignant mesothelioma.
</td>
<td style="text-align:left;">
Ultrastruct Pathol
</td>
</tr>
<tr>
<td style="text-align:left;">
Symptomatic and quality of life changes after extrapleural pneumonectomy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Surg Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Tumorigenic properties of alternative osteopontin isoforms in mesothelioma.
</td>
<td style="text-align:left;">
Biochem. Biophys. Res. Commun.
</td>
</tr>
<tr>
<td style="text-align:left;">
Usefulness of EMA, GLUT-1, and XIAP for the cytologic diagnosis of malignant mesothelioma in body cavity fluids.
</td>
<td style="text-align:left;">
Am. J. Clin. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions.
</td>
<td style="text-align:left;">
Am. J. Respir. Crit. Care Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesothelioma: an unusual case diagnosed on pleural fluid cytology and immunocytochemistry.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Serum mesothelin has a higher diagnostic utility than hyaluronic acid in malignant mesothelioma.
</td>
<td style="text-align:left;">
Clin. Biochem.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Update in respiratory disease and environmental exposure: an invisible relationship].
</td>
<td style="text-align:left;">
Arch. Bronconeumol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Dual time point FDG PET for evaluation of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Nucl Med Commun
</td>
</tr>
<tr>
<td style="text-align:left;">
CXCR4+FOXP3+CD25+ lymphocytes accumulate in CXCL12-expressing malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int J Immunopathol Pharmacol
</td>
</tr>
<tr>
<td style="text-align:left;">
Growth inhibition by tyrosine kinase inhibitors in mesothelioma cell lines.
</td>
<td style="text-align:left;">
Eur. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Recurrent malignant peritoneal mesothelioma: radiological manifestations.
</td>
<td style="text-align:left;">
Abdom Imaging
</td>
</tr>
<tr>
<td style="text-align:left;">
Impact of accelerator-based boron neutron capture therapy (AB-BNCT) on the treatment of multiple liver tumors and malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Radiother Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic value of 18F-FDG PET/CT in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Mol Imaging Biol
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemosensitivity and cytokine sensitivity of malignant mesothelioma.
</td>
<td style="text-align:left;">
Cancer Chemother. Pharmacol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma cells resist anoikis as quiescent pluricellular aggregates.
</td>
<td style="text-align:left;">
Cell Death Differ.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Recycle of jute bags; asbestos in agriculture, exposure and pathology ].
</td>
<td style="text-align:left;">
G Ital Med Lav Ergon
</td>
</tr>
<tr>
<td style="text-align:left;">
Association of transforming growth factor beta1 gene polymorphisms and asbestos-induced fibrosis and tumors.
</td>
<td style="text-align:left;">
J. Investig. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Protumorigenic role of HAPLN1 and its IgV domain in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Screening for malignant pleural mesothelioma and lung cancer in individuals with a history of asbestos exposure.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Updated clinical information on multitargeted antifolates in lung cancer.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: medical treatment update.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Fine-needle aspiration of a well-differentiated papillary mesothelioma in the inguinal hernia sac: A case report and review of literature.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Future Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Future developments in the management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Expert Rev Anticancer Ther
</td>
</tr>
<tr>
<td style="text-align:left;">
[First-line treatment with pemetrexed in association with cisplatin in patients with non-operable malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Rev Pneumol Clin
</td>
</tr>
<tr>
<td style="text-align:left;">
Extrapleural pneumonectomy with reconstruction of diaphragm and pericardium using autologous materials.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: genome-wide expression patterns reflecting general resistance mechanisms and a proposal of novel targets.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Animal models of malignant pleural effusion.
</td>
<td style="text-align:left;">
Curr Opin Pulm Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Four-gene expression ratio test for survival in patients undergoing surgery for mesothelioma.
</td>
<td style="text-align:left;">
J. Natl. Cancer Inst.
</td>
</tr>
<tr>
<td style="text-align:left;">
Can “steroid switching” improve steroid-induced psychosis in a patient with advanced cancer?
</td>
<td style="text-align:left;">
J Palliat Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Comparison of conventional and novel PET tracers for imaging mesothelioma in nude mice with subcutaneous and intrapleural xenografts.
</td>
<td style="text-align:left;">
Nucl. Med. Biol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos–a legacy and a persistent problem.
</td>
<td style="text-align:left;">
J R Nav Med Serv
</td>
</tr>
<tr>
<td style="text-align:left;">
Expanded applications of diagnostic and therapeutic thoracoscopy.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma-associated antigens recognized by tumor-infiltrating B cells and the clinical significance of the antibody titers.
</td>
<td style="text-align:left;">
Cancer Sci.
</td>
</tr>
<tr>
<td style="text-align:left;">
All-trans-retinoic acid inhibits tumour growth of malignant pleural mesothelioma in mice.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
</tr>
<tr>
<td style="text-align:left;">
COX-2 specific inhibitors enhance the cytotoxic effects of pemetrexed in mesothelioma cell lines.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of the folate receptor genes FOLR1 and FOLR3 differentiates ovarian carcinoma from breast carcinoma and malignant mesothelioma in serous effusions.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Spontaneous pneumothorax and lung carcinoma: should one consider synchronous malignant pleural mesothelioma?
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
A biphasic malignant mesothelioma of the peritoneum and pleura in a horse.
</td>
<td style="text-align:left;">
DTW. Dtsch. Tierarztl. Wochenschr.
</td>
</tr>
<tr>
<td style="text-align:left;">
Imaging a Genetically Engineered Oncolytic Vaccinia Virus (GLV-1h99) Using a Human Norepinephrine Transporter Reporter Gene.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Potential of dual time point FDG-PET imaging in differentiating malignant from benign pleural disease.
</td>
<td style="text-align:left;">
Mol Imaging Biol
</td>
</tr>
<tr>
<td style="text-align:left;">
Combined FDG-PET/CT in response evaluation of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Estrogen receptor-beta affects the prognosis of human malignant mesothelioma.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant peritoneal mesothelioma].
</td>
<td style="text-align:left;">
Chirurgia (Bucur)
</td>
</tr>
<tr>
<td style="text-align:left;">
Metastatic tumors in fine needle aspiration biopsy of the thyroid.
</td>
<td style="text-align:left;">
Acta Cytol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Laparoscopic intraperitoneal hyperthermic perfusion in palliation of malignant ascites. Case report].
</td>
<td style="text-align:left;">
G Chir
</td>
</tr>
<tr>
<td style="text-align:left;">
[Case of malignant pleural mesothelioma with long-term disease control after 4 different lines of systemic chemotherapy and pleurodesis].
</td>
<td style="text-align:left;">
Nihon Kokyuki Gakkai Zasshi
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical utility of diagnostic markers for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Monaldi Arch Chest Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Adaptation of a commercial fluorescent in situ hybridization test to the diagnosis of malignant cells in effusions.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Is malignant pleural mesothelioma a surgical disease? A review of 83 consecutive extra-pleural pneumonectomies.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
18F-fluoro-2-deoxy-D-glucose positron emission tomography and positron emission tomography/computed tomography imaging of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Med Imaging Radiat Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Improving the outcome in malignant pleural mesothelioma: nonaggressive or aggressive approach?
</td>
<td style="text-align:left;">
Curr Opin Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Impact of malignant mesothelioma in Taiwan: a 27-year review of population-based cancer registry data.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Outcome for patients with malignant pleural mesothelioma referred for Trimodality therapy in Western Australia.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: current treatments and emerging drugs.
</td>
<td style="text-align:left;">
Expert Opin Emerg Drugs
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytokine alteration and speculated immunological pathophysiology in silicosis and asbestos-related diseases.
</td>
<td style="text-align:left;">
Environ Health Prev Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Current therapies for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Environ Health Prev Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Evolution of pleural cancers and malignant pleural mesothelioma incidence in France between 1980 and 2005.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Scoring system for differential diagnosis of malignant mesothelioma and reactive mesothelial cells on cytology specimens.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed in the treatment of advanced non-squamous lung cancer.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Interobserver variations in diagnosing asbestosis according to the ILO classification.
</td>
<td style="text-align:left;">
Arh Hig Rada Toksikol
</td>
</tr>
<tr>
<td style="text-align:left;">
Lung cancer gene expression database analysis incorporating prior knowledge with support vector machine-based classification method.
</td>
<td style="text-align:left;">
J. Exp. Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Lymphangiomatoid pattern in diffuse malignant mesothelioma of the pleura: a report of six cases.
</td>
<td style="text-align:left;">
Virchows Arch.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Asbestos as a risk factor for pulmonary diseases].
</td>
<td style="text-align:left;">
Prz. Lek.
</td>
</tr>
<tr>
<td style="text-align:left;">
Evidence-based guidelines to optimize the selection of antibody panels in cytopathology: pleural effusions with malignant epithelioid cells.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: clinicopathology of 16 extrapleural pneumonectomy patients with special reference to early stage features.
</td>
<td style="text-align:left;">
Pathol. Int.
</td>
</tr>
<tr>
<td style="text-align:left;">
The urokinase receptor supports tumorigenesis of human malignant pleural mesothelioma cells.
</td>
<td style="text-align:left;">
Am. J. Respir. Cell Mol. Biol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma].
</td>
<td style="text-align:left;">
Rev Prat
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of surgery in the management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J BUON
</td>
</tr>
<tr>
<td style="text-align:left;">
Docetaxel plus gemcitabine as first-line treatment in malignant pleural mesothelioma: a single institution phase II study.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Genome-wide profile of pleural mesothelioma versus parietal and visceral pleura: the emerging gene portrait of the mesothelioma phenotype.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
</tr>
<tr>
<td style="text-align:left;">
A 74-year-old man with an enlarging pleural-based mass that was not a mesothelioma.
</td>
<td style="text-align:left;">
Thorac Cardiovasc Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Extrapleural pneumonectomy for malignant pleural mesothelioma: outcomes of treatment and prognostic factors.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
[C-arm computed tomography for transarterial chemoperfusion and chemo-embolization of thoracic lesions].
</td>
<td style="text-align:left;">
Radiologe
</td>
</tr>
<tr>
<td style="text-align:left;">
[Epidermal growth factor receptor aberrations in malignant mesotheliomas].
</td>
<td style="text-align:left;">
Rinsho Byori
</td>
</tr>
<tr>
<td style="text-align:left;">
Solitary fibrous tumor of the pleura: surgery and clinical course in 18 cases.
</td>
<td style="text-align:left;">
Asian Cardiovasc Thorac Ann
</td>
</tr>
<tr>
<td style="text-align:left;">
Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy.
</td>
<td style="text-align:left;">
Hum. Gene Ther.
</td>
</tr>
<tr>
<td style="text-align:left;">
Three decades of experience in the surgical multi-modality management of pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: an update on biomarkers and treatment.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Tenascin-X is a novel diagnostic marker of malignant mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Hemithoracic radiotherapy after extrapleural pneumonectomy for malignant pleural mesothelioma: a dosimetric comparison of two well-described techniques.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic factors according to the treatment schedule in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Protein profiling of pleural effusions to identify malignant pleural mesothelioma using SELDI-TOF MS.
</td>
<td style="text-align:left;">
Technol. Cancer Res. Treat.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Immunocytochemical identification of carcinomas of unknown primaries on fine-needle-aspiration-biopsies].
</td>
<td style="text-align:left;">
Pathologe
</td>
</tr>
<tr>
<td style="text-align:left;">
Comparison of CT and integrated PET-CT based radiation therapy planning in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Radiat Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Survival after trimodality therapy for malignant pleural mesothelioma: Radical Pleurectomy, chemotherapy with Cisplatin/Pemetrexed and radiotherapy.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Intrapleural polymeric films containing cisplatin for malignant pleural mesothelioma in a rat tumour model: a preliminary study.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Proteomic differential display analysis identified upregulated astrocytic phosphoprotein PEA-15 in human malignant pleural mesothelioma cell lines.
</td>
<td style="text-align:left;">
Proteomics
</td>
</tr>
<tr>
<td style="text-align:left;">
Ambulatory intercostal drainage for the management of malignant pleural effusion: a single center experience.
</td>
<td style="text-align:left;">
Ann. Surg. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural fluid mesothelin for the differential diagnosis of exudative pleural effusions.
</td>
<td style="text-align:left;">
Med Clin (Barc)
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed-induced pneumonitis: a case report.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Activated cAMP response element binding protein is overexpressed in human mesotheliomas and inhibits apoptosis.
</td>
<td style="text-align:left;">
Am. J. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Current status of screening for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Semin. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Recent advances in mesothelioma staging.
</td>
<td style="text-align:left;">
Semin. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Current trends in radiologic management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Semin. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pathologic evaluation of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Semin. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma: path to multimodality treatment.
</td>
<td style="text-align:left;">
Semin. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Radiation therapy options for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Semin. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Making the case for molecular staging of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Semin. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma with long-term tumor disappearance of a local relapse after surgery: a case report.
</td>
<td style="text-align:left;">
J Med Case Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
Mechanisms of FUS1/TUSC2 deficiency in mesothelioma and its tumorigenic transcriptional effects.
</td>
<td style="text-align:left;">
Mol. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Combined treatment with cisplatin and sirolimus to enhance cell death in human mesothelioma.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Polymorphisms in the putative micro-RNA-binding sites of mesothelin gene are associated with serum levels of mesothelin-related protein.
</td>
<td style="text-align:left;">
Occup Environ Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Primary small cell carcinoma of the pleura: a case report with immunohistochemical and molecular genetic analyses of KIT and PDGFRA genes.
</td>
<td style="text-align:left;">
Med. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical value of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiation of malignant mesothelioma from asbestos-related benign pleural disease: an observational pilot study.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
An orthotopic implantation mouse model of human malignant pleural mesothelioma for in vivo photon counting analysis and evaluation of the effect of S-1 therapy.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Second-line treatment for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Treat. Rev.
</td>
</tr>
<tr>
<td style="text-align:left;">
Estimation of pulmonary motion in healthy subjects and patients with intrathoracic tumors using 3D-dynamic MRI: initial results.
</td>
<td style="text-align:left;">
Korean J Radiol
</td>
</tr>
<tr>
<td style="text-align:left;">
Intrapleural cisplatin and cytarabine in the management of malignant pleural effusions: a Lung Cancer Study Group trial.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Survival and relapse pattern after trimodality therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Gen Thorac Cardiovasc Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Molecular targets in malignant pleural mesothelioma treatment.
</td>
<td style="text-align:left;">
Curr Drug Targets
</td>
</tr>
<tr>
<td style="text-align:left;">
Cellular and molecular basis of the asbestos-related diseases.
</td>
<td style="text-align:left;">
Am. Rev. Respir. Dis.
</td>
</tr>
<tr>
<td style="text-align:left;">
Neurotensin expression and outcome of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Biochimie
</td>
</tr>
<tr>
<td style="text-align:left;">
[Carcinoembryonic antigen in serum and pleural fluid to distinguish between bronchial carcinoma and pleural mesothelioma].
</td>
<td style="text-align:left;">
Dtsch. Med. Wochenschr.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma presenting as low back pain: diagnosed by bone scan coordinating with F-18 FDG PET/CT.
</td>
<td style="text-align:left;">
Spine
</td>
</tr>
<tr>
<td style="text-align:left;">
A novel translational approach for human malignant pleural mesothelioma: heparanase-assisted dual virotherapy.
</td>
<td style="text-align:left;">
Oncogene
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment with interleukin-2 in malignant pleural mesothelioma: immunological and angiogenetic assessment and prognostic impact.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic value of soluble mesothelin-related peptides for malignant mesothelioma: a meta-analysis.
</td>
<td style="text-align:left;">
Respir Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines.
</td>
<td style="text-align:left;">
Cancer Chemother. Pharmacol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Therapeutic strategies for resectable malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Nihon Geka Gakkai Zasshi
</td>
</tr>
<tr>
<td style="text-align:left;">
Cisplatin-induced expression of Gb3 enables verotoxin-1 treatment of cisplatin resistance in malignant pleural mesothelioma cells.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Case-control study of pleural mesothelioma in workers with social security in Mexico.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of blood group-related antigens and Helix pomatia agglutinin in malignant pleural mesothelioma and pulmonary adenocarcinoma.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma: biology, diagnosis and therapeutic approaches.
</td>
<td style="text-align:left;">
Curr Mol Pharmacol
</td>
</tr>
<tr>
<td style="text-align:left;">
Comparison of diagnostic quality and accuracy in color-coded versus gray-scale DCE-MR imaging display.
</td>
<td style="text-align:left;">
Int J Comput Assist Radiol Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Chest CT combined with artificial pneumothorax: value in determining origin and extent of tumor.
</td>
<td style="text-align:left;">
AJR Am J Roentgenol
</td>
</tr>
<tr>
<td style="text-align:left;">
Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trials.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Sorafenib inhibits ERK1/2 and MCL-1(L) phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Biol. Ther.
</td>
</tr>
<tr>
<td style="text-align:left;">
Differentially expressed alternatively spliced genes in malignant pleural mesothelioma identified using massively parallel transcriptome sequencing.
</td>
<td style="text-align:left;">
BMC Med. Genet.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma.
</td>
<td style="text-align:left;">
Br. Med. Bull.
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of folate receptor alpha (FRalpha) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapy.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Multimodality treatment of malignant pleural mesothelioma with or without immunotherapy: does it change anything?
</td>
<td style="text-align:left;">
Interact Cardiovasc Thorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
IMP3/L523S, a novel immunocytochemical marker that distinguishes benign and malignant cells: the expression profiles of IMP3/L523S in effusion cytology.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Occupational cancers in Poland, 1995-2003].
</td>
<td style="text-align:left;">
Med Pr
</td>
</tr>
<tr>
<td style="text-align:left;">
A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions.
</td>
<td style="text-align:left;">
Mol. Ther.
</td>
</tr>
<tr>
<td style="text-align:left;">
Cold-plasma coagulation in the treatment of malignant pleural mesothelioma: results of a combined approach.
</td>
<td style="text-align:left;">
Interact Cardiovasc Thorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Respir. Crit. Care Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Sarcomatoid mesothelioma: a clinical-pathologic correlation of 326 cases.
</td>
<td style="text-align:left;">
Mod. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Role of integrated 18-fluorodeoxyglucose position emission tomography-computed tomography in patients surveillance after multimodality therapy of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Biological agents involved in malignant mesothelioma: relevance as biomarkers or therapeutic targets.
</td>
<td style="text-align:left;">
Curr Cancer Drug Targets
</td>
</tr>
<tr>
<td style="text-align:left;">
Primary pleural epithelioid angiosarcoma. A case report and review of the literature.
</td>
<td style="text-align:left;">
Pathol. Res. Pract.
</td>
</tr>
<tr>
<td style="text-align:left;">
Computed tomography of asbestos-related pulmonary parenchymal and pleural diseases.
</td>
<td style="text-align:left;">
Clin. Chest Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Increasing of malignant pleural mesothelioma: burning issue in Split-Dalmatian County, Croatia.
</td>
<td style="text-align:left;">
Coll Antropol
</td>
</tr>
<tr>
<td style="text-align:left;">
Second surgery for recurrence of malignant pleural mesothelioma after extrapleural pneumonectomy.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
[Management of pleural disease].
</td>
<td style="text-align:left;">
Arch. Bronconeumol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Predictors of mortality within three months in the patients with malignant pleural effusion.
</td>
<td style="text-align:left;">
Eur. J. Intern. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Kindlin-2 is expressed in malignant mesothelioma and is required for tumor cell adhesion and migration.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgical assessment of malignant pleural mesothelioma: have we reached a critical stage?
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Downregulation of Bcl-xL and Mcl-1 is sufficient to induce cell death in mesothelioma cells highly refractory to conventional chemotherapy.
</td>
<td style="text-align:left;">
Carcinogenesis
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II study of gemcitabine plus docetaxel as second-line treatment in malignant pleural mesothelioma: a single institution study.
</td>
<td style="text-align:left;">
Am. J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Podoplanin is a useful marker for identifying mesothelioma in malignant effusions.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Localized intrapancreatic malignant mesothelioma: a rare entity that may be confused with other pancreatic neoplasms.
</td>
<td style="text-align:left;">
Virchows Arch.
</td>
</tr>
<tr>
<td style="text-align:left;">
Knockdown of COPA, identified by loss-of-function screen, induces apoptosis and suppresses tumor growth in mesothelioma mouse model.
</td>
<td style="text-align:left;">
Genomics
</td>
</tr>
<tr>
<td style="text-align:left;">
Medical thoracoscopy vs CT scan-guided Abrams pleural needle biopsy for diagnosis of patients with pleural effusions: a randomized, controlled trial.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Minute localized malignant pleural mesothelioma coexisting with multiple adenocarcinomas.
</td>
<td style="text-align:left;">
Gen Thorac Cardiovasc Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Cigarette smoking, asbestos exposure, and malignant mesothelioma.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
hsa-miR-29c* is linked to the prognosis of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Gene therapy for mesothelioma and lung cancer.
</td>
<td style="text-align:left;">
Am. J. Respir. Cell Mol. Biol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Respir. Crit. Care Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
What’s the place of immunotherapy in malignant mesothelioma treatments?
</td>
<td style="text-align:left;">
Cell Adh Migr
</td>
</tr>
<tr>
<td style="text-align:left;">
A novel clinical role for angiopoietin-1 in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
</tr>
<tr>
<td style="text-align:left;">
Deciduoid mesothelioma of the pleura in an adolescent boy.
</td>
<td style="text-align:left;">
Pediatr Hematol Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical investigation of malignant mesothelioma in Japan.
</td>
<td style="text-align:left;">
J. Cancer Res. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
The influence of the diagnostic technique on the histopathological diagnosis in malignant mesothelioma.
</td>
<td style="text-align:left;">
Virchows Arch A Pathol Anat Histopathol
</td>
</tr>
<tr>
<td style="text-align:left;">
Current concepts in chemotherapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin Respir J
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment of malignant pleural mesothelioma with liposomized doxorubicine: prolonged time to progression and good survival. A Nordic study.
</td>
<td style="text-align:left;">
Clin Respir J
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma.
</td>
<td style="text-align:left;">
Intern Med J
</td>
</tr>
<tr>
<td style="text-align:left;">
[A case of malignant pleural mesothelioma that responded to cisplatin plus pemetrexed rechallenge].
</td>
<td style="text-align:left;">
Gan To Kagaku Ryoho
</td>
</tr>
<tr>
<td style="text-align:left;">
The differential diagnosis of epithelial-type mesothelioma from adenocarcinoma and reactive mesothelial proliferation.
</td>
<td style="text-align:left;">
J. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Factors affecting soluble mesothelin related protein levels in an asbestos-exposed population.
</td>
<td style="text-align:left;">
Clin. Chem. Lab. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Life after first-line chemotherapy in malignant pleural mesothelioma: a North-East England experience.
</td>
<td style="text-align:left;">
Clin Oncol (R Coll Radiol)
</td>
</tr>
<tr>
<td style="text-align:left;">
Tissue and serum EGFR as prognostic factors in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Obtaining an upper estimate of the survival benefit associated with surgery for mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
In vitro anti-mesothelioma activity of cisplatin-gemcitabine combinations: evidence for sequence-dependent effects.
</td>
<td style="text-align:left;">
Cancer Chemother. Pharmacol.
</td>
</tr>
<tr>
<td style="text-align:left;">
A novel prognostic model for malignant mesothelioma incorporating quantitative FDG-PET imaging with clinical parameters.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Localized malignant pleural mesothelioma showing a thoracic mass and metastasizing to the stomach.
</td>
<td style="text-align:left;">
Intern. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Volumetric modulation arc radiotherapy compared with static gantry intensity-modulated radiotherapy for malignant pleural mesothelioma tumor: a feasibility study.
</td>
<td style="text-align:left;">
Int. J. Radiat. Oncol. Biol. Phys.
</td>
</tr>
<tr>
<td style="text-align:left;">
Proton therapy for malignant pleural mesothelioma after extrapleural pleuropneumonectomy.
</td>
<td style="text-align:left;">
Int. J. Radiat. Oncol. Biol. Phys.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma in Italy.
</td>
<td style="text-align:left;">
Indian J Occup Environ Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Translational therapies for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Expert Rev Respir Med
</td>
</tr>
<tr>
<td style="text-align:left;">
PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Radiologic manifestation of primary pleural tumors].
</td>
<td style="text-align:left;">
Acta Chir Iugosl
</td>
</tr>
<tr>
<td style="text-align:left;">
Assessment of therapy responses and prediction of survival in malignant pleural mesothelioma through computer-aided volumetric measurement on computed tomography scans.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Soluble mesothelin-related protein in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Egypt Natl Canc Inst
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma in a patient with anthophyllite asbestos fibres in the lungs.
</td>
<td style="text-align:left;">
Ann Occup Hyg
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemotherapy induced pathologic complete response in malignant pleural mesothelioma: a review and case report.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Value of D2-40 in the differential diagnosis of pleural neoplasms with emphasis on its positivity in solitary fibrous tumor.
</td>
<td style="text-align:left;">
Appl. Immunohistochem. Mol. Morphol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic factors for 100 patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Arch Environ Occup Health
</td>
</tr>
<tr>
<td style="text-align:left;">
Activity of doxorubicin and cisplatin combination chemotherapy in patients with diffuse malignant pleural mesothelioma. An Italian Lung Cancer Task Force (FONICAP) Phase II study.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant peritoneal mesothelioma].
</td>
<td style="text-align:left;">
Rev Gastroenterol Peru
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed safety and pharmacokinetics in patients with third-space fluid.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Volume-based parameter of 18)F-FDG PET/CT in malignant pleural mesothelioma: prediction of therapeutic response and prognostic implications.
</td>
<td style="text-align:left;">
Ann. Surg. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pro-tumorigenic effects of miR-31 loss in mesothelioma.
</td>
<td style="text-align:left;">
J. Biol. Chem.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Monitoring the effectiveness of surgical treatment of malignant pleural effusions].
</td>
<td style="text-align:left;">
Klin Onkol
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: the standard of care and challenges for future management.
</td>
<td style="text-align:left;">
Crit. Rev. Oncol. Hematol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Second generation sequencing of the mesothelioma tumor genome.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
</tr>
<tr>
<td style="text-align:left;">
Soluble mesothelin-related Peptide and osteopontin as markers of response in malignant mesothelioma.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
9p21 deletion in the diagnosis of malignant mesothelioma, using fluorescence in situ hybridization analysis.
</td>
<td style="text-align:left;">
Pathol. Int.
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgery for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Expert Rev Respir Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
</tr>
<tr>
<td style="text-align:left;">
WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer.
</td>
<td style="text-align:left;">
Cancer Immunol. Immunother.
</td>
</tr>
<tr>
<td style="text-align:left;">
The efficacy of the frontline platinum-based combination chemotherapy in malignant peritoneal mesothelioma.
</td>
<td style="text-align:left;">
Jpn. J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Synergistic antitumor effects of regulatory T cell blockade combined with pemetrexed in murine malignant mesothelioma.
</td>
<td style="text-align:left;">
J. Immunol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Osteoarthropathy].
</td>
<td style="text-align:left;">
Gan To Kagaku Ryoho
</td>
</tr>
<tr>
<td style="text-align:left;">
CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection.
</td>
<td style="text-align:left;">
Cancer Immunol. Immunother.
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelin (MSLN) promoter is hypomethylated in malignant mesothelioma, but its expression is not associated with methylation status of the promoter.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Integrin-linked kinase, phosphorylated AKT and the prognosis of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Vinflunine: review of a new vinca alkaloid and its potential role in oncology.
</td>
<td style="text-align:left;">
J Oncol Pharm Pract
</td>
</tr>
<tr>
<td style="text-align:left;">
Multimodality approach to malignant pleural mesothelioma. A case report.
</td>
<td style="text-align:left;">
Ann Ital Chir
</td>
</tr>
<tr>
<td style="text-align:left;">
Establishment of in vivo fluorescence imaging in mouse models of malignant mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Putative cancer stem cells in malignant pleural mesothelioma show resistance to cisplatin and pemetrexed.
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
In vitro and in vivo therapeutic efficacy of the PPAR-γ agonist troglitazone in combination with cisplatin against malignant pleural mesothelioma cell growth.
</td>
<td style="text-align:left;">
Cancer Sci.
</td>
</tr>
<tr>
<td style="text-align:left;">
Molecular imaging of mesothelioma by detection of manganese-superoxide dismutase activity using manganese-enhanced magnetic resonance imaging.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Methylation of MGMT in malignant pleural mesothelioma occurs in a subset of patients and is associated with the T allele of the rs16906252 MGMT promoter SNP.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Secretion of intelectin-1 from malignant pleural mesothelioma into pleural effusion.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffusion-weighted MRI of malignant pleural mesothelioma: preliminary assessment of apparent diffusion coefficient in histologic subtypes.
</td>
<td style="text-align:left;">
AJR Am J Roentgenol
</td>
</tr>
<tr>
<td style="text-align:left;">
Usefulness of the nude mouse model in mesothelioma based on a direct patient-xenograft comparison.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Prevalence of in vitro chemotherapeutic drug resistance in primary malignant pleural mesothelioma: result in a cohort of 203 resection specimens.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunocytochemistry of CD146 is useful to discriminate between malignant pleural mesothelioma and reactive mesothelium.
</td>
<td style="text-align:left;">
Mod. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Analysis of the effect of radiotherapy on malignant pleural mesothelioma when given on adjuvant or palliative basis.
</td>
<td style="text-align:left;">
Zhongguo Fei Ai Za Zhi
</td>
</tr>
<tr>
<td style="text-align:left;">
Extrapleural pneumonectomy, photodynamic therapy and intensity modulated radiation therapy for the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Biol. Ther.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesothelioma.
</td>
<td style="text-align:left;">
Curr Opin Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
[Technical pitfalls of pleural dissection in extrapleural pneumonectomy].
</td>
<td style="text-align:left;">
Kyobu Geka
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural liposarcoma mimicking carcinoma in pleural effusion cytology: a case report.
</td>
<td style="text-align:left;">
Acta Cytol.
</td>
</tr>
<tr>
<td style="text-align:left;">
SV40 associated miRNAs are not detectable in mesotheliomas.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Performance of biomarkers SMRP, CA125, and CYFRA 21-1 as potential tumor markers for malignant mesothelioma and lung cancer in a cohort of workers formerly exposed to asbestos.
</td>
<td style="text-align:left;">
Arch. Toxicol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Primary Pericardial Mesothelioma: Report of a Patient and Literature Review.
</td>
<td style="text-align:left;">
Case Rep Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Incidence of extrapleural malignant mesothelioma and asbestos exposure, from the Italian national register.
</td>
<td style="text-align:left;">
Occup Environ Med
</td>
</tr>
<tr>
<td style="text-align:left;">
[Lung asbestos fibre burden in textile workers with malignant mesothelioma].
</td>
<td style="text-align:left;">
Med Lav
</td>
</tr>
<tr>
<td style="text-align:left;">
Sensitivity of urinary mesothelin in patients with malignant mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytological differential diagnosis among adenocarcinoma, epithelial mesothelioma, and reactive mesothelial cells in serous effusions by immunocytochemistry.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of thyroid transcription factor-1 in malignant pleural effusions.
</td>
<td style="text-align:left;">
Pathol. Oncol. Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Expectations after ban on asbestos].
</td>
<td style="text-align:left;">
Arh Hig Rada Toksikol
</td>
</tr>
<tr>
<td style="text-align:left;">
[Incidence of malignant pleural mesothelioma in Split-Dalmatia County].
</td>
<td style="text-align:left;">
Arh Hig Rada Toksikol
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma in patients hospitalised at the Clinical Hospital Centre Rijeka between 1989 and 2008].
</td>
<td style="text-align:left;">
Arh Hig Rada Toksikol
</td>
</tr>
<tr>
<td style="text-align:left;">
[Immunological aspects of asbestos-related diseases].
</td>
<td style="text-align:left;">
Arh Hig Rada Toksikol
</td>
</tr>
<tr>
<td style="text-align:left;">
Genetically engineered oncolytic Newcastle disease virus effectively induces sustained remission of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Mol. Cancer Ther.
</td>
</tr>
<tr>
<td style="text-align:left;">
A diagnostic assay based on microRNA expression accurately identifies malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Mol Diagn
</td>
</tr>
<tr>
<td style="text-align:left;">
A₃ receptors are overexpressed in pleura from patients with mesothelioma and reduce cell growth via Akt/nuclear factor-κB pathway.
</td>
<td style="text-align:left;">
Am. J. Respir. Crit. Care Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Frequency of use and predictors of cancer-directed surgery in the management of malignant pleural mesothelioma in a community-based (Surveillance, Epidemiology, and End Results [SEER]) population.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
A clinical, radiographic and laboratory evaluation of prognostic factors in 363 patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Respiration
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemical characterization of exhaled breath to differentiate between patients with malignant plueral mesothelioma from subjects with similar professional asbestos exposure.
</td>
<td style="text-align:left;">
Anal Bioanal Chem
</td>
</tr>
<tr>
<td style="text-align:left;">
[Second-line therapy in patients with malignant pleural mesothelioma. A French retrospective study (2005-2006)].
</td>
<td style="text-align:left;">
Rev Pneumol Clin
</td>
</tr>
<tr>
<td style="text-align:left;">
[A case of diffuse peritoneal malignant mesothelioma–intraabdominal administration of cisplatin is useful for diminishing ascites].
</td>
<td style="text-align:left;">
Gan To Kagaku Ryoho
</td>
</tr>
<tr>
<td style="text-align:left;">
Overexpression of SOCS3 exhibits preclinical antitumor activity against malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment of malignant pleural mesothelioma: current status and future directions.
</td>
<td style="text-align:left;">
Monaldi Arch Chest Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Contribution of positron emission tomography in pleural disease.
</td>
<td style="text-align:left;">
Rev Mal Respir
</td>
</tr>
<tr>
<td style="text-align:left;">
Intensity-modulated radiation therapy with simultaneous integrated boost in unresected left-sided pleural mesothelioma: a case report.
</td>
<td style="text-align:left;">
Tumori
</td>
</tr>
<tr>
<td style="text-align:left;">
MT1-MMP plays an important role in an invasive activity of malignant pleural mesothelioma cell.
</td>
<td style="text-align:left;">
Exp. Mol. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
The use of insulin like-growth factor II messenger RNA binding protein-3 in diagnostic pathology.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: a population-based study of survival.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytopathology of malignant mesothelioma. Reappraisal of the diagnostic value of collagen cores.
</td>
<td style="text-align:left;">
Cytopathology
</td>
</tr>
<tr>
<td style="text-align:left;">
Induction of senescence markers after neo-adjuvant chemotherapy of malignant pleural mesothelioma and association with clinical outcome: an exploratory analysis.
</td>
<td style="text-align:left;">
Eur. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
TS, DHFR and GARFT expression in non-squamous cell carcinoma of NSCLC and malignant pleural mesothelioma patients treated with pemetrexed.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytokeratin 19 fragment/carcinoembryonic antigen ratio in pleural effusion is a useful marker for detecting malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pericardial mesothelioma following thoracal radiotherapy; dissemination from pericardium to pleura.
</td>
<td style="text-align:left;">
Tuberk Toraks
</td>
</tr>
<tr>
<td style="text-align:left;">
Sarcomatoid neoplasms of the lung and pleura.
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Translational advances in pleural malignancies.
</td>
<td style="text-align:left;">
Respirology
</td>
</tr>
<tr>
<td style="text-align:left;">
What is the best way to diagnose and stage malignant pleural mesothelioma?
</td>
<td style="text-align:left;">
Interact Cardiovasc Thorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Cutaneous needle track seeding of mesothelioma diagnosed by fine needle aspiration cytology: a case report.
</td>
<td style="text-align:left;">
Acta Cytol.
</td>
</tr>
<tr>
<td style="text-align:left;">
CT in differential diagnosis of diffuse pleural disease.
</td>
<td style="text-align:left;">
AJR Am J Roentgenol
</td>
</tr>
<tr>
<td style="text-align:left;">
The use of pleural fluid sCD44v6/std ratio for distinguishing mesothelioma from other pleural malignancies.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
The therapeutic efficacy of S-1 against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice.
</td>
<td style="text-align:left;">
Cancer Chemother. Pharmacol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant peritoneal mesothelioma: a case report].
</td>
<td style="text-align:left;">
Rev Med Liege
</td>
</tr>
<tr>
<td style="text-align:left;">
Fine-needle aspiration biopsies for gene expression ratio-based diagnostic and prognostic tests in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Premature senescence induced by DNA demethylating agent (Decitabine) as therapeutic option for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma with prominent adenomatoid features: a clinicopathologic and immunohistochemical study of 10 cases.
</td>
<td style="text-align:left;">
Ann Diagn Pathol
</td>
</tr>
<tr>
<td style="text-align:left;">
An analysis of the utility of handheld PET probes for the intraoperative localization of malignant tissue.
</td>
<td style="text-align:left;">
J. Gastrointest. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Audit of patients with mesothelioma treated with pemetrexed in a single institution in Western Australia.
</td>
<td style="text-align:left;">
Asia Pac J Clin Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Proteomic differential display analysis shows up-regulation of 14-3-3 sigma protein in human scirrhous-type gastric carcinoma cells.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Value of immunohistochemistry in distinguishing malignant epithelial tumors in the pleura].
</td>
<td style="text-align:left;">
Zhongguo Fei Ai Za Zhi
</td>
</tr>
<tr>
<td style="text-align:left;">
Estrogen receptor β exerts tumor repressive functions in human malignant pleural mesothelioma via EGFR inactivation and affects response to gefitinib.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
</tr>
<tr>
<td style="text-align:left;">
Continued pemetrexed and platin-based chemotherapy in patients with malignant pleural mesothelioma (MPM): value of 18F-FDG-PET/CT.
</td>
<td style="text-align:left;">
Eur J Radiol
</td>
</tr>
<tr>
<td style="text-align:left;">
Current evidence base of FDG-PET/CT imaging in the clinical management of malignant pleural mesothelioma: emerging significance of image segmentation and global disease assessment.
</td>
<td style="text-align:left;">
Mol Imaging Biol
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma and asbestos, fifty years of evidence: Chris Wagner and the contribution of the Italian occupational medicine community.
</td>
<td style="text-align:left;">
Med Lav
</td>
</tr>
<tr>
<td style="text-align:left;">
Quantitative measurement of lung reexpansion in malignant pleural mesothelioma patients undergoing pleurectomy/decortication.
</td>
<td style="text-align:left;">
Acad Radiol
</td>
</tr>
<tr>
<td style="text-align:left;">
Physical aspects of external beam radiotherapy for the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Radiat. Oncol. Biol. Phys.
</td>
</tr>
<tr>
<td style="text-align:left;">
Can “steroid switching” improve steroid-induced musical hallucinations in a patient with terminal cancer?
</td>
<td style="text-align:left;">
J Palliat Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Pericardial mesothelioma and asbestos exposure.
</td>
<td style="text-align:left;">
Int J Hyg Environ Health
</td>
</tr>
<tr>
<td style="text-align:left;">
Identification of cancer stem cell markers in human malignant mesothelioma cells.
</td>
<td style="text-align:left;">
Biochem. Biophys. Res. Commun.
</td>
</tr>
<tr>
<td style="text-align:left;">
Vascular endothelial growth factor in pleural fluid for differential diagnosis of benign and malignant origin and its clinical applications.
</td>
<td style="text-align:left;">
Interact Cardiovasc Thorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma: a clinical study of 238 cases.
</td>
<td style="text-align:left;">
Ind Health
</td>
</tr>
<tr>
<td style="text-align:left;">
[A case of peritoneal mesothelioma with direct invasion to gastric mucosa].
</td>
<td style="text-align:left;">
Korean J Gastroenterol
</td>
</tr>
<tr>
<td style="text-align:left;">
Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
European guidelines for the management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Pol. Arch. Med. Wewn.
</td>
</tr>
<tr>
<td style="text-align:left;">
Cervical endometriosis associated with malignant pleural mesothelioma mimicking cervical cancer–Occam’s razor or the “third man”.
</td>
<td style="text-align:left;">
Fertil. Steril.
</td>
</tr>
<tr>
<td style="text-align:left;">
Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: where do we stand?
</td>
<td style="text-align:left;">
Cancer Treat. Rev.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesothelioma in New Caledonia: associations with environmental risk factors.
</td>
<td style="text-align:left;">
Environ. Health Perspect.
</td>
</tr>
<tr>
<td style="text-align:left;">
Antiangiogenic therapies for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Front Biosci (Landmark Ed)
</td>
</tr>
<tr>
<td style="text-align:left;">
Establishment of a cell line from a Japanese patient useful for generating an in vivo model of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Sci.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: CT manifestations in 50 cases.
</td>
<td style="text-align:left;">
AJR Am J Roentgenol
</td>
</tr>
<tr>
<td style="text-align:left;">
FDG PET/CT patterns of treatment failure of malignant pleural mesothelioma: relationship to histologic type, treatment algorithm, and survival.
</td>
<td style="text-align:left;">
Eur. J. Nucl. Med. Mol. Imaging
</td>
</tr>
<tr>
<td style="text-align:left;">
The pleura in health and disease.
</td>
<td style="text-align:left;">
Semin Respir Crit Care Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Dasatinib: an anti-tumour agent via Src inhibition.
</td>
<td style="text-align:left;">
Curr Drug Targets
</td>
</tr>
<tr>
<td style="text-align:left;">
Exposure to asbestos: correlation between blood levels of mesothelin and frequency of micronuclei in peripheral blood lymphocytes.
</td>
<td style="text-align:left;">
Mutat. Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical-therapeutic management of thoracoscopy in pleural effusion: a groundbreaking technique in the twenty-first century.
</td>
<td style="text-align:left;">
Clin Transl Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Targeted therapies in malignant pleural mesothelioma: a review of clinical studies.
</td>
<td style="text-align:left;">
Anticancer Drugs
</td>
</tr>
<tr>
<td style="text-align:left;">
Does positron emission tomography offer prognostic information in malignant pleural mesothelioma?
</td>
<td style="text-align:left;">
Interact Cardiovasc Thorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
A practical guide of the Southwest Oncology Group to measure malignant pleural mesothelioma tumors by RECIST and modified RECIST criteria.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Volumetry: an alternative to assess therapy response for malignant pleural mesothelioma?
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
</tr>
<tr>
<td style="text-align:left;">
Telomerase activity in pleural malignant mesotheliomas.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
XRCC1 and ERCC1 variants modify malignant mesothelioma risk: a case-control study.
</td>
<td style="text-align:left;">
Mutat. Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Syntenic relationships between genomic profiles of fiber-induced murine and human malignant mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
A systematic review of lung-sparing extirpative surgery for pleural mesothelioma.
</td>
<td style="text-align:left;">
J R Soc Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Targeted drug delivery and penetration into solid tumors.
</td>
<td style="text-align:left;">
Med Res Rev
</td>
</tr>
<tr>
<td style="text-align:left;">
Advances in the biology of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Treat. Rev.
</td>
</tr>
<tr>
<td style="text-align:left;">
Platinum-based doublet chemotherapy in pre-treated malignant pleural mesothelioma (MPM) patients: a mono-institutional experience.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Epithelial-to-mesenchymal transition, cell polarity and stemness-associated features in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Lett.
</td>
</tr>
<tr>
<td style="text-align:left;">
No implication of Simian virus 40 in pathogenesis of malignant pleural mesothelioma in Slovenia.
</td>
<td style="text-align:left;">
Tumori
</td>
</tr>
<tr>
<td style="text-align:left;">
Staging of patients after extrapleural pneumonectomy for malignant pleural mesothelioma–institutional review and current update.
</td>
<td style="text-align:left;">
Interact Cardiovasc Thorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos-related disease.
</td>
<td style="text-align:left;">
Intern Med J
</td>
</tr>
<tr>
<td style="text-align:left;">
Tumor type influences the effectiveness of pleurodesis in malignant effusions.
</td>
<td style="text-align:left;">
Lung
</td>
</tr>
<tr>
<td style="text-align:left;">
Platinum-bisphosphonate complexes have proven to be inactive chemotherapeutics targeted for malignant mesothelioma because of inappropriate hydrolysis.
</td>
<td style="text-align:left;">
J. Inorg. Biochem.
</td>
</tr>
<tr>
<td style="text-align:left;">
Is pleurectomy and decortication superior to palliative care in the treatment of malignant pleural mesothelioma?
</td>
<td style="text-align:left;">
Interact Cardiovasc Thorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma risk among nuclear workers: a review.
</td>
<td style="text-align:left;">
J Radiol Prot
</td>
</tr>
<tr>
<td style="text-align:left;">
Downregulated microRNAs in the differential diagnosis of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
5-Aminolevulinic acid-induced fluorescence diagnosis of pleural malignant tumor.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Identification of novel markers for the diagnosis of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Decreased CXCR3 expression in CD4+ T cells exposed to asbestos or derived from asbestos-exposed patients.
</td>
<td style="text-align:left;">
Am. J. Respir. Cell Mol. Biol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleomorphic epithelioid diffuse malignant pleural mesothelioma: a clinicopathological review and conceptual proposal to reclassify as biphasic or sarcomatoid mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Serial measurements of mesothelioma serum biomarkers in asbestos-exposed individuals: a prospective longitudinal cohort study.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Temsirolimus inhibits malignant pleural mesothelioma growth in vitro and in vivo: synergism with chemotherapy.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Computerized segmentation and measurement of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Med Phys
</td>
</tr>
<tr>
<td style="text-align:left;">
Pathology of the pleura: what the pulmonologists need to know.
</td>
<td style="text-align:left;">
Respirology
</td>
</tr>
<tr>
<td style="text-align:left;">
Resistance to caspase-8 and -9 fragments in a malignant pleural mesothelioma cell line with acquired cisplatin-resistance.
</td>
<td style="text-align:left;">
Cell Death Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Is serum thioredoxin-1 a useful clinical marker for malignant pleural mesothelioma?
</td>
<td style="text-align:left;">
Antioxid. Redox Signal.
</td>
</tr>
<tr>
<td style="text-align:left;">
Breath analysis in asbestos-related disorders: a review of the literature and potential future applications.
</td>
<td style="text-align:left;">
J Breath Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Role of protein kinase C β and vascular endothelial growth factor receptor in malignant pleural mesothelioma: Therapeutic implications and the usefulness of Caenorhabditis elegans model organism.
</td>
<td style="text-align:left;">
J Carcinog
</td>
</tr>
<tr>
<td style="text-align:left;">
An unusually large pleural mesothelioma with an outstanding clinical response and long lasting survival: a case report and literature review.
</td>
<td style="text-align:left;">
Tumori
</td>
</tr>
<tr>
<td style="text-align:left;">
Extrapleural pneumonectomy or supportive care: treatment of malignant pleural mesothelioma?
</td>
<td style="text-align:left;">
Interact Cardiovasc Thorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
[Occupational morbidity and mortality in malignant neoplasms among persons professionally exposed to asbestos dust].
</td>
<td style="text-align:left;">
Gig Tr Prof Zabol
</td>
</tr>
<tr>
<td style="text-align:left;">
Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesothelioma–which is best?
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
The diagnostic utility of p16 FISH and GLUT-1 immunohistochemical analysis in mesothelial proliferations.
</td>
<td style="text-align:left;">
Am. J. Clin. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma: facts, myths, and hypotheses.
</td>
<td style="text-align:left;">
J. Cell. Physiol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Synergistic effect of non-transmissible Sendai virus vector encoding the c-myc suppressor FUSE-binding protein-interacting repressor plus cisplatin in the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Sci.
</td>
</tr>
<tr>
<td style="text-align:left;">
Molecular biomarkers in malignant mesothelioma: state of the art.
</td>
<td style="text-align:left;">
Pathology
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed in the treatment of thoracic malignancies: a single centre experience in Singapore.
</td>
<td style="text-align:left;">
Singapore Med J
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma of the spermatic cord.
</td>
<td style="text-align:left;">
Korean J Urol
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgical treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Curr Treat Options Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemotherapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Curr Treat Options Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Antiproliferative effects of novel aliphatic acetogenin analogs against aggressive solid tumor cell lines.
</td>
<td style="text-align:left;">
In Vivo
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic significance of carcinoembryonic antigen in the differential diagnosis of malignant mesothelioma.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Soluble markers for diagnosis of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Biomark Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Imaging of mesothelioma.
</td>
<td style="text-align:left;">
Recent Results Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pathohistological diagnosis and differential diagnosis.
</td>
<td style="text-align:left;">
Recent Results Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma and analysis of tissue fiber content.
</td>
<td style="text-align:left;">
Recent Results Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemotherapy and radiotherapy for mesothelioma.
</td>
<td style="text-align:left;">
Recent Results Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Usefulness of Claudin 4 in the cytological diagnosis of serosal effusions.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Update on malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Semin Respir Crit Care Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Multicystic mesothelioma of the pericardium.
</td>
<td style="text-align:left;">
Pathol. Int.
</td>
</tr>
<tr>
<td style="text-align:left;">
Medical treatment of mesothelioma: anything new?
</td>
<td style="text-align:left;">
Curr Oncol Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: when is radiation therapy indicated?
</td>
<td style="text-align:left;">
Expert Rev Anticancer Ther
</td>
</tr>
<tr>
<td style="text-align:left;">
Summary of prognostic factors and patient selection for extrapleural pneumonectomy in the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Surg. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
A case report of metastasis of malignant mesothelioma to the oral gingiva.
</td>
<td style="text-align:left;">
Head Neck Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos-related benign disease and cancer: symptoms and treatment.
</td>
<td style="text-align:left;">
Anticancer Drugs
</td>
</tr>
<tr>
<td style="text-align:left;">
Circulating and tumor-infiltrating myeloid cells predict survival in human pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Intensity-modulated radiotherapy after extrapleural pneumonectomy in the combined-modality treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
The diminishing role of surgery in pleural disease.
</td>
<td style="text-align:left;">
Curr Opin Pulm Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Recognition of pleural mesothelioma by mucin-1(950-958)/human leukocyte antigen A*0201-specific CD8+ T-cells.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
</tr>
<tr>
<td style="text-align:left;">
A 5-aza-2’-deoxycytidine/valproate combination induces cytotoxic T-cell response against mesothelioma.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos exposure affects poly(ADP-ribose) polymerase-1 activity: role in asbestos-induced carcinogenesis.
</td>
<td style="text-align:left;">
Mutagenesis
</td>
</tr>
<tr>
<td style="text-align:left;">
Review on clinical trials of targeted treatments in malignant mesothelioma.
</td>
<td style="text-align:left;">
Cancer Chemother. Pharmacol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Natural-killer cell-mediated cytotoxicity of blood-lymphocytes from patients with malignant mesothelioma treated by intrapleural interleukin-2.
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Genes associated with prognosis after surgery for malignant pleural mesothelioma promote tumor cell survival in vitro.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Curr Oncol Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
Two novel polymorphisms in 5’ flanking region of the mesothelin gene are associated with soluble mesothelin-related peptide (SMRP) levels.
</td>
<td style="text-align:left;">
Int. J. Biol. Markers
</td>
</tr>
<tr>
<td style="text-align:left;">
A patient-like human malignant pleural mesothelioma nude-mouse model.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleurectomy, intrapleural cisplatin and interferon followed by systemic carboplatin plus interferon in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Inactivation of Merlin in malignant mesothelioma cells and the Hippo signaling cascade dysregulation.
</td>
<td style="text-align:left;">
Pathol. Int.
</td>
</tr>
<tr>
<td style="text-align:left;">
Detection of integrin-linked kinase in the serum of patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Combined chemotherapy with cytotoxic and targeted compounds for the management of human malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Trends Pharmacol. Sci.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Usefulness of 18F-FDG PET-CT in the presurgical assessment of malignant pleural mesothelioma treated with neoadjuvant chemotherapy].
</td>
<td style="text-align:left;">
Rev Esp Med Nucl
</td>
</tr>
<tr>
<td style="text-align:left;">
A trial of intrapleural adenoviral-mediated Interferon-α2b gene transfer for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Respir. Crit. Care Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Tumor cell repopulation between cycles of chemotherapy is inhibited by regulatory T-cell depletion in a murine mesothelioma model.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Combined serum mesothelin and plasma osteopontin measurements in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
[Value of tomotherapy in malignant pleural mesothelioma: first clinical results].
</td>
<td style="text-align:left;">
Rev Mal Respir
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural malignant mesothelioma epidemic: incidence, modalities of asbestos exposure and occupations involved from the Italian National Register.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed in malignant pleural mesothelioma and the clinical outcome.
</td>
<td style="text-align:left;">
Clin Respir J
</td>
</tr>
<tr>
<td style="text-align:left;">
Outcomes and complications following medical thoracoscopy.
</td>
<td style="text-align:left;">
Clin Respir J
</td>
</tr>
<tr>
<td style="text-align:left;">
Cell-growth and migration inhibition of human mesothelioma cells induced by 3-O-methylfunicone from Penicillium pinophilum and cisplatin.
</td>
<td style="text-align:left;">
Invest New Drugs
</td>
</tr>
<tr>
<td style="text-align:left;">
Re-evaluating the role of palliative radiotherapy in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma at era of helical tomotherapy: results of two institutions in combining chemotherapy, surgery and radiotherapy.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Intrathoracic chemo-thermotherapy with radiofrequency waves after extrapleural pneumonectomy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Interact Cardiovasc Thorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural effusion: what lies underneath?
</td>
<td style="text-align:left;">
BMJ Case Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
Establishing locoregional control of malignant pleural mesothelioma using high-dose radiotherapy and (18) F-FDG PET/CT scan correlation.
</td>
<td style="text-align:left;">
J Med Imaging Radiat Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
A case of diffused malignant pleural mesothelioma forming small multiple disseminations with intraoperatively suspicious carcinoid tumors.
</td>
<td style="text-align:left;">
Ann Thorac Cardiovasc Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
[Exploratory study on the detection of markers for diagnosing early-stage malignant mesothelioma].
</td>
<td style="text-align:left;">
Nihon Eiseigaku Zasshi
</td>
</tr>
<tr>
<td style="text-align:left;">
[Current status and future direction of Japan’s clinical trial for malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Nihon Eiseigaku Zasshi
</td>
</tr>
<tr>
<td style="text-align:left;">
ERK2 is essential for the growth of human epithelioid malignant mesotheliomas.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study.
</td>
<td style="text-align:left;">
Lancet Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Death receptor 5 and cellular FLICE-inhibitory protein regulate pemetrexed-induced apoptosis in human lung cancer cells.
</td>
<td style="text-align:left;">
Eur. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesothelioma side populations have a precursor phenotype.
</td>
<td style="text-align:left;">
Carcinogenesis
</td>
</tr>
<tr>
<td style="text-align:left;">
Predicting survival in malignant mesothelioma.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: clinicopathologic and survival characteristic in a consecutive series of 40 patients.
</td>
<td style="text-align:left;">
Ann Thorac Cardiovasc Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Occupation and work-related ill-health in UK construction workers.
</td>
<td style="text-align:left;">
Occup Med (Lond)
</td>
</tr>
<tr>
<td style="text-align:left;">
Validity of procalcitonin and C-reactive protein measurement when differentiating between benign and malignant pleural effusion.
</td>
<td style="text-align:left;">
Clin. Lab.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesothelioma instigates tumor-associated fibroblasts to promote progression via a malignant cytokine network.
</td>
<td style="text-align:left;">
Am. J. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Chronic inflammation in tumor stroma is an independent predictor of prolonged survival in epithelioid malignant pleural mesothelioma patients.
</td>
<td style="text-align:left;">
Cancer Immunol. Immunother.
</td>
</tr>
<tr>
<td style="text-align:left;">
Coactivation of receptor tyrosine kinases in malignant mesothelioma as a rationale for combination targeted therapy.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
The relationship between tumor MSLN methylation and serum mesothelin (SMRP) in mesothelioma.
</td>
<td style="text-align:left;">
Epigenetics
</td>
</tr>
<tr>
<td style="text-align:left;">
Prospective clinical and radiologic study of zeolite-exposed Turkish immigrants in Sweden.
</td>
<td style="text-align:left;">
Respiration
</td>
</tr>
<tr>
<td style="text-align:left;">
Receptor tyrosine kinase inhibitors and cytotoxic drugs affect pleural mesothelioma cell proliferation: insight into EGFR and ERK1/2 as antitumor targets.
</td>
<td style="text-align:left;">
Biochem. Pharmacol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression and regulation of B7-H3 immunoregulatory receptor, in human mesothelial and mesothelioma cells: immunotherapeutic implications.
</td>
<td style="text-align:left;">
J. Cell. Physiol.
</td>
</tr>
<tr>
<td style="text-align:left;">
The cytostatic effects of lovastatin on ACC-MESO-1 cells.
</td>
<td style="text-align:left;">
J. Surg. Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Missed opportunities to counsel patients with malignant pleural mesothelioma about causation and potential compensation.
</td>
<td style="text-align:left;">
Am. J. Med. Sci.
</td>
</tr>
<tr>
<td style="text-align:left;">
SEOM guidelines for the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin Transl Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
CBP501-calmodulin binding contributes to sensitizing tumor cells to cisplatin and bleomycin.
</td>
<td style="text-align:left;">
Mol. Cancer Ther.
</td>
</tr>
<tr>
<td style="text-align:left;">
Proteomic surfaceome analysis of mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Tissue factor pathway inhibitor attenuates the progression of malignant pleural mesothelioma in nude mice.
</td>
<td style="text-align:left;">
Am. J. Respir. Cell Mol. Biol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of the Ets transcription factor EHF in serous ovarian carcinoma effusions is a marker of poor survival.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Is adenosine deaminase in pleural fluid a useful marker for differentiating tuberculosis from lung cancer or mesothelioma in Japan, a country with intermediate incidence of tuberculosis?
</td>
<td style="text-align:left;">
Acta Med. Okayama
</td>
</tr>
<tr>
<td style="text-align:left;">
BIRC5 promoter SNPs do not affect nuclear survivin expression and survival of malignant pleural mesothelioma patients.
</td>
<td style="text-align:left;">
J. Cancer Res. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Germline BAP1 mutations predispose to malignant mesothelioma.
</td>
<td style="text-align:left;">
Nat. Genet.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma in Singapore.
</td>
<td style="text-align:left;">
Asian Pac. J. Cancer Prev.
</td>
</tr>
<tr>
<td style="text-align:left;">
Desmoplastic malignant mesothelioma of the pericardium: Description of a case and review of the literature.
</td>
<td style="text-align:left;">
Lung India
</td>
</tr>
<tr>
<td style="text-align:left;">
Safety and effectiveness of pemetrexed in patients with malignant pleural mesothelioma based on all-case drug-registry study.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Increasing incidence of malignant mesothelioma after exposure to asbestos during home maintenance and renovation.
</td>
<td style="text-align:left;">
Med. J. Aust.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pre-clinical mouse models of primary and metastatic pleural cancers of the lung and breast and the use of bioluminescent imaging to monitor pleural tumor burden.
</td>
<td style="text-align:left;">
Curr Protoc Pharmacol
</td>
</tr>
<tr>
<td style="text-align:left;">
Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Immunol. Immunother.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Current status of surgical treatment for malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Kyobu Geka
</td>
</tr>
<tr>
<td style="text-align:left;">
Raltitrexed plus cisplatin is cost-effective compared with pemetrexed plus cisplatin in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant epithelioid pleural mesothelioma versus peripheral pulmonary adenocarcinoma: a histochemical, ultrastructural, and immunohistologic study of 103 cases.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Benign pulmonary lesions that may be misdiagnosed as malignant.
</td>
<td style="text-align:left;">
Semin Diagn Pathol
</td>
</tr>
<tr>
<td style="text-align:left;">
Metastatic proximal epithelioid sarcoma in pleural effusion: cytopathologic findings and differential diagnosis.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
The fake fat phenomenon in organizing pleuritis: a source of confusion with desmoplastic malignant mesotheliomas.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Automated ERCC1 immunochemistry on hybrid cytology/tissue microarray of malignant effusions: evaluation of antibodies 8F1 and D-10.
</td>
<td style="text-align:left;">
J Clin Bioinforma
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
A nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Mod. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Strong anti-tumor effect of NVP-AUY922, a novel Hsp90 inhibitor, on non-small cell lung cancer.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Raltitrexed in mesothelioma.
</td>
<td style="text-align:left;">
Expert Rev Anticancer Ther
</td>
</tr>
<tr>
<td style="text-align:left;">
Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. the NCIC Clinical Trials Group.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Low calretinin expression and high neutrophil-to-lymphocyte ratio are poor prognostic factors in patients with malignant mesothelioma undergoing extrapleural pneumonectomy.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Sustained expression of steroid receptor coactivator SRC-2/TIF-2 is associated with better prognosis in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
SASP mediates chemoresistance and tumor-initiating-activity of mesothelioma cells.
</td>
<td style="text-align:left;">
Oncogene
</td>
</tr>
<tr>
<td style="text-align:left;">
Aquaporin 1 is an independent prognostic factor in pleural malignant mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical implications of 18F-fluorodeoxyglucose positron emission tomography/computed tomography at delayed phase for diagnosis and prognosis of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesothelioma mortality and asbestos exposure mapping in Italy.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Polycomb repressor complex-2 is a novel target for mesothelioma therapy.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Low ERCC1 expression in malignant pleural mesotheliomas treated with cisplatin and vinorelbine predicts prolonged progression-free survival.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Flow cytometric measurement of cellular FLICE-inhibitory protein (c-FLIP) in ovarian carcinoma effusions.
</td>
<td style="text-align:left;">
Cytopathology
</td>
</tr>
<tr>
<td style="text-align:left;">
PET-guided dose escalation tomotherapy in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Strahlenther Onkol
</td>
</tr>
<tr>
<td style="text-align:left;">
An in vivo platform for tumor biomarker assessment.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
</tr>
<tr>
<td style="text-align:left;">
Proteomic study of malignant pleural mesothelioma by laser microdissection and two-dimensional difference gel electrophoresis identified cathepsin D as a novel candidate for a differential diagnosis biomarker.
</td>
<td style="text-align:left;">
J Proteomics
</td>
</tr>
<tr>
<td style="text-align:left;">
Gene therapy for lung neoplasms.
</td>
<td style="text-align:left;">
Clin. Chest Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Mortality and cancer morbidity in cohorts of asbestos cement workers and referents.
</td>
<td style="text-align:left;">
Br J Ind Med
</td>
</tr>
<tr>
<td style="text-align:left;">
New pemetrexed-peptide conjugates: synthesis, characterization and in vitro cytostatic effect on non-small cell lung carcinoma (NCI-H358) and human leukemia (HL-60) cells.
</td>
<td style="text-align:left;">
J. Pept. Sci.
</td>
</tr>
<tr>
<td style="text-align:left;">
Transient but not stable ZEB1 knockdown dramatically inhibits growth of malignant pleural mesothelioma cells.
</td>
<td style="text-align:left;">
Ann. Surg. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of calretinin by breast carcinoma and the potential for misdiagnosis of mesothelioma.
</td>
<td style="text-align:left;">
Histopathology
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse malignant peritoneal mesothelioma–an update on treatment.
</td>
<td style="text-align:left;">
Cancer Treat. Rev.
</td>
</tr>
<tr>
<td style="text-align:left;">
National survey of malignant mesothelioma and asbestos exposure in Japan.
</td>
<td style="text-align:left;">
Cancer Sci.
</td>
</tr>
<tr>
<td style="text-align:left;">
Population-based survival for malignant mesothelioma after introduction of novel chemotherapy.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
</tr>
<tr>
<td style="text-align:left;">
Aberrant DNA methylation profile in pleural fluid for differential diagnosis of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Sci.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Anti-angiogenic factors in thoracic oncology: successes, failures and prospects].
</td>
<td style="text-align:left;">
Rev Mal Respir
</td>
</tr>
<tr>
<td style="text-align:left;">
Vorinostat/SAHA-induced apoptosis in malignant mesothelioma is FLIP/caspase 8-dependent and HR23B-independent.
</td>
<td style="text-align:left;">
Eur. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
[Tumoral markers and monoclonal antibodies].
</td>
<td style="text-align:left;">
Rev Prat
</td>
</tr>
<tr>
<td style="text-align:left;">
[Diagnosis and prognosis of malignant mesothelioma].
</td>
<td style="text-align:left;">
Rev Prat
</td>
</tr>
<tr>
<td style="text-align:left;">
Butein impairs the protumorigenic activity of malignant pleural mesothelioma cells.
</td>
<td style="text-align:left;">
Cell Cycle
</td>
</tr>
<tr>
<td style="text-align:left;">
BRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesothelioma.
</td>
<td style="text-align:left;">
J. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical impact of extrapleural pneumonectomy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Surg. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
The application of cold-plasma coagulation on the visceral pleura results in a predictable depth of necrosis without fistula generation.
</td>
<td style="text-align:left;">
Interact Cardiovasc Thorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
A review of transcriptome studies combined with data mining reveals novel potential markers of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Mutat. Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Novel therapies in phase II and III trials for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Natl Compr Canc Netw
</td>
</tr>
<tr>
<td style="text-align:left;">
Effect of dispersants of multi-walled carbon nanotubes on cellular uptake and biological responses.
</td>
<td style="text-align:left;">
Int J Nanomedicine
</td>
</tr>
<tr>
<td style="text-align:left;">
Practical approaches to diagnose and treat for T0 malignant pleural mesothelioma: a proposal for diagnostic total parietal pleurectomy.
</td>
<td style="text-align:left;">
Int. J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pathological and molecular biological approaches to early mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Plasma cell membrane localization of c-MET predicts longer survival in patients with malignant mesothelioma: a series of 157 cases from the MESOPATH Group.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
CD26 overexpression is associated with prolonged survival and enhanced chemosensitivity in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of interleukin-4 receptor alpha in human pleural mesothelioma is associated with poor survival and promotion of tumor inflammation.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment failure after extrapleural pneumonectomy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
A pathological complete response after preoperative chemotherapy with carboplatin and pemetrexed in malignant pleural mesothelioma: A case report.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Elucidation mechanism of different biological responses to multi-walled carbon nanotubes using four cell lines.
</td>
<td style="text-align:left;">
Int J Nanomedicine
</td>
</tr>
<tr>
<td style="text-align:left;">
Epithelial malignant pleural mesothelioma after extrapleural pneumonectomy: stratification of survival with CT-derived tumor volume.
</td>
<td style="text-align:left;">
AJR Am J Roentgenol
</td>
</tr>
<tr>
<td style="text-align:left;">
Heme oxygenase-1 promoter polymorphism is associated with risk of malignant mesothelioma.
</td>
<td style="text-align:left;">
Lung
</td>
</tr>
<tr>
<td style="text-align:left;">
Synthesis, characterization and antiproliferative activity on mesothelioma cell lines of bis(carboxylato)platinum(IV) complexes based on picoplatin.
</td>
<td style="text-align:left;">
Dalton Trans
</td>
</tr>
<tr>
<td style="text-align:left;">
Mechanisms of pleurodesis.
</td>
<td style="text-align:left;">
Respiration
</td>
</tr>
<tr>
<td style="text-align:left;">
Preclinical studies identify novel targeted pharmacological strategies for treatment of human malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Br. J. Pharmacol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Photodynamic drug delivery enhancement in tumours does not depend on leukocyte-endothelial interaction in a human mesothelioma xenograft model.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
The new case for cervical mediastinoscopy in selection for radical surgery for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Is α7-nAChR a possible target for lung cancer and malignant pleural mesothelioma treatment?
</td>
<td style="text-align:left;">
Curr Drug Targets
</td>
</tr>
<tr>
<td style="text-align:left;">
[Desmoplastic mesothelioma with bony metastases. A case report].
</td>
<td style="text-align:left;">
Rev Pneumol Clin
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural fluid cytological yield and visceral pleural invasion in patients with epithelioid malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
BioKnife, a uPA activity-dependent oncolytic Sendai virus, eliminates pleural spread of malignant mesothelioma via simultaneous stimulation of uPA expression.
</td>
<td style="text-align:left;">
Mol. Ther.
</td>
</tr>
<tr>
<td style="text-align:left;">
Adjuvant intensity-modulated proton therapy in malignant pleural mesothelioma. A comparison with intensity-modulated radiotherapy and a spot size variation assessment.
</td>
<td style="text-align:left;">
Strahlenther Onkol
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic value of 18F-FDG standard uptake value by integrated PET/CT in the staging of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Technol. Cancer Res. Treat.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Clinical analysis of 45 patients with malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Zhongguo Fei Ai Za Zhi
</td>
</tr>
<tr>
<td style="text-align:left;">
Fluorescence thoracoscopy in the detection of pleural malignancy.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Am J Health Syst Pharm
</td>
</tr>
<tr>
<td style="text-align:left;">
[An autopsied case of primary malignant pericardial mesothelioma diagnosed antemortally].
</td>
<td style="text-align:left;">
Nihon Kokyuki Gakkai Zasshi
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma with multiple nodules].
</td>
<td style="text-align:left;">
Nihon Kokyuki Gakkai Zasshi
</td>
</tr>
<tr>
<td style="text-align:left;">
First-line chemotherapy with liposomal doxorubicin plus cisplatin for patients with advanced malignant pleural mesothelioma: phase II trial.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnosis and treatment of pleural mesothelioma.
</td>
<td style="text-align:left;">
Semin Surg Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Epithelioid lesions of the serosa.
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunohistochemistry and molecular diagnostics of pleural malignant mesothelioma.
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma not associated with asbestos exposure.
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Lymphoproliferative conditions of the serosa.
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Molecular changes in mesothelioma with an impact on prognosis and treatment.
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Hemithoracic intensity-modulated radiotherapy using helical tomotherapy for patients after extrapleural pneumonectomy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Radiat. Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Dtsch. Med. Wochenschr.
</td>
</tr>
<tr>
<td style="text-align:left;">
Soluble mesothelin-related peptides levels in patients with malignant mesothelioma.
</td>
<td style="text-align:left;">
Dis. Markers
</td>
</tr>
<tr>
<td style="text-align:left;">
Is there a single spot size and grid for intensity modulated proton therapy? Simulation of head and neck, prostate and mesothelioma cases.
</td>
<td style="text-align:left;">
Med Phys
</td>
</tr>
<tr>
<td style="text-align:left;">
The diagnostic value of immunohistochemically detected methylthioadenosine phosphorylase deficiency in malignant pleural mesotheliomas.
</td>
<td style="text-align:left;">
Histopathology
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunity and malignant mesothelioma: from mesothelial cell damage to tumor development and immune response-based therapies.
</td>
<td style="text-align:left;">
Cancer Lett.
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemoprevention of asbestos-linked cancers: a systematic review.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Systemic treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Future Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a brief report.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Tunneling nanotubes provide a unique conduit for intercellular transfer of cellular contents in human malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
</tr>
<tr>
<td style="text-align:left;">
Advances in malignant pleural mesothelioma therapy: targeting EphA2 a novel approach.
</td>
<td style="text-align:left;">
Am J Cancer Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma: a review.
</td>
<td style="text-align:left;">
Ochsner J
</td>
</tr>
<tr>
<td style="text-align:left;">
A comparison of epidermal growth factor receptor expression in malignant peritoneal and pleural mesothelioma.
</td>
<td style="text-align:left;">
Pathol. Int.
</td>
</tr>
<tr>
<td style="text-align:left;">
[microRNAs as biological indicators of environmental and occupational exposure to asbestos].
</td>
<td style="text-align:left;">
G Ital Med Lav Ergon
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of cytological evaluation of pleural fluid in diagnosing malignant mesothelioma.
</td>
<td style="text-align:left;">
Med. Pregl.
</td>
</tr>
<tr>
<td style="text-align:left;">
Novel intrapleural therapies for malignant diseases.
</td>
<td style="text-align:left;">
Respiration
</td>
</tr>
<tr>
<td style="text-align:left;">
An overview of neoadjuvant chemotherapy in the multimodality treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Treat. Rev.
</td>
</tr>
<tr>
<td style="text-align:left;">
Exploratory analysis of activation of PTEN-PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM).
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic factors in malignant pleural mesothelioma: a retrospective study.
</td>
<td style="text-align:left;">
Intern. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Incarcerated inguinal hernia from metastatic pleural mesothelioma: PET/CT imaging.
</td>
<td style="text-align:left;">
Clin Nucl Med
</td>
</tr>
<tr>
<td style="text-align:left;">
[Bilateral pleural mesothelioma–case report].
</td>
<td style="text-align:left;">
Z Gesamte Inn Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Complete response and long-term survival in malignant pleural mesothelioma: case report.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
[‘Malignant peritoneal mesothelioma’: a condition difficult to diagnose].
</td>
<td style="text-align:left;">
Ned Tijdschr Geneeskd
</td>
</tr>
<tr>
<td style="text-align:left;">
Overexpression and potential targeting of the oncofoetal antigen 5T4 in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Aberrant expression of cell cycle regulatory genes predicts overall and disease free survival in malignant pleural mesothelioma patients.
</td>
<td style="text-align:left;">
Exp. Mol. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Estimating treatment effects from a randomized clinical trial in the presence of a secondary treatment.
</td>
<td style="text-align:left;">
Biostatistics
</td>
</tr>
<tr>
<td style="text-align:left;">
The circadian clock gene BMAL1 is a novel therapeutic target for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Effect of increasing experience on dosimetric and clinical outcomes in the management of malignant pleural mesothelioma with intensity-modulated radiation therapy.
</td>
<td style="text-align:left;">
Int. J. Radiat. Oncol. Biol. Phys.
</td>
</tr>
<tr>
<td style="text-align:left;">
Anti-angiogenic therapies for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Expert Opin Investig Drugs
</td>
</tr>
<tr>
<td style="text-align:left;">
SOCS-1 gene delivery cooperates with cisplatin plus pemetrexed to exhibit preclinical antitumor activity against malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Radical pleurectomy and intraoperative photodynamic therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Nitric oxide (NO) enhances pemetrexed cytotoxicity via NO‑cGMP signaling in lung adenocarcinoma cells in vitro and in vivo.
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytologic re-evaluation of negative effusions from patients with malignant mesothelioma.
</td>
<td style="text-align:left;">
Pathologica
</td>
</tr>
<tr>
<td style="text-align:left;">
[Asbestos-induced lung diseases].
</td>
<td style="text-align:left;">
Ugeskr. Laeg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Interaction and cross-resistance of cisplatin and pemetrexed in malignant pleural mesothelioma cell lines.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
</tr>
<tr>
<td style="text-align:left;">
SU6668, a multiple tyrosine kinase inhibitor, inhibits progression of human malignant pleural mesothelioma in an orthotopic model.
</td>
<td style="text-align:left;">
Respirology
</td>
</tr>
<tr>
<td style="text-align:left;">
Postmortem findings of malignant pleural mesothelioma: a two-center study of 318 patients.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Topotecan and pegylated liposomal doxorubicin combination as palliative treatment in patients with pretreated advanced malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int J Clin Pharmacol Ther
</td>
</tr>
<tr>
<td style="text-align:left;">
Interleukin gene polymorphisms in pneumoconiosis.
</td>
<td style="text-align:left;">
Int. J. Mol. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Antitumor activity of MEK and PI3K inhibitors against malignant pleural mesothelioma cells in vitro and in vivo.
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Bilateral dissemination of malignant pleural mesothelioma via iatrogenic buffalo chest: a rare route of disease progression.
</td>
<td style="text-align:left;">
Gen Thorac Cardiovasc Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Perifosine as a potential novel anti-cancer agent inhibits EGFR/MET-AKT axis in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural intensity-modulated radiotherapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Radiat. Oncol. Biol. Phys.
</td>
</tr>
<tr>
<td style="text-align:left;">
High SUVmax on FDG-PET indicates pleomorphic subtype in epithelioid malignant pleural mesothelioma: supportive evidence to reclassify pleomorphic as nonepithelioid histology.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Increased circulating miR-625-3p: a potential biomarker for patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Molecular pathogenesis of malignant mesothelioma.
</td>
<td style="text-align:left;">
Expert Rev Mol Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Resection of a giant, invasive malignant solitary fibrous tumor of pleura.
</td>
<td style="text-align:left;">
Gen Thorac Cardiovasc Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Cancer incidence among Swedish pulp and paper mill workers: a cohort study of sulphate and sulphite mills.
</td>
<td style="text-align:left;">
Int Arch Occup Environ Health
</td>
</tr>
<tr>
<td style="text-align:left;">
Validation of prognostic factors in malignant pleural mesothelioma: a retrospective analysis of data from patients seeking compensation from the New South Wales Dust Diseases Board.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Investigational approaches for mesothelioma.
</td>
<td style="text-align:left;">
Front Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma in US automotive mechanics: reported vs expected number of cases from 1975 to 2007.
</td>
<td style="text-align:left;">
Regul. Toxicol. Pharmacol.
</td>
</tr>
<tr>
<td style="text-align:left;">
PET scan contribution in chest tumor management: a systematic review for thoracic surgeons.
</td>
<td style="text-align:left;">
Tumori
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos and SV40 in malignant pleural mesothelioma from a hyperendemic area of north-eastern Italy.
</td>
<td style="text-align:left;">
Tumori
</td>
</tr>
<tr>
<td style="text-align:left;">
Effects of combined therapies on the survival of pleural mesothelioma patients treated in Brescia, 1982-2006.
</td>
<td style="text-align:left;">
Tumori
</td>
</tr>
<tr>
<td style="text-align:left;">
Increased frequency of circulating invariant natural killer T cells in malignant pleural mesothelioma patients.
</td>
<td style="text-align:left;">
Cancer Biol. Ther.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Mesothelioma and mesothelial hyperplasia].
</td>
<td style="text-align:left;">
Zhonghua Nei Ke Za Zhi
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos-related pleuropulmonary diseases: benign and malignant.
</td>
<td style="text-align:left;">
Postgrad Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Cancer incidence in a chlorochemical plant in Isère, France: an occupational cohort study, 1979-2002.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: from the bench to the bedside.
</td>
<td style="text-align:left;">
Respiration
</td>
</tr>
<tr>
<td style="text-align:left;">
Activated leukocyte cell-adhesion molecule (ALCAM) promotes malignant phenotypes of malignant mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Human epidemiology: a review of fiber type and characteristics in the development of malignant and nonmalignant disease.
</td>
<td style="text-align:left;">
Environ. Health Perspect.
</td>
</tr>
<tr>
<td style="text-align:left;">
Elimination of asbestos use and asbestos-related diseases: an unfinished story.
</td>
<td style="text-align:left;">
Cancer Sci.
</td>
</tr>
<tr>
<td style="text-align:left;">
CCL2, galectin-3, and SMRP combination improves the diagnosis of mesothelioma in pleural effusions.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Distribution and trends in mesothelioma mortality in Italy from 1974 to 2006.
</td>
<td style="text-align:left;">
Int Arch Occup Environ Health
</td>
</tr>
<tr>
<td style="text-align:left;">
Role of hedgehog signaling in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Natural diterpenes from coffee, cafestol and kahweol induce apoptosis through regulation of specificity protein 1 expression in human malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Biomed. Sci.
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical role of pleural effusion MMP-3 levels in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncol Lett
</td>
</tr>
<tr>
<td style="text-align:left;">
Pretreatment serum C-reactive protein levels predict benefit from multimodality treatment including radical surgery in malignant pleural mesothelioma: a retrospective multicenter analysis.
</td>
<td style="text-align:left;">
Ann. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Extracellular protease imaging for cell mass tracking of xenografted human malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Ther Umsch
</td>
</tr>
<tr>
<td style="text-align:left;">
[Chemotherapy for malignant tumors of lung and pleura].
</td>
<td style="text-align:left;">
Ther Umsch
</td>
</tr>
<tr>
<td style="text-align:left;">
AMP converted from intracellularly transported adenosine upregulates p53 expression to induce malignant pleural mesothelioma cell apoptosis.
</td>
<td style="text-align:left;">
Cell. Physiol. Biochem.
</td>
</tr>
<tr>
<td style="text-align:left;">
Meningeal and brainstem infiltration by a malignant mesothelioma.
</td>
<td style="text-align:left;">
BMJ Case Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
Circulating endothelial cell (CEC) as a diagnostic and prognostic marker in malignant pleural mesothelioma (MPM).
</td>
<td style="text-align:left;">
Ann. Surg. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
A case report of an extremely rare and aggressive tumor: primary malignant pericardial mesothelioma.
</td>
<td style="text-align:left;">
Rare Tumors
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytomorphologic features of metastatic urothelial carcinoma in serous effusions.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
</tr>
<tr>
<td style="text-align:left;">
Characterization of DNA hypermethylation in two cases of peritoneal mesothelioma.
</td>
<td style="text-align:left;">
Tumour Biol.
</td>
</tr>
<tr>
<td style="text-align:left;">
A somatic TSHR mutation in a patient with lung adenocarcinoma with bronchioloalveolar carcinoma, coronary artery disease and severe chronic obstructive pulmonary disease.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Diffuse malignant mesothelioma. Presentation of 10 cases and review of the literature].
</td>
<td style="text-align:left;">
Rev Med Panama
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse malignant mesothelioma.
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Revisiting cutaneous adverse reactions to pemetrexed.
</td>
<td style="text-align:left;">
Oncol Lett
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos-related disease: screening and diagnosis.
</td>
<td style="text-align:left;">
Adv Clin Chem
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytoreductive surgery and hyperthermic intrathoracic chemotherapy perfusion for malignant pleural tumours: perioperative management and clinical experience.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Folylpoly-glutamate synthetase expression is associated with tumor response and outcome from pemetrexed-based chemotherapy in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II clinical trial of first or second-line treatment with bortezomib in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Molecular resistance fingerprint of pemetrexed and platinum in a long-term survivor of mesothelioma.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
</tr>
<tr>
<td style="text-align:left;">
Patterns of care for malignant pleural mesothelioma patients compensated by the Dust Diseases Board in New South Wales, Australia.
</td>
<td style="text-align:left;">
Intern Med J
</td>
</tr>
<tr>
<td style="text-align:left;">
Withaferin A inhibits the proteasome activity in mesothelioma in vitro and in vivo.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
</tr>
<tr>
<td style="text-align:left;">
Convergent signaling in the regulation of connective tissue growth factor in malignant mesothelioma: TGFβ signaling and defects in the Hippo signaling cascade.
</td>
<td style="text-align:left;">
Cell Cycle
</td>
</tr>
<tr>
<td style="text-align:left;">
Parakeratotic-like cells in effusions - A clue to diagnosis of malignant mesothelioma.
</td>
<td style="text-align:left;">
Cytojournal
</td>
</tr>
<tr>
<td style="text-align:left;">
Paratesticular mesothelioma in young age. Case report.
</td>
<td style="text-align:left;">
Klin Onkol
</td>
</tr>
<tr>
<td style="text-align:left;">
Quality of life after radical pleurectomy decortication for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Therapeutic antitumor efficacy of anti-epidermal growth factor receptor antibody, cetuximab, against malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Histone deacetylase inhibitors as potential therapeutic agents for the treatment of malignant mesothelioma.
</td>
<td style="text-align:left;">
Anticancer Agents Med Chem
</td>
</tr>
<tr>
<td style="text-align:left;">
3T MRI in evaluation of asbestos-related thoracic diseases - preliminary results.
</td>
<td style="text-align:left;">
Radiol Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Health-related quality of life and inflammatory markers in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Support Care Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Comprehensive treatment of malignant mesothelioma patients after the failure of systemic chemotherapy.
</td>
<td style="text-align:left;">
Cryobiology
</td>
</tr>
<tr>
<td style="text-align:left;">
Association of biomarker levels with severity of asbestos-related diseases.
</td>
<td style="text-align:left;">
Saf Health Work
</td>
</tr>
<tr>
<td style="text-align:left;">
CREST biorepository for translational studies on malignant mesothelioma, lung cancer and other respiratory tract diseases: Informatics infrastructure and standardized annotation.
</td>
<td style="text-align:left;">
Exp Ther Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Intratumoral Wnt2B expression affects tumor proliferation and survival in malignant pleural mesothelioma patients.
</td>
<td style="text-align:left;">
Exp Ther Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Development of a guideline on reading CT images of malignant pleural mesothelioma and selection of the reference CT films.
</td>
<td style="text-align:left;">
Eur J Radiol
</td>
</tr>
<tr>
<td style="text-align:left;">
DNA repair polymorphisms and treatment outcomes of patients with malignant mesothelioma treated with gemcitabine-platinum combination chemotherapy.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Role of conservative (palliative) care-only in the management of advanced malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Soluble mesothelin-related protein in pleural effusion from patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Exp Ther Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Distinguishing benign from malignant mesothelial cells in effusions by Glut-1, EMA, and Desmin expression: an evidence-based approach.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Case reports of primary pulmonary adenocarcinoma with pleural spread: so-called pseudomesotheliomatous adenocarcinoma.
</td>
<td style="text-align:left;">
Pathol. Int.
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma mortality surveillance and asbestos exposure tracking in Italy.
</td>
<td style="text-align:left;">
Ann. Ist. Super. Sanita
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural fluid cell-free DNA integrity index to identify cytologically negative malignant pleural effusions including mesotheliomas.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Mitochondrial-targeted nitroxides disrupt mitochondrial architecture and inhibit expression of peroxiredoxin 3 and FOXM1 in malignant mesothelioma cells.
</td>
<td style="text-align:left;">
J. Cell. Physiol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Analysis of “dry” mesothelioma with ultrasound guided biopsies.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos exposure and survival in malignant mesothelioma: a description of 122 consecutive cases at an occupational clinic.
</td>
<td style="text-align:left;">
Int J Occup Environ Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Sphingosine kinase 1 is required for mesothelioma cell proliferation: role of histone acetylation.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
</tr>
<tr>
<td style="text-align:left;">
Carbonic anhydrase IX in malignant pleural mesotheliomas: a potential target for anti-cancer therapy.
</td>
<td style="text-align:left;">
Bioorg. Med. Chem.
</td>
</tr>
<tr>
<td style="text-align:left;">
Heterozygous loss of NF2 is an early molecular alteration in well-differentiated papillary mesothelioma of the peritoneum.
</td>
<td style="text-align:left;">
Cancer Genet
</td>
</tr>
<tr>
<td style="text-align:left;">
Toxic epidermal necrolysis related to Cisplatin and pemetrexed for metastatic non-small cell lung cancer.
</td>
<td style="text-align:left;">
Onkologie
</td>
</tr>
<tr>
<td style="text-align:left;">
Recombinant human endostatin (endostar) decreased recurrent ascites, pleural fluid and ascitic VEGF in a case of advanced mesothelioma.
</td>
<td style="text-align:left;">
J Chemother
</td>
</tr>
<tr>
<td style="text-align:left;">
Serum concentration of integrin-linked kinase in malignant pleural mesothelioma and after asbestos exposure.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Spinal cord compression: an unusual presentation of malignant pleural mesothelioma. A case report and review of the literature.
</td>
<td style="text-align:left;">
Tumori
</td>
</tr>
<tr>
<td style="text-align:left;">
Pegylated liposomal doxorubicin in malignant pleural mesothelioma: a possible guardian for long-term survival.
</td>
<td style="text-align:left;">
Onco Targets Ther
</td>
</tr>
<tr>
<td style="text-align:left;">
Early detection of malignant pleural mesothelioma in asbestos-exposed individuals with a noninvasive proteomics-based surveillance tool.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
</tr>
<tr>
<td style="text-align:left;">
ME1. A monoclonal antibody that distinguishes epithelial-type malignant mesothelioma from pulmonary adenocarcinoma and extrapulmonary malignancies.
</td>
<td style="text-align:left;">
Am. J. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Optimization of response classification criteria for patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of FDG PET-CT in differential diagnosis of pleural pathologies.
</td>
<td style="text-align:left;">
Rev Esp Med Nucl Imagen Mol
</td>
</tr>
<tr>
<td style="text-align:left;">
Initial analysis of the international association for the study of lung cancer mesothelioma database.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Outcome and prognostic factors of pleural mesothelioma after surgical diagnosis and/or pleurodesis.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Improved survival after introduction of chemotherapy for malignant pleural mesothelioma in Slovenia: Population-based survey of 444 patients.
</td>
<td style="text-align:left;">
Radiol Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Excision repair cross complementation group 1 and thymidylate synthase expression in patients with mesothelioma.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
A predictive equation to adjust for clinical variables in soluble mesothelin-related protein (SMRP) levels.
</td>
<td style="text-align:left;">
Clin. Chem. Lab. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Three-dimensional stereoscopic volume rendering of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Utilisation of a thoracic oncology database to capture radiological and pathological images for evaluation of response to chemotherapy in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
BMJ Open
</td>
</tr>
<tr>
<td style="text-align:left;">
Glutathione S-transferase P1-1 as a target for mesothelioma treatment.
</td>
<td style="text-align:left;">
Cancer Sci.
</td>
</tr>
<tr>
<td style="text-align:left;">
The recurrence of malignant pleural mesothelioma 14 years after extrapleural pneumonectomy: possible histological transformation.
</td>
<td style="text-align:left;">
Pathol. Int.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pleural mesothelioma–case report].
</td>
<td style="text-align:left;">
Acta Med Croatica
</td>
</tr>
<tr>
<td style="text-align:left;">
[PleurX drainage catheter for palliative treatment of malignant pleural effusion].
</td>
<td style="text-align:left;">
Pneumologie
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic significance of metabolic response by positron emission tomography after neoadjuvant chemotherapy for resectable malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical utility of 18-fluorodeoxyglucose positron emission tomography/computed tomography in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Exp Ther Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Disease volumes as a marker for patient response in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Novel genes and pathways modulated by syndecan-1: implications for the proliferation and cell-cycle regulation of malignant mesothelioma cells.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
</tr>
<tr>
<td style="text-align:left;">
Nonselective transarterial chemoperfusion: a palliative treatment for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Radiology
</td>
</tr>
<tr>
<td style="text-align:left;">
Incidence and survival of malignant pleural mesothelioma in norway: a population-based study of 1686 cases.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Tomotherapy after pleurectomy/decortication or biopsy for malignant pleural mesothelioma allows the delivery of high dose of radiation in patients with intact lung.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Talc pleurodesis as surgical palliation of patients with malignant pleural effusion. Analysis of factors affecting survival.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Performance characteristics of semirigid thoracoscopy in pleural effusions of undetermined etiology.
</td>
<td style="text-align:left;">
J Bronchology Interv Pulmonol
</td>
</tr>
<tr>
<td style="text-align:left;">
Multimodal therapy of malignant pleural mesothelioma: is the replacement of radical surgery imminent?
</td>
<td style="text-align:left;">
Interact Cardiovasc Thorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Intraoperative hyperthermic chemotherapy perfusion for malignant pleural mesothelioma: an in vitro evaluation.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnosis of malignant pericarditis: a single centre experience.
</td>
<td style="text-align:left;">
Kardiol Pol
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleurectomy decortication in the treatment of the “trapped lung” in benign and malignant pleural effusions.
</td>
<td style="text-align:left;">
Thorac Surg Clin
</td>
</tr>
<tr>
<td style="text-align:left;">
18F-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography fused imaging in malignant mesothelioma patients: looking from outside is not enough.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma: a soon to be forgotten disease in the United States?
</td>
<td style="text-align:left;">
J Bronchology Interv Pulmonol
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed plus carboplatin or cisplatin as neoadjuvant treatment of operable malignant pleural mesothelioma (MPM).
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Mechanisms of cisplatin-induced cell death in malignant mesothelioma cells: role of inhibitor of apoptosis proteins (IAPs) and caspases.
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos-related malignant mesothelioma: growth, cytology, tumorigenicity and consistent chromosome findings in cell lines from five patients.
</td>
<td style="text-align:left;">
Carcinogenesis
</td>
</tr>
<tr>
<td style="text-align:left;">
Extraskeletal osteosarcoma of the pleura:report of a case.
</td>
<td style="text-align:left;">
Ann Thorac Cardiovasc Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Factors predicting poor survival after lung-sparing radical pleurectomy of IMIG stage III malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma in Eastern Asia.
</td>
<td style="text-align:left;">
Asian Pac. J. Cancer Prev.
</td>
</tr>
<tr>
<td style="text-align:left;">
Patterns of failure, toxicity, and survival after extrapleural pneumonectomy and hemithoracic intensity-modulated radiation therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Evaluation of soluble mesothelin-related peptide as a diagnostic marker of malignant pleural mesothelioma effusions: its contribution to cytology.
</td>
<td style="text-align:left;">
Cancer Invest.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Computerized tomography in a case of malignant mesothelioma with atypical clinical manifestations].
</td>
<td style="text-align:left;">
Minerva Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Antibody therapy for malignant mesothelioma: humanized anti-cD26 mAb therapy].
</td>
<td style="text-align:left;">
Nippon Rinsho
</td>
</tr>
<tr>
<td style="text-align:left;">
Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1).
</td>
<td style="text-align:left;">
BMC Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic usefulness of p16/CDKN2A FISH in distinguishing between sarcomatoid mesothelioma and fibrous pleuritis.
</td>
<td style="text-align:left;">
Am. J. Clin. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
A seven-year disease-free survivor of malignant pleural mesothelioma treated with hyperthermia and chemotherapy: a case report.
</td>
<td style="text-align:left;">
J Med Case Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma: new insights into a rare disease.
</td>
<td style="text-align:left;">
Cancer Treat. Rev.
</td>
</tr>
<tr>
<td style="text-align:left;">
Individual predictors of increased serum mesothelin in asbestos-exposed workers.
</td>
<td style="text-align:left;">
Med. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma of the pleura. Analysis of its immunohistochemical aspects].
</td>
<td style="text-align:left;">
Ann Pathol
</td>
</tr>
<tr>
<td style="text-align:left;">
Podoplanin overexpression in human mesothelioma cell lines enhances the tumorigenic phenotype.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma - Update on Diagnostic Strategies.
</td>
<td style="text-align:left;">
Clin Pulm Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleurodesis outcome in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Thorax
</td>
</tr>
<tr>
<td style="text-align:left;">
PARP1 inhibition affects pleural mesothelioma cell viability and uncouples AKT/mTOR axis via SIRT1.
</td>
<td style="text-align:left;">
J. Cell. Mol. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical characteristics, treatment and survival outcomes in malignant mesothelioma: eighteen years’ experience in Turkey.
</td>
<td style="text-align:left;">
Asian Pac. J. Cancer Prev.
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II trial of neoadjuvant pemetrexed plus cisplatin followed by surgery and radiation in the treatment of pleural mesothelioma.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
What is the survival after surgery for localized malignant pleural mesothelioma?
</td>
<td style="text-align:left;">
Interact Cardiovasc Thorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Effects of treatment regimens on survival in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur Rev Med Pharmacol Sci
</td>
</tr>
<tr>
<td style="text-align:left;">
Orthotopic pleural mesothelioma in mice: SPECT/CT and MR imaging with HER1- and HER2-targeted radiolabeled antibodies.
</td>
<td style="text-align:left;">
Radiology
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma: diagnosis and treatment].
</td>
<td style="text-align:left;">
Rev Pneumol Clin
</td>
</tr>
<tr>
<td style="text-align:left;">
Changes in pulmonary function tests predict radiological response to chemotherapy in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Metachronous malignant mesothelioma and pulmonary adenocarcinoma.
</td>
<td style="text-align:left;">
Turk Patoloji Derg
</td>
</tr>
<tr>
<td style="text-align:left;">
Morphologic and immunocytochemical performances of effusion cell blocks prepared using 3 different methods.
</td>
<td style="text-align:left;">
Am. J. Clin. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
The malignancy grading method is not a reliable assessment of malignancy in mesothelioma.
</td>
<td style="text-align:left;">
J. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Is survivin expression prognostic or predictive in malignant pleural mesothelioma?
</td>
<td style="text-align:left;">
Virchows Arch.
</td>
</tr>
<tr>
<td style="text-align:left;">
The expression of Axl receptor tyrosine kinase influences the tumour phenotype and clinical outcome of patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
SMO expression level correlates with overall survival in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Exp. Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Local and systemic exposure of cisplatin during hyperthermic intrathoracic chemotherapy perfusion after pleurectomy and decortication for treatment of pleural malignancies.
</td>
<td style="text-align:left;">
J Surg Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Gene therapy for malignant mesothelioma: current prospects and challenges.
</td>
<td style="text-align:left;">
Cancer Gene Ther.
</td>
</tr>
<tr>
<td style="text-align:left;">
[A case report: an university professor suffering from malignant mesothelioma].
</td>
<td style="text-align:left;">
G Ital Med Lav Ergon
</td>
</tr>
<tr>
<td style="text-align:left;">
[Identification and characterization of microRNA involving in malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
G Ital Med Lav Ergon
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma: analysis of a hospital case series].
</td>
<td style="text-align:left;">
G Ital Med Lav Ergon
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgery in mesothelioma–where do we go after MARS?
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemotherapy management of malignant pleural mesothelioma: a phase II study comparing two popular chemotherapy regimens.
</td>
<td style="text-align:left;">
Clin Transl Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: update on treatment options with a focus on novel therapies.
</td>
<td style="text-align:left;">
Clin. Chest Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Rare pleural tumors.
</td>
<td style="text-align:left;">
Clin. Chest Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
The endoplasmic reticulum stress marker CHOP predicts survival in malignant mesothelioma.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Therapeutic targeting malignant mesothelioma with a novel 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate via its selective uptake by the proton-coupled folate transporter.
</td>
<td style="text-align:left;">
Cancer Chemother. Pharmacol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: factors influencing the prognosis.
</td>
<td style="text-align:left;">
Oncology (Williston Park, N.Y.)
</td>
</tr>
<tr>
<td style="text-align:left;">
Laparoscopic repair of secondary parahiatal hernia with incarceration of the stomach: a case report.
</td>
<td style="text-align:left;">
J Med Case Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
Changes of mesothelin and osteopontin levels over time in formerly asbestos-exposed power industry workers.
</td>
<td style="text-align:left;">
Int Arch Occup Environ Health
</td>
</tr>
<tr>
<td style="text-align:left;">
Hypoxia affects in vitro growth of newly established cell lines from patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Biomed. Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Hyperthermic intraoperative pleural cisplatin chemotherapy extends interval to recurrence and survival among low-risk patients with malignant pleural mesothelioma undergoing surgical macroscopic complete resection.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Differential mutation profiles and similar intronic TP53 polymorphisms in asbestos-related lung cancer and pleural mesothelioma.
</td>
<td style="text-align:left;">
Mutagenesis
</td>
</tr>
<tr>
<td style="text-align:left;">
Reduced folate carrier and folylpolyglutamate synthetase, but not thymidylate synthase predict survival in pemetrexed-treated patients suffering from malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Pneumoconiosis and malignant mesothelioma in a family operated metal casting business that used industrial talc from New York state.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Morphology of 9p21 homozygous deletion-positive pleural mesothelioma cells analyzed using fluorescence in situ hybridization and virtual microscope system in effusion cytology.
</td>
<td style="text-align:left;">
Cancer Cytopathol
</td>
</tr>
<tr>
<td style="text-align:left;">
Multimodality treatment of pleural mesothelioma.
</td>
<td style="text-align:left;">
Surg. Oncol. Clin. N. Am.
</td>
</tr>
<tr>
<td style="text-align:left;">
Oestrogen receptors are prognostic factors in malignant peritoneal mesothelioma.
</td>
<td style="text-align:left;">
J. Cancer Res. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Anti-Yo antibody-mediated paraneoplastic cerebellar degeneration in a female patient with pleural malignant mesothelioma.
</td>
<td style="text-align:left;">
Jpn. J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Circulating tumor cells as a diagnostic test for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Expert Opin Med Diagn
</td>
</tr>
<tr>
<td style="text-align:left;">
Gli as a novel therapeutic target in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
</tr>
<tr>
<td style="text-align:left;">
Regional differences in incidence of malignant mesothelioma in Denmark.
</td>
<td style="text-align:left;">
Dan Med J
</td>
</tr>
<tr>
<td style="text-align:left;">
Thymidylate synthase and folyl-polyglutamate synthase are not clinically useful markers of response to pemetrexed in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Lung volume measurements as a surrogate marker for patient response in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Sequential binary gene ratio tests define a novel molecular diagnostic strategy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
A feasibility study of induction pemetrexed plus cisplatin followed by pleurectomy/decortication aimed at macroscopic complete resection for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Jpn. J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
PET/CT demonstration and monitoring of thoracic and abdominal wall mesothelioma.
</td>
<td style="text-align:left;">
Clin Nucl Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Development of a biosensor for detection of pleural mesothelioma cancer biomarker using surface imprinting.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
</tr>
<tr>
<td style="text-align:left;">
Phenotypes and karyotypes of human malignant mesothelioma cell lines.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
</tr>
<tr>
<td style="text-align:left;">
TRAIL and proteasome inhibitors combination induces a robust apoptosis in human malignant pleural mesothelioma cells through Mcl-1 and Akt protein cleavages.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Downregulation of Sp1 is involved in honokiol-induced cell cycle arrest and apoptosis in human malignant pleural mesothelioma cells.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic value of mesothelin in pleural fluids: comparison with CYFRA 21-1 and CEA.
</td>
<td style="text-align:left;">
Med. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Endothelial cell protein C receptor opposes mesothelioma growth driven by tissue factor.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Current and future options for the diagnosis of malignant pleural effusion.
</td>
<td style="text-align:left;">
Expert Opin Med Diagn
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapy.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic delay in malignant pleural mesothelioma due to physicians fixation on history with non-exposure to asbestos.
</td>
<td style="text-align:left;">
BMJ Case Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
The N-ERC index is a novel monitoring and prognostic marker for advanced malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Bone metastases with nerve root compression as a late complication in patient with epithelial pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Calretinin is essential for mesothelioma cell growth/survival in vitro: a potential new target for malignant mesothelioma therapy?
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Serum HMGB1 as a prognostic marker for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Survival of mesothelioma in a palliative medical care unit in egypt.
</td>
<td style="text-align:left;">
Asian Pac. J. Cancer Prev.
</td>
</tr>
<tr>
<td style="text-align:left;">
Genetic variants associated with increased risk of malignant pleural mesothelioma: a genome-wide association study.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
</tr>
<tr>
<td style="text-align:left;">
EZH2, a unique marker of malignancy in effusion cytology.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Good response of malignant pleural effusion from carcinoma of unknown primary site to the anti-tuberculosis therapy: a case report.
</td>
<td style="text-align:left;">
Int J Clin Exp Pathol
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic surgical pathology in lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Proton magnetic resonance metabolomic characterization of ovarian serous carcinoma effusions: chemotherapy-related effects and comparison with malignant mesothelioma and breast carcinoma.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Value of Glut-1 and Koc markers in the differential diagnosis of reactive mesothelial hyperplasia, malignant mesothelioma and pulmonary adenocarcinoma.
</td>
<td style="text-align:left;">
Turk Patoloji Derg
</td>
</tr>
<tr>
<td style="text-align:left;">
PET/CT versus body coil PET/MRI: how low can you go?
</td>
<td style="text-align:left;">
Insights Imaging
</td>
</tr>
<tr>
<td style="text-align:left;">
Thymidylate synthase expression determines pemetrexed targets and resistance development in tumour cells.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
</tr>
<tr>
<td style="text-align:left;">
Management of malignant pleural mesothelioma: have we made any progress?
</td>
<td style="text-align:left;">
Panminerva Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Molecular pathogenesis of malignant mesothelioma.
</td>
<td style="text-align:left;">
Carcinogenesis
</td>
</tr>
<tr>
<td style="text-align:left;">
Radical pleurectomy and chemoradiation for malignant pleural mesothelioma: the outcome of incomplete resections.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Relationship between 18 FDG PET-CT findings and the survival of 177 patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur Rev Med Pharmacol Sci
</td>
</tr>
<tr>
<td style="text-align:left;">
A novel targeting therapy of malignant mesothelioma using anti-podoplanin antibody.
</td>
<td style="text-align:left;">
J. Immunol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos and the lung in the 21st century: an update.
</td>
<td style="text-align:left;">
Clin Respir J
</td>
</tr>
<tr>
<td style="text-align:left;">
Peritoneal mesothelioma: the site of origin matters.
</td>
<td style="text-align:left;">
Am Soc Clin Oncol Educ Book
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: incidence, etiology, diagnosis, treatment, and occupational health.
</td>
<td style="text-align:left;">
Dtsch Arztebl Int
</td>
</tr>
<tr>
<td style="text-align:left;">
EphB4 as a therapeutic target in mesothelioma.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelin is more useful in pleural effusion than in serum in the diagnosis of pleural mesothelioma.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Surgical aspects of malignant pleural mesothelioma: from the perspective of pathology].
</td>
<td style="text-align:left;">
Chirurg
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgery in the treatment of malignant pleural mesothelioma: recruitment into trials should be the default position.
</td>
<td style="text-align:left;">
Thorax
</td>
</tr>
<tr>
<td style="text-align:left;">
BAK and NOXA are critical determinants of mitochondrial apoptosis induced by bortezomib in mesothelioma.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
</tr>
<tr>
<td style="text-align:left;">
Systematic review of pleurectomy in the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Combination of mesothelin and CEA significantly improves the differentiation between malignant pleural mesothelioma, benign asbestos disease, and lung cancer.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of epigenetics in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Meta-analysis of microRNA-183 family expression in human cancer studies comparing cancer tissues with noncancerous tissues.
</td>
<td style="text-align:left;">
Gene
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse intrapulmonary malignant mesothelioma masquerading as interstitial lung disease: a distinctive variant of mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
ERCC1, MLH1, MSH2, MSH6, and βIII-tubulin: resistance proteins associated with response and outcome to platinum-based chemotherapy in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Therapies currently in Phase II trials for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Expert Opin Investig Drugs
</td>
</tr>
<tr>
<td style="text-align:left;">
Defect in recruiting effector memory CD8+ T-cells in malignant pleural effusions compared to normal pleural fluid.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
miR-1 induces growth arrest and apoptosis in malignant mesothelioma.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
MUC1 has prognostic significance in malignant peritoneal mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Biol. Markers
</td>
</tr>
<tr>
<td style="text-align:left;">
No association between simian virus 40 and diffuse malignant mesothelioma of the pleura in Iranian patients: a molecular and epidemiologic case-control study of 60 patients.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Challenges and controversies in the diagnosis of malignant mesothelioma: Part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and microRNA.
</td>
<td style="text-align:left;">
J. Clin. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Intensity-modulated radiotherapy and volumetric-modulated arc therapy for malignant pleural mesothelioma after extrapleural pleuropneumonectomy.
</td>
<td style="text-align:left;">
J Appl Clin Med Phys
</td>
</tr>
<tr>
<td style="text-align:left;">
Primary pericardial mesothelioma: a rare entity.
</td>
<td style="text-align:left;">
Case Rep Oncol Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Tsc1-Tp53 loss induces mesothelioma in mice, and evidence for this mechanism in human mesothelioma.
</td>
<td style="text-align:left;">
Oncogene
</td>
</tr>
<tr>
<td style="text-align:left;">
[Prognosis related clinical and molecular factors in malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Zhonghua Jie He He Hu Xi Za Zhi
</td>
</tr>
<tr>
<td style="text-align:left;">
SAHA overcomes FLIP-mediated inhibition of SMAC mimetic-induced apoptosis in mesothelioma.
</td>
<td style="text-align:left;">
Cell Death Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical value of mesothelin in pleural effusions versus histology by medical thoracoscopy: brief report.
</td>
<td style="text-align:left;">
Med. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Enhancement of in vitro cell motility and invasiveness of human malignant pleural mesothelioma cells through the HIF-1α-MUC1 pathway.
</td>
<td style="text-align:left;">
Cancer Lett.
</td>
</tr>
<tr>
<td style="text-align:left;">
Secondline chemotherapy versus best supportive care in patient with malignant pleural mesothelioma: a retrospective study.
</td>
<td style="text-align:left;">
Asian Pac. J. Cancer Prev.
</td>
</tr>
<tr>
<td style="text-align:left;">
The use of indwelling pleural catheters for the management of malignant pleural effusion–direct costs in a Dutch hospital.
</td>
<td style="text-align:left;">
Respiration
</td>
</tr>
<tr>
<td style="text-align:left;">
Overexpression of EPH receptor B2 in malignant mesothelioma correlates with oncogenic behavior.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
An oncolytic vaccinia virus expressing the human sodium iodine symporter prolongs survival and facilitates SPECT/CT imaging in an orthotopic model of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Surgery
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma, airborne asbestos, and the need for accuracy in chrysotile risk assessments.
</td>
<td style="text-align:left;">
New Solut
</td>
</tr>
<tr>
<td style="text-align:left;">
Identification of pregnancy-associated plasma protein A as a migration-promoting gene in malignant pleural mesothelioma cells: a potential therapeutic target.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
Negative modulation of mitochondrial oxidative phosphorylation by epigallocatechin-3 gallate leads to growth arrest and apoptosis in human malignant pleural mesothelioma cells.
</td>
<td style="text-align:left;">
Biochim. Biophys. Acta
</td>
</tr>
<tr>
<td style="text-align:left;">
Risk factors associated with asbestos-related diseases: a community-based case-control study.
</td>
<td style="text-align:left;">
BMC Public Health
</td>
</tr>
<tr>
<td style="text-align:left;">
Chronic exposure to carbon nanotubes induces invasion of human mesothelial cells through matrix metalloproteinase-2.
</td>
<td style="text-align:left;">
ACS Nano
</td>
</tr>
<tr>
<td style="text-align:left;">
Variability of tumor area measurements for response assessment in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Med Phys
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma in a clerk working in an asbestos factory.
</td>
<td style="text-align:left;">
Ann. Acad. Med. Singap.
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells.
</td>
<td style="text-align:left;">
J Transl Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos and erionite prime and activate the NLRP3 inflammasome that stimulates autocrine cytokine release in human mesothelial cells.
</td>
<td style="text-align:left;">
Part Fibre Toxicol
</td>
</tr>
<tr>
<td style="text-align:left;">
Patterns of disease progression on 18F-fluorodeoxyglucose positron emission tomography-computed tomography in patients with malignant pleural mesothelioma undergoing multimodality therapy with pleurectomy/decortication.
</td>
<td style="text-align:left;">
Nucl Med Commun
</td>
</tr>
<tr>
<td style="text-align:left;">
Long non coding RNAs (lncRNAs) are dysregulated in Malignant Pleural Mesothelioma (MPM).
</td>
<td style="text-align:left;">
PLoS ONE
</td>
</tr>
<tr>
<td style="text-align:left;">
Systematic review of trimodality therapy for patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Do we need a revised staging system for malignant pleural mesothelioma? Analysis of the IASLC database.
</td>
<td style="text-align:left;">
Ann Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: an epidemiological perspective.
</td>
<td style="text-align:left;">
Ann Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Hyaluronan and N-ERC/mesothelin as key biomarkers in a specific two-step model to predict pleural malignant mesothelioma.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
</tr>
<tr>
<td style="text-align:left;">
Antitumor impact of interferon-γ producing CD1d-restricted NKT cells in murine malignant mesothelioma.
</td>
<td style="text-align:left;">
J. Immunother.
</td>
</tr>
<tr>
<td style="text-align:left;">
Imaging in pleural mesothelioma: a review of the 11th International Conference of the International Mesothelioma Interest Group.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
The value of pemetrexed for the treatment of malignant pleural mesothelioma: a comprehensive review.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytoreductive surgery and post-operative heated pleural chemotherapy for the management of pleural surface malignancy.
</td>
<td style="text-align:left;">
Int J Hyperthermia
</td>
</tr>
<tr>
<td style="text-align:left;">
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.
</td>
<td style="text-align:left;">
Lancet Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression profile and function of Wnt signaling mechanisms in malignant mesothelioma cells.
</td>
<td style="text-align:left;">
Biochem. Biophys. Res. Commun.
</td>
</tr>
<tr>
<td style="text-align:left;">
CD90 is a diagnostic marker to differentiate between malignant pleural mesothelioma and lung carcinoma with immunohistochemistry.
</td>
<td style="text-align:left;">
Am. J. Clin. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Giant benign solitary fibrous tumour of the pleura (&gt; 15 cm): role of radiological pathological correlations in management. Report of 3 cases and review of the literature.
</td>
<td style="text-align:left;">
Pathologica
</td>
</tr>
<tr>
<td style="text-align:left;">
Localized Intrasplenic Mesothelioma: A Case Report.
</td>
<td style="text-align:left;">
Int. J. Surg. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
The hexacarbonyldicobalt derivative of aspirin acts as a CO-releasing NSAID on malignant mesothelioma cells.
</td>
<td style="text-align:left;">
Metallomics
</td>
</tr>
<tr>
<td style="text-align:left;">
The association of 18F-FDG PET/CT parameters with survival in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur. J. Nucl. Med. Mol. Imaging
</td>
</tr>
<tr>
<td style="text-align:left;">
Florid mesothelial hyperplasia of the tunica vaginalis mimicking malignant mesothelioma: a clinicopathologic study of 12 cases.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Estrogen receptor β activation impairs mitochondrial oxidative metabolism and affects malignant mesothelioma cell growth in vitro and in vivo.
</td>
<td style="text-align:left;">
Oncogenesis
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma with bone metastases.
</td>
<td style="text-align:left;">
Med. Pediatr. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma presenting as acute empyema with severe leukocytosis.
</td>
<td style="text-align:left;">
Ann Thorac Cardiovasc Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Targeting of the Hedgehog signal transduction pathway suppresses survival of malignant pleural mesothelioma cells in vitro.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: current and future perspectives.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment of malignant pleural effusion.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant transformation of well-differentiated papillary mesothelioma 13 years after the diagnosis: a case report.
</td>
<td style="text-align:left;">
Clin Respir J
</td>
</tr>
<tr>
<td style="text-align:left;">
Intracavitary chemotherapy.
</td>
<td style="text-align:left;">
Crit. Rev. Oncol. Hematol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical characteristics of patients with malignant pleural mesothelioma harboring somatic BAP1 mutations.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Hesperidin Induces Apoptosis by Inhibiting Sp1 and Its Regulatory Protein in MSTO-211H Cells.
</td>
<td style="text-align:left;">
Biomol Ther (Seoul)
</td>
</tr>
<tr>
<td style="text-align:left;">
Stratification of malignant pleural mesothelioma prognosis using recursive partitioning analysis.
</td>
<td style="text-align:left;">
Lung
</td>
</tr>
<tr>
<td style="text-align:left;">
Lymph node involvement and metastatic lymph node ratio influence the survival of malignant pleural mesothelioma: a French multicenter retrospective study.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
</tr>
<tr>
<td style="text-align:left;">
Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic nutritional index predicts outcomes of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Cancer Res. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Gemcitabine and vinorelbine as second-line or beyond treatment in patients with malignant pleural mesothelioma pretreated with platinum plus pemetrexed chemotherapy.
</td>
<td style="text-align:left;">
Int. J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Follow-up study of 100 malignant pleural mesotheliomas.
</td>
<td style="text-align:left;">
Thorac Cardiovasc Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleuroscopic punch biopsy using insulated-tip diathermic knife-2 for the diagnosis of desmoplastic malignant mesothelioma.
</td>
<td style="text-align:left;">
J Bronchology Interv Pulmonol
</td>
</tr>
<tr>
<td style="text-align:left;">
Comparison of the diagnostic accuracy of the MSLN gene products, mesothelin and megakaryocyte potentiating factor, as biomarkers for mesothelioma in pleural effusions and serum.
</td>
<td style="text-align:left;">
Dis. Markers
</td>
</tr>
<tr>
<td style="text-align:left;">
The degree of microRNA-34b/c methylation in serum-circulating DNA is associated with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
¹⁸F-FDG uptake on PET is a predictive marker of thymidylate synthase expression in patients with thoracic neoplasms.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunological effects of the TGFβ-blocking antibody GC1008 in malignant pleural mesothelioma patients.
</td>
<td style="text-align:left;">
Oncoimmunology
</td>
</tr>
<tr>
<td style="text-align:left;">
The diagnostic distinction between malignant mesothelioma of the pleura and adenocarcinoma of the lung as defined by a monoclonal antibody (B72.3).
</td>
<td style="text-align:left;">
Am. J. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunohistochemical staining for vimentin and keratin in malignant mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma presenting as a gradually enlarging pneumothorax.
</td>
<td style="text-align:left;">
Case Rep Pulmonol
</td>
</tr>
<tr>
<td style="text-align:left;">
Identification of a seven glycopeptide signature for malignant pleural mesothelioma in human serum by selected reaction monitoring.
</td>
<td style="text-align:left;">
Clin Proteomics
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pleural lymphatics and pleural diseases related to fibres].
</td>
<td style="text-align:left;">
Rev Pneumol Clin
</td>
</tr>
<tr>
<td style="text-align:left;">
Radical pleurectomy/decortication followed by high dose of radiation therapy for malignant pleural mesothelioma. Final results with long-term follow-up.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Keratin and epithelial membrane antigen immunoreactivity in nonneoplastic fibrous pleural lesions: implications for the diagnosis of desmoplastic mesothelioma.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma: 2013 state of the art].
</td>
<td style="text-align:left;">
Bull Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Antigenic phenotype of malignant mesotheliomas and pulmonary adenocarcinomas. An immunohistologic analysis demonstrating the value of Leu M1 antigen.
</td>
<td style="text-align:left;">
Am. J. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Leser–Trélat syndrome in malignant mesothelioma and pulmonary adenocarcinoma: is the EGFR pathway part of the syndrome?
</td>
<td style="text-align:left;">
Virchows Arch.
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytoskeletal proteins as tissue-specific markers in cytopathology.
</td>
<td style="text-align:left;">
Exp. Cell Biol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinicopathologic characteristics of malignant mesotheliomas arising in patients with a history of radiation for Hodgkin and non-Hodgkin lymphoma.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Extrapleural and cardiophrenic lymph nodes: prevalence, clinical significance and diagnostic value.
</td>
<td style="text-align:left;">
Radiol Med
</td>
</tr>
<tr>
<td style="text-align:left;">
AHNAK is highly expressed and plays a key role in cell migration and invasion in mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Localized fibrous tumour of serosal surfaces. Immunohistochemical and ultrastructural evidence for a type of mesothelioma.
</td>
<td style="text-align:left;">
Virchows Arch A Pathol Anat Histopathol
</td>
</tr>
<tr>
<td style="text-align:left;">
Iron overload as a major targetable pathogenesis of asbestos-induced mesothelial carcinogenesis.
</td>
<td style="text-align:left;">
Redox Rep.
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgical pathology of lung cancer.
</td>
<td style="text-align:left;">
Semin Respir Crit Care Med
</td>
</tr>
<tr>
<td style="text-align:left;">
[Helical tomotherapy in the treatment of malignant pleural mesothelioma: The impact of low doses on pulmonary and oesophageal toxicity].
</td>
<td style="text-align:left;">
Cancer Radiother
</td>
</tr>
<tr>
<td style="text-align:left;">
FDG PET/CT is useful for detecting infiltration to the port site in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Gen Thorac Cardiovasc Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant cardiac tamponade.
</td>
<td style="text-align:left;">
Acta Cardiol
</td>
</tr>
<tr>
<td style="text-align:left;">
An enzyme immunoassay for auto-antibodies to keratin in normal human serum and in pleural fluids from patients with various malignant or non-malignant lung diseases.
</td>
<td style="text-align:left;">
J Clin Lab Immunol
</td>
</tr>
<tr>
<td style="text-align:left;">
Targeted delivery of let-7a microRNA encapsulated ephrin-A1 conjugated liposomal nanoparticles inhibit tumor growth in lung cancer.
</td>
<td style="text-align:left;">
Int J Nanomedicine
</td>
</tr>
<tr>
<td style="text-align:left;">
Circulating tumor cells (CTCs) in malignant pleural mesothelioma (MPM).
</td>
<td style="text-align:left;">
Ann. Surg. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Radiotherapy for the treatment of pain in malignant pleural mesothelioma: a systematic review.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
[Immunopathology of diffuse malignant mesothelioma].
</td>
<td style="text-align:left;">
Zentralbl Allg Pathol
</td>
</tr>
<tr>
<td style="text-align:left;">
Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Solitary fibrous tumors of the pleura: a case report and review of the literature.
</td>
<td style="text-align:left;">
Tumori
</td>
</tr>
<tr>
<td style="text-align:left;">
An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Pharmacological targeting of p53 through RITA is an effective antitumoral strategy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cell Cycle
</td>
</tr>
<tr>
<td style="text-align:left;">
Proteome screening of pleural effusions identifies galectin 1 as a diagnostic biomarker and highlights several prognostic biomarkers for malignant mesothelioma.
</td>
<td style="text-align:left;">
Mol. Cell Proteomics
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic histochemical and immunohistochemical studies in malignant mesothelioma.
</td>
<td style="text-align:left;">
J Surg Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Antitumor effect and antiangiogenic potential of the mTOR inhibitor temsirolimus against malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnosis and treatment of malignant pleural effusion.
</td>
<td style="text-align:left;">
Cancer Metastasis Rev.
</td>
</tr>
<tr>
<td style="text-align:left;">
Antineoplastic activity of povidone-iodine on different mesothelioma cell lines: results of in vitro study.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma incidence and survival in the Republic of Ireland 1994-2009.
</td>
<td style="text-align:left;">
Cancer Epidemiol
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of immunohistochemical evaluation in the diagnosis of malignant mesothelioma of the pleura.
</td>
<td style="text-align:left;">
Vojnosanit Pregl
</td>
</tr>
<tr>
<td style="text-align:left;">
Is soluble mesothelin-related protein an upfront predictive marker of pleural mesothelioma? A prospective study on Italian workers exposed to asbestos.
</td>
<td style="text-align:left;">
Oncology
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed combined with platinum-based chemotherapy for advanced malignant peritoneal mesothelioma: retrospective analysis of six cases.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Comparative proteomic analysis of malignant pleural mesothelioma evidences an altered expression of nuclear lamin and filament-related proteins.
</td>
<td style="text-align:left;">
Proteomics Clin Appl
</td>
</tr>
<tr>
<td style="text-align:left;">
Radiotherapy applications of patients with malignant mesothelioma: A single center experience.
</td>
<td style="text-align:left;">
Rep Pract Oncol Radiother
</td>
</tr>
<tr>
<td style="text-align:left;">
Claudin-4 immunohistochemistry is highly effective in distinguishing adenocarcinoma from malignant mesothelioma in effusion cytology.
</td>
<td style="text-align:left;">
Cancer Cytopathol
</td>
</tr>
<tr>
<td style="text-align:left;">
Circulating fibrinogen is a prognostic and predictive biomarker in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
How useful is GLUT-1 in differentiating mesothelial hyperplasia and fibrosing pleuritis from epithelioid and sarcomatoid mesotheliomas? An international collaborative study.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Systemic treatment of malignant pleural mesothelioma: new agents in clinical trials raise hope of relevant improvements.
</td>
<td style="text-align:left;">
Curr Opin Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
A feasibility study evaluating Surgery for Mesothelioma After Radiation Therapy: the “SMART” approach for resectable malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
The diagnosis of thoracic malignant mesothelioma: practical considerations and recent developments.
</td>
<td style="text-align:left;">
Turk Patoloji Derg
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunotherapy for malignant pleural mesothelioma. Current status and future prospects.
</td>
<td style="text-align:left;">
Am. J. Respir. Cell Mol. Biol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical outcome of postoperative highly conformal versus 3D conformal radiotherapy in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Radiat Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic factors in patients presenting with pleural effusion revealing malignancy.
</td>
<td style="text-align:left;">
Respiration
</td>
</tr>
<tr>
<td style="text-align:left;">
MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of carbonic anhydrase IX (CAIX) in malignant mesothelioma. An immunohistochemical and immunocytochemical study.
</td>
<td style="text-align:left;">
Neoplasma
</td>
</tr>
<tr>
<td style="text-align:left;">
New applications of magnetic resonance imaging for thoracic oncology.
</td>
<td style="text-align:left;">
Semin Respir Crit Care Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Predictors of long-term survival following radical surgery for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
A microfluidic platform for chemoresistive testing of multicellular pleural cancer spheroids.
</td>
<td style="text-align:left;">
Lab Chip
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse malignant epithelioid mesothelioma in a background of benign multicystic peritoneal mesothelioma: a case report and review of the literature.
</td>
<td style="text-align:left;">
BMJ Case Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
[Clinicopathological characteristics and prognosis of malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Zhonghua Jie He He Hu Xi Za Zhi
</td>
</tr>
<tr>
<td style="text-align:left;">
Occupational and non-occupational attributable risk of asbestos exposure for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Thorax
</td>
</tr>
<tr>
<td style="text-align:left;">
The journey of mesothelioma: from postmortem to FNA.
</td>
<td style="text-align:left;">
BMJ Case Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
A Case Report of IgG4-Related Disease Clinically Mimicking Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Tuberc Respir Dis (Seoul)
</td>
</tr>
<tr>
<td style="text-align:left;">
Multimodal management of malignant pleural mesothelioma: where are we today?
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
</tr>
<tr>
<td style="text-align:left;">
CEA, AFP, CA125, CA153 and CA199 in malignant pleural effusions predict the cause.
</td>
<td style="text-align:left;">
Asian Pac. J. Cancer Prev.
</td>
</tr>
<tr>
<td style="text-align:left;">
Intrapleural natural beta interferon in the treatment of malignant pleural effusions.
</td>
<td style="text-align:left;">
Oncology
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma.
</td>
<td style="text-align:left;">
Pak J Med Sci
</td>
</tr>
<tr>
<td style="text-align:left;">
Preclinical evaluation of microRNA-34b/c delivery for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Acta Med. Okayama
</td>
</tr>
<tr>
<td style="text-align:left;">
Role of microRNAs in malignant mesothelioma.
</td>
<td style="text-align:left;">
Cell. Mol. Life Sci.
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis.
</td>
<td style="text-align:left;">
BMJ Open
</td>
</tr>
<tr>
<td style="text-align:left;">
Systemic but not topical TRAIL-expressing mesenchymal stem cells reduce tumour growth in malignant mesothelioma.
</td>
<td style="text-align:left;">
Thorax
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies.
</td>
<td style="text-align:left;">
Cancer Immunol Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Pathologic complete remission of malignant pleural mesothelioma after combined modality treatment: a case report.
</td>
<td style="text-align:left;">
Acta Clin Belg
</td>
</tr>
<tr>
<td style="text-align:left;">
Semirigid thoracoscopy: an effective method for diagnosing pleural malignancies.
</td>
<td style="text-align:left;">
Radiol Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant intraperitoneal mesothelioma-Başkent University experience.
</td>
<td style="text-align:left;">
J Turk Ger Gynecol Assoc
</td>
</tr>
<tr>
<td style="text-align:left;">
CD74: a new prognostic factor for patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Cilengitide inhibits attachment and invasion of malignant pleural mesothelioma cells through antagonism of integrins αvβ3 and αvβ5.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
</tr>
<tr>
<td style="text-align:left;">
CARP-1 functional mimetics are a novel class of small molecule inhibitors of malignant pleural mesothelioma cells.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgery for malignant pleural mesothelioma: why, when and what?
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Radiological review of pleural tumors.
</td>
<td style="text-align:left;">
Indian J Radiol Imaging
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic accuracy of osteopontin for malignant pleural mesothelioma: a systematic review and meta-analysis.
</td>
<td style="text-align:left;">
Clin. Chim. Acta
</td>
</tr>
<tr>
<td style="text-align:left;">
[The role of systemic therapies of non-small cell lung cancer and malignant pleural mesothelioma: updated expert recommendations].
</td>
<td style="text-align:left;">
Pneumonol Alergol Pol
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pleural effusion cytology of asbestos-associated malignant mesothelioma and lung carcinoma in the diagnosis of occupational diseases by the statutory accident insurance funds].
</td>
<td style="text-align:left;">
Pneumologie
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma: new aspects of medical therapy].
</td>
<td style="text-align:left;">
Pneumologie
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgical management of malignant pleural mesothelioma: impact of surgery on survival and quality of life-relation to chemotherapy, radiotherapy, and alternative therapies.
</td>
<td style="text-align:left;">
ISRN Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
[Peritoneal malignant mesothelioma: review and recent data].
</td>
<td style="text-align:left;">
Ann Pathol
</td>
</tr>
<tr>
<td style="text-align:left;">
Impact of a nursing education program about caring for patients in Japan with malignant pleural mesothelioma on nurses’ knowledge, difficulties and attitude: a randomized control trial.
</td>
<td style="text-align:left;">
Nurse Educ Today
</td>
</tr>
<tr>
<td style="text-align:left;">
Small cell carcinoma presenting with massive pleural spread mimicking malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Intern. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Comparison of cisplatin plus pemetrexed and cisplatin plus gemcitabine for the treatment of malignant pleural mesothelioma in Japanese patients.
</td>
<td style="text-align:left;">
Respir Investig
</td>
</tr>
<tr>
<td style="text-align:left;">
A retrospective review of the palliative surgical management of malignant pleural effusions.
</td>
<td style="text-align:left;">
BMJ Support Palliat Care
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic factors influencing survival in 35 patients with malignant peritoneal mesothelioma.
</td>
<td style="text-align:left;">
Neoplasma
</td>
</tr>
<tr>
<td style="text-align:left;">
Methotrexate and gemcitabine combination chemotherapy for the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Mol Clin Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression profiling stratifies mesothelioma tumors and signifies deregulation of spindle checkpoint pathway and microtubule network with therapeutic implications.
</td>
<td style="text-align:left;">
Ann. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic factors affecting survival in malignant pleural mesothelioma: analysis of 125 subjects.
</td>
<td style="text-align:left;">
Tumori
</td>
</tr>
<tr>
<td style="text-align:left;">
Catheter tract metastasis associated with indwelling pleural catheters.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
A phase II trial of prolonged, continuous infusion of low-dose gemcitabine plus cisplatin in patients with advanced malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Chemother. Pharmacol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Disulfiram suppresses growth of the malignant pleural mesothelioma cells in part by inducing apoptosis.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
</tr>
<tr>
<td style="text-align:left;">
Strengths, weaknesses, and opportunities of diagnostic breathomics in pleural mesothelioma-a hypothesis.
</td>
<td style="text-align:left;">
Cancer Epidemiol. Biomarkers Prev.
</td>
</tr>
<tr>
<td style="text-align:left;">
A biphasic tumor of the mediastinum with features of synovial sarcoma. A report of four cases.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Significance of osteopontin in the sensitivity of malignant pleural mesothelioma to pemetrexed.
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant peritoneal mesothelioma: clinicopathological characteristics of two cases.
</td>
<td style="text-align:left;">
Case Rep Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Relationship between prognosis and neutrophil: lymphocyte and platelet:lymphocyte ratios in patients with malignant pleural mesotheliomas.
</td>
<td style="text-align:left;">
Asian Pac. J. Cancer Prev.
</td>
</tr>
<tr>
<td style="text-align:left;">
Autocrine CSF-1R signaling drives mesothelioma chemoresistance via AKT activation.
</td>
<td style="text-align:left;">
Cell Death Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Extrapleural pneumonectomy for malignant mesothelioma: an Italian multicenter retrospective study.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma and the Society of Thoracic Surgeons Database: an analysis of surgical morbidity and mortality.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical utility of 18F-FDG positron emission tomography in malignant peritoneal mesothelioma.
</td>
<td style="text-align:left;">
Q J Nucl Med Mol Imaging
</td>
</tr>
<tr>
<td style="text-align:left;">
Synchronous occurrence of pulmonary adenocarcinoma and pleural diffuse malignant mesothelioma.
</td>
<td style="text-align:left;">
Pathologica
</td>
</tr>
<tr>
<td style="text-align:left;">
Distribution of silver-stained interphase nucleolar organizer regions as a parameter to distinguish neoplastic from nonneoplastic reactive cells in human effusions.
</td>
<td style="text-align:left;">
Acta Cytol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Regulation of somatostatin receptor 4-mediated cytostatic effects by CD26 in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Elevated PDGFRB gene copy number gain is prognostic for improved survival outcomes in resected malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann Diagn Pathol
</td>
</tr>
<tr>
<td style="text-align:left;">
CD26-mediated regulation of periostin expression contributes to migration and invasion of malignant pleural mesothelioma cells.
</td>
<td style="text-align:left;">
Biochem. Biophys. Res. Commun.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma metastatic to the submandibular salivary gland, simulating glandular hypertrophy, diagnosed by fine-needle aspiration biopsy: a case report and literature review.
</td>
<td style="text-align:left;">
World J Surg Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Supplementary prognostic variables for pleural mesothelioma: a report from the IASLC staging committee.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Desmoplastic small round cell tumor with sphere-like clusters mimicking adenocarcinoma.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of keratin 5 as a distinctive feature of epithelial and biphasic mesotheliomas. An immunohistochemical study using monoclonal antibody AE14.
</td>
<td style="text-align:left;">
Virchows Arch., B, Cell Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Physician-based ultrasound-guided biopsy for diagnosing pleural disease.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Immune therapies for malignant mesothelioma.
</td>
<td style="text-align:left;">
Expert Rev Anticancer Ther
</td>
</tr>
<tr>
<td style="text-align:left;">
Tumor/stromal caveolin-1 expression patterns in pleural mesothelioma define a subgroup of the epithelial histotype with poorer prognosis.
</td>
<td style="text-align:left;">
Am. J. Clin. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Signal transducer and activator of transcription 1 (STAT1) acts like an oncogene in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Virchows Arch.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: a single-center experience in Turkey.
</td>
<td style="text-align:left;">
Med. Sci. Monit.
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma risk after 40 years since first exposure to asbestos: a pooled analysis.
</td>
<td style="text-align:left;">
Thorax
</td>
</tr>
<tr>
<td style="text-align:left;">
Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship.
</td>
<td style="text-align:left;">
Sci Transl Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Autofluorescence thoracoscopy in pleural disease: does it have clinical relevance?
</td>
<td style="text-align:left;">
Expert Rev Respir Med
</td>
</tr>
<tr>
<td style="text-align:left;">
EUS-guided fine needle tissue acquisition for the diagnosis of pleural metastases from endometrial cancer.
</td>
<td style="text-align:left;">
Eur Rev Med Pharmacol Sci
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesothelioma: an institutional experience of 66 cases.
</td>
<td style="text-align:left;">
Korean J Pathol
</td>
</tr>
<tr>
<td style="text-align:left;">
Management of malignant pleural mesothelioma-The European experience.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Assessment of cisplatin concentration and depth of penetration in human lung tissue after hyperthermic exposure.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Efficacy of phase 1 trials in malignant pleural mesothelioma: description of a series of patients at a single institution.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Cisplatin-resistant cells in malignant pleural mesothelioma cell lines show ALDH(high)CD44(+) phenotype and sphere-forming capacity.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
GAS5 long non-coding RNA in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Mol. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Flex-rigid pleuroscopy under local anesthesia in patients with dry pleural dissemination on radiography.
</td>
<td style="text-align:left;">
Jpn. J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Intrathoracic schwannoma].
</td>
<td style="text-align:left;">
Medicina (B Aires)
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic factors in elderly patients with malignant pleural mesothelioma: results of a multicenter survey.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Synergistic antitumor activity of recombinant human Apo2L/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in combination with carboplatin and pemetrexed in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Carbonic anhydrase IX (CAIX) does not differentiate between benign and malignant mesothelium.
</td>
<td style="text-align:left;">
Am. J. Clin. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Third-space fluid distribution of pemetrexed in non-small cell lung cancer patients.
</td>
<td style="text-align:left;">
Cancer Chemother. Pharmacol.
</td>
</tr>
<tr>
<td style="text-align:left;">
ERCC1 as a biological marker guiding management in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Asian Pac. J. Cancer Prev.
</td>
</tr>
<tr>
<td style="text-align:left;">
Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial.
</td>
<td style="text-align:left;">
Lancet
</td>
</tr>
<tr>
<td style="text-align:left;">
Interventional therapies for malignant pleural effusions: the present and the future.
</td>
<td style="text-align:left;">
Respirology
</td>
</tr>
<tr>
<td style="text-align:left;">
Nonamplified FGFR1 is a growth driver in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Mol. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Epithelioid malignant mesothelioma presenting with features of gastric tumor in a child.
</td>
<td style="text-align:left;">
Int J Clin Exp Pathol
</td>
</tr>
<tr>
<td style="text-align:left;">
New histone deacetylase inhibitors improve cisplatin antitumor properties against thoracic cancer cells.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
[SENTIERI Project: discussion and conclusions].
</td>
<td style="text-align:left;">
Epidemiol Prev
</td>
</tr>
<tr>
<td style="text-align:left;">
Metastatic mesothelioma to the thyroid.
</td>
<td style="text-align:left;">
Cytojournal
</td>
</tr>
<tr>
<td style="text-align:left;">
Polymorphisms in folate pathway and pemetrexed treatment outcome in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Radiol Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Imaging findings from a case of pleural low-grade fibromyxoid sarcoma similar to mesothelioma with pleural effusion.
</td>
<td style="text-align:left;">
Clin Respir J
</td>
</tr>
<tr>
<td style="text-align:left;">
Performance of osteopontin in the diagnosis of malignant pleural mesothelioma: a meta-analysis.
</td>
<td style="text-align:left;">
Int J Clin Exp Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic coronary surgery in a case of malignant mesothelioma previously managed with trimodality treatment.
</td>
<td style="text-align:left;">
Heart Lung Circ
</td>
</tr>
<tr>
<td style="text-align:left;">
Local recurrence of lung adenocarcinoma 10 years after left upper lobectomy resembling pseudomesotheliomatous adenocarcinoma: a case report.
</td>
<td style="text-align:left;">
J Nippon Med Sch
</td>
</tr>
<tr>
<td style="text-align:left;">
The homeobox gene EMX2 is a prognostic and predictive marker in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
CD157 enhances malignant pleural mesothelioma aggressiveness and predicts poor clinical outcome.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
EF24 and RAD001 potentiates the anticancer effect of platinum-based agents in human malignant pleural mesothelioma (MSTO-211H) cells and protects nonmalignant mesothelial (MET-5A) cells.
</td>
<td style="text-align:left;">
Hum Exp Toxicol
</td>
</tr>
<tr>
<td style="text-align:left;">
Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma.
</td>
<td style="text-align:left;">
Thorax
</td>
</tr>
<tr>
<td style="text-align:left;">
Wilms tumor 1/cytokeratin dual-color immunostaining reveals distinctive staining patterns in metastatic melanoma, metastatic carcinoma, and mesothelial cells in pleural fluids: an effective first-line test for the workup of malignant effusions.
</td>
<td style="text-align:left;">
Cancer Cytopathol
</td>
</tr>
<tr>
<td style="text-align:left;">
Newly established ELISA for N-ERC/mesothelin improves diagnostic accuracy in patients with suspected pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Photodynamic therapy enhanced by hyperbaric oxygenation in palliation of malignant pleural mesothelioma: clinical experience.
</td>
<td style="text-align:left;">
Photodiagnosis Photodyn Ther
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of microRNAs in the diagnosis and treatment of malignant pleural mesothelioma–a short review.
</td>
<td style="text-align:left;">
Microrna
</td>
</tr>
<tr>
<td style="text-align:left;">
Serum albumin as a significant prognostic factor in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Tumour Biol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Activation of Nrf2 pathways correlates with resistance of NSCLC cell lines to CBP501 in vitro.
</td>
<td style="text-align:left;">
Mol. Cancer Ther.
</td>
</tr>
<tr>
<td style="text-align:left;">
Sarcomatoid malignant mesothelioma presenting with intramedullary spinal cord metastasis: a case report and literature review.
</td>
<td style="text-align:left;">
Global Spine J
</td>
</tr>
<tr>
<td style="text-align:left;">
Predictive value of systemic and local inflammation parameters in talc pleurodesis assessment.
</td>
<td style="text-align:left;">
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub
</td>
</tr>
<tr>
<td style="text-align:left;">
Current issues in malignant pleural mesothelioma evaluation and management.
</td>
<td style="text-align:left;">
Oncologist
</td>
</tr>
<tr>
<td style="text-align:left;">
Failure patterns after hemithoracic pleural intensity modulated radiation therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Radiat. Oncol. Biol. Phys.
</td>
</tr>
<tr>
<td style="text-align:left;">
Role of CT in assessing pleural malignancy prior to thoracoscopy.
</td>
<td style="text-align:left;">
Thorax
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma and central nervous system metastases. Report of two cases, pooled analysis, and systematic review.
</td>
<td style="text-align:left;">
Ann Am Thorac Soc
</td>
</tr>
<tr>
<td style="text-align:left;">
Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score.
</td>
<td style="text-align:left;">
Thorax
</td>
</tr>
<tr>
<td style="text-align:left;">
A commercially available preparation of Staphylococcus aureus bio-products potently inhibits tumour growth in a murine model of mesothelioma.
</td>
<td style="text-align:left;">
Respirology
</td>
</tr>
<tr>
<td style="text-align:left;">
Gamma knife radiosurgery of brain metastasis from malignant pleural mesothelioma–report of three cases with autopsy study in a case.
</td>
<td style="text-align:left;">
Nagoya J Med Sci
</td>
</tr>
<tr>
<td style="text-align:left;">
Silica exposure and altered regulation of autoimmunity.
</td>
<td style="text-align:left;">
Environ Health Prev Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Hyponatraemia is a predictor of clinical outcome for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Support Care Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Photodynamic diagnoses of malignant pleural diseases using the autofluorescence imaging system.
</td>
<td style="text-align:left;">
Ann Thorac Cardiovasc Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic and prognostic value of soluble syndecan-1 in pleural malignancies.
</td>
<td style="text-align:left;">
Biomed Res Int
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural and peritoneal mesothelioma consequential to brief indirect asbestos exposure.
</td>
<td style="text-align:left;">
J Clin Imaging Sci
</td>
</tr>
<tr>
<td style="text-align:left;">
Identification of actionable mutations in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Should we continue to offer extrapleural pneumonectomy to selected mesothelioma patients? A single center experience comparing surgical and non-surgical management.
</td>
<td style="text-align:left;">
Jpn. J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Accuracy of fluorodeoxyglucose-PET imaging for differentiating benign from malignant pleural effusions: a meta-analysis.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Ultrasound-guided medical thoracoscopy in the absence of pleural effusion.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Fibroblast growth factor receptor inhibition is active against mesothelioma and synergizes with radio- and chemotherapy.
</td>
<td style="text-align:left;">
Am. J. Respir. Crit. Care Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Ratio of intratumoral macrophage phenotypes is a prognostic factor in epithelioid malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
</tr>
<tr>
<td style="text-align:left;">
Past trends and future prediction of mesothelioma incidence in an industrialized area of Italy, the Veneto Region.
</td>
<td style="text-align:left;">
Cancer Epidemiol
</td>
</tr>
<tr>
<td style="text-align:left;">
Extrapleural pneumonectomy in the treatment of epithelioid malignant pleural mesothelioma: novel prognostic implications of combined N1 and N2 nodal involvement based on experience in 529 patients.
</td>
<td style="text-align:left;">
Ann. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
The clinicopathological characteristics with long-term outcomes in malignant mesothelioma.
</td>
<td style="text-align:left;">
Med. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Sarcomatoid malignant mesothelioma: a clinicopathologic and immunohistochemical analysis of 22 cases].
</td>
<td style="text-align:left;">
Zhonghua Bing Li Xue Za Zhi
</td>
</tr>
<tr>
<td style="text-align:left;">
Tuberculosis and risk of cancer: a Danish nationwide cohort study.
</td>
<td style="text-align:left;">
Int. J. Tuberc. Lung Dis.
</td>
</tr>
<tr>
<td style="text-align:left;">
Systematic review of response rates of sarcomatoid malignant pleural mesotheliomas in clinical trials.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Comparison of genomic abnormality in malignant mesothelioma by the site of origin.
</td>
<td style="text-align:left;">
J. Clin. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
MiR-379/411 cluster regulates IL-18 and contributes to drug resistance in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
</tr>
<tr>
<td style="text-align:left;">
High incidence of lung cancer and malignant mesothelioma linked to erionite fibre exposure in a rural community in Central Mexico.
</td>
<td style="text-align:left;">
Occup Environ Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Analysis of microRNA expression signatures in malignant pleural mesothelioma, pleural inflammation, and atypical mesothelial hyperplasia reveals common predictive tumorigenesis-related targets.
</td>
<td style="text-align:left;">
Exp. Mol. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
A multicentre non-blinded randomised controlled trial to assess the impact of regular early specialist symptom control treatment on quality of life in malignant mesothelioma (RESPECT-MESO): study protocol for a randomised controlled trial.
</td>
<td style="text-align:left;">
Trials
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: visual assessment by using pleural pointillism at diffusion-weighted MR imaging.
</td>
<td style="text-align:left;">
Radiology
</td>
</tr>
<tr>
<td style="text-align:left;">
Correlation between TS, MTHFR, and ERCC1 gene polymorphisms and the efficacy of platinum in combination with pemetrexed first-line chemotherapy in mesothelioma patients.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
[Correlation of computed tomography imaging and clinical prognosis of pleural mesothelioma].
</td>
<td style="text-align:left;">
Zhonghua Yi Xue Za Zhi
</td>
</tr>
<tr>
<td style="text-align:left;">
Characterization and drug sensitivity profiling of primary malignant mesothelioma cells from pleural effusions.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Airways microbiota: Hidden Trojan horses in asbestos exposed individuals?
</td>
<td style="text-align:left;">
Med. Hypotheses
</td>
</tr>
<tr>
<td style="text-align:left;">
Local and systemic therapies for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Curr Treat Options Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Electron microscopy remains the gold standard for the diagnosis of epithelial malignant mesothelioma: a case study.
</td>
<td style="text-align:left;">
Ultrastruct Pathol
</td>
</tr>
<tr>
<td style="text-align:left;">
Reproducibility of histological subtyping of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Virchows Arch.
</td>
</tr>
<tr>
<td style="text-align:left;">
Long progression-free survival by pemetrexed continuation maintenance therapy following cisplatin-based chemotherapy in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Intern. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pseudo-tumor mimicking indwelling pleural catheter tract metastasis in mesothelioma.
</td>
<td style="text-align:left;">
J Bronchology Interv Pulmonol
</td>
</tr>
<tr>
<td style="text-align:left;">
Advances in malignant peritoneal mesothelioma.
</td>
<td style="text-align:left;">
Int J Colorectal Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Downregulation of thymidylate synthase and E2F1 by arsenic trioxide in mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Evaluation of imaging techniques for the assessment of tumour progression in an orthotopic rat model of malignant pleural mesothelioma†.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Use of computed tomography and positron emission tomography/computed tomography for staging of local extent in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Comput Assist Tomogr
</td>
</tr>
<tr>
<td style="text-align:left;">
Upregulation of microRNA-31 associates with a poor prognosis of malignant pleural mesothelioma with sarcomatoid component.
</td>
<td style="text-align:left;">
Med. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Cisplatin in combination with Phenethyl Isothiocyanate (PEITC), a potential new therapeutic strategy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinicopathological characteristics of pulmonary epithelioid hemangioendothelioma: A report of four cases and review of the literature.
</td>
<td style="text-align:left;">
Oncol Lett
</td>
</tr>
<tr>
<td style="text-align:left;">
Hyaluronic Acid concentration in pleural fluid: diagnostic aid for tuberculous pleurisy.
</td>
<td style="text-align:left;">
J Clin Med Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity.
</td>
<td style="text-align:left;">
Sci Transl Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival.
</td>
<td style="text-align:left;">
Carcinogenesis
</td>
</tr>
<tr>
<td style="text-align:left;">
Estimation of an optimal chemotherapy utilization rate for malignant pleural mesothelioma: an evidence-based benchmark for cancer care.
</td>
<td style="text-align:left;">
Asia Pac J Clin Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Combination effect of photodynamic therapy using NPe6 with pemetrexed for human malignant pleural mesothelioma cells.
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Intercellular communication in malignant pleural mesothelioma: properties of tunneling nanotubes.
</td>
<td style="text-align:left;">
Front Physiol
</td>
</tr>
<tr>
<td style="text-align:left;">
Quantitative analyses at baseline and interim PET evaluation for response assessment and outcome definition in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur. J. Nucl. Med. Mol. Imaging
</td>
</tr>
<tr>
<td style="text-align:left;">
Therapeutic activity of glycoengineered anti-GM2 antibodies against malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Sci.
</td>
</tr>
<tr>
<td style="text-align:left;">
Caring for patients with malignant pleural mesothelioma in Japan: evaluation of a Palliative Care Educational Program.
</td>
<td style="text-align:left;">
Asian Pac. J. Cancer Prev.
</td>
</tr>
<tr>
<td style="text-align:left;">
FISH analysis of intrapulmonary malignant mesothelioma without a clinically detectable primary pleural lesion: an autopsy case.
</td>
<td style="text-align:left;">
Jpn. J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Survival in Patients With Malignant Pleural Effusions Who Developed Pleural Infection: A Retrospective Case Review From Six UK Centers.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
[Contribution of pleural fluid analysis to the diagnosis of pleural effusion].
</td>
<td style="text-align:left;">
Med Clin (Barc)
</td>
</tr>
<tr>
<td style="text-align:left;">
A common polymorphism within MSLN affects miR-611 binding site and soluble mesothelin levels in healthy people.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytokeratin 19 expression in primary thoracic tumors and lymph node metastases.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Current controversies in the management of malignant pleural effusions.
</td>
<td style="text-align:left;">
Semin Respir Crit Care Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: new hope in the horizon with novel therapeutic strategies.
</td>
<td style="text-align:left;">
Cancer Treat. Rev.
</td>
</tr>
<tr>
<td style="text-align:left;">
Prevalence of BRCA-1 associated protein 1 germline mutation in sporadic malignant pleural mesothelioma cases.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Predictors of clinical use of pleurodesis and/or indwelling pleural catheter therapy for malignant pleural effusion.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Synergistic activity of the c-Met and tubulin inhibitor tivantinib (ARQ197) with pemetrexed in mesothelioma cells.
</td>
<td style="text-align:left;">
Curr Drug Targets
</td>
</tr>
<tr>
<td style="text-align:left;">
[A clinical study of six surgically treated patients with malignant tumors arising from chronic pleuritis and pyothorax].
</td>
<td style="text-align:left;">
Nihon Kyobu Geka Gakkai Zasshi
</td>
</tr>
<tr>
<td style="text-align:left;">
Amosite mesothelioma in a cohort of asbestos workers.
</td>
<td style="text-align:left;">
Scand J Work Environ Health
</td>
</tr>
<tr>
<td style="text-align:left;">
MiR-score: a novel 6-microRNA signature that predicts survival outcomes in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Mol Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Photodynamic therapy for lung cancer and malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Semin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Cancer mortality in relation to measures of occupational exposure to crocidolite at Wittenoom Gorge in Western Australia.
</td>
<td style="text-align:left;">
Br J Ind Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Combination of arginine deprivation with TRAIL treatment as a targeted-therapy for mesothelioma.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural fluid mesothelin as an adjunct to the diagnosis of pleural malignant mesothelioma.
</td>
<td style="text-align:left;">
Dis. Markers
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinicopathologic and survival characteristics of malignant pleural mesothelioma registered in hospital cancer registry.
</td>
<td style="text-align:left;">
Tanaffos
</td>
</tr>
<tr>
<td style="text-align:left;">
Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Detection of circulating tumour cells in peripheral blood of patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Biomark
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical significance of soluble CD26 in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
</tr>
<tr>
<td style="text-align:left;">
Novel induction therapies for pleural mesothelioma.
</td>
<td style="text-align:left;">
Semin. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Henoch-Schonlein purpura in mesothelioma.
</td>
<td style="text-align:left;">
Respirol Case Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
Adenosine deaminase inhibitor EHNA exhibits a potent anticancer effect against malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cell. Physiol. Biochem.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pemetrexed-induced scleroderma-like changes in the lower legs].
</td>
<td style="text-align:left;">
Ann Dermatol Venereol
</td>
</tr>
<tr>
<td style="text-align:left;">
Overexpression of activin-A and -B in malignant mesothelioma - attenuated Smad3 signaling responses and ERK activation promote cell migration and invasive growth.
</td>
<td style="text-align:left;">
Exp. Cell Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Third-line chemotherapy with carboplatin, gemcitabine and liposomised doxorubicin for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Med. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Protocol for the surgical and large bore procedures in malignant pleural mesothelioma and radiotherapy trial (SMART Trial): an RCT evaluating whether prophylactic radiotherapy reduces the incidence of procedure tract metastases.
</td>
<td style="text-align:left;">
BMJ Open
</td>
</tr>
<tr>
<td style="text-align:left;">
Acute lower limb ischemia complicating pemetrexed and carboplatin combination chemotherapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann Ital Chir
</td>
</tr>
<tr>
<td style="text-align:left;">
[Current surgical therapy for malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Kyobu Geka
</td>
</tr>
<tr>
<td style="text-align:left;">
Detection of malignant mesothelioma using nuclear structure of mesothelial cells in effusion cytology specimens.
</td>
<td style="text-align:left;">
Cytometry A
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical experience of volumetric modulated arc therapy for malignant pleural mesothelioma after extrapleural pneumonectomy.
</td>
<td style="text-align:left;">
J. Radiat. Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Tumoral CD10 expression correlates with aggressive histology and prognosis in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Surg. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM).
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Testing mapping algorithms of the cancer-specific EORTC QLQ-C30 onto EQ-5D in malignant mesothelioma.
</td>
<td style="text-align:left;">
Health Qual Life Outcomes
</td>
</tr>
<tr>
<td style="text-align:left;">
Wnt7A is a putative prognostic and chemosensitivity marker in human malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
</tr>
<tr>
<td style="text-align:left;">
Ki67 index is an independent prognostic factor in epithelioid but not in non-epithelioid malignant pleural mesothelioma: a multicenter study.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Oncogenic mutation profiling in new lung cancer and mesothelioma cell lines.
</td>
<td style="text-align:left;">
Onco Targets Ther
</td>
</tr>
<tr>
<td style="text-align:left;">
A case of advanced malignant pleural mesothelioma treatment with chemotherapy and photodynamic therapy.
</td>
<td style="text-align:left;">
Tuberc Respir Dis (Seoul)
</td>
</tr>
<tr>
<td style="text-align:left;">
Is Radiotherapy Useful for Treating Pain in Mesothelioma?: A Phase II Trial.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
High Incidence of Somatic BAP1 alterations in sporadic malignant mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Persistent lung expansion after pleural talc poudrage in non-surgically resected malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Itraconazole therapy in a pancreatic adenocarcinoma patient: A case report.
</td>
<td style="text-align:left;">
J Oncol Pharm Pract
</td>
</tr>
<tr>
<td style="text-align:left;">
New and emerging therapeutic options for malignant pleural mesothelioma: review of early clinical trials.
</td>
<td style="text-align:left;">
Cancer Manag Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Feasibility and performance of an adaptive contrast-oriented FDG PET/CT quantification technique for global disease assessment of malignant pleural mesothelioma and a brief review of the literature.
</td>
<td style="text-align:left;">
Hell J Nucl Med
</td>
</tr>
<tr>
<td style="text-align:left;">
New biomarkers in the selection of patients for talcage of pleural cavity in the palliative therapy of malign pleural exudate.
</td>
<td style="text-align:left;">
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant Pleural Mesothelioma: Accuracy of CT Against Immunohistochemical Test Among the Mexican Population.
</td>
<td style="text-align:left;">
Arch. Med. Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Searching for targets for the systemic therapy of mesothelioma.
</td>
<td style="text-align:left;">
Ann. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: history, controversy and future of a manmade epidemic.
</td>
<td style="text-align:left;">
Eur Respir Rev
</td>
</tr>
<tr>
<td style="text-align:left;">
Evaluation of androgen receptor and GATA binding protein 3 as immunohistochemical markers in the diagnosis of metastatic breast carcinoma to the lung.
</td>
<td style="text-align:left;">
Pathol. Int.
</td>
</tr>
<tr>
<td style="text-align:left;">
[A case of malignant peritoneal mesothelioma without deletion of p16].
</td>
<td style="text-align:left;">
Gan To Kagaku Ryoho
</td>
</tr>
<tr>
<td style="text-align:left;">
Intrapleural Fibrinolysis for the Treatment of Indwelling Pleural Catheter-Related Symptomatic Loculations: A Multicenter Observational Study.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Changing pattern in malignant mesothelioma survival.
</td>
<td style="text-align:left;">
Transl Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Interim results of pleurectomy/decortication and intraoperative intrapleural hyperthermic cisplatin perfusion for patients with malignant pleural mesothelioma intolerable to extrapleural pneumonectomy.
</td>
<td style="text-align:left;">
Gen Thorac Cardiovasc Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Hemithoracic radiation therapy after extrapleural pneumonectomy for malignant pleural mesothelioma: Toxicity and outcomes at an Australian institution.
</td>
<td style="text-align:left;">
J Med Imaging Radiat Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
MicroRNA and mRNA features of malignant pleural mesothelioma and benign asbestos-related pleural effusion.
</td>
<td style="text-align:left;">
Biomed Res Int
</td>
</tr>
<tr>
<td style="text-align:left;">
The effect of chemotherapy on health-related quality of life in mesothelioma: results from the SWAMP trial.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Liposomal pemetrexed: formulation, characterization and in vitro cytotoxicity studies for effective management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Biol. Pharm. Bull.
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression status of candidate genes in mesothelioma tissues and cell lines.
</td>
<td style="text-align:left;">
Mutat. Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Updated patterns of failure after multimodality therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).
</td>
<td style="text-align:left;">
PLoS ONE
</td>
</tr>
<tr>
<td style="text-align:left;">
Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database.
</td>
<td style="text-align:left;">
J. Surg. Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Unusual appearance of malignant peritoneal mesothelioma.
</td>
<td style="text-align:left;">
J Comput Assist Tomogr
</td>
</tr>
<tr>
<td style="text-align:left;">
[Role of the Sonic Hedgehog pathway in thoracic cancers].
</td>
<td style="text-align:left;">
Rev Mal Respir
</td>
</tr>
<tr>
<td style="text-align:left;">
Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial.
</td>
<td style="text-align:left;">
Lancet Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
The efficacy of pemetrexed and bevacizumab intrapleural injection for malignant pleural mesothelioma-mediated malignant pleural effusion.
</td>
<td style="text-align:left;">
Indian J Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study.
</td>
<td style="text-align:left;">
Lancet Respir Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic accuracy of calretinin for malignant mesothelioma in serous effusions: a meta-analysis.
</td>
<td style="text-align:left;">
Sci Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
Blockade of aquaporin 1 inhibits proliferation, motility, and metastatic potential of mesothelioma in vitro but not in an in vivo model.
</td>
<td style="text-align:left;">
Dis. Markers
</td>
</tr>
<tr>
<td style="text-align:left;">
NF2 blocks Snail-mediated p53 suppression in mesothelioma.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
Loss of miR-223 and JNK Signaling Contribute to Elevated Stathmin in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Mol. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic factors in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Effects of extended pleurectomy and decortication on quality of life and pulmonary function in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
A new prognostic index for overall survival in malignant pleural mesothelioma: the rPHS (regimen, PS, histology or stage) index.
</td>
<td style="text-align:left;">
Jpn. J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Intratumoral macrophage phenotype and CD8+ T lymphocytes as potential tools to predict local tumor outgrowth at the intervention site in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Breast cancer or metastasis? An unusual case of metastatic malignant pleural mesothelioma to the breast.
</td>
<td style="text-align:left;">
World J Surg Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Importance of the cell block technique in diagnosing patients with non-small cell carcinoma accompanied by pleural effusion.
</td>
<td style="text-align:left;">
Asian Pac. J. Cancer Prev.
</td>
</tr>
<tr>
<td style="text-align:left;">
An 8-Year-Old Child with Malignant Deciduoid Mesothelioma of the Abdomen: Report of a Case and Review of the Literature.
</td>
<td style="text-align:left;">
Pediatr. Dev. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pathologic diagnosis of malignant mesothelioma: chronological prospect and advent of recommendations and guidelines.
</td>
<td style="text-align:left;">
Ann. Ist. Super. Sanita
</td>
</tr>
<tr>
<td style="text-align:left;">
Demographics, management and survival of patients with malignant pleural mesothelioma in the National Lung Cancer Audit in England and Wales.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Defining the minimal important difference for the visual analogue scale assessing dyspnea in patients with malignant pleural effusions.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
</tr>
<tr>
<td style="text-align:left;">
[Comparing the results of pathologic diagnosis of mesothelioma between Chinese and Japanese experts].
</td>
<td style="text-align:left;">
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic factors in malignant pleural mesothelioma: a retrospective study of 60 Turkish patients.
</td>
<td style="text-align:left;">
J Cancer Res Ther
</td>
</tr>
<tr>
<td style="text-align:left;">
BAP1 mutation is a frequent somatic event in peritoneal malignant mesothelioma.
</td>
<td style="text-align:left;">
J Transl Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Single-dose dexamethasone for the prevention of pemetrexed associated cutaneous adverse reactions.
</td>
<td style="text-align:left;">
J Oncol Pharm Pract
</td>
</tr>
<tr>
<td style="text-align:left;">
Intrapleural Photodynamic Therapy for Mesothelioma: What Place and Which Future?
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Local treatment of a pleural mesothelioma tumor with ONCOS-102 induces a systemic antitumor CD8<sup>+</sup> T-cell response, prominent infiltration of CD8<sup>+</sup> lymphocytes and Th1 type polarization.
</td>
<td style="text-align:left;">
Oncoimmunology
</td>
</tr>
<tr>
<td style="text-align:left;">
First-in-human, phase I study of elisidepsin (PM02734) administered as a 30-min or as a 3-hour intravenous infusion every three weeks in patients with advanced solid tumors.
</td>
<td style="text-align:left;">
Invest New Drugs
</td>
</tr>
<tr>
<td style="text-align:left;">
Inhibition of autophagy sensitizes malignant pleural mesothelioma cells to dual PI3K/mTOR inhibitors.
</td>
<td style="text-align:left;">
Cell Death Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Humoral immunity alterations after environmental asbestos exposure.
</td>
<td style="text-align:left;">
Respiration
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma patient derived tumor xenografts with defined BAP1 mutations that mimic the molecular characteristics of human malignant mesothelioma.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Positron Emission Tomography/Computed Tomography for the Pleural Staging of Malignant Pleural Mesothelioma: How Accurate Is It?
</td>
<td style="text-align:left;">
Respiration
</td>
</tr>
<tr>
<td style="text-align:left;">
Loss of the deubiquitylase BAP1 alters class I histone deacetylase expression and sensitivity of mesothelioma cells to HDAC inhibitors.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
p16/CDKN2A FISH in Differentiation of Diffuse Malignant Peritoneal Mesothelioma From Mesothelial Hyperplasia and Epithelial Ovarian Cancer.
</td>
<td style="text-align:left;">
Am. J. Clin. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
The established and future biomarkers of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Treat. Rev.
</td>
</tr>
<tr>
<td style="text-align:left;">
An IR Navigation System for Pleural PDT.
</td>
<td style="text-align:left;">
Front Phys
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgical cytoreduction restores the antitumor efficacy of a Listeria monocytogenes vaccine in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Immunol. Lett.
</td>
</tr>
<tr>
<td style="text-align:left;">
Monte Carlo simulation of light fluence calculation during pleural PDT.
</td>
<td style="text-align:left;">
Proc SPIE Int Soc Opt Eng
</td>
</tr>
<tr>
<td style="text-align:left;">
Diarachidonoylphosphoethanolamine induces necrosis/necroptosis of malignant pleural mesothelioma cells.
</td>
<td style="text-align:left;">
Cell. Signal.
</td>
</tr>
<tr>
<td style="text-align:left;">
Targeting glucosylceramide synthase induction of cell surface globotriaosylceramide (Gb3) in acquired cisplatin-resistance of lung cancer and malignant pleural mesothelioma cells.
</td>
<td style="text-align:left;">
Exp. Cell Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Comparison of mesothelin and fibulin-3 in pleural fluid and serum as markers in malignant mesothelioma.
</td>
<td style="text-align:left;">
Curr Opin Pulm Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant Pleural Mesothelioma : Rationale for a New TNM Classification.
</td>
<td style="text-align:left;">
Acta Chir. Belg.
</td>
</tr>
<tr>
<td style="text-align:left;">
BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations.
</td>
<td style="text-align:left;">
Mod. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma due to non-occupational asbestos exposure from the Italian national surveillance system (ReNaM): epidemiology and public health issues.
</td>
<td style="text-align:left;">
Occup Environ Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural neoplastic pathology.
</td>
<td style="text-align:left;">
Respir Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Differential diagnosis of pleural mesothelioma using Logic Learning Machine.
</td>
<td style="text-align:left;">
BMC Bioinformatics
</td>
</tr>
<tr>
<td style="text-align:left;">
Differential p16/INK4A cyclin-dependent kinase inhibitor expression correlates with chemotherapy efficacy in a cohort of 88 malignant pleural mesothelioma patients.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma in the southwestern part of The Netherlands.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical Evaluation of ErbB-Targeted CAR T-Cells, Following Intracavity Delivery in Patients with ErbB-Expressing Solid Tumors.
</td>
<td style="text-align:left;">
Methods Mol. Biol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Are pleural plaques an appropriate endpoint for risk analyses?
</td>
<td style="text-align:left;">
Inhal Toxicol
</td>
</tr>
<tr>
<td style="text-align:left;">
Combinatorial anti-angiogenic gene therapy in a human malignant mesothelioma model.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Prognostic factors in diffuse malignant mesothelioma of the pleura].
</td>
<td style="text-align:left;">
Pneumologie
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse malignant pleural mesothelioma in an urban hospital: clinical spectrum and trend in incidence over time.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Sarcomatoid mesothelioma: future advances in diagnosis, biomolecular assessment, and therapeutic options in a poor-outcome disease.
</td>
<td style="text-align:left;">
Tumori
</td>
</tr>
<tr>
<td style="text-align:left;">
Phosphatidylinositol Induces Caspase-Independent Apoptosis of Malignant Pleural Mesothelioma Cells by Accumulating AIF in the Nucleus.
</td>
<td style="text-align:left;">
Cell. Physiol. Biochem.
</td>
</tr>
<tr>
<td style="text-align:left;">
Research priorities in mesothelioma: A James Lind Alliance Priority Setting Partnership.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
miR-193a-3p is a potential tumor suppressor in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant peritoneal mesothelioma: a series of 19 cases.
</td>
<td style="text-align:left;">
Digestion
</td>
</tr>
<tr>
<td style="text-align:left;">
Cynara scolymus affects malignant pleural mesothelioma by promoting apoptosis and restraining invasion.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
Gene-asbestos interaction in malignant pleural mesothelioma susceptibility.
</td>
<td style="text-align:left;">
Carcinogenesis
</td>
</tr>
<tr>
<td style="text-align:left;">
Epidemiologic surveillance of mesothelioma in Umbria.
</td>
<td style="text-align:left;">
Ann Ig
</td>
</tr>
<tr>
<td style="text-align:left;">
The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers.
</td>
<td style="text-align:left;">
Oncoimmunology
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic Score of Long-Term Survival After Surgery for Malignant Pleural Mesothelioma: A Multicenter Analysis.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma cells breaking bad: loss of integrin α7 promotes cell motility and poor clinical outcomes in patients.
</td>
<td style="text-align:left;">
J. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Survival from malignant mesothelioma: where are we now?
</td>
<td style="text-align:left;">
J R Coll Physicians Edinb
</td>
</tr>
<tr>
<td style="text-align:left;">
Hedgehog Signaling in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Genes (Basel)
</td>
</tr>
<tr>
<td style="text-align:left;">
A clinical protocol to inhibit the HGF/c-Met pathway for malignant mesothelioma with an intrapleural injection of adenoviruses expressing the NK4 gene.
</td>
<td style="text-align:left;">
Springerplus
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic Ability of FDG-PET/CT in the Detection of Malignant Pleural Effusion.
</td>
<td style="text-align:left;">
Medicine (Baltimore)
</td>
</tr>
<tr>
<td style="text-align:left;">
Downregulation of TBXAS1 in an iron-induced malignant mesothelioma model.
</td>
<td style="text-align:left;">
Cancer Sci.
</td>
</tr>
<tr>
<td style="text-align:left;">
Long-term Outcome of Patients With Undiagnosed Pleural Effusion.
</td>
<td style="text-align:left;">
Arch. Bronconeumol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Cul4A overexpression associated with Gli1 expression in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Cell. Mol. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Loss of expression of BAP1 is a useful adjunct, which strongly supports the diagnosis of mesothelioma in effusion cytology.
</td>
<td style="text-align:left;">
Mod. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant Mesothelioma Diagnosis.
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
NLRP1 and NLRP3 polymorphisms in mesothelioma patients and asbestos exposed individuals a population-based autopsy study from North East Italy.
</td>
<td style="text-align:left;">
Infect. Agents Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Inhibition of NADPH oxidase 4 induces apoptosis in malignant mesothelioma: Role of reactive oxygen species.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
</tr>
<tr>
<td style="text-align:left;">
Molecular Pharmacology of Malignant Pleural Mesothelioma: Challenges and Perspectives From Preclinical and Clinical Studies.
</td>
<td style="text-align:left;">
Curr Drug Targets
</td>
</tr>
<tr>
<td style="text-align:left;">
[MULTIMODAL APPROACH IN THE TREATMENT OF PATIENTS WITH MALIGNANT PLEURAL LESIONS].
</td>
<td style="text-align:left;">
Vopr Onkol
</td>
</tr>
<tr>
<td style="text-align:left;">
Frequent genomic rearrangements of BRCA1 associated protein-1 (BAP1) gene in Japanese malignant mesothelioma-characterization of deletions at exon level.
</td>
<td style="text-align:left;">
J. Hum. Genet.
</td>
</tr>
<tr>
<td style="text-align:left;">
Computational genomic analysis of PARK7 interactome reveals high BBS1 gene expression as a prognostic factor favoring survival in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Physiol. Lung Cell Mol. Physiol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma treatment: Are we on target? A review.
</td>
<td style="text-align:left;">
J Adv Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic significance of the lymphocyte-to-monocyte ratio in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Characterization of hypoxia in malignant pleural mesothelioma with FMISO PET-CT.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Two Different Serum MiRNA Signatures Correlate with the Clinical Outcome and Histological Subtype in Pleural Malignant Mesothelioma Patients.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
</tr>
<tr>
<td style="text-align:left;">
Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesothelioma and occupational and non-occupational asbestos exposure: a case-control study with quantitative risk assessment.
</td>
<td style="text-align:left;">
Occup Environ Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Granulocyte-colony stimulating factor (G-CSF) producing malignant pleural mesothelioma: Report of a case.
</td>
<td style="text-align:left;">
Thorac Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
The expression and clinical effects of alpha-methylacyl-CoA racemase (AMACR/ P504S) as an immunohistochemical marker in malign pleural mesothelioma.
</td>
<td style="text-align:left;">
Turk J Med Sci
</td>
</tr>
<tr>
<td style="text-align:left;">
Radical Radiation Therapy After Lung-Sparing Surgery for Malignant Pleural Mesothelioma: Survival, Pattern of Failure, and Prognostic Factors.
</td>
<td style="text-align:left;">
Int. J. Radiat. Oncol. Biol. Phys.
</td>
</tr>
<tr>
<td style="text-align:left;">
An immunohistochemical comparison of two TTF-1 monoclonal antibodies in atypical squamous lesions and sarcomatoid carcinoma of the lung, and pleural malignant mesothelioma.
</td>
<td style="text-align:left;">
J. Clin. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Autophagy Correlates with the Therapeutic Responsiveness of Malignant Pleural Mesothelioma in 3D Models.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
</tr>
<tr>
<td style="text-align:left;">
Deletion status of p16 in effusion smear preparation correlates with that of underlying malignant pleural mesothelioma tissue.
</td>
<td style="text-align:left;">
Cancer Sci.
</td>
</tr>
<tr>
<td style="text-align:left;">
Akt Kinase-Interacting Protein 1 Signals through CREB to Drive Diffuse Malignant Mesothelioma.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Imaging in pleural mesothelioma: A review of the 12th International Conference of the International Mesothelioma Interest Group.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Improvement of malignant pleural mesothelioma immunotherapy by epigenetic modulators.
</td>
<td style="text-align:left;">
Curr Top Med Chem
</td>
</tr>
<tr>
<td style="text-align:left;">
Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies.
</td>
<td style="text-align:left;">
Expert Rev Respir Med
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of endobronchial ultrasound-guided fine needle aspiration in the diagnosis of pleural mesothelioma.
</td>
<td style="text-align:left;">
Cytopathology
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant Pleural Mesothelioma Outcomes in the Era of Combined Platinum and Folate Antimetabolite Chemotherapy.
</td>
<td style="text-align:left;">
Lung Cancer Int
</td>
</tr>
<tr>
<td style="text-align:left;">
A New Prognostic Score Supporting Treatment Allocation for Multimodality Therapy for Malignant Pleural Mesothelioma: A Review of 12 Years’ Experience.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Extended Pleurectomy and Decortication for Malignant Pleural Mesothelioma Is an Effective and Safe Cytoreductive Surgery in the Elderly.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Inhibition of Src family kinases overcomes anoikis resistance induced by spheroid formation and facilitates cisplatin-induced apoptosis in human mesothelioma cells.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
</tr>
<tr>
<td style="text-align:left;">
Trimodality Treatment of Malignant Pleural Mesothelioma: An Institutional Review.
</td>
<td style="text-align:left;">
Am. J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Critical review about MDM2 in cancer: Possible role in malignant mesothelioma and implications for treatment.
</td>
<td style="text-align:left;">
Crit. Rev. Oncol. Hematol.
</td>
</tr>
<tr>
<td style="text-align:left;">
The diagnosis, therapy and prognosis of diffuse malignant mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic value of several biomarkers for the patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Tumour Biol.
</td>
</tr>
<tr>
<td style="text-align:left;">
An asbestos-exposed family with multiple cases of pleural malignant mesothelioma without inheritance of a predisposing BAP1 mutation.
</td>
<td style="text-align:left;">
Cancer Genet
</td>
</tr>
<tr>
<td style="text-align:left;">
Advances in the diagnosis, treatment and prognosis of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann Transl Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Systemic therapy options for malignant pleural mesothelioma beyond first-line therapy: a systematic review.
</td>
<td style="text-align:left;">
Expert Rev Respir Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Epithelioid pleural mesothelioma concurrently associated with miliary pulmonary metastases and minimal change nephrotic syndrome - A hitherto undescribed case.
</td>
<td style="text-align:left;">
Pathol. Res. Pract.
</td>
</tr>
<tr>
<td style="text-align:left;">
Successful palliation for an aged patient with primary pericardial mesothelioma.
</td>
<td style="text-align:left;">
World J Surg Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Health expenditures for cases of pleural mesothelioma].
</td>
<td style="text-align:left;">
Med Lav
</td>
</tr>
<tr>
<td style="text-align:left;">
A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Germline BAP1 mutation in a family with high incidence of multiple primary cancers and a potential gene-environment interaction.
</td>
<td style="text-align:left;">
Cancer Lett.
</td>
</tr>
<tr>
<td style="text-align:left;">
Which is the Role of Pneumonectomy in the Era of Parenchymal-Sparing Procedures? Early/Long-Term Survival and Functional Results of a Single-Center Experience.
</td>
<td style="text-align:left;">
Lung
</td>
</tr>
<tr>
<td style="text-align:left;">
Identification of circulating miRNAs profiles that distinguish malignant pleural mesothelioma from lung adenocarcinoma.
</td>
<td style="text-align:left;">
EXCLI J
</td>
</tr>
<tr>
<td style="text-align:left;">
Targeting immune checkpoints: New opportunity for mesothelioma treatment?
</td>
<td style="text-align:left;">
Cancer Treat. Rev.
</td>
</tr>
<tr>
<td style="text-align:left;">
Response evaluation in mesothelioma: Beyond RECIST.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Utility of BAP1 Immunohistochemistry and p16 (CDKN2A) FISH in the Diagnosis of Malignant Mesothelioma in Effusion Cytology Specimens.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Tomotherapy PET-guided dose escalation: A dosimetric feasibility study for patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Strahlenther Onkol
</td>
</tr>
<tr>
<td style="text-align:left;">
Paraneoplastic nephritic syndrome and concurrent solitary mediastinal lymph node metastasis from mesothelioma of testis diagnosed by endobronchial ultrasound: Unusual manifestations of an extremely rare tumor.
</td>
<td style="text-align:left;">
J Cancer Res Ther
</td>
</tr>
<tr>
<td style="text-align:left;">
Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression and activity of eIF6 trigger malignant pleural mesothelioma growth in vivo.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
MesobanK UK: an international mesothelioma bioresource.
</td>
<td style="text-align:left;">
Thorax
</td>
</tr>
<tr>
<td style="text-align:left;">
Imaging characteristics of pleural tumours.
</td>
<td style="text-align:left;">
Insights Imaging
</td>
</tr>
<tr>
<td style="text-align:left;">
Advanced therapeutic approach for the treatment of malignant pleural mesothelioma via the intrapleural administration of liposomal pemetrexed.
</td>
<td style="text-align:left;">
J Control Release
</td>
</tr>
<tr>
<td style="text-align:left;">
Systemic approach to malignant pleural mesothelioma: what news of chemotherapy, targeted agents and immunotherapy?
</td>
<td style="text-align:left;">
Tumori
</td>
</tr>
<tr>
<td style="text-align:left;">
Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model.
</td>
<td style="text-align:left;">
J Vis Exp
</td>
</tr>
<tr>
<td style="text-align:left;">
The immunohistochemical diagnosis of mesothelioma. Differentiation of mesothelioma and lung adenocarcinoma.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma.
</td>
<td style="text-align:left;">
Mod. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Lapatinib enhances trastuzumab-mediated antibody-dependent cellular cytotoxicity via upregulation of HER2 in malignant mesothelioma cells.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
</tr>
<tr>
<td style="text-align:left;">
Methylation-associated Silencing of microRNA-126 and its Host Gene EGFL7 in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
MMP-7 is a highly specific negative marker for benign and malignant mesothelial cells in serous effusions.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed-Induced Rash May Be Prevented by Supplementary Corticosteroids.
</td>
<td style="text-align:left;">
Biol. Pharm. Bull.
</td>
</tr>
<tr>
<td style="text-align:left;">
Vinca alkaloids in the therapeutic management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Treat. Rev.
</td>
</tr>
<tr>
<td style="text-align:left;">
Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial.
</td>
<td style="text-align:left;">
Lancet Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Sensitivity of human pleural mesothelioma to oncolytic measles virus depends on defects of the type I interferon response.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
MDM2 and HIF1alpha expression levels in different histologic subtypes of malignant pleural mesothelioma: correlation with pathological and clinical data.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study).
</td>
<td style="text-align:left;">
BMC Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Gender-Specific Molecular and Clinical Features Underlie Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Tremelimumab for the treatment of malignant mesothelioma.
</td>
<td style="text-align:left;">
Expert Opin Biol Ther
</td>
</tr>
<tr>
<td style="text-align:left;">
Trimodality strategy for treating malignant pleural mesothelioma: results of a feasibility study of induction pemetrexed plus cisplatin followed by extrapleural pneumonectomy and postoperative hemithoracic radiation (Japan Mesothelioma Interest Group 0601 Trial).
</td>
<td style="text-align:left;">
Int. J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Brain metastases in malignant pleural mesothelioma. Case report and review of the literature.
</td>
<td style="text-align:left;">
Am. J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Diarachidonoylphosphoethanolamine induces apoptosis of malignant pleural mesothelioma cells through a Trx/ASK1/p38 MAPK pathway.
</td>
<td style="text-align:left;">
J. Pharmacol. Sci.
</td>
</tr>
<tr>
<td style="text-align:left;">
Biologic therapy and gene therapy in the multimodality treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann Transl Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Adoption of pleurectomy and decortication for malignant mesothelioma leads to similar survival as extrapleural pneumonectomy.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytomorphometry of serosal effusion in dogs.
</td>
<td style="text-align:left;">
Pol J Vet Sci
</td>
</tr>
<tr>
<td style="text-align:left;">
Brain metastases in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin. Exp. Metastasis
</td>
</tr>
<tr>
<td style="text-align:left;">
Invasive pleural malignant mesothelioma with rib destruction and concurrent osteosarcoma in a dog.
</td>
<td style="text-align:left;">
Acta Vet. Scand.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pembrolizumab for the treatment of thoracic malignancies: current landscape and future directions.
</td>
<td style="text-align:left;">
Future Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Fibrocyte-like cells mediate acquired resistance to anti-angiogenic therapy with bevacizumab.
</td>
<td style="text-align:left;">
Nat Commun
</td>
</tr>
<tr>
<td style="text-align:left;">
High RRM1 Expression Is Associated with Adverse Outcome in Patients with Cisplatin/Vinorelbine-treated Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Extrapleural pneumonectomy for malignant pleural mesothelioma: is this an operation that should now be consigned to history?
</td>
<td style="text-align:left;">
Future Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
The MesoVATS trial: is there a future for video-assisted thoracoscopic surgery partial pleurectomy?
</td>
<td style="text-align:left;">
Future Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Management of recurrence after initial surgery for malignant pleural mesothelioma: a mini-review.
</td>
<td style="text-align:left;">
Future Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Biomarkers and prognostic factors for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Future Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
CT differentiation of diffuse malignant peritoneal mesothelioma and peritoneal carcinomatosis.
</td>
<td style="text-align:left;">
J. Gastroenterol. Hepatol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinically occult primary fallopian tube carcinoma presenting as a malignant pleural effusion.
</td>
<td style="text-align:left;">
Clin Respir J
</td>
</tr>
<tr>
<td style="text-align:left;">
Extended Tumor Control after Dendritic Cell Vaccination with Low-Dose Cyclophosphamide as Adjuvant Treatment in Patients with Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Respir. Crit. Care Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Analysis of the clinical diagnosis of asbestosis complicated with malignant mesothelioma].
</td>
<td style="text-align:left;">
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi
</td>
</tr>
<tr>
<td style="text-align:left;">
Localized benign and malignant fibrous tumors of the pleura. A clinicopathologic review of 223 cases.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Determinants of Survival in Malignant Pleural Mesothelioma: A Surveillance, Epidemiology, and End Results (SEER) Study of 14,228 Patients.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
</tr>
<tr>
<td style="text-align:left;">
CT differentiation of malignant peritoneal mesothelioma and tuberculous peritonitis.
</td>
<td style="text-align:left;">
Radiol Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural epitheliod hemangioendothelioma: What started as a liver fluke and ended up being almost mistaken for malignant mesothelioma.
</td>
<td style="text-align:left;">
Ann Thorac Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Closing faucets: the role of anti-angiogenic therapies in malignant pleural diseases.
</td>
<td style="text-align:left;">
Clin Transl Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
MTA1 promotes metastasis of MPM via suppression of E-cadherin.
</td>
<td style="text-align:left;">
J. Exp. Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical Investigation of Benign Asbestos Pleural Effusion.
</td>
<td style="text-align:left;">
Pulm Med
</td>
</tr>
<tr>
<td style="text-align:left;">
[Analysis of misdiagnosis of 38 cases of solitary fibrous tumor of the pleura].
</td>
<td style="text-align:left;">
Zhonghua Jie He He Hu Xi Za Zhi
</td>
</tr>
<tr>
<td style="text-align:left;">
Patterns in the incidence, mortality and survival of malignant pleural and peritoneal mesothelioma, New South Wales, 1972-2009.
</td>
<td style="text-align:left;">
Aust N Z J Public Health
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesothelioma and lung cancer risks in relation to occupational history and asbestos lung burden.
</td>
<td style="text-align:left;">
Occup Environ Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Long-term results in malignant pleural mesothelioma treated with neoadjuvant chemotherapy, extrapleural pneumonectomy and intensity-modulated radiotherapy.
</td>
<td style="text-align:left;">
Radiat Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Non-islet Cell Tumour Hypoglycaemia (NICTH) in Malignant Mesothelioma: Case Report.
</td>
<td style="text-align:left;">
Malays J Med Sci
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical role of a new prognostic score using platelet-to-lymphocyte ratio in patients with malignant pleural mesothelioma undergoing extrapleural pneumonectomy.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
</td>
<td style="text-align:left;">
Lancet
</td>
</tr>
<tr>
<td style="text-align:left;">
Germline BAP1 Mutational Landscape of Asbestos-Exposed Malignant Mesothelioma Patients with Family History of Cancer.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
DNA copy number gains in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncol Lett
</td>
</tr>
<tr>
<td style="text-align:left;">
Infant pleuropulmonary blastoma: report of a rare case and review of literature.
</td>
<td style="text-align:left;">
Int J Clin Exp Pathol
</td>
</tr>
<tr>
<td style="text-align:left;">
HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
A rare clinical case - Solitary fibrous tumor of the pleura.
</td>
<td style="text-align:left;">
Respir Med Case Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
Massive localized malignant pleural mesothelioma (LMPM): manifestations on computed tomography in 6 cases.
</td>
<td style="text-align:left;">
Int J Clin Exp Med
</td>
</tr>
<tr>
<td style="text-align:left;">
A Novel Clinical Prediction Model for Prognosis in Malignant Pleural Mesothelioma Using Decision Tree Analysis.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
CT Scan-Guided Abrams’ Needle Pleural Biopsy versus Ultrasound-Assisted Cutting Needle Pleural Biopsy for Diagnosis in Patients with Pleural Effusion: A Randomized, Controlled Trial.
</td>
<td style="text-align:left;">
Respiration
</td>
</tr>
<tr>
<td style="text-align:left;">
KAT5 (Tip60) is a potential therapeutic target in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Constitutive expression and anticancer potency of a novel immunotoxin onconase-DV3.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
</tr>
<tr>
<td style="text-align:left;">
Incidence and survival trends for malignant pleural and peritoneal mesothelioma, Australia, 1982-2009.
</td>
<td style="text-align:left;">
Occup Environ Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Specimen weight and volume: important predictors of survival in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4-10 years in advance of clinical symptoms.
</td>
<td style="text-align:left;">
Clin Proteomics
</td>
</tr>
<tr>
<td style="text-align:left;">
The 2015 World Health Organization Classification of Tumors of the Pleura: Advances since the 2004 Classification.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Retrospective analysis of unknown primary cancers with malignant pleural effusion at initial diagnosis.
</td>
<td style="text-align:left;">
Thorac Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Protocol for PIT: a phase III trial of prophylactic irradiation of tracts in patients with malignant pleural mesothelioma following invasive chest wall intervention.
</td>
<td style="text-align:left;">
BMJ Open
</td>
</tr>
<tr>
<td style="text-align:left;">
Iron signature in asbestos-induced malignant pleural mesothelioma: A population-based autopsy study.
</td>
<td style="text-align:left;">
J. Toxicol. Environ. Health Part A
</td>
</tr>
<tr>
<td style="text-align:left;">
[Asbestos and respiratory diseases].
</td>
<td style="text-align:left;">
Presse Med
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesotheliomas with unknown exposure to asbestos: a re-examination].
</td>
<td style="text-align:left;">
Med Lav
</td>
</tr>
<tr>
<td style="text-align:left;">
Longitudinal Measurement of Pleural Fluid Biochemistry and Cytokines in Malignant Pleural Effusions.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Benign and Malignant Mesothelial Proliferation.
</td>
<td style="text-align:left;">
Surg Pathol Clin
</td>
</tr>
<tr>
<td style="text-align:left;">
Antagonizing the Hedgehog Pathway with Vismodegib Impairs Malignant Pleural Mesothelioma Growth In Vivo by Affecting Stroma.
</td>
<td style="text-align:left;">
Mol. Cancer Ther.
</td>
</tr>
<tr>
<td style="text-align:left;">
Contemporary Analysis of Prognostic Factors in Patients with Unresectable Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
A Randomized Phase II Study Adding Axitinib to Pemetrexed-Cisplatin in Patients with Malignant Pleural Mesothelioma: A Single-Center Trial Combining Clinical and Translational Outcomes.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Downregulation of thymidylate synthase by RNAi molecules enhances the antitumor effect of pemetrexed in an orthotopic malignant mesothelioma xenograft mouse model.
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Identification of cis- and trans-acting elements regulating calretinin expression in mesothelioma cells.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
Genome-wide analysis of abdominal and pleural malignant mesothelioma with DNA arrays reveals both common and distinct regions of copy number alteration.
</td>
<td style="text-align:left;">
Cancer Biol. Ther.
</td>
</tr>
<tr>
<td style="text-align:left;">
Human lung-derived mesenchymal stem cell-conditioned medium exerts in vitro antitumor effects in malignant pleural mesothelioma cell lines.
</td>
<td style="text-align:left;">
Stem Cell Res Ther
</td>
</tr>
<tr>
<td style="text-align:left;">
HOX transcription factors are potential targets and markers in malignant mesothelioma.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: an update on diagnosis and treatment options.
</td>
<td style="text-align:left;">
Ther Adv Respir Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncol Nurs Forum
</td>
</tr>
<tr>
<td style="text-align:left;">
[Primary malignant mesothelioma of the pericardium masquerading as malignant pleural mesothelioma: report of an autopsy case and review of the reported cases in Japan as to its invasion to neighboring organs].
</td>
<td style="text-align:left;">
Kokyu To Junkan
</td>
</tr>
<tr>
<td style="text-align:left;">
Role of MIF/CD74 signaling pathway in the development of pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
A proteomics-based approach identifies secreted protein acidic and rich in cysteine as a prognostic biomarker in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical and pathologic predictors of clinical outcome of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Tumori
</td>
</tr>
<tr>
<td style="text-align:left;">
Cutaneous Metastases From Malignant Mesothelioma of the Tunica Vaginalis Testis.
</td>
<td style="text-align:left;">
Am J Dermatopathol
</td>
</tr>
<tr>
<td style="text-align:left;">
Population pharmacokinetics and exposure-response relationship of amatuximab, an anti-mesothelin monoclonal antibody, in patients with malignant pleural mesothelioma and its application in dose selection.
</td>
<td style="text-align:left;">
Cancer Chemother. Pharmacol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Peritoneal mesothelioma metastasis to the tongue - Comparison with 8 pleural mesothelioma reports with tongue metastases.
</td>
<td style="text-align:left;">
Ann Med Surg (Lond)
</td>
</tr>
<tr>
<td style="text-align:left;">
BAP1 Immunohistochemistry and p16 FISH in the Diagnosis of Sarcomatous and Desmoplastic Mesotheliomas.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Plasma Biomarker Enrichment of Clinical Prognostic Indices in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
microRNAs are differentially regulated between MDM2-positive and negative malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations.
</td>
<td style="text-align:left;">
Nat. Genet.
</td>
</tr>
<tr>
<td style="text-align:left;">
Microfluidic gradient device for studying mesothelial cell migration and the effect of chronic carbon nanotube exposure.
</td>
<td style="text-align:left;">
J Micromech Microeng
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos Induces Oxidative Stress and Activation of Nrf2 Signaling in Murine Macrophages: Chemopreventive Role of the Synthetic Lignan Secoisolariciresinol Diglucoside (LGM2605).
</td>
<td style="text-align:left;">
Int J Mol Sci
</td>
</tr>
<tr>
<td style="text-align:left;">
Identifying Thoracic Malignancies Through Pleural Fluid Biomarkers: A Predictive Multivariate Model.
</td>
<td style="text-align:left;">
Medicine (Baltimore)
</td>
</tr>
<tr>
<td style="text-align:left;">
Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNα Combined with Chemotherapy.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Safety of indwelling pleural catheter use in patients undergoing chemotherapy: a five-year retrospective evaluation.
</td>
<td style="text-align:left;">
BMC Pulm Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic accuracy of sequential co-registered PET+MR in comparison to PET/CT in local thoracic staging of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemokines involved in the early inflammatory response and in pro-tumoral activity in asbestos-exposed workers from an Italian coastal area with territorial clusters of pleural malignant mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Novel Hyaluronan Formulation Enhances the Efficacy of Boron Neutron Capture Therapy for Murine Mesothelioma.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Advanced epithelioid pleural mesothelioma, long lasting disease stabilization and long term survival with cisplatin-pemetrexed chemotherapy re-challenge: a case report.
</td>
<td style="text-align:left;">
Clin Ter
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesothelioma: Case-report of uncommon occupational asbestos exposure in a small furniture industry.
</td>
<td style="text-align:left;">
Int J Occup Med Environ Health
</td>
</tr>
<tr>
<td style="text-align:left;">
Histopathology of removed indwelling pleural catheters from patients with malignant pleural diseases.
</td>
<td style="text-align:left;">
Respirology
</td>
</tr>
<tr>
<td style="text-align:left;">
Simian virus 40 may be associated with developing malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncol Lett
</td>
</tr>
<tr>
<td style="text-align:left;">
Impact of induction therapy on postoperative outcome after extrapleural pneumonectomy for malignant pleural mesothelioma: does induction-accelerated hemithoracic radiation increase the surgical risk?
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Immune response profiling of malignant pleural mesothelioma for diagnostic and prognostic biomarkers.
</td>
<td style="text-align:left;">
Biomarkers
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunocytochemical utility of claudin-4 versus those of Ber-EP4 and MOC-31 in effusion cytology.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Fatal pleural mesothelioma in Japan (2003-2008): evaluation of computed tomography findings.
</td>
<td style="text-align:left;">
Jpn J Radiol
</td>
</tr>
<tr>
<td style="text-align:left;">
An intrapleural administration of zoledronic acid for inoperable malignant mesothelioma patients: a phase I clinical study protocol.
</td>
<td style="text-align:left;">
Springerplus
</td>
</tr>
<tr>
<td style="text-align:left;">
Primary Malignant Neuroendocrine Tumour of Pleura: First Case Report.
</td>
<td style="text-align:left;">
Case Rep Oncol Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Deformable medical image registration of pleural cavity for photodynamic therapy by using finite-element based method.
</td>
<td style="text-align:left;">
Proc SPIE Int Soc Opt Eng
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed Maintenance Therapy Following Bevacizumab-Containing First-Line Chemotherapy in Advanced Malignant Pleural Mesothelioma: A Case Report and Literatures Review.
</td>
<td style="text-align:left;">
Medicine (Baltimore)
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic value of the lymphocyte-to-monocyte ratio and other inflammatory markers in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Environ Health Prev Med
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of the HGF/Met axis in mesothelioma.
</td>
<td style="text-align:left;">
Biochem. Soc. Trans.
</td>
</tr>
<tr>
<td style="text-align:left;">
A pilot study of volumetric-modulated arc therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Appl Clin Med Phys
</td>
</tr>
<tr>
<td style="text-align:left;">
Primary papillary serous neoplasia of the peritoneum: a clinicopathologic and ultrastructural study of eight cases.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytologic Differential Diagnosis of Malignant Mesothelioma and Reactive Mesothelial Cells With FISH Analysis of p16.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Comparative genetic analysis of a rare synchronous collision tumor composed of malignant pleural mesothelioma and primary pulmonary adenocarcinoma.
</td>
<td style="text-align:left;">
Diagn Pathol
</td>
</tr>
<tr>
<td style="text-align:left;">
Multiwalled carbon nanotubes intratracheally instilled into the rat lung induce development of pleural malignant mesothelioma and lung tumors.
</td>
<td style="text-align:left;">
Cancer Sci.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Diffuse neoplastic infiltration of leptomeninges by malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Recenti Prog Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant Mesothelioma Versus Metastatic Carcinoma of the Pleura: A CT Challenge.
</td>
<td style="text-align:left;">
Iran J Radiol
</td>
</tr>
<tr>
<td style="text-align:left;">
Pain in Malignant Pleural Mesothelioma: A Prospective Characterization Study.
</td>
<td style="text-align:left;">
Pain Med
</td>
</tr>
<tr>
<td style="text-align:left;">
BAP1 Immunostain and CDKN2A (p16) FISH Analysis: Clinical Applicability for the Diagnosis of Malignant Mesothelioma in Effusions.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Predictive value of BRCA1 expression on the efficacy of chemotherapy based on anti-microtubule agents: a pooled analysis across different malignancies and agents.
</td>
<td style="text-align:left;">
Ann Transl Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Massive chest wall resection and reconstruction for malignant disease.
</td>
<td style="text-align:left;">
Onco Targets Ther
</td>
</tr>
<tr>
<td style="text-align:left;">
Overexpression of micro ribonucleic acid-591 inhibits cell proliferation and invasion of malignant pleural mesothelioma cells.
</td>
<td style="text-align:left;">
Thorac Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Multimodality Imaging Review of Malignant Pleural Mesothelioma Diagnosis and Staging.
</td>
<td style="text-align:left;">
PET Clin
</td>
</tr>
<tr>
<td style="text-align:left;">
A Multimodality Imaging Review of Malignant Pleural Mesothelioma Response Assessment.
</td>
<td style="text-align:left;">
PET Clin
</td>
</tr>
<tr>
<td style="text-align:left;">
Geometric dose prediction model for hemithoracic intensity-modulated radiation therapy in mesothelioma patients with two intact lungs.
</td>
<td style="text-align:left;">
J Appl Clin Med Phys
</td>
</tr>
<tr>
<td style="text-align:left;">
Precision immunotherapy; dynamics in the cellular profile of pleural effusions in malignant mesothelioma patients.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
[Surgical therapy of malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Chirurg
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of “closed abdomen” hyperthermic intraperitoneal chemotherapy (HIPEC) in the palliative treatment of neoplastic ascites from peritoneal carcinomatosis: report of a single-center experience.
</td>
<td style="text-align:left;">
Support Care Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Conjunctival Metastasis from Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Ocul Oncol Pathol
</td>
</tr>
<tr>
<td style="text-align:left;">
Manumycin A induces apoptosis in malignant pleural mesothelioma through regulation of Sp1 and activation of the mitochondria-related apoptotic pathway.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
</tr>
<tr>
<td style="text-align:left;">
North American Multicenter Volumetric CT Study for Clinical Staging of Malignant Pleural Mesothelioma: Feasibility and Logistics of Setting Up a Quantitative Imaging Study.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Genomic copy number alterations in 33 malignant peritoneal mesothelioma analyzed by comparative genomic hybridization array.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer.
</td>
<td style="text-align:left;">
Epigenomics
</td>
</tr>
<tr>
<td style="text-align:left;">
Inhibition of PAI-1 Limits Tumor Angiogenesis Regardless of Angiogenic Stimuli in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Clinical Pathological Diagnosis, and Treatment for Pleural Mesothelioma].
</td>
<td style="text-align:left;">
Gan To Kagaku Ryoho
</td>
</tr>
<tr>
<td style="text-align:left;">
Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio reliable parameters as prognostic indicators in malignant mesothelioma?
</td>
<td style="text-align:left;">
Ther Clin Risk Manag
</td>
</tr>
<tr>
<td style="text-align:left;">
Use of p16 FISH for differential diagnosis of mesothelioma in smear preparations.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Present and future roles of FDG-PET/CT imaging in the management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Jpn J Radiol
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma in a 17-year old boy: A case report and literature review.
</td>
<td style="text-align:left;">
Respir Med Case Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: initial experience in integrated (18)F-FDG PET/MR imaging.
</td>
<td style="text-align:left;">
Clin Imaging
</td>
</tr>
<tr>
<td style="text-align:left;">
Impact of Age on Long-Term Outcomes of Surgery for Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
KCa1.1, a calcium-activated potassium channel subunit alpha 1, is targeted by miR-17-5p and modulates cell migration in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Mol. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
[Diagnosis and prognosis of malignant mesothelioma. A description of 8 clinical cases].
</td>
<td style="text-align:left;">
Minerva Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Drug carrier nanosystems in malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Tuberk Toraks
</td>
</tr>
<tr>
<td style="text-align:left;">
Conventional and high resolution computed tomography in the diagnosis of asbestos-related diseases.
</td>
<td style="text-align:left;">
Radiographics
</td>
</tr>
<tr>
<td style="text-align:left;">
Orotate phosphoribosyltransferase is overexpressed in malignant pleural mesothelioma: Dramatically responds one case in high OPRT expression.
</td>
<td style="text-align:left;">
Rare Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Kinesin family members KIF11 and KIF23 as potential therapeutic targets in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
The Genetic Landscape of Malignant Pleural Mesothelioma: Results from Massively Parallel Sequencing.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Synergistic anti-tumor efficacy of immunogenic adenovirus ONCOS-102 (Ad5/3-D24-GM-CSF) and standard of care chemotherapy in preclinical mesothelioma model.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Moving Immune Checkpoint Blockade in Thoracic Tumors beyond NSCLC.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Localized malignant pleural sarcomatoid mesothelioma misdiagnosed as benign localized fibrous tumor.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Nanoparticle-based targeted gene therapy for lung cancer.
</td>
<td style="text-align:left;">
Am J Cancer Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Antitumor effect of novel anti-podoplanin antibody NZ-12 against malignant pleural mesothelioma in an orthotopic xenograft model.
</td>
<td style="text-align:left;">
Cancer Sci.
</td>
</tr>
<tr>
<td style="text-align:left;">
Applications of Magnetic Resonance Imaging of the Thorax in Pleural Diseases: A State-of-the-Art Review.
</td>
<td style="text-align:left;">
Lung
</td>
</tr>
<tr>
<td style="text-align:left;">
Role of respiratory-triggered diffusion-weighted MRI in the assessment of pleural disease.
</td>
<td style="text-align:left;">
Br J Radiol
</td>
</tr>
<tr>
<td style="text-align:left;">
Circulating epigenetic biomarkers in lung malignancies: From early diagnosis to therapy.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) As Part of Lung-Sparing Multimodality Therapy in Patients With Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Comorbidity, postoperative morbidity and survival in patients undergoing radical surgery for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trial.
</td>
<td style="text-align:left;">
Lancet Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Thoracoscopy using flexible fiberoptic bronchoscopy–a preliminary report of experimental and clinical studies].
</td>
<td style="text-align:left;">
Zhonghua Nei Ke Za Zhi
</td>
</tr>
<tr>
<td style="text-align:left;">
A case of pseudoachalasia hiding a malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Tumori
</td>
</tr>
<tr>
<td style="text-align:left;">
Usefulness of Aquaporin 1 as a Prognostic Marker in a Prospective Cohort of Malignant Mesotheliomas.
</td>
<td style="text-align:left;">
Int J Mol Sci
</td>
</tr>
<tr>
<td style="text-align:left;">
Low Merlin expression and high Survivin labeling index are indicators for poor prognosis in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Mol Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Protocol of the Australasian Malignant Pleural Effusion-2 (AMPLE-2) trial: a multicentre randomised study of aggressive versus symptom-guided drainage via indwelling pleural catheters.
</td>
<td style="text-align:left;">
BMJ Open
</td>
</tr>
<tr>
<td style="text-align:left;">
P2X7 targeting inhibits growth of human mesothelioma.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
Dasatinib modulates sensitivity to pemetrexed in malignant pleural mesothelioma cell lines.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
c-Met expression and MET amplification in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann Diagn Pathol
</td>
</tr>
<tr>
<td style="text-align:left;">
NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016.
</td>
<td style="text-align:left;">
J Natl Compr Canc Netw
</td>
</tr>
<tr>
<td style="text-align:left;">
MicroRNA gene expression signatures in long-surviving malignant pleural mesothelioma patients.
</td>
<td style="text-align:left;">
Genom Data
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural Effusions from Patients with Mesothelioma Induce Recruitment of Monocytes and Their Differentiation into M2 Macrophages.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural Effusion of Patients with Malignant Mesothelioma Induces Macrophage-Mediated T Cell Suppression.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Cochrane corner: interventions for the management of malignant pleural effusions.
</td>
<td style="text-align:left;">
Thorax
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma with lacrimal gland metastasis.
</td>
<td style="text-align:left;">
Acta Ophthalmol
</td>
</tr>
<tr>
<td style="text-align:left;">
BRCA1-Associated Protein 1 (BAP1) Immunohistochemical Expression as a Diagnostic Tool in Malignant Pleural Mesothelioma Classification: A Large Retrospective Study.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
New therapeutic strategies for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Biochem. Pharmacol.
</td>
</tr>
<tr>
<td style="text-align:left;">
A Histomorphologic Grading System That Predicts Overall Survival in Diffuse Malignant Peritoneal Mesothelioma With Epithelioid Subtype.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
A case report of metastasis of malignant mesothelioma to the retromolar trigone.
</td>
<td style="text-align:left;">
World J Surg Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Combination of cisplatin and lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma: Report of two cases.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Flow cytometric analysis of malignant pleural mesotheliomas.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Positive nuclear BAP1 immunostaining helps differentiate non-small cell lung carcinomas from malignant mesothelioma.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
A Phase II Study of PF-03446962 in Patients with Advanced Malignant Pleural Mesothelioma. CCTG Trial IND.207.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Inhibition of the Polyamine Synthesis Pathway Is Synthetically Lethal with Loss of Argininosuccinate Synthase 1.
</td>
<td style="text-align:left;">
Cell Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
Pathology reporting of malignant pleural mesothelioma first diagnosis: A population-based approach.
</td>
<td style="text-align:left;">
Pathol. Res. Pract.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural irregularities and mediastinal pleural involvement in early stages of malignant pleural mesothelioma and benign asbestos pleural effusion.
</td>
<td style="text-align:left;">
Eur J Radiol
</td>
</tr>
<tr>
<td style="text-align:left;">
Genomic Landscape of Malignant Mesotheliomas.
</td>
<td style="text-align:left;">
Mol. Cancer Ther.
</td>
</tr>
<tr>
<td style="text-align:left;">
Potent efficacy signals from systemically administered oncolytic herpes simplex virus (HSV1716) in hepatocellular carcinoma xenograft models.
</td>
<td style="text-align:left;">
J Hepatocell Carcinoma
</td>
</tr>
<tr>
<td style="text-align:left;">
Calpeptin Prevents Malignant Pleural Mesothelioma Cell Proliferation via the Angiopoietin1/Tie2 System.
</td>
<td style="text-align:left;">
Asian Pac. J. Cancer Prev.
</td>
</tr>
<tr>
<td style="text-align:left;">
Sarcomatous tumor of the chest wall with osteochondroid differentiation. Evidence of mesothelial origin.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro.
</td>
<td style="text-align:left;">
Mol. Cancer Ther.
</td>
</tr>
<tr>
<td style="text-align:left;">
Medical thoracoscopy: Analysis on diagnostic yield through 30 years of experience.
</td>
<td style="text-align:left;">
Ann Thorac Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Quercetin and Cisplatin combined treatment altered cell cycle and mitogen activated protein kinase expressions in malignant mesotelioma cells.
</td>
<td style="text-align:left;">
BMC Complement Altern Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Evaluation of predictive value of pleural CEA in patients with pleural effusions and histological findings: A prospective study and literature review.
</td>
<td style="text-align:left;">
Clin. Biochem.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pembrolizumab-associated minimal change disease in a patient with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Co-existing tuberculosis and malignant mesothelioma with multiple sites venous thrombosis: a case report.
</td>
<td style="text-align:left;">
BMC Res Notes
</td>
</tr>
<tr>
<td style="text-align:left;">
Comparison of SKIP expression in malignant pleural mesotheliomas with Ki-67 proliferation index and prognostic parameters.
</td>
<td style="text-align:left;">
Pol J Pathol
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant Mesothelioma Effusions Are Infiltrated by CD3<sup>+</sup> T Cells Highly Expressing PD-L1 and the PD-L1<sup>+</sup> Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti-PD-L1 Antibody Avelumab.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural fluid from mesothelioma has potent biological activities.
</td>
<td style="text-align:left;">
Respirology
</td>
</tr>
<tr>
<td style="text-align:left;">
Metformin and survival of people with type 2 diabetes and pleural mesothelioma: A population-based retrospective cohort study.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial.
</td>
<td style="text-align:left;">
JAMA Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Promising in vivo efficacy of the BET bromodomain inhibitor OTX015/MK-8628 in malignant pleural mesothelioma xenografts.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
A Multicenter Study of Volumetric Computed Tomography for Staging Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
How does the timing of chemotherapy affect outcome following radical surgery for malignant pleural mesothelioma?
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma of the pleura with desmoplastic histology: a case series and literature review.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant Pleural Mesotheliomas].
</td>
<td style="text-align:left;">
Zentralbl Chir
</td>
</tr>
<tr>
<td style="text-align:left;">
BAP1 immunohistochemistry and p16 FISH results in combination provide higher confidence in malignant pleural mesothelioma diagnosis: ROC analysis of the two tests.
</td>
<td style="text-align:left;">
Pathol. Int.
</td>
</tr>
<tr>
<td style="text-align:left;">
Management of malignant pleural mesothelioma - part 1: epidemiology, diagnosis, and staging : Consensus of the Austrian Mesothelioma Interest Group (AMIG).
</td>
<td style="text-align:left;">
Wien. Klin. Wochenschr.
</td>
</tr>
<tr>
<td style="text-align:left;">
Validation of EORTC and CALGB prognostic models in surgical patients submitted to diagnostic, palliative or curative surgery for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Sci Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma in western Glasgow 1980-6.
</td>
<td style="text-align:left;">
Thorax
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesotheliomas in Lebanon: Witnessing a Change in Epidemiology.
</td>
<td style="text-align:left;">
Asian Pac. J. Cancer Prev.
</td>
</tr>
<tr>
<td style="text-align:left;">
Serum mesothelin, osteopontin and vimentin: useful markers for clinical monitoring of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Biol. Markers
</td>
</tr>
<tr>
<td style="text-align:left;">
The NLRP3 inflammasome in pathogenic particle and fibre-associated lung inflammation and diseases.
</td>
<td style="text-align:left;">
Part Fibre Toxicol
</td>
</tr>
<tr>
<td style="text-align:left;">
Intensity-modulated radiotherapy for relapsed malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Future Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Detection of malignant pleural mesothelioma in exhaled breath by multicapillary column/ion mobility spectrometry (MCC/IMS).
</td>
<td style="text-align:left;">
J Breath Res
</td>
</tr>
<tr>
<td style="text-align:left;">
The IASLC Mesothelioma Staging Project: Improving Staging of a Rare Disease Through International Participation.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma in South Africa, 1976-84: incidence and case characteristics.
</td>
<td style="text-align:left;">
Int J Epidemiol
</td>
</tr>
<tr>
<td style="text-align:left;">
Geographical patterns of mesothelioma incidence and asbestos exposure in Lombardy, Italy.
</td>
<td style="text-align:left;">
Med Lav
</td>
</tr>
<tr>
<td style="text-align:left;">
Patient-Derived Xenograft Establishment from Human Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
The IASLC Mesothelioma Staging Project: Proposals for Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
The IASLC Mesothelioma Staging Project: Proposals for Revisions of the N Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Screening of Pleural Mesotheliomas for DNA-damage Repair Players by Digital Gene Expression Analysis Can Enhance Clinical Management of Patients Receiving Platin-Based Chemotherapy.
</td>
<td style="text-align:left;">
J Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Rare presentation of a localised malignant pleural mesothelioma with cranial metastasis.
</td>
<td style="text-align:left;">
BMJ Case Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
Five years update on relationships between malignant pleural mesothelioma and exposure to asbestos and other elongated mineral particles.
</td>
<td style="text-align:left;">
J Toxicol Environ Health B Crit Rev
</td>
</tr>
<tr>
<td style="text-align:left;">
Tyler asbestos workers: A mortality update in a cohort exposed to amosite.
</td>
<td style="text-align:left;">
J Toxicol Environ Health B Crit Rev
</td>
</tr>
<tr>
<td style="text-align:left;">
Epithelioid peritoneal mesothelioma: a hybrid phenotype within a mesenchymal-epithelial/epithelial-mesenchymal transition framework.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
Glycodelin is a potential novel follow-up biomarker for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
Pulmonary tumor diagnosed as an undifferentiated sarcoma with epithelioid features: a case report.
</td>
<td style="text-align:left;">
J Med Case Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
Systemically Administered RNAi Molecule Sensitizes Malignant Pleural Mesotheliomal Cells to Pemetrexed Therapy.
</td>
<td style="text-align:left;">
Mol. Pharm.
</td>
</tr>
<tr>
<td style="text-align:left;">
Management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Thorac Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: A retrospective analysis of clinicopathological and survival data.
</td>
<td style="text-align:left;">
Thorac Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Amount of Epithelioid Differentiation Is a Predictor of Survival in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic value of fibulin-3 for malignant pleural mesothelioma: A systematic review and meta-analysis.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Current best practice in the evaluation and management of malignant pleural effusions.
</td>
<td style="text-align:left;">
Ther Adv Respir Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Calretinin but not caveolin-1 correlates with tumour histology and survival in malignant mesothelioma.
</td>
<td style="text-align:left;">
Pathology
</td>
</tr>
<tr>
<td style="text-align:left;">
Vascular endothelial growth factor promoter-based conditionally replicative adenoviruses effectively suppress growth of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Sci.
</td>
</tr>
<tr>
<td style="text-align:left;">
Tamoxifen Suppresses the Growth of Malignant Pleural Mesothelioma Cells.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Imaging in pleural mesothelioma: A review of the 13th International Conference of the International Mesothelioma Interest Group.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Myxoid variant epithelioid pleural mesothelioma defines a favourable prognosis group: an analysis of 191 patients with pleural malignant mesothelioma.
</td>
<td style="text-align:left;">
J. Clin. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Sarcomatoid Type Primary Pericardial Mesothelioma with a Long-term Survival after the Onset of Cardiac Tamponade.
</td>
<td style="text-align:left;">
Intern. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
In Vitro and In Vivo Antitumor Activity of [Pt(O,O’-acac)(γ-acac)(DMS)] in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
</tr>
<tr>
<td style="text-align:left;">
Genomic profiling of malignant peritoneal mesothelioma reveals recurrent alterations in epigenetic regulatory genes BAP1, SETD2, and DDX3X.
</td>
<td style="text-align:left;">
Mod. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Update on epidemiology, pathophysiology, diagnosis and treatment of malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Rev Med Inst Mex Seguro Soc
</td>
</tr>
<tr>
<td style="text-align:left;">
Residual fibre lung burden among patients with pleural mesothelioma who have been occupationally exposed to asbestos.
</td>
<td style="text-align:left;">
Occup Environ Med
</td>
</tr>
<tr>
<td style="text-align:left;">
The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?
</td>
<td style="text-align:left;">
Crit. Rev. Oncol. Hematol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Intrapleural Adenoviral-mediated Endothelial Cell Protein C Receptor Gene Transfer Suppresses the Progression of Malignant Pleural Mesothelioma in a Mouse Model.
</td>
<td style="text-align:left;">
Sci Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma and mesothelial hyperplasia: A new molecular tool for the differential diagnosis.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
SORORIN and PLK1 as potential therapeutic targets in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
3D Mass Spectrometry Imaging Reveals a Very Heterogeneous Drug Distribution in Tumors.
</td>
<td style="text-align:left;">
Sci Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
FAS and FASL genetic polymorphisms impact on clinical outcome of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Onco Targets Ther
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytotoxic T Cells in PD-L1-Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors.
</td>
<td style="text-align:left;">
Cancer Immunol Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Lysis of human malignant mesothelioma cells by natural killer (NK) and lymphokine-activated killer (LAK) cells.
</td>
<td style="text-align:left;">
Am. Rev. Respir. Dis.
</td>
</tr>
<tr>
<td style="text-align:left;">
Trametinib plus 4-Methylumbelliferone Exhibits Antitumor Effects by ERK Blockade and CD44 Downregulation and Affects PD-1 and PD-L1 in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Accelerated cell cycle progression of human regulatory T cell-like cell line caused by continuous exposure to asbestos fibers.
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic Utility of Pleural Fluid Cell Block versus Pleural Biopsy Collected by Flex-Rigid Pleuroscopy for Malignant Pleural Disease: A Single Center Retrospective Analysis.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
</tr>
<tr>
<td style="text-align:left;">
Elevated aspartate aminotransferase and monocyte counts predict unfavorable prognosis in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Neoplasma
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic and Prognostic Biomarkers in the Rational Assessment of Mesothelioma (DIAPHRAGM) study: protocol of a prospective, multicentre, observational study.
</td>
<td style="text-align:left;">
BMJ Open
</td>
</tr>
<tr>
<td style="text-align:left;">
Indomethacin augments lymphokine-activated killer cell generation by patients with malignant mesothelioma.
</td>
<td style="text-align:left;">
Clin. Immunol. Immunopathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Primary malignant pericardial mesothelioma with increased serum mesothelin diagnosed by surgical pericardial resection: A case report.
</td>
<td style="text-align:left;">
Mol Clin Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment.
</td>
<td style="text-align:left;">
Eur Respir Rev
</td>
</tr>
<tr>
<td style="text-align:left;">
Giant primary malignant mesothelioma of the liver: A case report.
</td>
<td style="text-align:left;">
Int J Surg Case Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
Serum-dependent growth patterns of two, newly established human mesothelioma cell lines.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Disease mapping of zero-excessive mesothelioma data in Flanders.
</td>
<td style="text-align:left;">
Ann Epidemiol
</td>
</tr>
<tr>
<td style="text-align:left;">
A Comparison of Singlet Oxygen Explicit Dosimetry (SOED) and Singlet Oxygen Luminescence Dosimetry (SOLD) for Photofrin-Mediated Photodynamic Therapy.
</td>
<td style="text-align:left;">
Cancers (Basel)
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of surgical intervention in lung cancer with carcinomatous pleuritis.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Open access phone triage for veterans with suspected malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Surg. Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Percutaneous Cryoablation for the Treatment of Recurrent Malignant Pleural Mesothelioma: Safety, Early-Term Efficacy, and Predictors of Local Recurrence.
</td>
<td style="text-align:left;">
J Vasc Interv Radiol
</td>
</tr>
<tr>
<td style="text-align:left;">
Loss of BRCA1-associated protein 1 (BAP1) expression is rare in non-small cell lung cancer.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Signal Transducer and Activator of Transcription 1 (STAT1) Knock-down Induces Apoptosis in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Pathol. Oncol. Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Minimal change disease associated with malignant pleural mesothelioma: case report and review of the literature.
</td>
<td style="text-align:left;">
BMJ Case Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
Advances in pleuroscopy.
</td>
<td style="text-align:left;">
Clin Respir J
</td>
</tr>
<tr>
<td style="text-align:left;">
Co-occurring Mutations of Tumor Suppressor Genes, <i>LATS2</i> and <i>NF2</i>, in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pericardial Effusion due to Primary Malignant Pericardial Mesothelioma: A Common Finding but an Uncommon Cause.
</td>
<td style="text-align:left;">
Case Rep Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant Mesothelioma Biomarkers: From Discovery to Use in Clinical Practice for Diagnosis, Monitoring, Screening, and Treatment.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Improving the Accuracy of Mesothelioma Diagnosis in China.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
The importance of EZH2 and MOC-31 expression in the differential diagnosis of benign and malignant effusions.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
The diagnostic performance of routinely acquired and reported computed tomography imaging in patients presenting with suspected pleural malignancy.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Incidence of malignant mesothelioma in Germany 2009-2013.
</td>
<td style="text-align:left;">
Cancer Causes Control
</td>
</tr>
<tr>
<td style="text-align:left;">
Deciduoid mesothelioma of the thorax: A comprehensive review of the scientific literature.
</td>
<td style="text-align:left;">
Clin Respir J
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic value of pretreatment volume-based quantitative <sup>18</sup>F-FDG PET/CT parameters in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Radiol
</td>
</tr>
<tr>
<td style="text-align:left;">
Metabolic response assessment with 18F-FDG-PET/CT is superior to modified RECIST for the evaluation of response to platinum-based doublet chemotherapy in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Radiol
</td>
</tr>
<tr>
<td style="text-align:left;">
Computer-aided volumetric assessment of malignant pleural mesothelioma on CT using a random walk-based method.
</td>
<td style="text-align:left;">
Int J Comput Assist Radiol Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
BAP1 Is Altered by Copy Number Loss, Mutation, and/or Loss of Protein Expression in More Than 70% of Malignant Peritoneal Mesotheliomas.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Chromosomal abnormalities and their correlations with asbestos exposure and survival in patients with mesothelioma.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Immune Checkpoints Aberrations and Malignant Mesothelioma: Assessment of Prognostic Value and Evaluation of Therapeutic Potentials.
</td>
<td style="text-align:left;">
Anticancer Agents Med Chem
</td>
</tr>
<tr>
<td style="text-align:left;">
Role of postoperative radiotherapy in the management of malignant pleural mesothelioma : A propensity score matching of the SEER database.
</td>
<td style="text-align:left;">
Strahlenther Onkol
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural Mesothelioma with No Asbestos Exposure: A Case Report.
</td>
<td style="text-align:left;">
J Clin Diagn Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Turning back the Wheel: Inducing Mesenchymal to Epithelial Transition via Wilms Tumor 1 Knockdown in Human Mesothelioma Cell Lines to Influence Proliferation, Invasiveness, and Chemotaxis.
</td>
<td style="text-align:left;">
Pathol. Oncol. Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Flex-rigid pleuroscopic biopsy with the SB knife Jr is a novel technique for diagnosis of malignant or benign fibrothorax.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Blockage of epithelial to mesenchymal transition and upregulation of let 7b are critically involved in ursolic acid induced apoptosis in malignant mesothelioma cell.
</td>
<td style="text-align:left;">
Int. J. Biol. Sci.
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic and prognostic utilities of humoral fibulin-3 in malignant pleural mesothelioma: Evidence from a meta-analysis.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
[Prognostic factors in cases of diffuse malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Nihon Kyobu Shikkan Gakkai Zasshi
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural fluid cytology samples in cases of suspected lung cancer: An experience from a tertiary care centre.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Long-term outcomes of intensity-modulated radiotherapy following extra-pleural pneumonectomy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Acta Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
MUC4, a novel immunohistochemical marker identified by gene expression profiling, differentiates pleural sarcomatoid mesothelioma from lung sarcomatoid carcinoma.
</td>
<td style="text-align:left;">
Mod. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pericardial mesothelioma : A systematic review of current practice.
</td>
<td style="text-align:left;">
Herz
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant Pleural Mesothelioma with Excessive Inflammation and High Level of Interleukin 6 - A Case Report].
</td>
<td style="text-align:left;">
Gan To Kagaku Ryoho
</td>
</tr>
<tr>
<td style="text-align:left;">
A Single-Institution Experience in Percutaneous Image-Guided Biopsy of Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Cardiovasc Intervent Radiol
</td>
</tr>
<tr>
<td style="text-align:left;">
Geographic and socioeconomic factors in patients with malignant pleural mesothelioma in New South Wales and their impact upon clinical outcomes.
</td>
<td style="text-align:left;">
Respirology
</td>
</tr>
<tr>
<td style="text-align:left;">
Tissue transglutaminase (TG2) enables survival of human malignant pleural mesothelioma cells in hypoxia.
</td>
<td style="text-align:left;">
Cell Death Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Stent Implantation for Superior Vena Cava Syndrome of Malignant Cause.
</td>
<td style="text-align:left;">
Rofo
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed-related interstitial lung disease reported from post marketing surveillance (malignant pleural mesothelioma/non-small cell lung cancer).
</td>
<td style="text-align:left;">
Jpn. J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostication and monitoring of mesothelioma using biomarkers: a systematic review.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
[Further comment on mesotheliomas].
</td>
<td style="text-align:left;">
Arkh. Patol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Podoplanin promotes progression of malignant pleural mesothelioma by regulating motility and focus formation.
</td>
<td style="text-align:left;">
Cancer Sci.
</td>
</tr>
<tr>
<td style="text-align:left;">
Switching off malignant mesothelioma: exploiting the hypoxic microenvironment.
</td>
<td style="text-align:left;">
Genes Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Unusual pleural effusion from vulvar squamous cell carcinoma: report of a case and review of the literature.
</td>
<td style="text-align:left;">
Pathologica
</td>
</tr>
<tr>
<td style="text-align:left;">
Comparison of outcomes following a cytological or histological diagnosis of malignant mesothelioma.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncoimmunology
</td>
</tr>
<tr>
<td style="text-align:left;">
Kdm6a and Kdm6b: Altered expression in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
A phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: The Ontario Clinical Oncology Group.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Pharmacokinetic evaluation of intrapleural perfusion with hyperthermic chemotherapy using cisplatin in patients with malignant pleural effusion.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: Comparison with 9p21 FISH and BAP1 immunohistochemistry.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical outcomes and prognostic factors of patients with advanced mesothelioma treated in a phase I clinical trials unit.
</td>
<td style="text-align:left;">
Eur. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Intracavitary ‘T4 immunotherapy’ of malignant mesothelioma using pan-ErbB re-targeted CAR T-cells.
</td>
<td style="text-align:left;">
Cancer Lett.
</td>
</tr>
<tr>
<td style="text-align:left;">
Radiation therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Radiother
</td>
</tr>
<tr>
<td style="text-align:left;">
Aberrant Cytokeratin 20 Reactivity in Epithelioid Malignant Mesothelioma: A Case Report.
</td>
<td style="text-align:left;">
Appl. Immunohistochem. Mol. Morphol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Real-time light dosimetry for intra-cavity photodynamic therapy: Application for pleural mesothelioma treatment.
</td>
<td style="text-align:left;">
Photodiagnosis Photodyn Ther
</td>
</tr>
<tr>
<td style="text-align:left;">
The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioid reaction following talc pleurodesis: a case report.
</td>
<td style="text-align:left;">
Gen Thorac Cardiovasc Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Is less also better? A single-institution experience on treatment of early stage Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Eur J Surg Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
The Controlling Nutritional Status Score Is a Significant Independent Predictor of Poor Prognosis in Patients With Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.
</td>
<td style="text-align:left;">
Lancet Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Physical function and health-related quality of life in patients undergoing surgical treatment for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Support Care Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Impact of tumour thickness on survival after radical radiation and surgery in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
</tr>
<tr>
<td style="text-align:left;">
Comparison of the Diagnostic Performance of Fibulin-3 and Mesothelin in Patients with Pleural Effusions from Malignant Mesothelioma.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Combinational therapy of crizotinib and afatinib for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Am J Cancer Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Improved Outcomes with Modern Lung-Sparing Trimodality Therapy in Patients with Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Targeting BAP1: a new paradigm for mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelin promoter variants are associated with increased soluble mesothelin-related peptide levels in asbestos-exposed individuals.
</td>
<td style="text-align:left;">
Occup Environ Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Integrated analysis of somatic mutations and immune microenvironment in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncoimmunology
</td>
</tr>
<tr>
<td style="text-align:left;">
A Novel Panel of Serum Biomarkers for MPM Diagnosis.
</td>
<td style="text-align:left;">
Dis. Markers
</td>
</tr>
<tr>
<td style="text-align:left;">
Serum HMGB1 as a Potential Biomarker for Patients with Asbestos-Related Diseases.
</td>
<td style="text-align:left;">
Dis. Markers
</td>
</tr>
<tr>
<td style="text-align:left;">
A second case of pericardial mesothelioma mimicking systemic lupus erythematosus in the literature in over 30 years: a case report.
</td>
<td style="text-align:left;">
J Med Case Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
Transcriptomic Analysis of the Claudin Interactome in Malignant Pleural Mesothelioma: Evaluation of the Effect of Disease Phenotype, Asbestos Exposure, and CDKN2A Deletion Status.
</td>
<td style="text-align:left;">
Front Physiol
</td>
</tr>
<tr>
<td style="text-align:left;">
A Proteomic Analysis of the Malignant Mesothelioma Secretome Using iTRAQ.
</td>
<td style="text-align:left;">
Cancer Genomics Proteomics
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic Cancers.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
A Novel BRCA1-Associated Protein-1 Isoform Affects Response of Mesothelioma Cells to Drugs Impairing BRCA1-Mediated DNA Repair.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Experimental lung tumors following specific intrabronchial application of chrysotile asbestos. Longitudinal light and electron microscopic investigations in rats.
</td>
<td style="text-align:left;">
Respiration
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: single-institution experience of 101 patients over a 15-year period.
</td>
<td style="text-align:left;">
Acta Chir. Belg.
</td>
</tr>
<tr>
<td style="text-align:left;">
CD44 and its ligand hyaluronan as potential biomarkers in malignant pleural mesothelioma: evidence and perspectives.
</td>
<td style="text-align:left;">
Respir. Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural malignant mesothelioma in dental laboratory technicians: A case series.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Epidemiology of Environmental Exposure and Malignant Mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Three-dimensional finite-element based deformable image registration for evaluation of pleural cavity irradiation during photodynamic therapy.
</td>
<td style="text-align:left;">
Med Phys
</td>
</tr>
<tr>
<td style="text-align:left;">
Prophylactic radiotherapy for procedure tract metastases in mesothelioma: a review.
</td>
<td style="text-align:left;">
Curr Opin Pulm Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Can CT and MR Shape and Textural Features Differentiate Benign Versus Malignant Pleural Lesions?
</td>
<td style="text-align:left;">
Acad Radiol
</td>
</tr>
<tr>
<td style="text-align:left;">
Inhibition of the platelet-derived growth factor receptor beta (PDGFRB) using gene silencing, crenolanib besylate, or imatinib mesylate hampers the malignant phenotype of mesothelioma cell lines.
</td>
<td style="text-align:left;">
Genes Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Mortality from cancer and other causes among Italian chrysotile asbestos miners.
</td>
<td style="text-align:left;">
Occup Environ Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Comprehensive immunohistochemical study of mesothelin (MSLN) using different monoclonal antibodies 5B2 and MN-1 in 1562 tumors with evaluation of its prognostic value in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
Growth suppressive effect of pegylated arginase in malignant pleural mesothelioma xenografts.
</td>
<td style="text-align:left;">
Respir. Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
miRNA regulation is important for DNA damage repair and recognition in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Virchows Arch.
</td>
</tr>
<tr>
<td style="text-align:left;">
Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses <i>NF2</i> Loss-Driven Tumorigenesis.
</td>
<td style="text-align:left;">
Mol. Cancer Ther.
</td>
</tr>
<tr>
<td style="text-align:left;">
Significant Clinical Benefit of Pemetrexed-based Chemotherapy for Advanced Diffuse Malignant Peritoneal Mesothelioma: A Case Presentation.
</td>
<td style="text-align:left;">
Indian J Med Paediatr Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Plasmatic extracellular vesicle microRNAs in malignant pleural mesothelioma and asbestos-exposed subjects suggest a 2-miRNA signature as potential biomarker of disease.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical Features and Treatment Outcome of Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Oncol Res Treat
</td>
</tr>
<tr>
<td style="text-align:left;">
Spontaneous massive hemopneumothorax: Double trouble with a twist.
</td>
<td style="text-align:left;">
Lung India
</td>
</tr>
<tr>
<td style="text-align:left;">
BAP1 mutations in high-grade meningioma: implications for patient care.
</td>
<td style="text-align:left;">
Neuro-oncology
</td>
</tr>
<tr>
<td style="text-align:left;">
Successful lung-sparing resection of synchronous pleural mesothelioma and contralateral lung cancer.
</td>
<td style="text-align:left;">
Surg Case Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
Induction of IL-17 production from human peripheral blood CD4+ cells by asbestos exposure.
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Dose-time-response association between occupational asbestos exposure and pleural mesothelioma.
</td>
<td style="text-align:left;">
Occup Environ Med
</td>
</tr>
<tr>
<td style="text-align:left;">
CAR T-cell therapy for lung cancer and malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Transl Res
</td>
</tr>
<tr>
<td style="text-align:left;">
A Subset of Malignant Mesotheliomas in Young Adults Are Associated With Recurrent EWSR1/FUS-ATF1 Fusions.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
SU-E-T-595: Comparison of Volumetric Modulated Arc Therapy (VMAT) and Static Intensity Modulated Radiotherapy (IMRT) for Malignant Pleural Mesothelioma in Patients with Intact Lungs/Post Pleurectomy.
</td>
<td style="text-align:left;">
Med Phys
</td>
</tr>
<tr>
<td style="text-align:left;">
Epidemiology of mesothelioma of the pericardium and tunica vaginalis testis.
</td>
<td style="text-align:left;">
Ann Epidemiol
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunotherapy and radiation therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Viroimmunotherapy of Thoracic Cancers.
</td>
<td style="text-align:left;">
Biomedicines
</td>
</tr>
<tr>
<td style="text-align:left;">
The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells.
</td>
<td style="text-align:left;">
Stem Cell Res Ther
</td>
</tr>
<tr>
<td style="text-align:left;">
Calretinin as a blood-based biomarker for mesothelioma.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Unusual Contiguous Soft Tissue Spread of Advanced Malignant Mesothelioma Detected by FDG PET/CT.
</td>
<td style="text-align:left;">
Nucl Med Mol Imaging
</td>
</tr>
<tr>
<td style="text-align:left;">
DCLK1 is correlated with MET and ERK5 expression, and associated with prognosis in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
Improved diagnosis and prognostication of patients with pleural malignant mesothelioma using biomarkers in pleural effusions and peripheral blood samples - a short report.
</td>
<td style="text-align:left;">
Cell Oncol (Dordr)
</td>
</tr>
<tr>
<td style="text-align:left;">
Whole exome sequencing of an asbestos-induced wild-type murine model of malignant mesothelioma.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Induction chemotherapy vs post-operative adjuvant therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Expert Rev Respir Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgery as part of radical treatment for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Curr Opin Pulm Med
</td>
</tr>
<tr>
<td style="text-align:left;">
First-line chemotherapy with pemetrexed plus cisplatin for malignant peritoneal mesothelioma.
</td>
<td style="text-align:left;">
Expert Rev Anticancer Ther
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG S0905).
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Posttranscriptional Regulation Controls Calretinin Expression in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Front Genet
</td>
</tr>
<tr>
<td style="text-align:left;">
Tissue-specific significance of BAP1 gene mutation in prognostic prediction and molecular taxonomy among different types of cancer.
</td>
<td style="text-align:left;">
Tumour Biol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
A pilot study of zoledronic acid in the treatment of patients with advanced malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer (Auckl)
</td>
</tr>
<tr>
<td style="text-align:left;">
Predicting Malignant and Paramalignant Pleural Effusions by Combining Clinical, Radiological and Pleural Fluid Analytical Parameters.
</td>
<td style="text-align:left;">
Lung
</td>
</tr>
<tr>
<td style="text-align:left;">
JQ1, a BET Inhibitor, Synergizes with Cisplatin and Induces Apoptosis in Highly Chemoresistant Malignant Pleural Mesothelioma Cells.
</td>
<td style="text-align:left;">
Curr Cancer Drug Targets
</td>
</tr>
<tr>
<td style="text-align:left;">
Association Between Clinicopathological Factors and Genomic Abnormalities Detected by FISH Analysis in Epithelioid Diffuse Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Surg. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Cost-effectiveness analysis of additional bevacizumab to pemetrexed plus cisplatin for malignant pleural mesothelioma based on the MAPS trial.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma.
</td>
<td style="text-align:left;">
Expert Opin Investig Drugs
</td>
</tr>
<tr>
<td style="text-align:left;">
Risk Factors of Mortality from All Asbestos-Related Diseases: A Competing Risk Analysis.
</td>
<td style="text-align:left;">
Can. Respir. J.
</td>
</tr>
<tr>
<td style="text-align:left;">
Germline mutations in DNA repair genes predispose asbestos-exposed patients to malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Lett.
</td>
</tr>
<tr>
<td style="text-align:left;">
Apoptosis by [Pt(O,O’-acac)(γ-acac)(DMS)] requires PKC-δ mediated p53 activation in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
</tr>
<tr>
<td style="text-align:left;">
The impact of surgical approach on quality of life for pleural malignant mesothelioma.
</td>
<td style="text-align:left;">
Ann Transl Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Intra-abdominal manifestations of pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann Transl Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant peritoneal mesothelioma: a review.
</td>
<td style="text-align:left;">
Ann Transl Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Randomized controlled trials in malignant pleural mesothelioma surgery-mistakes made and lessons learned.
</td>
<td style="text-align:left;">
Ann Transl Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Volumetric assessment in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann Transl Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: predictors and staging.
</td>
<td style="text-align:left;">
Ann Transl Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnosis and prognosis-review of biomarkers for mesothelioma.
</td>
<td style="text-align:left;">
Ann Transl Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Novel immunotherapy clinical trials in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann Transl Med
</td>
</tr>
<tr>
<td style="text-align:left;">
<i>In vitro</i> experimental models of mesothelioma revisited.
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Intraoperative near-infrared imaging of mesothelioma.
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Intraoperative adjuncts for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunotherapy for malignant pleural mesothelioma: current status and future directions.
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Radio-immunotherapy and chemo-immunotherapy as a novel treatment paradigm in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Drug development against the hippo pathway in mesothelioma.
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Targeting the epigenome in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Can malignant and inflammatory pleural effusions in dogs be distinguished using computed tomography?
</td>
<td style="text-align:left;">
Vet Radiol Ultrasound
</td>
</tr>
<tr>
<td style="text-align:left;">
Tumor suppressor candidate 2 (TUSC2, FUS-1) and human cancers.
</td>
<td style="text-align:left;">
Discov Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.
</td>
<td style="text-align:left;">
Lancet Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
The Drive For Self-Assertion And The Reality Principle In A Patient With Malignant Pleural Mesothelioma: The History of Giulia.
</td>
<td style="text-align:left;">
Am J Psychoanal
</td>
</tr>
<tr>
<td style="text-align:left;">
Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition.
</td>
<td style="text-align:left;">
Cancer Chemother. Pharmacol.
</td>
</tr>
<tr>
<td style="text-align:left;">
TRANSTHORACIC FINE NEEDLE ASPIRATION CYTOLOGY IN DIAGNOSING NON-RESOLVING PNEUMONIAS - A STUDY OF 170 CASES.
</td>
<td style="text-align:left;">
Med J Armed Forces India
</td>
</tr>
<tr>
<td style="text-align:left;">
Italian pool of asbestos workers cohorts: mortality trends of asbestos-related neoplasms after long time since first exposure.
</td>
<td style="text-align:left;">
Occup Environ Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic value of medical thoracoscopy in malignant pleural effusion.
</td>
<td style="text-align:left;">
BMC Pulm Med
</td>
</tr>
<tr>
<td style="text-align:left;">
The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell/pleomorphic (sarcomatoid) carcinomas of the lung: evidence-based guidelines from the International Mesothelioma Panel and the MESOPATH National Reference Center.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma segmentation for photodynamic therapy planning.
</td>
<td style="text-align:left;">
Comput Med Imaging Graph
</td>
</tr>
<tr>
<td style="text-align:left;">
Isolated thoracic perfusion with chemofiltration for progressive malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Onco Targets Ther
</td>
</tr>
<tr>
<td style="text-align:left;">
[Clinical and pathologic features of extrapleural sarcomatoid mesothelioma].
</td>
<td style="text-align:left;">
Zhonghua Bing Li Xue Za Zhi
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Heart Dosimetry is Correlated With Risk of Radiation Pneumonitis After Lung-Sparing Hemithoracic Pleural Intensity Modulated Radiation Therapy for Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Radiat. Oncol. Biol. Phys.
</td>
</tr>
<tr>
<td style="text-align:left;">
Long-Term Survival Outcomes of Cancer-Directed Surgery for Malignant Pleural Mesothelioma: Propensity Score Matching Analysis.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Estimated future incidence of malignant mesothelioma in South Korea: Projection from 2014 to 2033.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant Deciduoid Mesothelioma: case presentation of an exceptional variant and review of the literature.
</td>
<td style="text-align:left;">
BMC Clin Pathol
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma - Pleural cavity irradiation after decortication with helical tomotherapy.
</td>
<td style="text-align:left;">
Rep Pract Oncol Radiother
</td>
</tr>
<tr>
<td style="text-align:left;">
Pathological complete response in malignant pleural mesothelioma patients following induction chemotherapy: Predictive factors and outcomes.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Survival in Good Performance Malignant Pleural Mesothelioma Patients; Prognostic Factors and Predictors of Response
</td>
<td style="text-align:left;">
Asian Pac. J. Cancer Prev.
</td>
</tr>
<tr>
<td style="text-align:left;">
National Cancer Database Report on Pneumonectomy Versus Lung-Sparing Surgery for Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic Imaging and workup of Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Acta Biomed
</td>
</tr>
<tr>
<td style="text-align:left;">
Migrating pleural plaque in a patient with asbestos induced pleural disease: a case report.
</td>
<td style="text-align:left;">
J Occup Med Toxicol
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical staging of malignant pleural mesothelioma: current perspectives.
</td>
<td style="text-align:left;">
Lung Cancer (Auckl)
</td>
</tr>
<tr>
<td style="text-align:left;">
Chimeric Antigen Receptor (CAR) T Cell Therapy for Malignant Pleural Mesothelioma (MPM).
</td>
<td style="text-align:left;">
Cancers (Basel)
</td>
</tr>
<tr>
<td style="text-align:left;">
Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study.
</td>
<td style="text-align:left;">
Lancet Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Biomarkers for early diagnosis of malignant mesothelioma: Do we need another moonshot?
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
Oncolytic Viral Therapy for Mesothelioma.
</td>
<td style="text-align:left;">
Front Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Radiotherapy for the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lancet Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinicopathologic and genetic characteristics of young patients with pleural diffuse malignant mesothelioma.
</td>
<td style="text-align:left;">
Mod. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Secondary hypertrophic osteoarthropathy caused by non-pleural or pulmonary tumors.
</td>
<td style="text-align:left;">
Medicine (Baltimore)
</td>
</tr>
<tr>
<td style="text-align:left;">
Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Identification of ALK Rearrangements in Malignant Peritoneal Mesothelioma.
</td>
<td style="text-align:left;">
JAMA Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic significance of neutrophil-to-lymphocyte ratio in patients with malignant pleural mesothelioma: a meta-analysis.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
Role of new radiation techniques in the treatment of pleural mesothelioma.
</td>
<td style="text-align:left;">
Thorac Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical and biologic prognostic factors in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Thorac Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment for recurrence after extrapleural pneumonectomy for malignant pleural mesothelioma: A single institution experience.
</td>
<td style="text-align:left;">
Thorac Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
The value of delayed phase enhanced imaging in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Non-occupational exposure to asbestos and risk of pleural mesothelioma: review and meta-analysis.
</td>
<td style="text-align:left;">
Occup Environ Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Role of proton-coupled folate transporter in pemetrexed resistance of mesothelioma: clinical evidence and new pharmacological tools.
</td>
<td style="text-align:left;">
Ann. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Influence of Pleurectomy and Decortication in Health-Related Quality of Life Among Patients with Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
World J Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
A Case Report of Primary Pericardial Malignant Mesothelioma Treated with Pemetrexed and Cisplatin.
</td>
<td style="text-align:left;">
J. Korean Med. Sci.
</td>
</tr>
<tr>
<td style="text-align:left;">
Soluble Mesothelin-Related Peptides to Monitor Recurrence After Resection of Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural effusion biomarkers and computed tomography findings in diagnosing malignant pleural mesothelioma: A retrospective study in a single center.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
</tr>
<tr>
<td style="text-align:left;">
A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analogue Peptide Vaccine, After Multimodality Therapy for Patients with Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Downregulation of miR-99a/let-7c/miR-125b miRNA cluster predicts clinical outcome in patients with unresected malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
[Mesothelioma].
</td>
<td style="text-align:left;">
Pathologe
</td>
</tr>
<tr>
<td style="text-align:left;">
Evidence Suggesting the End of Universal Domestic Asbestos Exposure in Metsovo, NW Greece.
</td>
<td style="text-align:left;">
Respiration
</td>
</tr>
<tr>
<td style="text-align:left;">
Application of 3D Mass Spectrometry Imaging to TKIs.
</td>
<td style="text-align:left;">
Clin. Pharmacol. Ther.
</td>
</tr>
<tr>
<td style="text-align:left;">
Estimating past inhalation exposure to asbestos: A tool for risk attribution and disease screening.
</td>
<td style="text-align:left;">
Int J Hyg Environ Health
</td>
</tr>
<tr>
<td style="text-align:left;">
Carcinogenicity of multi-walled carbon nanotubes: challenging issue on hazard assessment.
</td>
<td style="text-align:left;">
J Occup Health
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunohistochemistry in Peritoneal Mesothelioma: A Single-Center Experience of 244 Cases.
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Extended pleurectomy decortication for malignant pleural mesothelioma in the elderly: the need for an inclusive yet selective approach.
</td>
<td style="text-align:left;">
Interact Cardiovasc Thorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
[Loss of BRCA associated protein 1 expression in malignant mesothelioma and its diagnostic application].
</td>
<td style="text-align:left;">
Zhonghua Bing Li Xue Za Zhi
</td>
</tr>
<tr>
<td style="text-align:left;">
The revised staging system for malignant pleural mesothelioma based on surveillance, epidemiology, and end results database.
</td>
<td style="text-align:left;">
Int J Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Comprehensive Pharmacogenomic Profiling of Malignant Pleural Mesothelioma Identifies a Subgroup Sensitive to FGFR Inhibition.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemical Profiling of Primary Mesothelioma Cultures Defines Subtypes with Different Expression Profiles and Clinical Responses.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Turkey National Mesothelioma Surveillance and Environmental Asbestos Exposure Control Program.
</td>
<td style="text-align:left;">
Int J Environ Res Public Health
</td>
</tr>
<tr>
<td style="text-align:left;">
An Overview of Asbestos and Malignant Pleural Mesothelioma: An Iranian Perspective
</td>
<td style="text-align:left;">
Asian Pac. J. Cancer Prev.
</td>
</tr>
<tr>
<td style="text-align:left;">
Loss of BAP1 Expression in Atypical Mesothelial Proliferations Helps to Predict Malignant Mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Role of thoracoscopy, mediastinoscopy and laparoscopy in the diagnosis and staging of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Vis Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Video assisted thoracoscopic and open chest surgery in diagnosis and treatment of malignant pleural diseases.
</td>
<td style="text-align:left;">
J Vis Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Retrospective study of hypersensitivity reactions to chemotherapeutic agents in a thoracic oncology service.
</td>
<td style="text-align:left;">
J Clin Pharm Ther
</td>
</tr>
<tr>
<td style="text-align:left;">
PD-L1 expression associated with worse survival outcome in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Asia Pac J Clin Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Chimeric Antigen Receptor (CAR) T-Cell Therapy for Thoracic Malignancies.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
External validation of prognostic indices for overall survival of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgical and non-surgical management of malignant pleural effusions.
</td>
<td style="text-align:left;">
Expert Rev Respir Med
</td>
</tr>
<tr>
<td style="text-align:left;">
4EGI-1 represses cap-dependent translation and regulates genome-wide translation in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Invest New Drugs
</td>
</tr>
<tr>
<td style="text-align:left;">
The promise and challenges of exploiting the proton-coupled folate transporter for selective therapeutic targeting of cancer.
</td>
<td style="text-align:left;">
Cancer Chemother. Pharmacol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Prophylactic radiotherapy in a single fraction of 10Gy at intervention pleural site in patient with malignant pleural mesothelioma: A retrospective monocentric cohort study].
</td>
<td style="text-align:left;">
Cancer Radiother
</td>
</tr>
<tr>
<td style="text-align:left;">
High dose irradiation after pleurectomy/decortication or biopsy for pleural mesothelioma treatment.
</td>
<td style="text-align:left;">
Cancer Radiother
</td>
</tr>
<tr>
<td style="text-align:left;">
<i>Ex vivo</i> evaluation of tumor cell specific drug responses in malignant pleural effusions.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
Matrix Metalloproteinases Polymorphisms as Prognostic Biomarkers in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Dis. Markers
</td>
</tr>
<tr>
<td style="text-align:left;">
Efficacy of Cell-Free and Concentrated Ascites Reinfusion Therapy for Palliative Care in a Patient with Malignant Pleural Mesothelioma: A Case Report.
</td>
<td style="text-align:left;">
J Nippon Med Sch
</td>
</tr>
<tr>
<td style="text-align:left;">
Temporal and spatial heterogeneity of programmed cell death 1-Ligand 1 expression in malignant mesothelioma.
</td>
<td style="text-align:left;">
Oncoimmunology
</td>
</tr>
<tr>
<td style="text-align:left;">
The analysis of novel microRNA mimic sequences in cancer cells reveals lack of specificity in stem-loop RT-qPCR-based microRNA detection.
</td>
<td style="text-align:left;">
BMC Res Notes
</td>
</tr>
<tr>
<td style="text-align:left;">
Proton Therapy for Malignant Pleural Mesothelioma: A Three Case Series Describing the Clinical and Dosimetric Advantages of Proton-Based Therapy.
</td>
<td style="text-align:left;">
Cureus
</td>
</tr>
<tr>
<td style="text-align:left;">
Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
Effect of an Indwelling Pleural Catheter vs Talc Pleurodesis on Hospitalization Days in Patients With Malignant Pleural Effusion: The AMPLE Randomized Clinical Trial.
</td>
<td style="text-align:left;">
JAMA
</td>
</tr>
<tr>
<td style="text-align:left;">
Activity of pirarubicin (4’-0-tetrahydropyranyladriamycin) in malignant mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Circulating complement component 4d (C4d) correlates with tumor volume, chemotherapeutic response and survival in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Sci Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
Plasma Fibulin-3 as a Potential Biomarker for Patients with Asbestos-Related Diseases in the Han Population.
</td>
<td style="text-align:left;">
Dis. Markers
</td>
</tr>
<tr>
<td style="text-align:left;">
Sudden death as the initial manifestation of diffuse pleural mesothelioma.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Breath analysis by gas chromatography-mass spectrometry and electronic nose to screen for pleural mesothelioma: a cross-sectional case-control study.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
CAR T-cell immunotherapy of MET-expressing malignant mesothelioma.
</td>
<td style="text-align:left;">
Oncoimmunology
</td>
</tr>
<tr>
<td style="text-align:left;">
Predictors of trimodality therapy and trends in therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
National Trends in the Epidemiology of Malignant Pleural Mesothelioma: A National Cancer Data Base Study.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Recent Advances in the Diagnosis of Malignant Mesothelioma: Focus on Approach in Challenging Cases and in Limited Tissue and Cytologic Samples.
</td>
<td style="text-align:left;">
Adv Anat Pathol
</td>
</tr>
<tr>
<td style="text-align:left;">
Targeting CXCR4 with [<sup>68</sup>Ga]Pentixafor: a suitable theranostic approach in pleural mesothelioma?
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
Aberrant Pax-8 expression in well-differentiated papillary mesothelioma and malignant mesothelioma of the peritoneum: a clinicopathologic study.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Proteasome stress sensitizes malignant pleural mesothelioma cells to bortezomib-induced apoptosis.
</td>
<td style="text-align:left;">
Sci Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos fibre burden in gallbladder: A case study.
</td>
<td style="text-align:left;">
Micron
</td>
</tr>
<tr>
<td style="text-align:left;">
The Association Between the FTO rs9939609 Variant and Malignant Pleural Mesothelioma Risk: A Case-Control Study.
</td>
<td style="text-align:left;">
Genet Test Mol Biomarkers
</td>
</tr>
<tr>
<td style="text-align:left;">
A genetic variant of NLRP1 gene is associated with asbestos body burden in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Toxicol. Environ. Health Part A
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic and Clinicopathological Significance of BAP1 Protein Expression in Different Types of Cancer-A Meta-Analysis.
</td>
<td style="text-align:left;">
Genet Test Mol Biomarkers
</td>
</tr>
<tr>
<td style="text-align:left;">
The epidemiology of malignant mesothelioma in women: gender differences and modalities of asbestos exposure.
</td>
<td style="text-align:left;">
Occup Environ Med
</td>
</tr>
<tr>
<td style="text-align:left;">
[Is malignant mesothelioma of the pleura only an occupational disease?].
</td>
<td style="text-align:left;">
Minerva Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Molecular heterogeneity of malignant pleural mesotheliomas].
</td>
<td style="text-align:left;">
Bull Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
A Nomogram to Predict Prognosis in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
World J Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
18F-Fluorodeoxyglucose PET/CT and dynamic contrast-enhanced MRI as imaging biomarkers in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Nucl Med Commun
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malign pleural mesothelioma - so far an undefeated tumor].
</td>
<td style="text-align:left;">
Vnitr Lek
</td>
</tr>
<tr>
<td style="text-align:left;">
Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Biol. Ther.
</td>
</tr>
<tr>
<td style="text-align:left;">
Radical multimodality therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cochrane Database Syst Rev
</td>
</tr>
<tr>
<td style="text-align:left;">
HSP90 inhibition alters the chemotherapy-driven rearrangement of the oncogenic secretome.
</td>
<td style="text-align:left;">
Oncogene
</td>
</tr>
<tr>
<td style="text-align:left;">
Minor regression and long-time survival (56 months) in a patient with malignant pleural mesothelioma under Viscum album and Helleborus niger extracts-a case report.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Biomarker-Integrated Neoadjuvant Dasatinib Trial in Resectable Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Germline and somatic variant identification using BGISEQ-500 and HiSeq X Ten whole genome sequencing.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
</tr>
<tr>
<td style="text-align:left;">
Success rate of medical thoracoscopy and talc pleurodesis in malignant pleurisy: A single-centre experience.
</td>
<td style="text-align:left;">
Respirology
</td>
</tr>
<tr>
<td style="text-align:left;">
Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: a multi-institutional study.
</td>
<td style="text-align:left;">
Mod. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical evaluation of circulating miR-548a-3p and -20a expression in malignant pleural mesothelioma patients.
</td>
<td style="text-align:left;">
Biomark Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Pseudomesotheliomatous carcinoma of the lung.
</td>
<td style="text-align:left;">
Vojnosanit Pregl
</td>
</tr>
<tr>
<td style="text-align:left;">
Heterogeneous Contributing Factors in MPM Disease Development and Progression: Biological Advances and Clinical Implications.
</td>
<td style="text-align:left;">
Int J Mol Sci
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma in situ.
</td>
<td style="text-align:left;">
Histopathology
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma as a difficult interdisciplinary problem.
</td>
<td style="text-align:left;">
Kardiochir Torakochirurgia Pol
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression analysis of HMGB1 in histological samples of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Histopathology
</td>
</tr>
<tr>
<td style="text-align:left;">
Survivin is a negative prognostic factor in malignant pleural effusion.
</td>
<td style="text-align:left;">
Eur. J. Clin. Invest.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Systemic Treatment of Malignant Pleural Mesothelioma].
</td>
<td style="text-align:left;">
Gan To Kagaku Ryoho
</td>
</tr>
<tr>
<td style="text-align:left;">
Therapeutic potential of targeting S100A11 in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncogenesis
</td>
</tr>
<tr>
<td style="text-align:left;">
Large-scale copy number analysis reveals variations in genes not previously associated with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
Multiple intracranial metastases from postoperative giant sarcomatoid malignant pleural mesothelioma: A case report and literature review.
</td>
<td style="text-align:left;">
Mol Clin Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Content validity and electronic PRO (ePRO) usability of the Lung Cancer Symptom Scale-Mesothelioma (LCSS-Meso) in mesothelioma patients.
</td>
<td style="text-align:left;">
Support Care Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment.
</td>
<td style="text-align:left;">
Oncoimmunology
</td>
</tr>
<tr>
<td style="text-align:left;">
Evaluating quality of life and cost implications of prophylactic radiotherapy in mesothelioma: Health economic analysis of the SMART trial.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
</tr>
<tr>
<td style="text-align:left;">
Radiofrequency Ablation Effectively Treated Focal Recurrence of Mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Vascular endothelial growth factor in pleural effusions and correlation with radiologic and biochemical parameters.
</td>
<td style="text-align:left;">
Niger J Clin Pract
</td>
</tr>
<tr>
<td style="text-align:left;">
Computed tomography in the evaluation of malignant pleural mesothelioma-Association of tumor size to a sarcomatoid histology, a more advanced TNM stage and poor survival.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Progress and challenges in Mesothelioma: From bench to bedside.
</td>
<td style="text-align:left;">
Respir Med
</td>
</tr>
<tr>
<td style="text-align:left;">
[Anti-tumor immunotherapy in malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Rev Mal Respir
</td>
</tr>
<tr>
<td style="text-align:left;">
Inflammatory Alteration of Human T Cells Exposed Continuously to Asbestos.
</td>
<td style="text-align:left;">
Int J Mol Sci
</td>
</tr>
<tr>
<td style="text-align:left;">
Outcomes of the Multimodal Treatment of Malignant Pleural Mesiothelioma: The Role of Surgery.
</td>
<td style="text-align:left;">
Korean J Thorac Cardiovasc Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
A prospective study to investigate the role of serial serum mesothelin in monitoring mesothelioma.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Secreted and Tissue miRNAs as Diagnosis Biomarkers of Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Int J Mol Sci
</td>
</tr>
<tr>
<td style="text-align:left;">
Survival prediction in mesothelioma using a scalable Lasso regression model: instructions for use and initial performance using clinical predictors.
</td>
<td style="text-align:left;">
BMJ Open Respir Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic Impact of Inflammation-related Biomarkers on Overall Survival of Patients with Inoperable Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
In Vivo
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant Mesothelioma and Its Non-Asbestos Causes.
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Stem Cells Application in Thoracic Surgery: Current Perspective and Future Directions.
</td>
<td style="text-align:left;">
Adv. Exp. Med. Biol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunohistochemical Expression of Aquaporin-1 in Fluoro-Edenite-Induced Malignant Mesothelioma: A Preliminary Report.
</td>
<td style="text-align:left;">
Int J Mol Sci
</td>
</tr>
<tr>
<td style="text-align:left;">
<sup>18</sup>F-FDG PET/CT in the management of patients with malignant pleural mesothelioma being considered for multimodality therapy: experience of a tertiary referral center.
</td>
<td style="text-align:left;">
Br J Radiol
</td>
</tr>
<tr>
<td style="text-align:left;">
The C-Reactive Protein/Albumin Ratio is a Novel Significant Prognostic Factor in Patients with Malignant Pleural Mesothelioma: A Retrospective Multi-institutional Study.
</td>
<td style="text-align:left;">
Ann. Surg. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelin and osteopontin as circulating markers of diffuse malignant peritoneal mesothelioma: A preliminary study.
</td>
<td style="text-align:left;">
Eur J Surg Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Rapid diffuse pleural thickening due to metastatic meningioma.
</td>
<td style="text-align:left;">
Respirol Case Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
Physicochemical and pharmacokinetic properties of polymeric films loaded with cisplatin for the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Polymeric films loaded with cisplatin for malignant pleural mesothelioma: a pharmacokinetic study in an ovine model.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Hyperthermic intrathoracic chemotherapy after extended pleurectomy and decortication for malignant pleura mesothelioma: an observational study on outcome and microcirculatory changes.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
The genetic susceptibility in the development of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical diagnosis of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Imaging of malignant pleural mesothelioma: it is possible a screening or early diagnosis program?-a systematic review about the use of screening programs in a population of asbestos exposed workers.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Endoscopic diagnosis and management of pleural effusion in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
The pathological and molecular diagnosis of malignant pleural mesothelioma: a literature review.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgery for malignant pleural mesothelioma: an international guidelines review.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of intracavitary therapies in the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemotherapy treatment in malignant pleural mesothelioma: a difficult history.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Target therapy: new drugs or new combinations of drugs in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
New horizons from immunotherapy in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Medical treatment of malignant pleural mesothelioma relapses.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Molecular markers and new diagnostic methods to differentiate malignant from benign mesothelial pleural proliferations: a literature review.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Serum mesothelin and other biomarkers: what have we learned in the last decade?
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Overexpressed genes in malignant pleural mesothelioma: implications in clinical management.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Reproducibility of Malignant Pleural Mesothelioma Histopathologic Subtyping.
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Macroscopic complete resection is not associated with improved survival in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Influence of inter-observer delineation variability on radiomics stability in different tumor sites.
</td>
<td style="text-align:left;">
Acta Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
</td>
<td style="text-align:left;">
Ann. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Aminopeptidase N/CD13 as a potential therapeutic target in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
</tr>
<tr>
<td style="text-align:left;">
Progress in the Management of Malignant Pleural Mesothelioma in 2017.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Live-Cell Mesothelioma Biobank to Explore Mechanisms of Tumor Progression.
</td>
<td style="text-align:left;">
Front Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
[Implementation of Hyperthermic Intrathoracic Chemotherapy (HITHOC) in Germany].
</td>
<td style="text-align:left;">
Zentralbl Chir
</td>
</tr>
<tr>
<td style="text-align:left;">
Drug repurposing in malignant pleural mesothelioma: a breath of fresh air?
</td>
<td style="text-align:left;">
Eur Respir Rev
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase I Study of Intrapleural Gene-Mediated Cytotoxic Immunotherapy in Patients with Malignant Pleural Effusion.
</td>
<td style="text-align:left;">
Mol. Ther.
</td>
</tr>
<tr>
<td style="text-align:left;">
Updates in the diagnosis and treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Curr Opin Pulm Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Targeting the Hippo Pathway Is a New Potential Therapeutic Modality for Malignant Mesothelioma.
</td>
<td style="text-align:left;">
Cancers (Basel)
</td>
</tr>
<tr>
<td style="text-align:left;">
Low-dose chest computed tomography screening of subjects exposed to asbestos.
</td>
<td style="text-align:left;">
Eur J Radiol
</td>
</tr>
<tr>
<td style="text-align:left;">
Inhibition of yes-associated protein down-regulates PD-L1 (CD274) expression in human malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Cell. Mol. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant Peritoneal Mesothelioma Presenting as Mucinous Ascites.
</td>
<td style="text-align:left;">
ACG Case Rep J
</td>
</tr>
<tr>
<td style="text-align:left;">
Involvement of Heparanase in the Pathogenesis of Mesothelioma: Basic Aspects and Clinical Applications.
</td>
<td style="text-align:left;">
J. Natl. Cancer Inst.
</td>
</tr>
<tr>
<td style="text-align:left;">
Quality of life of survivors of malignant pleural mesothelioma in Japan: a cross sectional study.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Primary Spinal Malignant Mesothelioma: A Case Report and Literature Review.
</td>
<td style="text-align:left;">
World Neurosurg
</td>
</tr>
<tr>
<td style="text-align:left;">
SYSTEMS-2: A randomised phase II study of radiotherapy dose escalation for pain control in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin Transl Radiat Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
MR Imaging of Pleural Neoplasms.
</td>
<td style="text-align:left;">
Top Magn Reson Imaging
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant Pleural Mesothelioma: Are There Imaging Characteristics Associated With Different Histologic Subtypes on Computed Tomography?
</td>
<td style="text-align:left;">
J Comput Assist Tomogr
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: diagnostic value of medical thoracoscopy and long-term prognostic analysis.
</td>
<td style="text-align:left;">
BMC Pulm Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Randomised controlled trial to compare the diagnostic yield of positron emission tomography CT (PET-CT) TARGETed pleural biopsy versus CT-guided pleural biopsy in suspected pleural malignancy (TARGET trial).
</td>
<td style="text-align:left;">
BMJ Open Respir Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Poor Prognostic Factors in Patients with Malignant Pleural Mesothelioma Classified as Pathological Stage IB According to the Eighth Edition TNM Classification.
</td>
<td style="text-align:left;">
Ann. Surg. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Comprehensive immunoproteogenomic analyses of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
JCI Insight
</td>
</tr>
<tr>
<td style="text-align:left;">
The current aetiology of malignant pleural effusion in the Western Cape Province, South Africa.
</td>
<td style="text-align:left;">
S. Afr. Med. J.
</td>
</tr>
<tr>
<td style="text-align:left;">
CA125 suppresses amatuximab immune-effector function and elevated serum levels are associated with reduced clinical response in first line mesothelioma patients.
</td>
<td style="text-align:left;">
Cancer Biol. Ther.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant cells from pleural fluids in malignant mesothelioma patients reveal novel mutations.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
New Perspectives on Diagnosis and Therapy of Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Front Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
A review of the cohorts with environmental and occupational mineral fiber exposure.
</td>
<td style="text-align:left;">
Arch Environ Occup Health
</td>
</tr>
<tr>
<td style="text-align:left;">
Video-assisted thoracoscopic PlasmaJet ablation for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Vis Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Ugeskr. Laeg.
</td>
</tr>
<tr>
<td style="text-align:left;">
In Silico and In Vitro Analyses of LncRNAs as Potential Regulators in the Transition from the Epithelioid to Sarcomatoid Histotype of Malignant Pleural Mesothelioma (MPM).
</td>
<td style="text-align:left;">
Int J Mol Sci
</td>
</tr>
<tr>
<td style="text-align:left;">
Prospective registry database of patients with malignant mesothelioma: directions for a future Japanese registry-based lung cancer study.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic factors and treatment outcomes of malignant pleural mesothelioma in Eastern Asian patients - A Taiwanese study.
</td>
<td style="text-align:left;">
J. Formos. Med. Assoc.
</td>
</tr>
<tr>
<td style="text-align:left;">
On the diagnosis of malignant pleural mesothelioma: A necropsy-based study of 171 cases (1997-2016).
</td>
<td style="text-align:left;">
Tumori
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma presenting as recurrent hydro-pneumothorax: An atypical case presentation and literature review.
</td>
<td style="text-align:left;">
Respir Med Case Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of plakophilin 3 in diffuse malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Histol. Histopathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Nintedanib Is Active in Malignant Pleural Mesothelioma Cell Models and Inhibits Angiogenesis and Tumor Growth <i>In Vivo</i>.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Ipilimumab/Nivolumab-related Opsoclonus-Myoclonus-Ataxia Syndrome Variant in a Patient with Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
J. Immunother.
</td>
</tr>
<tr>
<td style="text-align:left;">
Loss of C/EBP-β LIP drives cisplatin resistance in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Facility volume and postoperative outcomes for malignant pleural mesothelioma: A National Cancer Data Base analysis.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Aberrant Lck Signal via CD28 Costimulation Augments Antigen-Specific Functionality and Tumor Control by Redirected T Cells with PD-1 Blockade in Humanized Mice.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
A Phase I Trial of Surgical Resection and Intraoperative Hyperthermic Cisplatin and Gemcitabine for Pleural Mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Revised Modified Response Evaluation Criteria in Solid Tumors for Assessment of Response in Malignant Pleural Mesothelioma (Version 1.1).
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial.
</td>
<td style="text-align:left;">
Lancet Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Four immunohistochemical assays to measure the PD-L1 expression in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
A subgroup of pleural mesothelioma expresses ALK protein and may be targetable by combined rapamycin and crizotinib therapy.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
How to assess the best immunohistochemical panel in the diagnosis of malignant pleural mesothelioma in a pathology lab.
</td>
<td style="text-align:left;">
J Immunoassay Immunochem
</td>
</tr>
<tr>
<td style="text-align:left;">
Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study.
</td>
<td style="text-align:left;">
Lancet Respir Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Targeting Tie-2/angiopoietin axis in experimental mesothelioma confers differential responses and raises predictive implications.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
Longevity and pleural mesothelioma: age-period-cohort analysis of incidence data from the Surveillance, Epidemiology, and End Results (SEER) Program, 1973-2013.
</td>
<td style="text-align:left;">
BMC Res Notes
</td>
</tr>
<tr>
<td style="text-align:left;">
A preclinical model to investigate the role of surgically-induced inflammation in tumor responses to intraoperative photodynamic therapy.
</td>
<td style="text-align:left;">
Lasers Surg Med
</td>
</tr>
<tr>
<td style="text-align:left;">
The diagnostic role of BAP1 in serous effusions.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Utilization of Intensity-Modulated Radiation Therapy for Malignant Pleural Mesothelioma in the United States.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Effects of Reduction in Tumor Burden on Survival in Epithelioid Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Mayo Clin. Proc.
</td>
</tr>
<tr>
<td style="text-align:left;">
Is there a role for immunotherapy in malignant pleural mesothelioma?
</td>
<td style="text-align:left;">
Med. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Critical role of the Ror-family of receptor tyrosine kinases in invasion and proliferation of malignant pleural mesothelioma cells.
</td>
<td style="text-align:left;">
Genes Cells
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunohistochemically detectable metallothionein expression in malignant pleural mesotheliomas is strongly associated with early failure to platin-based chemotherapy.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
Soluble CD157 in pleural effusions: a complementary tool for the diagnosis of malignant mesothelioma.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgical Options for Malignant Mesothelioma: A Single-Center Experience.
</td>
<td style="text-align:left;">
Korean J Thorac Cardiovasc Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic yield of pleural fluid cytology in malignant effusions: an Australian tertiary centre experience.
</td>
<td style="text-align:left;">
Intern Med J
</td>
</tr>
<tr>
<td style="text-align:left;">
Aquaporin-1 expression in fluoro-edenite-induced mesothelioma effusions: An approach by cell-block procedure.
</td>
<td style="text-align:left;">
Cytopathology
</td>
</tr>
<tr>
<td style="text-align:left;">
FDG PET-derived parameters as prognostic tool in progressive malignant pleural mesothelioma treated patients.
</td>
<td style="text-align:left;">
Eur. J. Nucl. Med. Mol. Imaging
</td>
</tr>
<tr>
<td style="text-align:left;">
Integrated Histogenetic Analysis Reveals <i>BAP1</i>-Mutated Epithelioid Mesothelioma in a Patient With Cancer of Unknown Primary.
</td>
<td style="text-align:left;">
J Natl Compr Canc Netw
</td>
</tr>
<tr>
<td style="text-align:left;">
Inactivation of Tp53 and Pten drives rapid development of pleural and peritoneal malignant mesotheliomas.
</td>
<td style="text-align:left;">
J. Cell. Physiol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesothelioma: is the surgeon still there?
</td>
<td style="text-align:left;">
Ann. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Biomarkers for Early Diagnosis and Prognosis of Malignant Pleural Mesothelioma: The Quest Goes on.
</td>
<td style="text-align:left;">
Cancers (Basel)
</td>
</tr>
<tr>
<td style="text-align:left;">
Quantitative Clinical Staging for Patients With Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
J. Natl. Cancer Inst.
</td>
</tr>
<tr>
<td style="text-align:left;">
Biological mechanisms of non-linear dose-response for respirable mineral fibers.
</td>
<td style="text-align:left;">
Toxicol. Appl. Pharmacol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Trophoblast Glycoprotein is Associated With a Favorable Outcome for Mesothelioma and a Target for Antibody Drug Conjugates.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Multisensor Imaging-From Sample Preparation to Integrated Multimodal Interpretation of LA-ICPMS and MALDI MS Imaging Data.
</td>
<td style="text-align:left;">
Anal. Chem.
</td>
</tr>
<tr>
<td style="text-align:left;">
Nivolumab Immunotherapy in Malignant Mesothelioma: A Case Report Highlighting a New Opportunity for Exceptional Outcomes.
</td>
<td style="text-align:left;">
Am J Case Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemo-manipulation of tumor blood vessels by a metal-based anticancer complex enhances antitumor therapy.
</td>
<td style="text-align:left;">
Sci Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
Epidemiological surveillance of mesothelioma mortality in Italy.
</td>
<td style="text-align:left;">
Cancer Epidemiol
</td>
</tr>
<tr>
<td style="text-align:left;">
Biomarkers for Predicting Malignant Pleural Mesothelioma in a Mexican Population.
</td>
<td style="text-align:left;">
Int J Med Sci
</td>
</tr>
<tr>
<td style="text-align:left;">
Matrix Metalloproteinases Polymorphisms as Baseline Risk Predictors in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Radiol Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
A Clinical Trial of TumorGlow to Identify Residual Disease During Pleurectomy and Decortication.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Aggressive versus symptom-guided drainage of malignant pleural effusion via indwelling pleural catheters (AMPLE-2): an open-label randomised trial.
</td>
<td style="text-align:left;">
Lancet Respir Med
</td>
</tr>
<tr>
<td style="text-align:left;">
The Diagnosis of Pleural Tumors Other Than Mesothelioma.
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytopathologic Diagnosis of Epithelioid and Mixed-Type Malignant Mesothelioma: Ten Years of Clinical Experience in Relation to International Guidelines.
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
A systematic review and meta-analysis of second-line therapies for treatment of mesothelioma.
</td>
<td style="text-align:left;">
Respir Med
</td>
</tr>
<tr>
<td style="text-align:left;">
ERS/EACTS statement on the management of malignant pleural effusions.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
</tr>
<tr>
<td style="text-align:left;">
Mismatch Repair Protein Defects and Microsatellite Instability in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
ERS/EACTS statement on the management of malignant pleural effusions.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Genomics and Epigenetics of Malignant Mesothelioma.
</td>
<td style="text-align:left;">
High Throughput
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural tumours and tumour-like lesions.
</td>
<td style="text-align:left;">
Clin Radiol
</td>
</tr>
<tr>
<td style="text-align:left;">
Upcoming epidemic of asbestos-related malignant pleural mesothelioma in Taiwan: A prediction of incidence in the next 30 years.
</td>
<td style="text-align:left;">
J. Formos. Med. Assoc.
</td>
</tr>
<tr>
<td style="text-align:left;">
The Economic Impact of Clinical Research in an Italian Public Hospital: The Malignant Pleural Mesothelioma Case Study.
</td>
<td style="text-align:left;">
Int J Health Policy Manag
</td>
</tr>
<tr>
<td style="text-align:left;">
Measurement of telomere length in cells from pleural effusion: Asbestos exposure causes telomere shortening in pleural mesothelial cells.
</td>
<td style="text-align:left;">
Pathol. Int.
</td>
</tr>
<tr>
<td style="text-align:left;">
Double cancer comprising malignant pleural mesothelioma and squamous cell carcinoma of the lung treated with radiotherapy: A case report.
</td>
<td style="text-align:left;">
Mol Clin Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant Pleural Mesothelioma, Biphasic Type: An Unusual and Insidious Case of Rapidly Progressive Small Blue Cell Tumor.
</td>
<td style="text-align:left;">
Cureus
</td>
</tr>
<tr>
<td style="text-align:left;">
Benign and malignant pleural effusions in former Wittenoom crocidolite millers and miners.
</td>
<td style="text-align:left;">
Aust N Z J Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Inhibition of MDM2 via Nutlin-3A: A Potential Therapeutic Approach for Pleural Mesotheliomas with MDM2-Induced Inactivation of Wild-Type P53.
</td>
<td style="text-align:left;">
J Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgery in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Current treatments and trials in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin Respir J
</td>
</tr>
<tr>
<td style="text-align:left;">
Pseudomesotheliomatous Primary Squamous Cell Lung Carcinoma: The First Case Reported in Turkey and a Review of the Literature.
</td>
<td style="text-align:left;">
Open Med (Wars)
</td>
</tr>
<tr>
<td style="text-align:left;">
Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
ADP sensitizes ZL55 cells to the activity of cisplatin.
</td>
<td style="text-align:left;">
J. Cell. Physiol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications.
</td>
<td style="text-align:left;">
Pathology
</td>
</tr>
<tr>
<td style="text-align:left;">
Early-stage Clinical Characterization of Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
In Vivo
</td>
</tr>
<tr>
<td style="text-align:left;">
Ancillary studies in pleural, pericardial, and peritoneal effusion cytology.
</td>
<td style="text-align:left;">
Cancer Cytopathol
</td>
</tr>
<tr>
<td style="text-align:left;">
BAMLET kills chemotherapy-resistant mesothelioma cells, holding oleic acid in an activated cytotoxic state.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
</tr>
<tr>
<td style="text-align:left;">
Zoledronic acid in the management of mesothelioma - a feasibility study (Zol-A Trial): study protocol for a randomised controlled trial.
</td>
<td style="text-align:left;">
Trials
</td>
</tr>
<tr>
<td style="text-align:left;">
Anesthetic Management of Pleurectomy/Decortication Under Differential Lung Ventilation.
</td>
<td style="text-align:left;">
Kurume Med J
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma. Value of 67Ga scintigraphy compared to computerized tomography].
</td>
<td style="text-align:left;">
Rofo
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural malignant mesothelioma versus pleuropulmonary synovial sarcoma: a clinicopathological study of 22 cases with molecular analysis and survival data.
</td>
<td style="text-align:left;">
Pathology
</td>
</tr>
<tr>
<td style="text-align:left;">
Modification of existing patient-reported outcome measures: qualitative development of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM).
</td>
<td style="text-align:left;">
Qual Life Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Targeting CD26 suppresses proliferation of malignant mesothelioma cell via downmodulation of ubiquitin-specific protease 22.
</td>
<td style="text-align:left;">
Biochem. Biophys. Res. Commun.
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of Numb and Gli1 in malignant pleural mesothelioma and their clinical significance.
</td>
<td style="text-align:left;">
J Cancer Res Ther
</td>
</tr>
<tr>
<td style="text-align:left;">
Evaluation of the photon dose calculation accuracy in radiation therapy of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Cancer Res Ther
</td>
</tr>
<tr>
<td style="text-align:left;">
Adjuvant, neoadjuvant, and definitive radiation therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
[Diagnostic value of the combined determination of carcinoembryonic antigen (CEA) in pleural effusion and serum with an enzyme immunoassay (EIA). Sensitivity, specificity and relation to tumor type].
</td>
<td style="text-align:left;">
Wien. Klin. Wochenschr.
</td>
</tr>
<tr>
<td style="text-align:left;">
Preclinical investigation of folate receptor-targeted nanoparticles for photodynamic therapy of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Intensity-modulated radiotherapy is a safe and effective treatment for localized malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Thorac Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Autologous Dendritic Cell Therapy in Mesothelioma Patients Enhances Frequencies of Peripheral CD4 T Cells Expressing HLA-DR, PD-1, or ICOS.
</td>
<td style="text-align:left;">
Front Immunol
</td>
</tr>
<tr>
<td style="text-align:left;">
Novel platinum agents and mesenchymal stromal cells for thoracic malignancies: state of the art and future perspectives.
</td>
<td style="text-align:left;">
Expert Opin Ther Pat
</td>
</tr>
<tr>
<td style="text-align:left;">
Pathologic Grading of Malignant Pleural Mesothelioma: An Evidence-Based Proposal.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
An Occupational Legacy: Malignant Mesothelioma Incidence and Mortality in Wisconsin.
</td>
<td style="text-align:left;">
J. Occup. Environ. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Investigating unilateral pleural effusions: the role of cytology.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
</tr>
<tr>
<td style="text-align:left;">
Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Current efforts in research of pleural mesothelioma-An analysis of the ClinicalTrials.gov registry.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Tumor-specific genetic variants can be detected in circulating cell-free DNA of malignant pleural mesothelioma patients.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Highlights of the 14th international mesothelioma interest group meeting: Pathologic separation of benign from malignant mesothelial proliferations and histologic/molecular analysis of malignant mesothelioma subtypes.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Curcumin induces apoptosis and inhibits angiogenesis in murine malignant mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Berberine induces mitochondrial‑mediated apoptosis and protective autophagy in human malignant pleural mesothelioma NCI‑H2452 cells.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
</tr>
<tr>
<td style="text-align:left;">
Is There a Role for Cancer-Directed Surgery in Early-Stage Sarcomatoid or Biphasic Mesothelioma?
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Clinical and pathological profile of the pleural malignant mesothelioma: A retrospective study about 30 cases].
</td>
<td style="text-align:left;">
Rev Pneumol Clin
</td>
</tr>
<tr>
<td style="text-align:left;">
Quantitative mass spectrometry to identify protein markers for diagnosis of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Proteomics
</td>
</tr>
<tr>
<td style="text-align:left;">
Genomic Deletion of <i>BAP1</i> and <i>CDKN2A</i> Are Useful Markers for Quality Control of Malignant Pleural Mesothelioma (MPM) Primary Cultures.
</td>
<td style="text-align:left;">
Int J Mol Sci
</td>
</tr>
<tr>
<td style="text-align:left;">
Prophylactic procedure tract radiotherapy for malignant pleural mesothelioma: A systematic review and meta-analysis.
</td>
<td style="text-align:left;">
Clin Transl Radiat Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Brain-derived neurotrophic factor, a new soluble biomarker for malignant pleural mesothelioma involved in angiogenesis.
</td>
<td style="text-align:left;">
Mol. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Inhibiting crosstalk between MET signaling and mitochondrial dynamics and morphology: a novel therapeutic approach for lung cancer and mesothelioma.
</td>
<td style="text-align:left;">
Cancer Biol. Ther.
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunohistochemical evaluation of nuclear 5-hydroxymethylcytosine (5-hmC) accurately distinguishes malignant pleural mesothelioma from benign mesothelial proliferations.
</td>
<td style="text-align:left;">
Mod. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
p53 modeling as a route to mesothelioma patients stratification and novel therapeutic identification.
</td>
<td style="text-align:left;">
J Transl Med
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma: The role of surgery].
</td>
<td style="text-align:left;">
Rev Pneumol Clin
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnosis of malignant pleural mesothelioma from pleural fluid by Fourier transform-infrared spectroscopy coupled with chemometrics.
</td>
<td style="text-align:left;">
J Biomed Opt
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelin as a target for cervical cancer therapy.
</td>
<td style="text-align:left;">
Arch. Gynecol. Obstet.
</td>
</tr>
<tr>
<td style="text-align:left;">
Sensitivity to asbestos is increased in patients with mesothelioma and pathogenic germline variants in BAP1 or other DNA repair genes.
</td>
<td style="text-align:left;">
Genes Chromosomes Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Meet the researchers: an alternative method of engaging patients with research in mesothelioma.
</td>
<td style="text-align:left;">
Res Involv Engagem
</td>
</tr>
<tr>
<td style="text-align:left;">
Biomarkers in the diagnosis of pleural diseases: a 2018 update.
</td>
<td style="text-align:left;">
Ther Adv Respir Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical significance of serum DRAM1 mRNA, ARSA mRNA, hsa-miR-2053 and lncRNA-RP1-86D1.3 axis expression in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Cell. Biochem.
</td>
</tr>
<tr>
<td style="text-align:left;">
Prediction modelling using routine clinical parameters to stratify survival in Malignant Pleural Mesothelioma patients undergoing cytoreductive surgery.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Safety of Same-Day Vitamin B12 Supplementation in Patients Receiving Pemetrexed for the Treatment of Non-Small-Cell Lung Cancer or Pleural Mesothelioma: A Retrospective Analysis.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Metabolic Characterization of Antifolate Responsiveness and Non-responsiveness in Malignant Pleural Mesothelioma Cells.
</td>
<td style="text-align:left;">
Front Pharmacol
</td>
</tr>
<tr>
<td style="text-align:left;">
Updated meta-analysis of survival after extrapleural pneumonectomy versus pleurectomy/decortication in mesothelioma.
</td>
<td style="text-align:left;">
Gen Thorac Cardiovasc Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma in Finland: regional and gender variation.
</td>
<td style="text-align:left;">
Acta Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Differential Survival Characteristics of Sarcomatoid Subtype in Biphasic Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Peripheral Blood DNA Methylation as Potential Biomarker of Malignant Pleural Mesothelioma in Asbestos-Exposed Subjects.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Multimodality treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
F1000Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Factors influencing malignant mesothelioma survival: a retrospective review of the National Mesothelioma Virtual Bank cohort.
</td>
<td style="text-align:left;">
F1000Res
</td>
</tr>
<tr>
<td style="text-align:left;">
<sup>18</sup>F-FDG PET/CT in therapy response and in predicting responders or non-responders in malignant pleural mesothelioma patients, by using semi-quantitative mRECIST and EORTC criteria.
</td>
<td style="text-align:left;">
Hell J Nucl Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Reactivity of tumor cells in malignant effusions with a panel of monoclonal and polyclonal antibodies.
</td>
<td style="text-align:left;">
Tumour Biol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Primary malignant pleural tumors (mesotheliomas) presenting as localized masses. Fine needle aspiration cytologic findings, clinical and radiologic features and review of the literature.
</td>
<td style="text-align:left;">
Acta Cytol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Establishment and characterization of CRISPR/Cas9-mediated NF2<sup>-/-</sup> human mesothelial cell line: Molecular insight into fibroblast growth factor receptor 2 in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Sci.
</td>
</tr>
<tr>
<td style="text-align:left;">
Real-life treatment practice for malignant pleural mesothelioma in Belgium.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Soluble AXL is ubiquitously present in malignant serous effusions.
</td>
<td style="text-align:left;">
Gynecol. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
The use of patient-reported outcome measures (PROMs) in the management of malignant pleural mesothelioma: a descriptive literature survey.
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Breath analysis as a diagnostic and screening tool for malignant pleural mesothelioma: a systematic review.
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant peritoneal mesothelioma: a review.
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
</tr>
<tr>
<td style="text-align:left;">
The eighth TNM classification for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Extrapleural pneumonectomy: still indicated?
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Combined modality treatment in mesothelioma: a systemic literature review with treatment recommendations.
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Current chemotherapy strategies in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Is there a role for prophylactic radiotherapy to intervention tract sites in patients with malignant pleural mesothelioma?
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
</tr>
<tr>
<td style="text-align:left;">
A randomized phase II study of pleurectomy/decortication preceded or followed by (neo-)adjuvant chemotherapy in patients with early stage malignant pleural mesothelioma (EORTC 1205).
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment of malignant pleural mesothelioma with chemotherapy preceding versus after surgical resection.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Systemic Therapy Use and Outcomes After Relapse from Preoperative Radiation and Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Oncologist
</td>
</tr>
<tr>
<td style="text-align:left;">
Systematic review of quality of life following pleurectomy decortication and extrapleural pneumonectomy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Modeling Epidermal Growth Factor Inhibitor-mediated Enhancement of Photodynamic Therapy Efficacy Using 3D Mesothelioma Cell Culture.
</td>
<td style="text-align:left;">
Photochem. Photobiol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Detection of circulating tumor cells with a novel microfluidic system in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Sci.
</td>
</tr>
<tr>
<td style="text-align:left;">
Biodistribution and Tumor Uptake of <sup>67</sup>Ga-Nimotuzumab in a Malignant Pleural Mesothelioma Xenograft.
</td>
<td style="text-align:left;">
Molecules
</td>
</tr>
<tr>
<td style="text-align:left;">
Management of database: European Society of Thoracic Surgeons mesothelioma database-difficulties in improving quality data for rare tumour.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Whole-Body MRI: Comparison of Its Capability for TNM Staging of Malignant Pleural Mesothelioma With That of Coregistered PET/MRI, Integrated FDG PET/CT, and Conventional Imaging.
</td>
<td style="text-align:left;">
AJR Am J Roentgenol
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of BRCA1-associated protein 1 in the diagnosis of malignant mesothelioma in effusion and fine-needle aspiration cytology.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
A single centre phase II trial to assess the immunological activity of TroVax® plus pemetrexed/cisplatin in patients with malignant pleural mesothelioma - the SKOPOS trial.
</td>
<td style="text-align:left;">
Oncoimmunology
</td>
</tr>
<tr>
<td style="text-align:left;">
Combined modality treatment for malignant pleural mesothelioma: a single-centre long-term survival analysis using extrapleural pneumonectomy.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
The FAK inhibitor BI 853520 inhibits spheroid formation and orthotopic tumor growth in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Mol. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Catheter Tract Metastasis in Mesothelioma Patients with Indwelling Pleural Catheters: A Retrospective Cohort Study.
</td>
<td style="text-align:left;">
Respiration
</td>
</tr>
<tr>
<td style="text-align:left;">
BAP1 gene mutations in Egyptian patients with advanced sporadic malignant pleural mesothelioma (MPM): relation with clinical outcomes and survival.
</td>
<td style="text-align:left;">
Cancer Genet
</td>
</tr>
<tr>
<td style="text-align:left;">
Nodules and masses are associated with malignant pleural effusion in dogs and cats but many other intrathoracic CT features are poor predictors of the effusion type.
</td>
<td style="text-align:left;">
Vet Radiol Ultrasound
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural thickness after neoadjuvant chemotherapy is a prognostic factor in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma of the pleura.
</td>
<td style="text-align:left;">
Mayo Clin. Proc.
</td>
</tr>
<tr>
<td style="text-align:left;">
Case report: Steroid responsive mesothelioma-related pleural effusion.
</td>
<td style="text-align:left;">
Respir Med Case Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial.
</td>
<td style="text-align:left;">
JAMA Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Correlation of patient survival with clinical tumor measurements in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur Radiol
</td>
</tr>
<tr>
<td style="text-align:left;">
Population-based cohort study on health effects of asbestos exposure in Japan.
</td>
<td style="text-align:left;">
Cancer Sci.
</td>
</tr>
<tr>
<td style="text-align:left;">
MicroRNAs for the Diagnosis and Management of Malignant Pleural Mesothelioma: A Literature Review.
</td>
<td style="text-align:left;">
Front Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Heparanase inhibitors restrain mesothelioma.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic Accuracy of a Limited Immuno-panel of Calretinin and Ber-EP4 for Diagnosis of Malignant Effusions.
</td>
<td style="text-align:left;">
J Coll Physicians Surg Pak
</td>
</tr>
<tr>
<td style="text-align:left;">
Return to work after surgical treatment for malignant pleural mesothelioma: report of a case.
</td>
<td style="text-align:left;">
Gen Thorac Cardiovasc Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgical Risk and Survival Associated With Less Invasive Surgery for Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Semin. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
BAP1 Loss is a Useful Adjunct to Distinguish Malignant Mesothelioma Including the Adenomatoid-like Variant From Benign Adenomatoid Tumors.
</td>
<td style="text-align:left;">
Appl. Immunohistochem. Mol. Morphol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Progress of malignant mesothelioma research in basic science: A review of the 14th international conference of the international mesothelioma interest group (iMig2018).
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Molecular pathways and diagnosis in malignant mesothelioma: A review of the 14th International Conference of the International Mesothelioma Interest Group.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic factors of survival in patients with malignant pleural mesothelioma: an analysis of the National Cancer Database.
</td>
<td style="text-align:left;">
Carcinogenesis
</td>
</tr>
<tr>
<td style="text-align:left;">
Dosimetric Correlates of Pulmonary Toxicity in Patients with Malignant Pleural Mesothelioma Receiving Radiation Therapy to the Intact Lungs.
</td>
<td style="text-align:left;">
Pract Radiat Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Proc. Natl. Acad. Sci. U.S.A.
</td>
</tr>
<tr>
<td style="text-align:left;">
Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial.
</td>
<td style="text-align:left;">
Lancet Respir Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
</td>
<td style="text-align:left;">
Lancet Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Managing malignant pleural mesothelioma: experience and perceptions of health care professionals caring for people with mesothelioma.
</td>
<td style="text-align:left;">
Support Care Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Inhibition of collagen production delays malignant mesothelioma tumor growth in a murine model.
</td>
<td style="text-align:left;">
Biochem. Biophys. Res. Commun.
</td>
</tr>
<tr>
<td style="text-align:left;">
MesoTRAP: a feasibility study that includes a pilot clinical trial comparing video-assisted thoracoscopic partial pleurectomy decortication with indwelling pleural catheter in patients with trapped lung due to malignant pleural mesothelioma designed to address recruitment and randomisation uncertainties and sample size requirements for a phase III trial.
</td>
<td style="text-align:left;">
BMJ Open Respir Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Computed tomography features of local pleural recurrence in patients with malignant pleural mesothelioma treated with intensity-modulated pleural radiation therapy.
</td>
<td style="text-align:left;">
Eur Radiol
</td>
</tr>
<tr>
<td style="text-align:left;">
[Asbestos-induced malignant tumors].
</td>
<td style="text-align:left;">
Zentralbl Allg Pathol
</td>
</tr>
<tr>
<td style="text-align:left;">
Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Characteristics and long-term outcomes of advanced pleural mesothelioma in Latin America (MeSO-CLICaP).
</td>
<td style="text-align:left;">
Thorac Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Robust Cell Detection and Segmentation for Image Cytometry Reveal Th17 Cell Heterogeneity.
</td>
<td style="text-align:left;">
Cytometry A
</td>
</tr>
<tr>
<td style="text-align:left;">
Localized malignant pleural mesothelioma arising in the interlobar fissure: a unique surgical case masquerading clinicopathologically as primary lung adenocarcinoma.
</td>
<td style="text-align:left;">
SAGE Open Med Case Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Use of Immune Checkpoint Inhibitors in Mesothelioma.
</td>
<td style="text-align:left;">
Curr Treat Options Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study.
</td>
<td style="text-align:left;">
Int J Nanomedicine
</td>
</tr>
<tr>
<td style="text-align:left;">
[Possibilities of cytological diagnosis of the nature of the exudate at the stage of emergency.]
</td>
<td style="text-align:left;">
Klin. Lab. Diagn.
</td>
</tr>
<tr>
<td style="text-align:left;">
Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Physical function and health-related quality of life in the convalescent phase in surgically treated patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Support Care Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Multiple sclerosis outcomes after cancer immunotherapy.
</td>
<td style="text-align:left;">
Clin Transl Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant Pleural Mesothelioma: Is Tailoring the Second-Line Therapy Really “Raising the Bar?”
</td>
<td style="text-align:left;">
Curr Treat Options Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Relations between approved platinum drugs and non-coding RNAs in mesothelioma.
</td>
<td style="text-align:left;">
Noncoding RNA Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Interplay of non-coding RNAs and approved antimetabolites such as gemcitabine and pemetrexed in mesothelioma.
</td>
<td style="text-align:left;">
Noncoding RNA Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Intrapleural immunotherapy: An update on emerging treatment strategies for pleural malignancy.
</td>
<td style="text-align:left;">
Clin Respir J
</td>
</tr>
<tr>
<td style="text-align:left;">
About the diagnostic value of BAP-1 antibody in malignant pleural mesothelioma: a meta-analysis.
</td>
<td style="text-align:left;">
J Immunoassay Immunochem
</td>
</tr>
<tr>
<td style="text-align:left;">
Dynamic contrast-enhanced MRI of malignant pleural mesothelioma: a comparative study of pharmacokinetic models and correlation with mRECIST criteria.
</td>
<td style="text-align:left;">
Cancer Imaging
</td>
</tr>
<tr>
<td style="text-align:left;">
Development and Validation of a Prognostic Signature for Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Front Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Mol. Biol. Rep.
</td>
</tr>
<tr>
<td style="text-align:left;">
Presence of innate lymphoid cells in pleural effusions of primary and metastatic tumors: Functional analysis and expression of PD-1 receptor.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
A 75 year old male with recurrent unilateral pleural effusion and positive ANA.
</td>
<td style="text-align:left;">
Respir Med Case Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
Prolonged post-recurrence survival following pleurectomy/decortication for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncol Lett
</td>
</tr>
<tr>
<td style="text-align:left;">
Cryobiopsy during flex-rigid pleuroscopy: an emerging alternative biopsy method in malignant pleural mesothelioma. A comparative study of pathology.
</td>
<td style="text-align:left;">
Jpn. J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Highly expressed EZH2 in combination with BAP1 and MTAP loss, as detected by immunohistochemistry, is useful for differentiating malignant pleural mesothelioma from reactive mesothelial hyperplasia.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
High BIN1 expression has a favorable prognosis in malignant pleural mesothelioma and is associated with tumor infiltrating lymphocytes.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
The importance of FISH signal cut-off values for 9p21 deletion in malignant pleural mesothelioma: Is it underestimated?
</td>
<td style="text-align:left;">
Pathol. Res. Pract.
</td>
</tr>
<tr>
<td style="text-align:left;">
In commemoration of the 2018 Mataro Nagayo Prize: A road to early diagnosis and monitoring of asbestos-related mesothelioma.
</td>
<td style="text-align:left;">
Cancer Sci.
</td>
</tr>
<tr>
<td style="text-align:left;">
Making cold malignant pleural effusions hot: driving novel immunotherapies.
</td>
<td style="text-align:left;">
Oncoimmunology
</td>
</tr>
<tr>
<td style="text-align:left;">
Comparative genetics of diffuse malignant mesothelioma tumors of the peritoneumand pleura, with focus on BAP1 expression.
</td>
<td style="text-align:left;">
Pleura Peritoneum
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemosensitivity and resistance testing in malignant effusions with focus on primary malignant mesothelioma and metastatic adenocarcinoma.
</td>
<td style="text-align:left;">
Pleura Peritoneum
</td>
</tr>
<tr>
<td style="text-align:left;">
Normothermic intraperitoneal chemotherapy long term (NIPEC-LT) in the management of peritoneal surface malignancy, an overview.
</td>
<td style="text-align:left;">
Pleura Peritoneum
</td>
</tr>
<tr>
<td style="text-align:left;">
Tomotherapy in malignant mesothelioma: a planning study to establish dose constraints.
</td>
<td style="text-align:left;">
Strahlenther Onkol
</td>
</tr>
<tr>
<td style="text-align:left;">
Epidermal growth factor receptor (EGFR)-targeted therapies in mesothelioma.
</td>
<td style="text-align:left;">
Expert Opin Drug Deliv
</td>
</tr>
<tr>
<td style="text-align:left;">
Patterns of care and survival of older patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Geriatr Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma: An Open-Label, Multicenter, Phase III Randomized Trial.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
The forensic significance of pseudomesotheliomatous adenocarcinoma of the lung.
</td>
<td style="text-align:left;">
Forensic Sci Med Pathol
</td>
</tr>
<tr>
<td style="text-align:left;">
Unexpected longevity of a patient with malignant pleural mesothelioma: report of a case.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
The Investigation of Lipoxygenases as Therapeutic Targets in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Pathol. Oncol. Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Droplet digital PCR as a novel system for the detection of microRNA‑34b/c methylation in circulating DNA in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pseudomesotheliomatous Carcinoma with a High Pleural Hyaluronic Acid Concentration Arising from a Primary Esophageal Squamous Cell Carcinoma.
</td>
<td style="text-align:left;">
Am J Case Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic value of soluble mesothelin-related peptides in pleural effusion for malignant pleural mesothelioma: An updated meta-analysis.
</td>
<td style="text-align:left;">
Medicine (Baltimore)
</td>
</tr>
<tr>
<td style="text-align:left;">
Extra-pleural pneumonectomy in the era of image-guided intensity-modulated radiotherapy.
</td>
<td style="text-align:left;">
Radiol Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Primary malignant mesothelioma of the diaphragm with liver invasion: A case report and review of literature.
</td>
<td style="text-align:left;">
Medicine (Baltimore)
</td>
</tr>
<tr>
<td style="text-align:left;">
Disparities in Compliance With National Guidelines for the Treatment of Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pathological evaluation of the visceral pleura in the radical pleurectomy/decortication for malignant pleural mesothelioma patients.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Extra-pleural pneumonectomy.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
A Rare Case of Malignant Mesothelioma Presenting with Systemic Lupus Erythematosus Seropositivity: A Case Report and Review of Literature.
</td>
<td style="text-align:left;">
Cureus
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma in Lynch syndrome: A report of two cases and a review of the literature.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Whole-genome sequencing of human malignant mesothelioma tumours and cell lines.
</td>
<td style="text-align:left;">
Carcinogenesis
</td>
</tr>
<tr>
<td style="text-align:left;">
Unusual thoracic manifestations of epithelioid hemangioendothelioma.
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
First-ever Abscopal Effect after Palliative Radiotherapy and Immuno-gene Therapy for Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Cureus
</td>
</tr>
<tr>
<td style="text-align:left;">
Metastatic Clear Cell Renal Carcinoma Without Evidence of a Primary Renal Tumour Mimicking Advanced Stage of Malignant Lung Tumour.
</td>
<td style="text-align:left;">
Klin Onkol
</td>
</tr>
<tr>
<td style="text-align:left;">
50 Patients with Malignant Mesothelioma of Both the Pleura and Peritoneum: A Single-Institution Experience.
</td>
<td style="text-align:left;">
Ann. Surg. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Confocal Laser Endomicroscopy as a Guidance Tool for Pleural Biopsies in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Potential Diagnostic and Prognostic Role of Microenvironment in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnosis and characterization of malignant effusions through pleural fluid cytological examination.
</td>
<td style="text-align:left;">
Curr Opin Pulm Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Loco-regional staging of malignant pleural mesothelioma by integrated <sup>18</sup>F-FDG PET/MRI.
</td>
<td style="text-align:left;">
Eur J Radiol
</td>
</tr>
<tr>
<td style="text-align:left;">
Advances in pulmonary and pleural malignant disorders.
</td>
<td style="text-align:left;">
Clin Med (Lond)
</td>
</tr>
<tr>
<td style="text-align:left;">
Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial.
</td>
<td style="text-align:left;">
BMJ Open
</td>
</tr>
<tr>
<td style="text-align:left;">
Lymphangitic carcinomatosis: A common radiographic manifestation of local failure following extended pleurectomy/decortication in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Role of Immunotherapy in Small Cell Lung Cancer, Thymic Epithelial Tumors, and Mesothelioma.
</td>
<td style="text-align:left;">
Am Soc Clin Oncol Educ Book
</td>
</tr>
<tr>
<td style="text-align:left;">
Fast, Low-Dose Megavoltage-Topogram Localization on TomoTherapy: Initial Clinical Experience With Mesothelioma Patients.
</td>
<td style="text-align:left;">
Pract Radiat Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial.
</td>
<td style="text-align:left;">
Lancet Respir Med
</td>
</tr>
<tr>
<td style="text-align:left;">
The Use of Radiation Therapy for the Treatment of Malignant Pleural Mesothelioma: Expert Opinion from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
A Proposed System Toward Standardizing Surgical-Based Treatments for Malignant Pleural Mesothelioma, From the Joint National Cancer Institute-International Association for the Study of Lung Cancer-Mesothelioma Applied Research Foundation Taskforce.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
CDKN2A copy number and p16 expression in malignant pleural mesothelioma in relation to asbestos exposure.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Inactivation of <i>Bap1</i> Cooperates with Losses of <i>Nf2</i> and <i>Cdkn2a</i> to Drive the Development of Pleural Malignant Mesothelioma in Conditional Mouse Models.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
MicroRNA profiling in serous cavity specimens: Diagnostic challenges and new opportunities.
</td>
<td style="text-align:left;">
Cancer Cytopathol
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical Efficacy and Safety of Nivolumab: Results of a <u>M</u>ulticenter, Op<u>e</u>n-label, Single-a<u>r</u>m, Japanese Phase II study in Mal<u>i</u>gnant Pleural Meso<u>t</u>helioma (MERIT).
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
An unexpected cause of dysphagia: pleural mesothelioma.
</td>
<td style="text-align:left;">
Rev Esp Enferm Dig
</td>
</tr>
<tr>
<td style="text-align:left;">
[Recent Developments in the Regional Treatment of Peritoneal and Pleural Tumours (incl. HIPEC and HITOC)].
</td>
<td style="text-align:left;">
Zentralbl Chir
</td>
</tr>
<tr>
<td style="text-align:left;">
Advances in pathological diagnosis of mesothelioma: what pulmonologists should know.
</td>
<td style="text-align:left;">
Curr Opin Pulm Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Health-Related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Communication of a mesothelioma diagnosis: developing recommendations to improve the patient experience.
</td>
<td style="text-align:left;">
BMJ Open Respir Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of estrogen receptor beta (ERβ) and its prognostic value in pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
The Prevalence and Clinical Relevance of Nonexpandable Lung in Malignant Pleural Mesothelioma. A Prospective, Single-Center Cohort Study of 229 Patients.
</td>
<td style="text-align:left;">
Ann Am Thorac Soc
</td>
</tr>
<tr>
<td style="text-align:left;">
Evaluation of Matrix Metalloproteinase 9 Serum Concentration as a Biomarker in Malignant Mesothelioma.
</td>
<td style="text-align:left;">
Dis. Markers
</td>
</tr>
<tr>
<td style="text-align:left;">
Biomarkers for detecting malignant pleural mesothelioma: Protocol for a reanalysis of published data based on systematic reviews of diagnostic test accuracy.
</td>
<td style="text-align:left;">
Medicine (Baltimore)
</td>
</tr>
<tr>
<td style="text-align:left;">
Development of novel monoclonal antibodies with specific binding affinity for denatured human CD26 in formalin-fixed paraffin-embedded and decalcified specimens.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
</tr>
<tr>
<td style="text-align:left;">
Does Simian Virus 40 (SV40) Have a Role in UK Malignant Pleural Mesothelioma? No Role is Identified in a Sensitive RNA In Situ Hybridization Study on Potentially Affected Birth Cohorts.
</td>
<td style="text-align:left;">
Appl. Immunohistochem. Mol. Morphol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Breath Analysis: A Systematic Review of Volatile Organic Compounds (VOCs) in Diagnostic and Therapeutic Management of Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Cancers (Basel)
</td>
</tr>
<tr>
<td style="text-align:left;">
Evaluation of the psychometric properties and minimally important difference of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM).
</td>
<td style="text-align:left;">
J Patient Rep Outcomes
</td>
</tr>
<tr>
<td style="text-align:left;">
Prospective Study of the Utility of Computed Tomography Triage of Pleural Biopsy Strategies in Patients With Pleural Diseases.
</td>
<td style="text-align:left;">
J Bronchology Interv Pulmonol
</td>
</tr>
<tr>
<td style="text-align:left;">
Prolonged retention of liposomes in the pleural cavity of normal mice and high tumor distribution in mice with malignant pleural effusion, after intrapleural injection.
</td>
<td style="text-align:left;">
Int J Nanomedicine
</td>
</tr>
<tr>
<td style="text-align:left;">
Environmental Health Education for Asbestos-Contaminated Communities in Italy: The Casale Monferrato Case Study.
</td>
<td style="text-align:left;">
Ann Glob Health
</td>
</tr>
<tr>
<td style="text-align:left;">
Management of Clinically Lymph Node-Positive Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Semin. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
MicroRNA-215-5p Treatment Suppresses Mesothelioma Progression via the MDM2-p53-Signaling Axis.
</td>
<td style="text-align:left;">
Mol. Ther.
</td>
</tr>
<tr>
<td style="text-align:left;">
Synergistic Enhancement of Cellular Uptake With CD44-Expressing Malignant Pleural Mesothelioma by Combining Cationic Liposome and Hyaluronic Acid-Lipid Conjugate.
</td>
<td style="text-align:left;">
J Pharm Sci
</td>
</tr>
<tr>
<td style="text-align:left;">
An asbestos contaminated town in the vicinity of an asbestos-cement facility: The case study of Sibaté, Colombia.
</td>
<td style="text-align:left;">
Environ. Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
MTAP immunohistochemistry is an accurate and reproducible surrogate for CDKN2A fluorescence in situ hybridization in diagnosis of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Mod. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pattern of failure after adjuvant radiotherapy following extrapleural pneumonectomy of pleural mesothelioma in the SAKK 17/04 trial.
</td>
<td style="text-align:left;">
Radiother Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
What can independent research for mesothelioma achieve to treat this orphan disease?
</td>
<td style="text-align:left;">
Expert Opin Investig Drugs
</td>
</tr>
<tr>
<td style="text-align:left;">
Preliminary results of entire pleural intensity-modulated radiotherapy in a neoadjuvant setting for resectable malignant mesothelioma.
</td>
<td style="text-align:left;">
Radiat Oncol J
</td>
</tr>
<tr>
<td style="text-align:left;">
Interobserver variation in the assessment of the sarcomatoid and transitional components in biphasic mesotheliomas.
</td>
<td style="text-align:left;">
Mod. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Targeting angiogenesis for patients with unresectable malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Semin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Peritoneal mesothelioma and asbestos exposure: a population-based case-control study in Lombardy, Italy.
</td>
<td style="text-align:left;">
Occup Environ Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleurectomy/decortication and hyperthermic intrathoracic chemoperfusion using cisplatin and doxorubicin for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant deciduoid mesothelioma: a rare variant of epithelioid mesothelioma.
</td>
<td style="text-align:left;">
BMJ Case Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
Metastatic Pleural Effusion: An Unusual Presentation of Urothelial Bladder Carcinoma.
</td>
<td style="text-align:left;">
Cureus
</td>
</tr>
<tr>
<td style="text-align:left;">
Nivo-lution in Mesothelioma.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Simple and Rapid Quantification of the Multi-Enzyme Targeting Antifolate Pemetrexed in Human Plasma.
</td>
<td style="text-align:left;">
Ther Drug Monit
</td>
</tr>
<tr>
<td style="text-align:left;">
The Oncolytic Virus <i>dl</i>922-947 Triggers Immunogenic Cell Death in Mesothelioma and Reduces Xenograft Growth.
</td>
<td style="text-align:left;">
Front Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
A multicenter, randomized, phase II/III study of dendritic cells loaded with allogeneic tumor cell lysate (MesoPher) in subjects with mesothelioma as maintenance therapy after chemotherapy: DENdritic cell Immunotherapy for Mesothelioma (DENIM) trial.
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Molecular characterization of localized pleural mesothelioma.
</td>
<td style="text-align:left;">
Mod. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Heterologous sarcomatoid pleural mesothelioma with osteosarcomatous differentiation: a report of autopsy case that accomplished trimodality therapy and review of the literature.
</td>
<td style="text-align:left;">
Gen Thorac Cardiovasc Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma in situ: morphologic features and clinical outcome.
</td>
<td style="text-align:left;">
Mod. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma of the tunica vaginalis testis.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
The Prognostic Role of TNM Staging Compared With Tumor Volume and Number of Pleural Sites in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905).
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Cumulative asbestos exposure and mortality from asbestos related diseases in a pooled analysis of 21 asbestos cement cohorts in Italy.
</td>
<td style="text-align:left;">
Environ Health
</td>
</tr>
<tr>
<td style="text-align:left;">
Immune Signature of Malignant Pleural Mesothelioma as Assessed by Transcriptome Analysis.
</td>
<td style="text-align:left;">
Cancer Genomics Proteomics
</td>
</tr>
<tr>
<td style="text-align:left;">
Dropwort-induced metabolic reprogramming restrains YAP/TAZ/TEAD oncogenic axis in mesothelioma.
</td>
<td style="text-align:left;">
J. Exp. Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Association Between Simian Virus 40 and Human Tumors.
</td>
<td style="text-align:left;">
Front Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Role of asbestos clearance in explaining long-term risk of pleural and peritoneal cancer: a pooled analysis of cohort studies.
</td>
<td style="text-align:left;">
Occup Environ Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Targeting the C-terminus of galectin-9 induces mesothelioma apoptosis and M2 macrophage depletion.
</td>
<td style="text-align:left;">
Oncoimmunology
</td>
</tr>
<tr>
<td style="text-align:left;">
MESOTIP: Phase II multicenter randomized trial evaluating the association of PIPAC and systemic chemotherapy vs. systemic chemotherapy alone as 1st-line treatment of malignant peritoneal mesothelioma.
</td>
<td style="text-align:left;">
Pleura Peritoneum
</td>
</tr>
<tr>
<td style="text-align:left;">
Bidirectional chemotherapy allowing surgery and HIPEC for malignant peritoneal mesothelioma.
</td>
<td style="text-align:left;">
Pleura Peritoneum
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers.
</td>
<td style="text-align:left;">
Mol. Ther.
</td>
</tr>
<tr>
<td style="text-align:left;">
Multidisciplinary palliative treatment including isolated thoracic perfusion for progressive malignant pleural mesothelioma: a retrospective observational study.
</td>
<td style="text-align:left;">
J BUON
</td>
</tr>
<tr>
<td style="text-align:left;">
Phenotypic and functional analysis of malignant mesothelioma tumor-infiltrating lymphocytes.
</td>
<td style="text-align:left;">
Oncoimmunology
</td>
</tr>
<tr>
<td style="text-align:left;">
Multi-antigen Vaccination With Simultaneous Engagement of the OX40 Receptor Delays Malignant Mesothelioma Growth and Increases Survival in Animal Models.
</td>
<td style="text-align:left;">
Front Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Largely Unchanged Annual Incidence and Overall Survival of Pleural Mesothelioma in the USA.
</td>
<td style="text-align:left;">
World J Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Return to intended oncologic treatment after surgery for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant Pleural Effusion and Its Current Management: A Review.
</td>
<td style="text-align:left;">
Medicina (Kaunas)
</td>
</tr>
<tr>
<td style="text-align:left;">
Integration of Tumor-Treating Fields into the Multidisciplinary Management of Patients with Solid Malignancies.
</td>
<td style="text-align:left;">
Oncologist
</td>
</tr>
<tr>
<td style="text-align:left;">
Building a Bridge between Chemotherapy and Immunotherapy in Malignant Pleural Mesothelioma: Investigating the Effect of Chemotherapy on Immune Checkpoint Expression.
</td>
<td style="text-align:left;">
Int J Mol Sci
</td>
</tr>
<tr>
<td style="text-align:left;">
Radiologic Considerations and Standardization of Malignant Pleural Mesothelioma Imaging Within Clinical Trials: Consensus Statement from the NCI Thoracic Malignancy Steering Committee - International Association for the Study of Lung Cancer - Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Liquid Biopsy in Malignant Pleural Mesothelioma: State of the Art, Pitfalls, and Perspectives.
</td>
<td style="text-align:left;">
Front Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Carcinogenic effect of potassium octatitanate (POT) fibers in the lung and pleura of male Fischer 344 rats after intrapulmonary administration.
</td>
<td style="text-align:left;">
Part Fibre Toxicol
</td>
</tr>
<tr>
<td style="text-align:left;">
MicroRNA Signatures in Malignant Pleural Mesothelioma Effusions.
</td>
<td style="text-align:left;">
Dis. Markers
</td>
</tr>
<tr>
<td style="text-align:left;">
EPHA2 mutations with oncogenic characteristics in squamous cell lung cancer and malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncogenesis
</td>
</tr>
<tr>
<td style="text-align:left;">
Proceedings of the American Society of Cytopathology companion session at the 2019 United States and Canadian Academy of Pathology Annual meeting, part 2: effusion cytology with focus on theranostics and diagnosis of malignant mesothelioma.
</td>
<td style="text-align:left;">
J Am Soc Cytopathol
</td>
</tr>
<tr>
<td style="text-align:left;">
Determination of Mesothelin Levels in Pleural Effusion Does Not Help Predict Survival of Patients With Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Survival in patients with malignant pleural effusion undergoing talc pleurodesis.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant Mesothelioma: Has Anything Changed?
</td>
<td style="text-align:left;">
Semin Respir Crit Care Med
</td>
</tr>
<tr>
<td style="text-align:left;">
V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Mod. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Translating mesothelioma molecular genomics and dependencies into precision oncology-based therapies.
</td>
<td style="text-align:left;">
Semin. Cancer Biol.
</td>
</tr>
<tr>
<td style="text-align:left;">
EURACAN/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Development of a Novel Prognostic Risk Classification System for Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Modified Liquid-Based Cytology Technique for Immunocytochemistry in Effusion Specimen.
</td>
<td style="text-align:left;">
Asian Pac. J. Cancer Prev.
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase I study of YS110, a recombinant humanized monoclonal antibody to CD26, in Japanese patients with advanced malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Volumetric Modulated Arc Therapy After Lung Sparing Surgery for Malignant Pleural Mesothelioma: A Single Institution Experience.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma in construction workers: the Apulia regional mesothelioma register, Southern Italy.
</td>
<td style="text-align:left;">
BMC Res Notes
</td>
</tr>
<tr>
<td style="text-align:left;">
Molecular Analysis of a Patient With Neurofibromatosis 2 (NF2) and Peritoneal Malignant Mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
In-vivo imaging of methionine metabolism in patients with suspected malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Nucl Med Commun
</td>
</tr>
<tr>
<td style="text-align:left;">
In Vitro Characterization of Cisplatin and Pemetrexed Effects in Malignant Pleural Mesothelioma 3D Culture Phenotypes.
</td>
<td style="text-align:left;">
Cancers (Basel)
</td>
</tr>
<tr>
<td style="text-align:left;">
Bortezomib sensitivity is tissue dependent and high expression of the 20S proteasome precludes good response in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Manag Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Morphological difference between pleural mesothelioma cells in effusion smears with either BAP1 loss or 9p21 homozygous deletion and reactive mesothelial cells without the gene alterations.
</td>
<td style="text-align:left;">
Pathol. Int.
</td>
</tr>
<tr>
<td style="text-align:left;">
Establishment and characterization of human malignant pleural mesothelioma cell line SMC-1.
</td>
<td style="text-align:left;">
Sci. Sin., Ser. B, Chem. Biol. Agric. Med. Earth Sci.
</td>
</tr>
<tr>
<td style="text-align:left;">
Intracavitary cisplatin-fibrin chemotherapy after surgery for malignant pleural mesothelioma: A phase I trial.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Survival results in biphasic malignant pleural mesothelioma patients: A multicentric analysis.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Approved and emerging treatments of malignant pleural mesothelioma in elderly patients.
</td>
<td style="text-align:left;">
Expert Rev Respir Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Effects of the Storage Solution Type and Prolonged Storage on the Immunoreactivity of Cells.
</td>
<td style="text-align:left;">
Acta Cytol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Endoplasmic Reticulum Stress Signaling as a Therapeutic Target in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Cancers (Basel)
</td>
</tr>
<tr>
<td style="text-align:left;">
Adequate nephroprotection reduces renal complications after hyperthermic intrathoracic chemotherapy.
</td>
<td style="text-align:left;">
J Surg Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Dual-input tracer kinetic modeling of dynamic contrast-enhanced MRI in thoracic malignancies.
</td>
<td style="text-align:left;">
J Appl Clin Med Phys
</td>
</tr>
<tr>
<td style="text-align:left;">
Stereotactic Body Radiation Therapy (SBRT) as Salvage Therapy for Oligorecurrent Pleural Mesothelioma After Multi-Modality Therapy.
</td>
<td style="text-align:left;">
Front Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Functional Genomic Screen in Mesothelioma Reveals that Loss of Function of BRCA1-Associated Protein 1 Induces Chemoresistance to Ribonucleotide Reductase Inhibition.
</td>
<td style="text-align:left;">
Mol. Cancer Ther.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant Mesothelioma - Report of Two Cases with Different Presentations.
</td>
<td style="text-align:left;">
Indian J Occup Environ Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial.
</td>
<td style="text-align:left;">
Lancet Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Posterior Intercostal Lymph Nodes Double Recurrence and Death Risk in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
CD70 expression correlates with a worse prognosis in malignant pleural mesothelioma patients via immune evasion and enhanced invasiveness.
</td>
<td style="text-align:left;">
J. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Role of the contrast-enhanced spectral mammography for the diagnosis of breast metastases from extramammary neoplasms.
</td>
<td style="text-align:left;">
J BUON
</td>
</tr>
<tr>
<td style="text-align:left;">
Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interactions.
</td>
<td style="text-align:left;">
EBioMedicine
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic Value of Computed Tomography Imaging Features in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Respiration
</td>
</tr>
<tr>
<td style="text-align:left;">
Detection of Anaplastic Lymphoma Kinase-Rearranged Mesothelioma Cells in Ascites by Companion Diagnostics.
</td>
<td style="text-align:left;">
Acta Cytol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Multicystic peritoneal mesothelioma: a systematic review of the literature.
</td>
<td style="text-align:left;">
Pleura Peritoneum
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma in situ diagnosed by methylthioadenosine phosphorylase loss and homozygous deletion of CDKN2A: a case report.
</td>
<td style="text-align:left;">
Virchows Arch.
</td>
</tr>
<tr>
<td style="text-align:left;">
Emerging therapies in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Crit. Rev. Oncol. Hematol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Extrapleural pneumonectomies for pleural mesothelioma.
</td>
<td style="text-align:left;">
Expert Rev Respir Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Globular C1q Receptor (gC1qR/p32/HABP1) Is Overexpressed in Malignant Pleural Mesothelioma and Is Associated With Increased Survival in Surgical Patients Treated With Chemotherapy.
</td>
<td style="text-align:left;">
Front Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
[The occurrence of asbestos-related diseases among former employees of asbestos processing plants in Poland].
</td>
<td style="text-align:left;">
Med Pr
</td>
</tr>
<tr>
<td style="text-align:left;">
CRISPR Screening Identifies WEE1 as a Combination Target for Standard Chemotherapy in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Mol. Cancer Ther.
</td>
</tr>
<tr>
<td style="text-align:left;">
The mTOR Signaling Pathway Is Associated With the Prognosis of Malignant Pleural Mesothelioma After Multimodality Therapy.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Intrapleural urokinase directly under medical thoracoscopy for the diagnosis of tuberculous pleurisy.
</td>
<td style="text-align:left;">
Respirol Case Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
Elevated Circulating Activin A Levels in Patients With Malignant Pleural Mesothelioma Are Related to Cancer Cachexia and Reduced Response to Platinum-based Chemotherapy.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Secretome of pleural effusions associated with non-small cell lung cancer (NSCLC) and malignant mesothelioma: therapeutic implications.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
Extended pleurectomy decortication for the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Multimed Man Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Inhibition of cyclin-dependent kinase 7 down-regulates yes-associated protein expression in mesothelioma cells.
</td>
<td style="text-align:left;">
J. Cell. Mol. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Fibrolipoma of the left ventricle: an uncommon incidental autopsy finding.
</td>
<td style="text-align:left;">
Forensic Sci Med Pathol
</td>
</tr>
<tr>
<td style="text-align:left;">
Detection of TGF-β in pleural effusions for diagnosis and prognostic stratification of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Anaplastic Lymphoma Kinase Gene Rearrangement in Children and Young Adults With Mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Long-term benefit from immune modulation and anti-inflammatory treatment in metastatic mesothelioma.
</td>
<td style="text-align:left;">
Respir Med Case Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
Correlation of prechemotherapy urinary megalin ectodomain (A-megalin) levels with the development of cisplatin-induced nephrotoxicity: a prospective observational study.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
</td>
<td style="text-align:left;">
Lancet Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Metabolic rewiring and redox alterations in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Mortality and mesothelioma incidence among chrysotile asbestos miners in Balangero, Italy: A cohort study.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Serum levels of the chemokine CCL2 are elevated in malignant pleural mesothelioma patients.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Nivolumab for the treatment of unresectable pleural mesothelioma.
</td>
<td style="text-align:left;">
Expert Opin Biol Ther
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical utility of FDG-PET/CT for post-surgery surveillance of malignant pleural mesothelioma - Comparison with contrast-enhanced CT.
</td>
<td style="text-align:left;">
Oncotarget
</td>
</tr>
<tr>
<td style="text-align:left;">
<i>In-vitro</i> proliferation assay with recycled ascitic cancer cells in malignant pleural mesothelioma: A case report.
</td>
<td style="text-align:left;">
World J Clin Cases
</td>
</tr>
<tr>
<td style="text-align:left;">
A Phase II Study of Pazopanib in Patients with Malignant Pleural Mesothelioma: NCCTG N0623 (Alliance).
</td>
<td style="text-align:left;">
Oncologist
</td>
</tr>
<tr>
<td style="text-align:left;">
Novel Germline Mutations in DNA Damage Repair in Patients with Malignant Pleural Mesotheliomas.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
A gene-expression-based test can outperform bap1 and <i>p16</i> analyses in the differential diagnosis of pleural mesothelial proliferations.
</td>
<td style="text-align:left;">
Oncol Lett
</td>
</tr>
<tr>
<td style="text-align:left;">
A phase II trial of single oral FGF inhibitor, AZD4547, as second or third line therapy in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice.
</td>
<td style="text-align:left;">
J Vis Exp
</td>
</tr>
<tr>
<td style="text-align:left;">
Combined MEK and PI3K/p110β Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Analysis of mismatch repair (MMR) proteins expression in a series of malignant pleural mesothelioma (MPM) patients.
</td>
<td style="text-align:left;">
Clin Transl Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
LOX family and ZFPM2 as novel diagnostic biomarkers for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Biomark Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Screening of Pleural Mesothelioma Cell Lines for Kinase Activity May Identify New Mechanisms of Therapy Resistance in Patients Receiving Platin-Based Chemotherapy.
</td>
<td style="text-align:left;">
J Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Dosimetric Comparison of Lung-Sparing Radiation Therapy between Volumetric Arc Therapy and Helical Tomotherapy for Unresectable Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Biomed Res Int
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical Outcomes With Recurrence After Pleurectomy/Decortication for Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical feature of diagnostic challenging cases for pleural biopsy in patient with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Gen Thorac Cardiovasc Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
18F-fluorodeoxyglucose positron emission tomography in malignant pleural mesothelioma: diagnostic and prognostic performance and its correlation to pathological results.
</td>
<td style="text-align:left;">
Interact Cardiovasc Thorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnosis of Mesothelioma.
</td>
<td style="text-align:left;">
Surg Pathol Clin
</td>
</tr>
<tr>
<td style="text-align:left;">
The Role of Neoadjuvant Chemotherapy in Patients with Resectable Malignant Pleural Mesothelioma - An Institutional and National Analysis.
</td>
<td style="text-align:left;">
J. Natl. Cancer Inst.
</td>
</tr>
<tr>
<td style="text-align:left;">
An Emerging Model for Cancer Development from a Tumor Microenvironment Perspective in Mice and Humans.
</td>
<td style="text-align:left;">
Adv. Exp. Med. Biol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Differential Diagnosis of Malignant Pleural Mesothelioma on Cytology: A Gene Expression Panel versus BRCA1-Associated Protein 1 and p16 Tests.
</td>
<td style="text-align:left;">
J Mol Diagn
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future.
</td>
<td style="text-align:left;">
Front Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Paclitaxel-loaded expansile nanoparticles improve survival following cytoreductive surgery in pleural mesothelioma xenografts.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Utility of Nuclear Grading System in Epithelioid Malignant Pleural Mesothelioma in Biopsy-heavy Setting: An External Validation Study of 563 Cases.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Light Fluence Rate and Tissue Oxygenation (S<sub>t</sub> O<sub>2</sub> ) Distributions Within the Thoracic Cavity of Patients Receiving Intraoperative Photodynamic Therapy for Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Photochem. Photobiol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Effusion cytology of malignant mesothelioma enables earlier diagnosis and recognizes patients with better prognosis.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Exhaled Breath Analysis in Diagnosis of Malignant Pleural Mesothelioma: Systematic Review.
</td>
<td style="text-align:left;">
Int J Environ Res Public Health
</td>
</tr>
<tr>
<td style="text-align:left;">
Infrared navigation system for light dosimetry during pleural photodynamic therapy.
</td>
<td style="text-align:left;">
Phys Med Biol
</td>
</tr>
<tr>
<td style="text-align:left;">
Impact of Detecting Occult Pathologic Nodal Disease During Resection for Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic value of SUVmax on 18F-fluorodeoxyglucose PET/CT scan in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
</tr>
<tr>
<td style="text-align:left;">
[Establishment and characterization of patient derived xenograft model of malignant peritoneal mesothelioma in nude mice].
</td>
<td style="text-align:left;">
Zhonghua Bing Li Xue Za Zhi
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of imaging in malignant pleural mesothelioma: an update after the 2018 BTS guidelines.
</td>
<td style="text-align:left;">
Clin Radiol
</td>
</tr>
<tr>
<td style="text-align:left;">
A case of surgically treated bilateral metachronous malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Turk Gogus Kalp Damar Cerrahisi Derg
</td>
</tr>
<tr>
<td style="text-align:left;">
Genetic alterations of malignant pleural mesothelioma: association with tumor heterogeneity and overall survival.
</td>
<td style="text-align:left;">
Mol Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16).
</td>
<td style="text-align:left;">
Ann. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Preoperative prediction of unresectability in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Disease-Related Outcomes and Toxicities of Intensity Modulated Radiation Therapy After Lung-Sparing Pleurectomy for Malignant Pleural Mesothelioma: A Systematic Review.
</td>
<td style="text-align:left;">
Pract Radiat Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Impressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and EML4-ALK rearrangement.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
A phase II study of the combination of gemcitabine and imatinib mesylate in pemetrexed-pretreated patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
MicroRNA-98 is a prognostic factor for asbestos-induced mesothelioma.
</td>
<td style="text-align:left;">
J. Toxicol. Environ. Health Part A
</td>
</tr>
<tr>
<td style="text-align:left;">
Manipulating microRNAs for the Treatment of Malignant Pleural Mesothelioma: Past, Present and Future.
</td>
<td style="text-align:left;">
Front Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma cells secrete natriuretic peptides: Data and diagnostic clinical implications.
</td>
<td style="text-align:left;">
Respirology
</td>
</tr>
<tr>
<td style="text-align:left;">
ADAR2 Regulates Malignant Behaviour of Mesothelioma Cells Independent of RNA-editing Activity.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Histopathological features of epithelioid malignant pleural mesotheliomas in patients with extended survival.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Remarkable response to nivolumab in sarcomatoid malignant pleural mesothelioma with high PD-L1.
</td>
<td style="text-align:left;">
Respirol Case Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunotherapy in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Front Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Curcumin as an Anticancer Agent in Malignant Mesothelioma: A Review.
</td>
<td style="text-align:left;">
Int J Mol Sci
</td>
</tr>
<tr>
<td style="text-align:left;">
How I treat malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
ESMO Open
</td>
</tr>
<tr>
<td style="text-align:left;">
Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Intramedullary Metastasis to the Cervical Spinal Cord from Malignant Pleural Mesothelioma: Review of the Literature and Case Reports.
</td>
<td style="text-align:left;">
Asian J Neurosurg
</td>
</tr>
<tr>
<td style="text-align:left;">
Single-center study to determine the safety and efficacy of CT-707 in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non-small-cell lung cancer.
</td>
<td style="text-align:left;">
Thorac Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Utility of Claudin-4 versus BerEP4 and B72.3 in pleural fluids with metastatic lung adenocarcinoma.
</td>
<td style="text-align:left;">
J Am Soc Cytopathol
</td>
</tr>
<tr>
<td style="text-align:left;">
Progressive growth of a human pleural mesothelioma xenografted to athymic rats and mice.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse mesothelin expression leads to worse prognosis through enhanced cellular proliferation in colorectal cancer.
</td>
<td style="text-align:left;">
Oncol Lett
</td>
</tr>
<tr>
<td style="text-align:left;">
[Short and long term behaviour of pleural effusion cultures. (Report of 200 cases) (author’s transl)].
</td>
<td style="text-align:left;">
Pathol. Biol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Application of immunohistochemistry in diagnosis and management of malignant mesothelioma.
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemotherapy options versus “novel” therapies: how should we treat patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgery for pleural mesothelioma, when it is indicated and why: arguments against surgery for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
</tr>
<tr>
<td style="text-align:left;">
IgG4-related pleural disease with aortitis and submandibular glands involvement successfully treated with corticosteroid: case-based review.
</td>
<td style="text-align:left;">
Rheumatol. Int.
</td>
</tr>
<tr>
<td style="text-align:left;">
Randomised placebo-controlled cross-over study examining the role of anamorelin in mesothelioma (The ANTHEM study): rationale and protocol.
</td>
<td style="text-align:left;">
BMJ Open Respir Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Not gene therapy, but genetic surgery-the right strategy to attack cancer.
</td>
<td style="text-align:left;">
Mol. Gen. Microbiol. Virol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading?
</td>
<td style="text-align:left;">
Front Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
T cell receptor repertoire characteristics both before and following immunotherapy correlate with clinical response in mesothelioma.
</td>
<td style="text-align:left;">
J Immunother Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Tumour cell PD-L1 expression is prognostic in patients with malignant pleural effusion: the impact of C-reactive protein and immune-checkpoint inhibition.
</td>
<td style="text-align:left;">
Sci Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical Trials Eligibility of Patients With Malignant Pleural Mesothelioma: Use of Novel Therapies and Outcomes.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Detection of Circulating Tumor Cells (CTCs) in Malignant Pleural Mesothelioma (MPM) with the “Universal” CTC-Chip and An Anti-Podoplanin Antibody NZ-1.2.
</td>
<td style="text-align:left;">
Cells
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgery for Mesothelioma After Radiation Therapy (SMART); A Single Institution Experience.
</td>
<td style="text-align:left;">
Front Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
The Biology of Malignant Mesothelioma and the Relevance of Preclinical Models.
</td>
<td style="text-align:left;">
Front Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Fully Human Antibodies for Malignant Pleural Mesothelioma Targeting.
</td>
<td style="text-align:left;">
Cancers (Basel)
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment of bronchial fistula after extraplural pneumonectomy using flexible bronchoscopy with the administration of OK432, fibroblast growth factor basic and fibrin glue sealant.
</td>
<td style="text-align:left;">
Gen Thorac Cardiovasc Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
A Unique Gene-Silencing Approach, Using an Intelligent RNA Expression Device (iRed), Results in Minimal Immune Stimulation When Given by Local Intrapleural Injection in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Molecules
</td>
</tr>
<tr>
<td style="text-align:left;">
FDG-PET assessment of malignant pleural mesothelioma: Total Lesion volume and Total Lesion Glycolysis; the central role of volume.
</td>
<td style="text-align:left;">
J. Nucl. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
A phase II study of VP-16 and cisplatin in patients with unresectable malignant mesothelioma. An NCI Canada Clinical Trials Group Study.
</td>
<td style="text-align:left;">
Invest New Drugs
</td>
</tr>
<tr>
<td style="text-align:left;">
Differentiating Between Malignant Mesothelioma and Other Pleural Lesions Using Fourier Transform Infrared Spectroscopy.
</td>
<td style="text-align:left;">
Appl Spectrosc
</td>
</tr>
<tr>
<td style="text-align:left;">
Circulating Epigenetic Biomarkers in Malignant Pleural Mesothelioma: State of the Art and critical Evaluation.
</td>
<td style="text-align:left;">
Front Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Targeted Phototherapy for Malignant Pleural Mesothelioma: Near-Infrared Photoimmunotherapy Targeting Podoplanin.
</td>
<td style="text-align:left;">
Cells
</td>
</tr>
<tr>
<td style="text-align:left;">
Modulation of microRNA expression levels after naturally occurring asbestiform fibers exposure as a diagnostic biomarker of mesothelial neoplastic transformation.
</td>
<td style="text-align:left;">
Ecotoxicol. Environ. Saf.
</td>
</tr>
<tr>
<td style="text-align:left;">
Genomic analysis in short- and long-term patients with malignant pleura mesothelioma treated with palliative chemotherapy.
</td>
<td style="text-align:left;">
Eur. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic and clinicopathological utility of programmed death-ligand 1 in malignant pleural mesothelioma: A meta-analysis.
</td>
<td style="text-align:left;">
Int. Immunopharmacol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Putative Biomarkers for Malignant Pleural Mesothelioma Suggested by Proteomic Analysis of Cell Secretome.
</td>
<td style="text-align:left;">
Cancer Genomics Proteomics
</td>
</tr>
<tr>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
Med Lav
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment patterns among patients with malignant pleural mesothelioma: An Italian, population-based nationwide study.
</td>
<td style="text-align:left;">
Thorac Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Mutational Profiling of Driver Tumor Suppressor and Oncogenic Genes in Brazilian Malignant Pleural Mesotheliomas.
</td>
<td style="text-align:left;">
Pathobiology
</td>
</tr>
<tr>
<td style="text-align:left;">
Inhibition of miR-18a-3p reduces proliferation of mesothelioma cells and sensitizes them to cisplatin.
</td>
<td style="text-align:left;">
Oncol Lett
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant Pleural Mesothelioma: Genetic and Microenviromental Heterogeneity as an Unexpected Reading Frame and Therapeutic Challenge.
</td>
<td style="text-align:left;">
Cancers (Basel)
</td>
</tr>
<tr>
<td style="text-align:left;">
Breath Analysis for Early Detection of Malignant Pleural Mesothelioma: Volatile Organic Compounds (VOCs) Determination and Possible Biochemical Pathways.
</td>
<td style="text-align:left;">
Cancers (Basel)
</td>
</tr>
<tr>
<td style="text-align:left;">
Metformin-loaded chitosomes for treatment of malignant pleural mesothelioma - A rare thoracic cancer.
</td>
<td style="text-align:left;">
Int. J. Biol. Macromol.
</td>
</tr>
<tr>
<td style="text-align:left;">
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
</tr>
<tr>
<td style="text-align:left;">
Initial evaluation of nivolumab in patients with post-operative recurrence of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Jpn. J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Breast metastasis as the initial presentation of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Breast J
</td>
</tr>
<tr>
<td style="text-align:left;">
Irinotecan inducing sinus pause bradycardia in a patient with small round cell cancer.
</td>
<td style="text-align:left;">
BMJ Case Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
Cisplatin plus pemetrexed therapy and subsequent immune checkpoint inhibitor administration for malignant peritoneal mesothelioma without pleural lesions: Case report.
</td>
<td style="text-align:left;">
Medicine (Baltimore)
</td>
</tr>
<tr>
<td style="text-align:left;">
Impact of hypoxia on chemoresistance of mesothelioma mediated by the proton-coupled folate transporter, and preclinical activity of new anti-LDH-A compounds.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant asbestos-related disease in a population exposed to asbestos.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Comparison of modified Response Evaluation Criteria in Solid Tumors, European Organization for Research and Treatment of Cancer criteria, and PET Response Criteria in Solid Tumors for evaluation of tumor response to chemotherapy and prognosis prediction in patients with unresectable malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Nucl Med Commun
</td>
</tr>
<tr>
<td style="text-align:left;">
TGFα Promotes Chemoresistance of Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Cancers (Basel)
</td>
</tr>
<tr>
<td style="text-align:left;">
Indwelling pleural catheter versus talc pleurodesis for malignant pleural effusion: a meta-analysis.
</td>
<td style="text-align:left;">
Clin. Exp. Metastasis
</td>
</tr>
<tr>
<td style="text-align:left;">
Estimate of environmental and occupational components in the spatial distribution of malignant mesothelioma incidence in Lombardy (Italy).
</td>
<td style="text-align:left;">
Environ. Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Anti-PD-1 antibody combined with chemotherapy suppresses the growth of mesothelioma by reducing myeloid-derived suppressor cells.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Racial Disparities in Treatment Patterns and Survival Among Surgically Treated Malignant Pleural Mesothelioma Patients.
</td>
<td style="text-align:left;">
J Immigr Minor Health
</td>
</tr>
<tr>
<td style="text-align:left;">
Tumor-associated macrophage-derived inflammatory cytokine enhances malignant potential of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Sci.
</td>
</tr>
<tr>
<td style="text-align:left;">
Volumetric PET response assessment outperforms conventional criteria in patients receiving high-dose pembrolizumab for malignant mesothelioma.
</td>
<td style="text-align:left;">
J. Nucl. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
NTRK and ALK rearrangements in malignant pleural mesothelioma, pulmonary neuroendocrine tumours and non-small cell lung cancer.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Genomic-based ancillary assays offer improved diagnostic yield of effusion cytology with potential challenges in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Pathol. Int.
</td>
</tr>
<tr>
<td style="text-align:left;">
NLRP3 and CARD8 polymorphisms influence risk for asbestos-related diseases.
</td>
<td style="text-align:left;">
J Med Biochem
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos-related diseases.
</td>
<td style="text-align:left;">
Int. J. Tuberc. Lung Dis.
</td>
</tr>
<tr>
<td style="text-align:left;">
RapidPlan for Knowledge-Based Planning of Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Pract Radiat Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Predicting cancer using supervised machine learning: Mesothelioma.
</td>
<td style="text-align:left;">
Technol Health Care
</td>
</tr>
<tr>
<td style="text-align:left;">
Role of inflammation in the malignant transformation of pleural mesothelial cells induced by multi-walled carbon nanotubes.
</td>
<td style="text-align:left;">
Nanotoxicology
</td>
</tr>
<tr>
<td style="text-align:left;">
Involvement of the M-CSF/IL-34/CSF-1R pathway in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Immunother Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Cellular Immunotherapy and Locoregional Administration of CAR T-Cells in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Front Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Genomic profiling of multiple primary cancers including synchronous lung adenocarcinoma and bilateral malignant mesotheliomas: Identification of a novel BAP1 germline variant.
</td>
<td style="text-align:left;">
Pathol. Int.
</td>
</tr>
<tr>
<td style="text-align:left;">
TLD1433-Mediated Photodynamic Therapy with an Optical Surface Applicator in the Treatment of Lung Cancer Cells In Vitro.
</td>
<td style="text-align:left;">
Pharmaceuticals (Basel)
</td>
</tr>
<tr>
<td style="text-align:left;">
A Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma.
</td>
<td style="text-align:left;">
Oncologist
</td>
</tr>
<tr>
<td style="text-align:left;">
Gender-based Disparities in Receipt of Care and Survival in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural effusions and pneumothorax: Beyond simple plumbing: Expert opinions on knowledge gaps and essential next steps.
</td>
<td style="text-align:left;">
Respirology
</td>
</tr>
<tr>
<td style="text-align:left;">
Questioning the prognostic role of BAP-1 immunohistochemistry in malignant pleural mesothelioma: A single center experience with systematic review and meta-analysis.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical Features in Patients With Malignant Pleural Mesothelioma With 5-Year Survival and Evaluation of Original Diagnoses.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Comments on a recent case-control study of malignant mesothelioma of the pericardium and the tunica vaginalis testis.
</td>
<td style="text-align:left;">
Scand J Work Environ Health
</td>
</tr>
<tr>
<td style="text-align:left;">
Video-assisted biopsy and talc pleurodesis for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Multimed Man Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical long-term outcome of non-specific pleuritis (NSP) after surgical or medical thoracoscopy.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
<i>EIF4G1</i> and <i>RAN</i> as Possible Drivers for Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Int J Mol Sci
</td>
</tr>
<tr>
<td style="text-align:left;">
FDG PET versus CT radiomics to predict outcome in malignant pleural mesothelioma patients.
</td>
<td style="text-align:left;">
EJNMMI Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Ganetespib in Combination with Pemetrexed-Platinum Chemotherapy in Patients with Pleural Mesothelioma (MESO-02): A Phase Ib Trial.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Comparison between closed pleural biopsy and medical thoracoscopy for the diagnosis of undiagnosed exudative pleural effusions: a systematic review and meta-analysis.
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Preliminary study highlights the potential of immune checkpoint inhibitors in sarcomatoid mesothelioma.
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical significance of histologic subtyping of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Integrative approach to cytologic and molecular diagnosis of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Progress in the understanding of the immune microenvironment and immunotherapy in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Curr Drug Targets
</td>
</tr>
<tr>
<td style="text-align:left;">
Ovarian metastasis from malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Tumori
</td>
</tr>
<tr>
<td style="text-align:left;">
Interobserver Agreement in Histopathological Subtyping of Malignant Pleural Mesotheliomas.
</td>
<td style="text-align:left;">
Turk Patoloji Derg
</td>
</tr>
<tr>
<td style="text-align:left;">
Delayed-Phase Enhancement for Evaluation of Malignant Pleural Mesothelioma on Computed Tomography: A Prospective Cohort Study.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma Biomarkers: A Review Highlighting Contributions from the Early Detection Research Network.
</td>
<td style="text-align:left;">
Cancer Epidemiol. Biomarkers Prev.
</td>
</tr>
<tr>
<td style="text-align:left;">
Laser ablation inductively coupled plasma mass spectrometry as a Novel Clinical Imaging Tool to Detect Asbestos Fibres in Malignant Mesothelioma.
</td>
<td style="text-align:left;">
Rapid Commun. Mass Spectrom.
</td>
</tr>
<tr>
<td style="text-align:left;">
Connective tissue growth factor produced by cancer‑associated fibroblasts correlates with poor prognosis in epithelioid malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
</tr>
<tr>
<td style="text-align:left;">
Dual Inhibition of CDK4/6 and PI3K/AKT/mTOR Signaling Impairs Energy Metabolism in MPM Cancer Cells.
</td>
<td style="text-align:left;">
Int J Mol Sci
</td>
</tr>
<tr>
<td style="text-align:left;">
New vistas in malignant mesothelioma: MicroRNA architecture and NRF2/MAPK signal transduction.
</td>
<td style="text-align:left;">
Life Sci.
</td>
</tr>
<tr>
<td style="text-align:left;">
Normal Mesothelial Cell Lines Newly Derived from Human Pleural Biopsy Explants.
</td>
<td style="text-align:left;">
Am. J. Physiol. Lung Cell Mol. Physiol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Determinants of plasma calretinin in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
BMC Res Notes
</td>
</tr>
<tr>
<td style="text-align:left;">
Multiplex Soluble Biomarker Analysis from Pleural Effusion.
</td>
<td style="text-align:left;">
Biomolecules
</td>
</tr>
<tr>
<td style="text-align:left;">
Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Verification of a blood based targeted proteomics signature for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Epidemiol. Biomarkers Prev.
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytology, immunopathology and flow cytometry in the diagnosis of pleural and peritoneal effusions.
</td>
<td style="text-align:left;">
Lab. Invest.
</td>
</tr>
<tr>
<td style="text-align:left;">
The pleural manifestations of asbestos exposure.
</td>
<td style="text-align:left;">
Occup Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic factors in diffuse malignant pleural mesothelioma. A study of 167 patients.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women’s Hospital experience over two decades, 1965-1985.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Local administration of recombinant interferon-beta to patients with cancer-associated body cavity fluids].
</td>
<td style="text-align:left;">
Gan To Kagaku Ryoho
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of epithelial membrane antigen on malignant mesothelioma cells. An immunocytochemical and immunoelectron microscopic study.
</td>
<td style="text-align:left;">
Acta Cytol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma in a cohort of asbestos insulation workers: clinical presentation, diagnosis, and causes of death.
</td>
<td style="text-align:left;">
Br J Ind Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Case-control study of diet and mesothelioma in Louisiana.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of computed tomography scanning in the initial assessment and the follow-up of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinicopathologic studies on mesothelioma of the pleura. Differentiated approach to treatment.
</td>
<td style="text-align:left;">
Scand J Thorac Cardiovasc Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytophotometric determination of DNA in mesotheliomas and reactive mesothelial cells.
</td>
<td style="text-align:left;">
Anal. Quant. Cytol. Histol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Fine needle aspiration cytology of malignant mesothelioma.
</td>
<td style="text-align:left;">
Acta Cytol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Non-malignant asbestos diseases in workers in an electrochemical plant.
</td>
<td style="text-align:left;">
Br J Ind Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II trial of carboplatin (JM8) in treatment of patients with malignant mesothelioma.
</td>
<td style="text-align:left;">
Cancer Chemother. Pharmacol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Randomized comparison of cyclophosphamide, imidazole carboxamide, and adriamycin versus cyclophosphamide and adriamycin in patients with advanced stage malignant mesothelioma: a Sarcoma Intergroup Study.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Tumors of serosal tissue origin.
</td>
<td style="text-align:left;">
Clin. Lab. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Characterization of a human malignant mesothelioma cell line (H-MESO-1): a biphasic solid and ascitic tumor model.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Serum hyaluronate in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Benign and malignant mesothelial lesions of the pleura: quantitative study.
</td>
<td style="text-align:left;">
Appl Pathol
</td>
</tr>
<tr>
<td style="text-align:left;">
Monoclonal antibodies to human malignant mesothelioma.
</td>
<td style="text-align:left;">
J. Clin. Immunol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Accuracy of diagnostic procedures in the initial evaluation and follow-up of mesothelioma patients.
</td>
<td style="text-align:left;">
Respiration
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos and cancer: a cohort followed up to death.
</td>
<td style="text-align:left;">
Br J Ind Med
</td>
</tr>
<tr>
<td style="text-align:left;">
The cytologic diagnosis of mesothelioma.
</td>
<td style="text-align:left;">
Semin Diagn Pathol
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse malignant mesothelioma of the pleura–intrapleural treatment with doxorubicin.
</td>
<td style="text-align:left;">
Arch. Geschwulstforsch.
</td>
</tr>
<tr>
<td style="text-align:left;">
High incidence of malignant pleural mesothelioma in neighbouring villages of Northwestern Greece.
</td>
<td style="text-align:left;">
Respiration
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma with occupational and environmental asbestos exposure in an Illinois community hospital.
</td>
<td style="text-align:left;">
Arch. Intern. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant diffuse peritoneal mesothelioma: clinical and therapeutic aspects. Apropos of a case with gelatinous ascites].
</td>
<td style="text-align:left;">
Rev Med Interne
</td>
</tr>
<tr>
<td style="text-align:left;">
Cisplatin administered by the intracavitary route as treatment for malignant mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Applications of computerized interactive morphometry in pathology. II. A model for computer generated diagnosis.
</td>
<td style="text-align:left;">
Lab. Invest.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesotheliomas. Improved differential diagnosis from lung adenocarcinomas using monoclonal antibodies 44-3A6 and 624A12.
</td>
<td style="text-align:left;">
Am. J. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Primary malignant tumors of the pleura].
</td>
<td style="text-align:left;">
Rontgenblatter
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse malignant mesothelioma of pleura. Diagnosis and survival in 92 cases.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic value of ferritin analysis in pleural effusions.
</td>
<td style="text-align:left;">
Scand. J. Clin. Lab. Invest.
</td>
</tr>
<tr>
<td style="text-align:left;">
Cardiac abnormalities in patients with diffuse malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Computed tomography of pleural lesions with special reference to the mediastinal pleura.
</td>
<td style="text-align:left;">
Acta Radiol Diagn (Stockh)
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnosis of malignant pleural mesothelioma by axillary lymph node biopsy.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytopathology of asbestos-associated pulmonary disease.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Benign and malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin. Chest Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of concurrent determinations of pleural fluid and tissue carcinoembryonic antigen in the distinction of malignant mesothelioma from metastatic pleural malignancies.
</td>
<td style="text-align:left;">
Eur J Cancer Clin Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
The use of vimentin antibodies in the diagnosis of malignant mesothelioma.
</td>
<td style="text-align:left;">
Virchows Arch A Pathol Anat Histopathol
</td>
</tr>
<tr>
<td style="text-align:left;">
Comparison of needle biopsy with cytologic analysis for the evaluation of pleural effusion: analysis of 414 cases.
</td>
<td style="text-align:left;">
Mayo Clin. Proc.
</td>
</tr>
<tr>
<td style="text-align:left;">
Hyaluronic acid content of effusions as a diagnostic aid for malignant mesothelioma.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant diffuse pleural mesothelioma: a comparison between computed tomography and the conventional chest x-ray].
</td>
<td style="text-align:left;">
Digitale Bilddiagn
</td>
</tr>
<tr>
<td style="text-align:left;">
Trend and distribution of mesothelioma in Denmark.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Modified nucleosides in asbestos workers at high risk of malignant disease: results of a preliminary study applying discriminant analysis.
</td>
<td style="text-align:left;">
Br J Ind Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Trends in mortality from malignant mesothelioma of the pleura, and production and use of asbestos in Australia.
</td>
<td style="text-align:left;">
Med. J. Aust.
</td>
</tr>
<tr>
<td style="text-align:left;">
Biochemical and cytological features of diffuse mesotheliomas of the pleura.
</td>
<td style="text-align:left;">
Arch. Geschwulstforsch.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Bromocriptine in Parkinson’s disease: pleuropulmonary toxicity].
</td>
<td style="text-align:left;">
Ann Med Interne (Paris)
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pleural and peritoneal cytology].
</td>
<td style="text-align:left;">
Cesk Patol
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant fibrosarcomatous mesothelioma and benign pleural fibroma (localized fibrous mesothelioma) in tissue culture: a comparison of the in vitro pattern of growth in relation to the cell of origin.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma presenting in the pleura and peritoneum.
</td>
<td style="text-align:left;">
J Surg Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
[Diffuse malignant mesothelioma of the pleura and peritoneum].
</td>
<td style="text-align:left;">
Cesk Patol
</td>
</tr>
<tr>
<td style="text-align:left;">
[Rare malignant tumors of the lungs (44 cases)].
</td>
<td style="text-align:left;">
Vopr Onkol
</td>
</tr>
<tr>
<td style="text-align:left;">
[Asbestosis. Apropos of one case].
</td>
<td style="text-align:left;">
Poumon Coeur
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunohistochemical localization of prekeratin filaments in benign and malignant cells in effusions. Comparison with intermediate filament distribution by electron microscopy.
</td>
<td style="text-align:left;">
Am. J. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma of the pleura with extensive cardiac invasion and tricuspid orifice occlusion.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Thymostimulin in malignant pleural effusions.
</td>
<td style="text-align:left;">
Int J Tissue React
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma of the pleura: clinical aspects and symptomatic treatment.
</td>
<td style="text-align:left;">
Eur J Respir Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Keratins in malignant mesotheliomas and pleural adenocarcinomas: comparative immunohistochemical analysis with polyclonal and monoclonal antibodies.
</td>
<td style="text-align:left;">
Pathol. Res. Pract.
</td>
</tr>
<tr>
<td style="text-align:left;">
Zeolite bodies in human lungs from Turkey.
</td>
<td style="text-align:left;">
Lab. Invest.
</td>
</tr>
<tr>
<td style="text-align:left;">
Conventional treatment and its effect on survival of malignant pleural mesothelioma in Western Australia.
</td>
<td style="text-align:left;">
Aust N Z J Med
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pleural mesothelioma: 3 developmental forms].
</td>
<td style="text-align:left;">
Sem Hop
</td>
</tr>
<tr>
<td style="text-align:left;">
Fiber size and number in amphibole asbestos-induced mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Non-asbestos-related malignant mesothelioma. A review.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Localized mesothelioma of the pleura: benign and malignant variants.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnosis of pleural malignant mesothelioma in life–a practical approach.
</td>
<td style="text-align:left;">
J. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma of the pleura: a study of 52 treated and 64 untreated patients.
</td>
<td style="text-align:left;">
Thorax
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma of the pleura in Barrow-in-Furness.
</td>
<td style="text-align:left;">
Thorax
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma associated with the syndrome of inappropriate secretion of antidiuretic hormone.
</td>
<td style="text-align:left;">
Am. Rev. Respir. Dis.
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemotherapy of diffuse malignant mesothelioma. Phase II trials of single-agent 5-fluorouracil and adriamycin.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Benign mesothelial proliferation with effusion. Clinicopathologic entity that may mimic malignancy.
</td>
<td style="text-align:left;">
Am. J. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Histological types of malignant mesothelioma and asbestos exposure.
</td>
<td style="text-align:left;">
Br J Ind Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos-related diseases of lung and pleura: clinical picture and illustrative cases.
</td>
<td style="text-align:left;">
Postgrad Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Analysis of number, size and distribution patterns of lipid vacuoles in benign and malignant mesothelial cells.
</td>
<td style="text-align:left;">
Anal Quant Cytol
</td>
</tr>
<tr>
<td style="text-align:left;">
[Radiologic diagnosis in malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Radiol Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse malignant mesothelioma of pleura: diagnostic criteria based on an autopsy study.
</td>
<td style="text-align:left;">
Am. J. Clin. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
CT of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
AJR Am J Roentgenol
</td>
</tr>
<tr>
<td style="text-align:left;">
Brain metastases in malignant fibrous mesothelioma. Case report and review of the literature.
</td>
<td style="text-align:left;">
Acta Neuropathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
67Ga-transferrin and 67Ga-lactoferrin binding to tumor cells: specific versus nonspecific glycoprotein-cell interaction.
</td>
<td style="text-align:left;">
Eur J Nucl Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos exposure. An update on pleuropulmonary hazards.
</td>
<td style="text-align:left;">
Postgrad Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma in urban dogs.
</td>
<td style="text-align:left;">
Vet. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma at St Mary’s Hospital, Portsmouth–a review of 29 fatal cases.
</td>
<td style="text-align:left;">
Postgrad Med J
</td>
</tr>
<tr>
<td style="text-align:left;">
Propagation of a poorly differentiated human pulmonary adenocarcinoma in nude athymic rats.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma: incidence, asbestos exposure, and reclassification of histopathology.
</td>
<td style="text-align:left;">
Br J Ind Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma. The University of Minnesota experience.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: the role of computed tomography.
</td>
<td style="text-align:left;">
J Comput Tomogr
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma. A clinical review of 19 patients.
</td>
<td style="text-align:left;">
Scand J Thorac Cardiovasc Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
The radiology of thoracic malignant mesothelioma.
</td>
<td style="text-align:left;">
Crit Rev Diagn Imaging
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma in two pairs of siblings: is there a hereditary predisposing factor?
</td>
<td style="text-align:left;">
Eur J Respir Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Lactic dehydrogenase isoenzyme electrophoretic patterns in the diagnosis of pleural effusion.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse malignant mesothelioma: a review.
</td>
<td style="text-align:left;">
West. J. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma and asbestos].
</td>
<td style="text-align:left;">
Schweiz Med Wochenschr
</td>
</tr>
<tr>
<td style="text-align:left;">
Intrapleural Corynebacterium parvum for malignant pleural effusions.
</td>
<td style="text-align:left;">
Thorax
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse epithelial pleural mesothelioma presenting as a solitary lung mass.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Computed tomography of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Comput Assist Tomogr
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pleural mesothelioma. Problems, therapy and results].
</td>
<td style="text-align:left;">
Fortschr. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma arising after direct application of asbestos and fiber glass to the pericardium.
</td>
<td style="text-align:left;">
Am. Rev. Respir. Dis.
</td>
</tr>
<tr>
<td style="text-align:left;">
High-dose methotrexate with citrovorum factor and vincristine in the treatment of malignant mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural effusions.
</td>
<td style="text-align:left;">
Br J Hosp Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma in man and experimental animals.
</td>
<td style="text-align:left;">
Environ. Health Perspect.
</td>
</tr>
<tr>
<td style="text-align:left;">
Use of antisera to epithelial membrane antigen for the cytodiagnosis of malignancy in serous effusions.
</td>
<td style="text-align:left;">
J. Clin. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Development of radiological and clinical evidence of parenchymal fibrosis in men with non-malignant asbestos-related pleural lesions.
</td>
<td style="text-align:left;">
Br J Ind Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical staging and the tendency of malignant pleural mesotheliomas to remain localized.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
The value of adriamycin in the treatment of diffuse malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Desmoplastic diffuse mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Combined doxorubicin and radiation therapy in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Treat Rep
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma of the peritoneum].
</td>
<td style="text-align:left;">
Arkh. Patol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Metastatic mesothelioma of the pericardium].
</td>
<td style="text-align:left;">
Z Kardiol
</td>
</tr>
<tr>
<td style="text-align:left;">
Pulmonary asbestos body counts and electron probe analysis of asbestos body cores in patients with mesothelioma: a study of 25 cases.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma of the pleura: relation between histological type and clinical behaviour.
</td>
<td style="text-align:left;">
Thorax
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural biopsy in the diagnosis of malignant mesothelioma.
</td>
<td style="text-align:left;">
Thorax
</td>
</tr>
<tr>
<td style="text-align:left;">
Human malignant diffuse mesothelioma: submicroscopic study on the epithelial component.
</td>
<td style="text-align:left;">
J. Submicrosc. Cytol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma. Retrospective study of 16 cases].
</td>
<td style="text-align:left;">
Schweiz Med Wochenschr
</td>
</tr>
<tr>
<td style="text-align:left;">
A review of the treatment of diffuse malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
IARC Sci. Publ.
</td>
</tr>
<tr>
<td style="text-align:left;">
The clinical and radiological aspects of 185 cases of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
IARC Sci. Publ.
</td>
</tr>
<tr>
<td style="text-align:left;">
The comparative effects of three chrysotiles by injection and inhalation in rats.
</td>
<td style="text-align:left;">
IARC Sci. Publ.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma of the pericardium].
</td>
<td style="text-align:left;">
Arkh. Patol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Secreting peritoneal mesothelioma. Report of a case with cytological, ultrastructural, morphometric and histological studies.
</td>
<td style="text-align:left;">
Virchows Arch A Pathol Anat Histol
</td>
</tr>
<tr>
<td style="text-align:left;">
Learning from quantitation.
</td>
<td style="text-align:left;">
Anal Quant Cytol
</td>
</tr>
<tr>
<td style="text-align:left;">
[Current indications for thoracoscopy].
</td>
<td style="text-align:left;">
Rev Fr Mal Respir
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse malignant pleural mesothelioma in Glasgow.
</td>
<td style="text-align:left;">
Br J Dis Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesothelioma.
</td>
<td style="text-align:left;">
Scand J Thorac Cardiovasc Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical observations following asbestos exposure.
</td>
<td style="text-align:left;">
Environ. Health Perspect.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma: a metastasis to the face.
</td>
<td style="text-align:left;">
J Surg Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma with lung cancer complicating asbestosis.
</td>
<td style="text-align:left;">
Acta Pathol. Jpn.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesotheliomas and chemotherapy.
</td>
<td style="text-align:left;">
J Surg Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma: a review of 35 cases with diagnosis and prognosis.
</td>
<td style="text-align:left;">
Pathology
</td>
</tr>
<tr>
<td style="text-align:left;">
Aggressive multimodality therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunocytochemical typification of mesothelial cells in effusions: in vivo and in vitro models.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Radiotherapy in the treatment of malignant mesothelioma of the pleura, with special reference to its use in palliation.
</td>
<td style="text-align:left;">
Australas Radiol
</td>
</tr>
<tr>
<td style="text-align:left;">
[The clinical picture and therapy of malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Strahlenther Onkol
</td>
</tr>
<tr>
<td style="text-align:left;">
Markers for metastatic adenocarcinoma in serous effusion specimens.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunocytochemical characterization of malignant mesothelioma and carcinoma metastatic to the pleura: IOB3–a new tumor marker.
</td>
<td style="text-align:left;">
Lung
</td>
</tr>
<tr>
<td style="text-align:left;">
Production of granulocyte colony-stimulating factor by malignant mesothelioma.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical evaluation of seven tumour markers in lung cancer diagnosis: can any combination improve the results?
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant peritoneal mesothelioma after Thorotrast exposure.
</td>
<td style="text-align:left;">
Am. J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical features and current treatment of diffuse malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pseudomesotheliomatous carcinoma in HIV infection].
</td>
<td style="text-align:left;">
Dtsch. Med. Wochenschr.
</td>
</tr>
<tr>
<td style="text-align:left;">
Lack of apparent excess of malignant mesothelioma but increased overall malignancies of peritoneal cavity in Japanese autopsies with Thorotrast injection into blood vessels.
</td>
<td style="text-align:left;">
J. Cancer Res. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
OV 632 and MOC 31 in the diagnosis of mesothelioma and adenocarcinoma: an assessment of their use in formalin fixed and paraffin wax embedded material.
</td>
<td style="text-align:left;">
J. Clin. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Optimal management of malignant mesothelioma after subtotal pleurectomy: revisiting the role of intrapleural chemotherapy and postoperative radiation.
</td>
<td style="text-align:left;">
J Surg Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Intracavitary photodynamic therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Semin Surg Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunoreactivity for c-fos and c-myc protein with the monoclonal antibodies 14E10 and 6E10 in malignant mesothelioma and non-neoplastic mesothelium of the pleura.
</td>
<td style="text-align:left;">
Histol. Histopathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Evaluation of the clinical TNM staging system for malignant pleural mesothelioma: an assessment in 88 patients.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment of experimental human mesothelioma using adenovirus transfer of the herpes simplex thymidine kinase gene.
</td>
<td style="text-align:left;">
Ann. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural malignant mesothelioma and non-occupational exposure to asbestos in Casale Monferrato, Italy.
</td>
<td style="text-align:left;">
Occup Environ Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Early experience with videothoracoscopic hydrodissection pleurectomy in the treatment of malignant pleural effusion.
</td>
<td style="text-align:left;">
J Surg Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Parathyroid hormone-related protein antigen localization distinguishes between mesothelioma and adenocarcinoma of the lung.
</td>
<td style="text-align:left;">
J. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
A phase II trial investigating primary immunochemotherapy for malignant pleural mesothelioma and the feasibility of adjuvant immunochemotherapy after maximal cytoreduction.
</td>
<td style="text-align:left;">
Ann. Surg. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Glycosaminoglycans from two human malignant mesothelioma cell lines: determination, distribution, and effect of platelet-derived growth factor on their synthesis.
</td>
<td style="text-align:left;">
Biochem. Cell Biol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Biological and immunological aspects of malignant mesothelioma.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
</tr>
<tr>
<td style="text-align:left;">
Multiple-marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesotheliomas–an analysis of 18 cases and review of the literature.
</td>
<td style="text-align:left;">
Medicine (Baltimore)
</td>
</tr>
<tr>
<td style="text-align:left;">
Molecular deletion of 9p sequences in non-small cell lung cancer and malignant mesothelioma.
</td>
<td style="text-align:left;">
Genes Chromosomes Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Karyotypic changes in the preclinical and subsequent stages of malignant mesothelioma: a case report.
</td>
<td style="text-align:left;">
Cancer Genet. Cytogenet.
</td>
</tr>
<tr>
<td style="text-align:left;">
Characteristics of nine newly derived mesothelioma cell lines.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Intracavitary therapy of neoplastic effusions with cytokines: comparison among interferon alpha, beta and interleukin-2.
</td>
<td style="text-align:left;">
Support Care Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
[Diagnostic value of tissue polypeptide antigen in pleural effusions with malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Nihon Kyobu Shikkan Gakkai Zasshi
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic significance of DNA aneuploidy in diffuse malignant mesothelioma.
</td>
<td style="text-align:left;">
Cytometry
</td>
</tr>
<tr>
<td style="text-align:left;">
[Treatment of malignant pleural effusion by percutaneous catheter drainage and chemical pleurodesis].
</td>
<td style="text-align:left;">
Minerva Chir
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant tumors in an area with an asbestos processing plant.
</td>
<td style="text-align:left;">
Public Health Rev
</td>
</tr>
<tr>
<td style="text-align:left;">
Parietal pleurectomy for malignant pleural effusion.
</td>
<td style="text-align:left;">
Ann. Surg. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of growth factors and cytokines in the tumorigenesis and immunobiology of malignant mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Respir. Cell Mol. Biol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[High-resolution magnetic resonance tomography (HR-MRT) of the pleura and thoracic wall: normal findings and pathological changes].
</td>
<td style="text-align:left;">
Rofo
</td>
</tr>
<tr>
<td style="text-align:left;">
Video-assisted thoracoscopic pleurectomy in the management of malignant pleural effusion.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Interferon (IFN)-alpha and IFN-gamma in combination with methotrexate: in vitro sensitivity studies in four human mesothelioma cell lines.
</td>
<td style="text-align:left;">
Anticancer Drugs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignancies in the lung and pleura mimicking benign processes.
</td>
<td style="text-align:left;">
Semin Diagn Pathol
</td>
</tr>
<tr>
<td style="text-align:left;">
[Cardiac tamponade disclosing neoplasm: apropos of 23 cases].
</td>
<td style="text-align:left;">
Arch Mal Coeur Vaiss
</td>
</tr>
<tr>
<td style="text-align:left;">
Current approach to malignant mesothelioma of the pleura.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma and radical multimodality therapy: who benefits?
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma of the pericardium. An anatomo-clinical study of 10 cases].
</td>
<td style="text-align:left;">
Arch Mal Coeur Vaiss
</td>
</tr>
<tr>
<td style="text-align:left;">
[Fluoroscopically guided percutaneous fine-needle biopsy of the lung using the ROTEX needle: results in 890 patients with focal lung lesions].
</td>
<td style="text-align:left;">
Rofo
</td>
</tr>
<tr>
<td style="text-align:left;">
Combination chemotherapy with cisplatin-vinblastine in malignant mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma presenting as achalasia.
</td>
<td style="text-align:left;">
Intern. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Implantable access system for prolonged intrapleural immunotherapy.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
</tr>
<tr>
<td style="text-align:left;">
An autopsy case of malignant mesothelioma associated with asbestosis.
</td>
<td style="text-align:left;">
Pathol. Int.
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic flexible fiberoptic pleuroscopy in suspected malignant pleural effusions.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Doxorubicin retention and chemoresistance in human mesothelioma cell lines.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Proliferation in malignant mesothelioma as determined by mitosis counts and immunoreactivity for proliferating cell nuclear antigen (PCNA).
</td>
<td style="text-align:left;">
J. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic factors and survival in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma in families of asbestos workers].
</td>
<td style="text-align:left;">
Harefuah
</td>
</tr>
<tr>
<td style="text-align:left;">
Operation and intracavitary photodynamic therapy for malignant pleural mesothelioma: a phase II study.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Contemporary approaches in the investigation and treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Chest Surg. Clin. N. Am.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural and pericardial mesothelioma in a general teaching hospital during the last fourteen years.
</td>
<td style="text-align:left;">
Zhonghua Yi Xue Za Zhi (Taipei)
</td>
</tr>
<tr>
<td style="text-align:left;">
Transforming growth factor-beta 1 (TGF-beta 1)- and beta 2-like activities in malignant pleural effusions caused by malignant mesothelioma or primary lung cancer.
</td>
<td style="text-align:left;">
Clin. Exp. Immunol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Localized pleural mesothelioma. The clinical spectrum.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Metastatic epithelioid hemangioendothelioma in a pleural effusion: diagnosis by cytology.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Thoracic mesothelioma associated with abdominal mesenteric panniculitis.
</td>
<td style="text-align:left;">
Am. J. Gastroenterol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Trials in malignant mesothelioma. LCSG 851 and 882.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Intrapleural chemotherapy without pleurodesis for malignant pleural effusions. LCSG Trial 861.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma of the pericardium].
</td>
<td style="text-align:left;">
Medicina (B Aires)
</td>
</tr>
<tr>
<td style="text-align:left;">
A phase II trial of dose-escalated doxorubicin and ifosfamide/mesna in patients with malignant mesothelioma.
</td>
<td style="text-align:left;">
Ann. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Successful adenovirus-mediated gene transfer in an in vivo model of human malignant mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunohistochemical reactivity in mesothelioma and adenocarcinoma: a stepwise logistic regression analysis.
</td>
<td style="text-align:left;">
APMIS
</td>
</tr>
<tr>
<td style="text-align:left;">
Neoplasms of the mediastinum, chest wall, and pleura.
</td>
<td style="text-align:left;">
Curr Opin Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
[Localized pleural mesothelioma].
</td>
<td style="text-align:left;">
Helv Chir Acta
</td>
</tr>
<tr>
<td style="text-align:left;">
Intrapleural production of interleukin 6 during mesothelioma and its modulation by gamma-interferon treatment.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Effect of fibrous glass on rat pleural mesothelium. Histopathologic observations.
</td>
<td style="text-align:left;">
Am. J. Respir. Crit. Care Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma. Extrapleural pneumonectomy and pleurectomy.
</td>
<td style="text-align:left;">
Chest Surg. Clin. N. Am.
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytogenetic analysis of effusions from malignant mesothelioma. A diagnostic adjunct to cytology.
</td>
<td style="text-align:left;">
Acta Cytol.
</td>
</tr>
<tr>
<td style="text-align:left;">
C-erbB-2 oncoprotein immunostaining in serous effusions.
</td>
<td style="text-align:left;">
Cytopathology
</td>
</tr>
<tr>
<td style="text-align:left;">
The sensitivity of hyaluronan analysis of pleural fluid from patients with malignant mesothelioma and a comparison of different methods.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pleural mesothelioma: a clinicopathologic study of 42 cases].
</td>
<td style="text-align:left;">
Zhonghua Nei Ke Za Zhi
</td>
</tr>
<tr>
<td style="text-align:left;">
Cerebral metastases in pleural mesothelioma: case report and review of the literature.
</td>
<td style="text-align:left;">
J. Neurooncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[The kinetics of IL-2 after pleural administration in the treatment of neoplastic pleurisy].
</td>
<td style="text-align:left;">
Rev Mal Respir
</td>
</tr>
<tr>
<td style="text-align:left;">
AIDS and malignant mesothelioma–is there a connection?
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma: study of prognostic factors in a series of 188 cases].
</td>
<td style="text-align:left;">
Arch. Anat. Cytol. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Immunohistochemistry of mesotheliomas. Technique and current diagnostic contribution of immunohistochemical markers. General review].
</td>
<td style="text-align:left;">
Arch. Anat. Cytol. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos and nonasbestos fiber content in lung tissue of Japanese patients with malignant mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Interferon alpha and doxorubicin in malignant mesothelioma: a phase II study.
</td>
<td style="text-align:left;">
Aust N Z J Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Cohort mortality study of rock salt workers in Italy.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse pulmonary malignant mesothelioma: response to doxorubicin and 5-azacytidine.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical utility of liquid-chromatographic analysis of effusions for hyaluronate content.
</td>
<td style="text-align:left;">
Clin. Chem.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesothelioma and exposure to asbestos: evaluation from work histories and analysis of asbestos bodies in bronchoalveolar lavage fluid or lung tissue in 131 patients.
</td>
<td style="text-align:left;">
Occup Environ Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment of primary or metastatic pleural effusion with intracavitary cytosine arabinoside and cisplatin. A phase II study.
</td>
<td style="text-align:left;">
Acta Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment of malignant pleural mesothelioma with cisplatin, mitomycin C and alpha interferon.
</td>
<td style="text-align:left;">
Oncology
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic and therapeutic thoracoscopy: techniques and indications in pulmonary medicine.
</td>
<td style="text-align:left;">
Tuber. Lung Dis.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Survey for primary tumor site in patients with initial clinical presentation of bone metastasis].
</td>
<td style="text-align:left;">
Kaku Igaku
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pericardial mesothelioma. Evolution and update in the last decade].
</td>
<td style="text-align:left;">
Pathologica
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma of the pleura with an unusual course].
</td>
<td style="text-align:left;">
Ugeskr. Laeg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pulmonary complications of asbestos exposure.
</td>
<td style="text-align:left;">
Am Fam Physician
</td>
</tr>
<tr>
<td style="text-align:left;">
Localized pleural mesothelioma.
</td>
<td style="text-align:left;">
J Belge Radiol
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
High doses of intrapleural cisplatin in a case of malignant pleural mesothelioma. Clinical observations and pharmacokinetic analyses.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Pharmacokinetics of intrapleural recombinant interleukin-2 in immunotherapy for malignant pleural effusion.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Carcinoembryonic antigen-like reactivity in malignant mesothelioma. A comparison between different commercially available antibodies.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma. Multivariate analysis of prognostic factors on 113 patients.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 1: Diagnosis.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 2: Prognosis and staging.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse malignant mesothelioma of the pleura: a clinicopathological study of six patients with a prolonged symptom-free interval or extended survival after biopsy and a review of the literature of long-term survival.
</td>
<td style="text-align:left;">
Virchows Arch A Pathol Anat Histopathol
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant peritoneal mesothelioma].
</td>
<td style="text-align:left;">
Harefuah
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemotaxis and haptotaxis of human malignant mesothelioma cells: effects of fibronectin, laminin, type IV collagen, and an autocrine motility factor-like substance.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pleural mesothelioma. Review of 3 cases and role of thoracoscopy].
</td>
<td style="text-align:left;">
Rev Med Suisse Romande
</td>
</tr>
<tr>
<td style="text-align:left;">
In vitro effects of recombinant human interferon gamma on human mesothelioma cell lines.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
[Nose and paranasal sinus malignancies with reference to occupational medicine aspects. A case study].
</td>
<td style="text-align:left;">
HNO
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma caused by environmental exposure to asbestos or erionite in rural Turkey: CT findings in 84 patients.
</td>
<td style="text-align:left;">
AJR Am J Roentgenol
</td>
</tr>
<tr>
<td style="text-align:left;">
Round atelectasis and Metsovo lung.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Hypertrophic osteoarthropathy in childhood malignancy.
</td>
<td style="text-align:left;">
Med. Pediatr. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Intrapleural recombinant IL-2 in passive immunotherapy for malignant pleural effusion.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of ultrasound assisted thoracoscopy in the diagnosis of pleural disease. Clinical experience in 687 cases.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical aspects of malignant mesothelioma in Australia.
</td>
<td style="text-align:left;">
Aust N Z J Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Natural history and epidemiology of malignant mesothelioma.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleurectomy/decortication and adjuvant therapy for malignant mesothelioma.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
[Cardiac block caused by metastasis of lung adenocarcinoma to the bundle of His].
</td>
<td style="text-align:left;">
Minerva Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical and pathological features of thoracic neoplasia in the horse.
</td>
<td style="text-align:left;">
Equine Vet. J.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma: clinical characteristics, prognostic factors and treatment].
</td>
<td style="text-align:left;">
Arch. Bronconeumol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Thoracoscopic management of malignant pleural effusions.
</td>
<td style="text-align:left;">
Clin. Chest Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Smooth muscle tumours presenting as pleural neoplasms.
</td>
<td style="text-align:left;">
Histopathology
</td>
</tr>
<tr>
<td style="text-align:left;">
The differential expression of N-cadherin and E-cadherin distinguishes pleural mesotheliomas from lung adenocarcinomas.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Multiparameter flow cytometric DNA analysis of effusions: a prospective study of 36 cases compared with routine cytology and immunohistochemistry.
</td>
<td style="text-align:left;">
Mod. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
FISH in the evaluation of pleural and ascitic fluids.
</td>
<td style="text-align:left;">
Cancer Genet. Cytogenet.
</td>
</tr>
<tr>
<td style="text-align:left;">
Biphasic synovial sarcomas arising in the pleural cavity. A clinicopathologic study of five cases.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
The proposed new international TNM staging system for malignant pleural mesothelioma: application to imaging.
</td>
<td style="text-align:left;">
AJR Am J Roentgenol
</td>
</tr>
<tr>
<td style="text-align:left;">
Parental cancer and genetic predisposition in malignant pleural mesothelioma: a case-control study.
</td>
<td style="text-align:left;">
Cancer Lett.
</td>
</tr>
<tr>
<td style="text-align:left;">
Cancer in electrical workers: an analysis of cancer registrations in England, 1981-87.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
The importance of surgical staging in the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemotherapy in malignant pleural mesothelioma. A review.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Combined systemic chemoimmunotherapy in advanced diffuse malignant mesothelioma. Report of a phase I-II study of weekly cisplatin/interferon alfa-2a.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgery followed by intracavitary plus systemic chemotherapy in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Tumori
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma after radiation therapy for breast cancer. A report of two additional patients.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Transsternal transpericardial operations in the treatment of bronchopleural fistulas after pneumonectomy.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Extensive pulmonary metastases in malignant pleural mesothelioma. A rare clinical and radiographic presentation.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of platelet-derived growth factor (PDGF) and PDGF receptors in human malignant mesothelioma in vitro and in vivo.
</td>
<td style="text-align:left;">
J. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Stereological evaluation of malignant mesothelioma versus benign pleural hyperplasia.
</td>
<td style="text-align:left;">
Pathol. Res. Pract.
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical course of human epithelial-type malignant pleural mesothelioma replicated in an orthotopic-transplant nude mouse model.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
The calcium binding protein calretinin is a selective marker for malignant pleural mesotheliomas of the epithelial type.
</td>
<td style="text-align:left;">
Pathol. Res. Pract.
</td>
</tr>
<tr>
<td style="text-align:left;">
A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment and survival in diffuse malignant pleural mesothelioma; a study of 83 cases from the Massachusetts General Hospital.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Stimulatory effects of pleural fluids from mesothelioma patients on CD44 expression, hyaluronan production and cell proliferation in primary cultures of normal mesothelial and transformed cells.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Combined chemotherapy in pleurectomized malignant pleural mesothelioma patients.
</td>
<td style="text-align:left;">
J Chemother
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytologic effects of photodynamic therapy in body fluids.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Diagnosis and treatment of pleural mesothelioma: a report of 40 cases].
</td>
<td style="text-align:left;">
Zhonghua Zhong Liu Za Zhi
</td>
</tr>
<tr>
<td style="text-align:left;">
Concomitant malignant mesothelioma of the pleura, peritoneum, and tunica vaginalis testis.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic value of CA 72-4, carcinoembryonic antigen, CA 15-3, and CA 19-9 assay in pleural fluid. A study of 207 patients.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment of pleural mesothelioma in an immunocompetent rat model utilizing adenoviral transfer of the herpes simplex virus thymidine kinase gene.
</td>
<td style="text-align:left;">
Hum. Gene Ther.
</td>
</tr>
<tr>
<td style="text-align:left;">
Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Results in 120 consecutive patients.
</td>
<td style="text-align:left;">
Ann. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Lepidic intrapulmonary growth of malignant mesothelioma presenting as recurrent hydropneumothorax.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Small cell carcinoma of lung simulating pleural mesothelioma. Report of 4 cases with autopsy confirmation.
</td>
<td style="text-align:left;">
Pathol. Res. Pract.
</td>
</tr>
<tr>
<td style="text-align:left;">
Analysis of pleural effusions using flow cytometry.
</td>
<td style="text-align:left;">
Respiration
</td>
</tr>
<tr>
<td style="text-align:left;">
p53 gene product in pleural effusions. Practical use in distinguishing benign from malignant cells.
</td>
<td style="text-align:left;">
Acta Cytol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Endobronchial inflammatory pseudotumour in a patient with B-cell chronic lymphocytic leukemia and malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Acta Clin Belg
</td>
</tr>
<tr>
<td style="text-align:left;">
Laparoscopy: an important tool in the staging of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Surg. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma of the pleura].
</td>
<td style="text-align:left;">
Orv Hetil
</td>
</tr>
<tr>
<td style="text-align:left;">
Manganese superoxide dismutase in human pleural mesothelioma cell lines.
</td>
<td style="text-align:left;">
Free Radic. Biol. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
From the archives of the AFIP. Malignant pleural mesothelioma: radiologic-pathologic correlation.
</td>
<td style="text-align:left;">
Radiographics
</td>
</tr>
<tr>
<td style="text-align:left;">
[Two cases of recurrent hydropneumothorax caused by malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Nihon Kyobu Geka Gakkai Zasshi
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant vascular tumors of the serous membranes mimicking mesothelioma. A report of 14 cases.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Fibronectin expression and organization in mesothelial and mesothelioma cells.
</td>
<td style="text-align:left;">
Am. J. Physiol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Safety of intrapleurally administered recombinant adenovirus carrying herpes simplex thymidine kinase DNA followed by ganciclovir therapy in nonhuman primates.
</td>
<td style="text-align:left;">
Hum. Gene Ther.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma of the pleura: correlations between thoracoscopy and radiology].
</td>
<td style="text-align:left;">
Radiol Med
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pulmonary embolism in malignancy of the lung: a retrospective clinical evaluation and pathomorphologic personal material].
</td>
<td style="text-align:left;">
Pneumonol Alergol Pol
</td>
</tr>
<tr>
<td style="text-align:left;">
Differential diagnosis of malignant and reactive cells from serous effusions: image and texture analysis study.
</td>
<td style="text-align:left;">
Anal Cell Pathol
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
A case of malignant pleural mesothelioma with metastasis to the orbit.
</td>
<td style="text-align:left;">
Jpn. J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Fibrous tumors localized in the pleura].
</td>
<td style="text-align:left;">
G Chir
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunohistochemical phenotype of malignant mesothelioma: predictive value of CA125 and HBME-1 expression.
</td>
<td style="text-align:left;">
Histopathology
</td>
</tr>
<tr>
<td style="text-align:left;">
Effusion cytology after extrapleural pneumonectomy for treatment of malignant mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Clin. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Proportionate mortality among unionized construction ironworkers.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunohistochemical differences between hyaluronan- and non-hyaluronan-producing malignant mesothelioma.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
</tr>
<tr>
<td style="text-align:left;">
Recurrent DNA copy number changes in 1q, 4q, 6q, 9p, 13q, 14q and 22q detected by comparative genomic hybridization in malignant mesothelioma.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma in Rome, Italy 1980-1995. A retrospective study of 79 patients.
</td>
<td style="text-align:left;">
Tumori
</td>
</tr>
<tr>
<td style="text-align:left;">
Response to chemotherapy of brain metastases from malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Tumori
</td>
</tr>
<tr>
<td style="text-align:left;">
WT1 mutation in malignant mesothelioma and WT1 immunoreactivity in relation to p53 and growth factor receptor expression, cell-type transition, and prognosis.
</td>
<td style="text-align:left;">
J. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleurectomy/decortication for palliation in malignant pleural mesothelioma: results of surgery.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Distinction between pleural mesothelioma and pulmonary adenocarcinoma using MOC31 in an asbestos sprayer.
</td>
<td style="text-align:left;">
Respir Med
</td>
</tr>
<tr>
<td style="text-align:left;">
[Venous endoprosthesis. Palliative treatment of superior caval syndrome of neoplastic origin].
</td>
<td style="text-align:left;">
J Radiol
</td>
</tr>
<tr>
<td style="text-align:left;">
[Problems in diagnosis and therapy of malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Med. Klin. (Munich)
</td>
</tr>
<tr>
<td style="text-align:left;">
Combined cisplatin, doxorubicin, and mitomycin for the treatment of advanced pleural mesothelioma: a phase II FONICAP trial. Italian Lung Cancer Task Force.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Pseudomesotheliomatous angiosarcoma: a pleuropulmonary lesion simulating malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Histopathology
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse malignant pleural mesotheslioma at CAMC: a retrospective study of 50 patients.
</td>
<td style="text-align:left;">
W V Med J
</td>
</tr>
<tr>
<td style="text-align:left;">
[Occupational neoplasms in Poland in the years 1971-1994].
</td>
<td style="text-align:left;">
Med Pr
</td>
</tr>
<tr>
<td style="text-align:left;">
[Thoracoscopy in malignant pleural effusions].
</td>
<td style="text-align:left;">
Zhonghua Zhong Liu Za Zhi
</td>
</tr>
<tr>
<td style="text-align:left;">
[Use of a bronchoscope for thoracoscopic observation and diagnosis of pleural plaques].
</td>
<td style="text-align:left;">
Nihon Kyobu Shikkan Gakkai Zasshi
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant epithelial neoplasm consistent with primitive cystic hepatic neoplasm with mesothelial differentiation: a case report.
</td>
<td style="text-align:left;">
Zhonghua Yi Xue Za Zhi (Taipei)
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma in south east England: clinicopathological experience of 272 cases.
</td>
<td style="text-align:left;">
Thorax
</td>
</tr>
<tr>
<td style="text-align:left;">
Latency periods in asbestos-related mesothelioma of the pleura.
</td>
<td style="text-align:left;">
Eur. J. Cancer Prev.
</td>
</tr>
<tr>
<td style="text-align:left;">
Metastatic malignant mesothelioma presenting as colonic polyps.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Clear cell tumors of unknown nature and origin: a systematic approach to diagnosis.
</td>
<td style="text-align:left;">
Semin Diagn Pathol
</td>
</tr>
<tr>
<td style="text-align:left;">
Pericardiectomy in dogs: 22 cases (1978-1994).
</td>
<td style="text-align:left;">
J. Am. Vet. Med. Assoc.
</td>
</tr>
<tr>
<td style="text-align:left;">
Proteoglycan synthesis induced by transforming and basic fibroblast growth factors in human malignant mesothelioma is mediated through specific receptors and the tyrosine kinase intracellular pathway.
</td>
<td style="text-align:left;">
Biochimie
</td>
</tr>
<tr>
<td style="text-align:left;">
Multimodality therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Brachytherapy for non-small cell lung cancer and selected neoplasms of the chest.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
High-performance capillary electrophoretic analysis of hyaluronan in effusions from human malignant mesothelioma.
</td>
<td style="text-align:left;">
J. Chromatogr. B Biomed. Sci. Appl.
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemotherapy for malignant mesothelioma.
</td>
<td style="text-align:left;">
Semin. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Extrapleural pneumonectomy in the setting of multimodality therapy for diffuse malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Semin. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
New therapies in the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Semin. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma diagnosed after chest trauma.
</td>
<td style="text-align:left;">
Am Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural malignancies including mesothelioma.
</td>
<td style="text-align:left;">
Curr Opin Pulm Med
</td>
</tr>
<tr>
<td style="text-align:left;">
Silica-induced pleural disease: an unusual case mimicking malignant mesothelioma.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Experimental assessment of photodynamic therapy with chlorins for malignant mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma in general practice; complex pain problems].
</td>
<td style="text-align:left;">
Ned Tijdschr Geneeskd
</td>
</tr>
<tr>
<td style="text-align:left;">
Optimization of a battery using nine immunocytochemical variables for distinguishing between epithelial mesothelioma and adenocarcinoma.
</td>
<td style="text-align:left;">
APMIS
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural malignant mesothelioma and environmental asbestos exposure in Casale Monferrato, Piedmont. Preliminary analysis of a case-control study.
</td>
<td style="text-align:left;">
Med Lav
</td>
</tr>
<tr>
<td style="text-align:left;">
The experience of the Mesothelioma Registry of Tuscany in assessing health hazard associated with asbestos exposure.
</td>
<td style="text-align:left;">
Med Lav
</td>
</tr>
<tr>
<td style="text-align:left;">
[GC12, marker of cells of mesodermal origin. Value and application to cytodiagnosis of serous effusions].
</td>
<td style="text-align:left;">
Arch. Anat. Cytol. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Environmental and indoor air exposure to asbestos fiber dust as a risk and causal factor of diffuse malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Zentralbl Hyg Umweltmed
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma of the pleura. Morphometric study].
</td>
<td style="text-align:left;">
Pathologica
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant peripheral nerve sheath tumor of the pleura with epithelial and rhabdomyoblastic differentiation: report of a case clinically simulating mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
A review of chemotherapy trials for malignant mesothelioma.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
The use of epithelial membrane antigen and silver-stained nucleolar organizer regions testing in the differential diagnosis of mesothelioma from benign reactive mesothelioses.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Comparison of DNA copy number changes in malignant mesothelioma, adenocarcinoma and large-cell anaplastic carcinoma of the lung.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
HBME-1 and antithrombomodulin in the differential diagnosis of malignant mesothelioma of pleura.
</td>
<td style="text-align:left;">
J. Clin. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Effects of interleukin-2 for the treatment of malignant mesothelioma.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase I study of paclitaxel as a radiation sensitizer in the treatment of mesothelioma and non-small-cell lung cancer.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Higher doses of alpha-interferon do not increase the activity of the weekly cisplatin-interferon combination in advanced malignant mesothelioma.
</td>
<td style="text-align:left;">
Eur. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Effectiveness of cisplatin, paclitaxel, and suramin against human malignant mesothelioma xenografts in athymic nude mice.
</td>
<td style="text-align:left;">
J Surg Oncol
</td>
</tr>
<tr>
<td style="text-align:left;">
[The clinical utility of asbestos body counts in bronchoalveolar lavage fluid].
</td>
<td style="text-align:left;">
Nihon Kyobu Shikkan Gakkai Zasshi
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma of the pleura with etiological association to asbestos: report of 3 clinical cases].
</td>
<td style="text-align:left;">
Rev Assoc Med Bras (1992)
</td>
</tr>
<tr>
<td style="text-align:left;">
[Cancer risk in asbestos-cement industry workers in Poland].
</td>
<td style="text-align:left;">
Med Pr
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical features and epidemiology of malignant pleural mesothelioma in west Glasgow 1987-1992.
</td>
<td style="text-align:left;">
Scott Med J
</td>
</tr>
<tr>
<td style="text-align:left;">
Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.
</td>
<td style="text-align:left;">
Chest
</td>
</tr>
<tr>
<td style="text-align:left;">
Effect of simian virus large T antigen expression on cell cycle control and apoptosis in rat pleural mesothelial cells exposed to DNA damaging agents.
</td>
<td style="text-align:left;">
Oncogene
</td>
</tr>
<tr>
<td style="text-align:left;">
Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Hepatocyte growth factor/scatter factor stimulates chemotaxis and growth of malignant mesothelioma cells through c-met receptor.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Thoracoscopy–state of the art.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Value of thoracoscopy and talc pleurodesis in diagnosis and palliative treatment of malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Praxis (Bern 1994)
</td>
</tr>
<tr>
<td style="text-align:left;">
Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Hyperplastic mesothelial cells in lymph nodes: report of six cases of a benign process that can stimulate metastatic involvement by mesothelioma or carcinoma.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
E-cadherin and calretinin: a useful combination of immunochemical markers for differentiation between mesothelioma and metastatic adenocarcinoma.
</td>
<td style="text-align:left;">
Histopathology
</td>
</tr>
<tr>
<td style="text-align:left;">
Utility of the antibodies CA 19-9, HBME-1, and thrombomodulin in the diagnosis of malignant mesothelioma and adenocarcinoma in cytology.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
The usefulness of CYFRA 21-1 in diagnosing and monitoring malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Acta Med. Okayama
</td>
</tr>
<tr>
<td style="text-align:left;">
Translocation (3;3)(p14;q29) as the primary chromosome abnormality in a peritoneal mesothelioma.
</td>
<td style="text-align:left;">
Cancer Genet. Cytogenet.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Central lung embolism in chronic interstitial pneumopathy].
</td>
<td style="text-align:left;">
Praxis (Bern 1994)
</td>
</tr>
<tr>
<td style="text-align:left;">
Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma.
</td>
<td style="text-align:left;">
Hum. Gene Ther.
</td>
</tr>
<tr>
<td style="text-align:left;">
A urokinase receptor mRNA binding protein from rabbit lung fibroblasts and mesothelial cells.
</td>
<td style="text-align:left;">
Am. J. Physiol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Gene therapy for malignant mesothelioma: a novel approach for an incurable cancer with increased incidence in Louisiana.
</td>
<td style="text-align:left;">
J La State Med Soc
</td>
</tr>
<tr>
<td style="text-align:left;">
[Clinical evaluation of benign asbestos pleurisy].
</td>
<td style="text-align:left;">
Nihon Kokyuki Gakkai Zasshi
</td>
</tr>
<tr>
<td style="text-align:left;">
SV40-like DNA sequences in pleural mesothelioma, bronchopulmonary carcinoma, and non-malignant pulmonary diseases.
</td>
<td style="text-align:left;">
J. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
A comparative evaluation of immunohistochemical markers for the differential diagnosis of malignant pleural tumours.
</td>
<td style="text-align:left;">
Histopathology
</td>
</tr>
<tr>
<td style="text-align:left;">
Static DNA cytometry as a diagnostic aid in effusion cytology: I. DNA aneuploidy for identification and differentiation of primary and secondary tumors of the serous membranes.
</td>
<td style="text-align:left;">
Anal. Quant. Cytol. Histol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Static DNA cytometry as a diagnostic aid in effusion cytology: II. DNA aneuploidy for identification of neoplastic cells in equivocal effusions.
</td>
<td style="text-align:left;">
Anal. Quant. Cytol. Histol.
</td>
</tr>
<tr>
<td style="text-align:left;">
CT and MR in pleural disease.
</td>
<td style="text-align:left;">
Clin. Chest Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Gene therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Hematol. Oncol. Clin. North Am.
</td>
</tr>
<tr>
<td style="text-align:left;">
Thoracoscopy in undiagnosed pleural effusions.
</td>
<td style="text-align:left;">
S. Afr. Med. J.
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of immunohistochemistry in the diagnosis of malignant mesothelioma.
</td>
<td style="text-align:left;">
Monaldi Arch Chest Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Establishment and preliminary characterization of human malignant mesothelioma cell lines.
</td>
<td style="text-align:left;">
Monaldi Arch Chest Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunobiology and immune defense mechanisms of mesothelioma cells.
</td>
<td style="text-align:left;">
Monaldi Arch Chest Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Systemic drug therapy of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Monaldi Arch Chest Dis
</td>
</tr>
<tr>
<td style="text-align:left;">
Medical thoracoscopy in the diagnosis of unexplained pleural effusion.
</td>
<td style="text-align:left;">
Respirology
</td>
</tr>
<tr>
<td style="text-align:left;">
Hepatocyte growth factor/scatter factor and its receptor c-Met are overexpressed and associated with an increased microvessel density in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Cancer Res. Clin. Oncol.
</td>
</tr>
<tr>
<td style="text-align:left;">
The diagnosis of desmoplastic malignant mesothelioma and its distinction from fibrous pleurisy: a histologic and immunohistochemical analysis of 31 cases including p53 immunostaining.
</td>
<td style="text-align:left;">
Am. J. Clin. Pathol.
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytokeratin markers in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Detect. Prev.
</td>
</tr>
<tr>
<td style="text-align:left;">
Localized malignant mesothelioma: a case report.
</td>
<td style="text-align:left;">
Am Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
[Unusual metastasis of a malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Pneumologie
</td>
</tr>
<tr>
<td style="text-align:left;">
[Standards, Options, and Recommendations for the management of patients with malignant mesothelioma of the pleura. Fédération Nationale des Centres de Lutte Contre le Cancer].
</td>
<td style="text-align:left;">
Bull Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Detection of SV40-like DNA sequences in pleural mesothelioma, bronchopulmonary carcinoma and other pulmonary diseases.
</td>
<td style="text-align:left;">
Dev. Biol. Stand.
</td>
</tr>
<tr>
<td style="text-align:left;">
Changes in expression and microheterogeneity of the genetic variants of human alpha1-acid glycoprotein in malignant mesothelioma.
</td>
<td style="text-align:left;">
J. Chromatogr. B Biomed. Sci. Appl.
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase I clinical and pharmacological study of liposome-entrapped NDDP administered intrapleurally in patients with malignant pleural effusions.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
</tr>
<tr>
<td style="text-align:left;">
Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: a Phase II study.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment results of 17 patients with diffuse pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann Thorac Cardiovasc Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
The value of anti-calretinin antibody in the differential diagnosis of normal and reactive mesothelia versus metastatic tumors in effusion cytology.
</td>
<td style="text-align:left;">
Pathol. Res. Pract.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pleural malignant mesothelioma with osseous cartilaginous and rhabdomyogenic differentiation].
</td>
<td style="text-align:left;">
Nihon Kokyuki Gakkai Zasshi
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant diffuse mesothelioma: contribution of 23 cases].
</td>
<td style="text-align:left;">
Rev Clin Esp
</td>
</tr>
<tr>
<td style="text-align:left;">
Adenocarcinoma simulating mesothelioma: a clinicopathologic and immunohistochemical study of 29 cases.
</td>
<td style="text-align:left;">
Ann Diagn Pathol
</td>
</tr>
<tr>
<td style="text-align:left;">
The treatment of malignant mesothelioma with a gene modified cancer cell line: a phase I study.
</td>
<td style="text-align:left;">
Hum. Gene Ther.
</td>
</tr>
<tr>
<td style="text-align:left;">
Localized fibrous tumours of the pleura: 15 new cases and review of the literature.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
</tr>
<tr>
<td style="text-align:left;">
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
</tr>
<tr>
<td style="text-align:left;">
Synovial sarcoma of the pleura and its differentiation from other primary pleural tumours: a clinicopathological and immunohistochemical review of three cases.
</td>
<td style="text-align:left;">
Histopathology
</td>
</tr>
<tr>
<td style="text-align:left;">
Cancer in ex-asbestos cement workers in Israel, 1953-1992.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
</tr>
<tr>
<td style="text-align:left;">
Primary pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma. II. Modern therapeutic concepts].
</td>
<td style="text-align:left;">
Srp Arh Celok Lek
</td>
</tr>
<tr>
<td style="text-align:left;">
Interleukin 8: an autocrine growth factor for malignant mesothelioma.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
</tr>
<tr>
<td style="text-align:left;">
[Treatment strategy in pleural mesothelioma].
</td>
<td style="text-align:left;">
Langenbecks Arch Chir Suppl Kongressbd
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytologic diagnosis of malignant mesothelioma, with particular emphasis on the epithelial noncohesive cell type.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
</tr>
</tbody>
</table></li>
</ol>
<p><br></p>

          </div>

          



          
        </div>

        <div class="body-footer">
          
          

          
        </div>

      </article>

      <footer class="site-footer">
  
  <p class="powered-by">
    
      <a href="/mesothelioma/privacy/">Privacy Policy</a>
    
    
        &middot; 
      <a href="/mesothelioma/terms/">Terms</a>
    
    
        &middot; 
      <a href="/mesothelioma/supp/faq/">FAQ</a>
    
  </p>
  

  <p class="powered-by">
    BioHub - UFPE &middot; 

    Powered by the
    <a href="https://sourcethemes.com/academic/" target="_blank" rel="noopener">Academic theme</a> for
    <a href="https://gohugo.io" target="_blank" rel="noopener">Hugo</a>.

    
  </p>
</footer>


    </main>
  </div>
</div>


      

    
    
    
      <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery/3.4.1/jquery.min.js" integrity="sha256-CSXorXvZcTkaix6Yvo6HppcZGetbYMGWSFlBw8HfCJo=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.imagesloaded/4.1.4/imagesloaded.pkgd.min.js" integrity="sha256-lqvxZrPLtfffUl2G/e7szqSvPBILGbwmsGE1MKlOi0Q=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.isotope/3.0.6/isotope.pkgd.min.js" integrity="sha256-CBrpuqrMhXwcLLUd5tvQ4euBHCdh7wGlDfNz8vbu/iI=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.5.7/jquery.fancybox.min.js" integrity="sha256-yt2kYMy0w8AbtF89WXb2P1rfjcP/HTHLT7097U8Y5b8=" crossorigin="anonymous"></script>

      

      
        
        <script src="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.18.1/highlight.min.js" integrity="sha256-eOgo0OtLL4cdq7RdwRUiGKLX9XsIJ7nGhWEKbohmVAQ=" crossorigin="anonymous"></script>
        
        <script src="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.18.1/languages/r.min.js"></script>
        
      

    

    
    

    
    
    <script>const code_highlighting = true;</script>
    

    
    
    <script>const isSiteThemeDark = false;</script>
    

    
    
    
    
    
    
    <script>
      const search_config = {"indexURI":"/mesothelioma/index.json","minLength":1,"threshold":0.3};
      const i18n = {"no_results":"No results found","placeholder":"Search...","results":"results found"};
      const content_type = {
        'post': "Posts",
        'project': "Projects",
        'publication' : "Publications",
        'talk' : "Talks"
        };
    </script>
    

    
    
    <script src="https://cdnjs.cloudflare.com/ajax/libs/anchor-js/4.1.1/anchor.min.js" integrity="sha256-pB/deHc9CGfFpJRjC43imB29Rse8tak+5eXqntO94ck=" crossorigin="anonymous"></script>
    <script>
      anchors.add();
    </script>
    

    
    
    <script id="search-hit-fuse-template" type="text/x-template">
      <div class="search-hit" id="summary-{{key}}">
      <div class="search-hit-content">
        <div class="search-hit-name">
          <a href="{{relpermalink}}">{{title}}</a>
          <div class="article-metadata search-hit-type">{{type}}</div>
          <p class="search-hit-description">{{snippet}}</p>
        </div>
      </div>
      </div>
    </script>
    

    
    
    <script src="https://cdnjs.cloudflare.com/ajax/libs/fuse.js/3.2.1/fuse.min.js" integrity="sha256-VzgmKYmhsGNNN4Ph1kMW+BjoYJM2jV5i4IlFoeZA9XI=" crossorigin="anonymous"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/mark.js/8.11.1/jquery.mark.min.js" integrity="sha256-4HLtjeVgH0eIB3aZ9mLYF6E8oU5chNdjU6p6rrXpl9U=" crossorigin="anonymous"></script>
    

    
    

    
    

    
    
    <script id="dsq-count-scr" src="https://procovid19.disqus.com/count.js" async></script>
    

    
    
    
    
    
    
    
    
    
      
    
    
    
    
    <script src="/mesothelioma/js/academic.min.37431be2d92d7fb0160054761ab79602.js"></script>

    






  
  

  
<div id="modal" class="modal fade" role="dialog">
  <div class="modal-dialog">
    <div class="modal-content">
      <div class="modal-header">
        <h5 class="modal-title">Cite</h5>
        <button type="button" class="close" data-dismiss="modal" aria-label="Close">
          <span aria-hidden="true">&times;</span>
        </button>
      </div>
      <div class="modal-body">
        <pre><code class="tex hljs"></code></pre>
      </div>
      <div class="modal-footer">
        <a class="btn btn-outline-primary my-1 js-copy-cite" href="#" target="_blank">
          <i class="fas fa-copy"></i> Copy
        </a>
        <a class="btn btn-outline-primary my-1 js-download-cite" href="#" target="_blank">
          <i class="fas fa-download"></i> Download
        </a>
        <div id="modal-error"></div>
      </div>
    </div>
  </div>
</div>

</body>
</html>
